<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Hematol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Hematol Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">617</journal-id><journal-id journal-id-type="pmc-domain">jhemonc</journal-id><journal-title-group><journal-title>Journal of Hematology &amp; Oncology</journal-title></journal-title-group><issn pub-type="epub">1756-8722</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11603676</article-id><article-id pub-id-type="pmcid-ver">PMC11603676.1</article-id><article-id pub-id-type="pmcaid">11603676</article-id><article-id pub-id-type="pmcaiid">11603676</article-id><article-id pub-id-type="pmid">39609851</article-id><article-id pub-id-type="doi">10.1186/s13045-024-01628-4</article-id><article-id pub-id-type="publisher-id">1628</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Personalized nanovaccines for treating solid cancer metastases</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Feng</surname><given-names initials="T">Tang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Hu</surname><given-names initials="J">Jia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wen</surname><given-names initials="J">Jirui</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qian</surname><given-names initials="Z">Zhiyong</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Che</surname><given-names initials="G">Guowei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="Q">Qinghua</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhu</surname><given-names initials="L">Lingling</given-names></name><address><email>zhulingling8262023@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/011ashp19</institution-id><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Department of Medical Oncology, Cancer Center, West China Hospital, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, Sichuan China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/011ashp19</institution-id><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Department of Biotherapy, Cancer Center, West China Hospital, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, Sichuan China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Lung Cancer Center/Lung Cancer Institute, West China Hospital, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, Sichuan China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/011ashp19</institution-id><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Deep Underground Space Medical Center, West China Hospital, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, Sichuan China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, </institution><institution>Sichuan University, </institution></institution-wrap>Chengdu, China </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>17</volume><issue-id pub-id-type="pmc-issue-id">452600</issue-id><elocation-id>115</elocation-id><history><date date-type="received"><day>11</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>28</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-30 08:25:31.540"><day>30</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13045_2024_Article_1628.pdf"/><abstract id="Abs1"><p id="Par1">Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical response rate to vaccines remains&#8201;&lt;&#8201;30%. Nanoparticles stabilize vaccines and improve antigen recognition and presentation, resulting in high tumor penetration or accumulation, effective co-distribution of drugs to the secondary lymphatic system, and adaptable antigen or adjuvant administration. Such vaccine-like nanomedicines have the ability to eradicate the primary tumors as well as to prevent or eliminate metastases. This review examines state-of-the-art nanocarriers developed to deliver tumor vaccines to metastases, including synthetic, semi-biogenic, and biogenic nanosystems. Moreover, it highlights the physical and pharmacological properties that enhance their anti-metastasis efficiency. This review also addresses the combination of nanovaccines with cancer immunotherapy to target various steps in the metastatic cascade, drawing insights from preclinical and clinical studies. The review concludes with a critical analysis of the challenges and frameworks linked to the clinical translation of cancer nanovaccines.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cancer vaccine</kwd><kwd>Clinical translation</kwd><kwd>Metastasis</kwd><kwd>Nanoparticle</kwd><kwd>Tumor</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China</institution></funding-source><award-id>32401087</award-id><award-id>No. 82202989</award-id><principal-award-recipient><name name-style="western"><surname>Feng</surname><given-names>Tang</given-names></name><name name-style="western"><surname>Che</surname><given-names>Guowei</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Sichuan Science and Technology Program</institution></funding-source><award-id>2023NSFSC1742</award-id><principal-award-recipient><name name-style="western"><surname>Che</surname><given-names>Guowei</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Sichuan Province Science and Technology Activities Funding for Returned Overseas Scholars</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par68">Owing to the high risk of metastasis, cancer continues to be the most malignant illness globally, despite enormous advancements in therapy and diagnostics [<xref ref-type="bibr" rid="CR1">1</xref>] Specifically, metastases are the leading causes of&#160;cancer&#160;and mortality in&#160;patients with cancer, accounting for approximately 90% of cancer-associated fatalities [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. An efficient and highly specific anti-metastatic therapeutic strategy should effectively remove primary tumors as well as induce systemic immunity to inhibit distant metastases [<xref ref-type="bibr" rid="CR4">4</xref>]. Tumor metastasis reprograms distant organ microenvironments systemically, impacting immune cell function or phenotypes [<xref ref-type="bibr" rid="CR5">5</xref>]. Environmental regulation throughout the metastatic cascade can enhance tumor cell dissemination [<xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, eliminating metastatic tumors requires systemic immune activation and long-term immune memory. However, metastatic tumors are characterized by their immunosuppressive tumor microenvironment (TME), thus limiting the efficacy of systemic anti-tumor immune responses for the majority of patients [<xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>]. Nonetheless, metastatic cells outside of the immunosuppressive TME are more vulnerable to immune elimination, providing a therapeutic opportunity to utilize immune cells in the metastatic cascade [<xref ref-type="bibr" rid="CR10">10</xref>]. Immunotherapy is considered optimal for treating metastasis because it functions by boosting the immune response of the body and selectively countering the inherently immunosuppressive effects of the TME. Rather than directly combating metastatic tumor cells such as in traditional therapies, immunotherapy stimulates immune cells to target rare metastatic tumor cells [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par69">Cancer vaccines represent a potentially effective immunotherapeutic strategy that activate the immune system of a patient, facilitating the establishment of long-term immune memory for fighting tumors. This approach has the potential to prevent metastasis, highlighting its stance as a favorable treatment option [<xref ref-type="bibr" rid="CR12">12</xref>]. However, to date, sipuleucel-T is the only Food and Drug Administration-authorized anti-tumor&#160;vaccine for metastatic cancer [<xref ref-type="bibr" rid="CR13">13</xref>]. Despite active preclinical and clinical investigations, numerous therapeutic cancer vaccines have failed to demonstrate efficacy [<xref ref-type="bibr" rid="CR14">14</xref>]. A majority of the candidate vaccines featuring &#8220;minimalist&#8221; compositions have not met expectations because of factors including poor immunogenicity of certain antigens, the immunosuppressive nature of the TME, challenges with in vivo instability, and the random dispersal of vaccine formulations [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Owing to the low immunogenicity of tumor antigens and the immunosuppressive TME, another challenge in cancer vaccine therapy is triggering a controlled yet robust tumor-specific T-cell response by delivering&#160;antigens&#160;and&#160;adjuvants efficiently [<xref ref-type="bibr" rid="CR17">17</xref>]. This is particularly challenging because it is necessary to disrupt the immunosuppressive TME throughout the metastatic cascade [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par70">Considering metastatic cells spread extensively to distant organs and are highly heterogeneous and small in size, tracking and treating tumor metastases present unique challenges. Systemic factors influencing the nutritional, metabolic, and inflammatory activity of the body can affect all stages of metastasis via reprogramming the metastasis-specific immunosuppressive systemic microenvironment [<xref ref-type="bibr" rid="CR19">19</xref>]. Furthermore, surface markers of metastatic cells exhibit marked variability among patients, as well as within the same patient or similar cell types [<xref ref-type="bibr" rid="CR20">20</xref>]. This heterogeneity further enhances the metastatic potential of tumor cells. The TME of immune cells and their expression of immune-regulatory receptors increase immunosuppression in metastatic tumors, establishing a vicious cycle that further augments tumor cell growth and alteration in the metastasis-specific microenvironment (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR21">21</xref>]. Consequently, there is a growing demand for the application of precision medicine in the context of targeting metastasis [<xref ref-type="bibr" rid="CR22">22</xref>]. Precision medicine aims to provide a personalized treatment with a foundation undergirded by the application of patient-specific data, i.e., genetic profiles, comorbidities, or environmental exposure [<xref ref-type="bibr" rid="CR23">23</xref>]. This approach is intended to improve overall survival rates for a wide array of malignancies [<xref ref-type="bibr" rid="CR24">24</xref>]. Precision medicine makes use of enhanced medication specificity, more precise patient stratification, and optimal doses or combinatorial approaches, including nanomedicine [<xref ref-type="bibr" rid="CR23">23</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Schematic illustration of cancer nanovaccine therapy and increasingly immunosuppressive TME of metastatic cascade</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13045_2024_1628_Fig1_HTML.jpg"/></fig></p><p id="Par71">The cascade of cancer vaccines involves multiple stages: antigen identification, encapsulation, delivery, release, and presentation to T cells, especially in lymphatic vessels (inner ring). Increasing immunosuppression of immune cells in the TME and expression of immune-regulatory receptors establish a vicious cycle that further enhances tumor cell growth and alteration in the metastasis-specific microenvironment (left and right ring). The metastatic cascade includes three main steps: (1) primary tumor, (2) metastasizing dissemination involving circulating tumor cells (CTCs), and (3) metastatic colonization involving pre-metastatic niches and disseminated tumor cell settlement and colonization (outer ring). tumor microenvironment (TME); subcutaneous (S.C.); tumor-associated macrophages (TAM); natural killer (NK).</p><p id="Par72">Recently, several potential therapeutic advantages for metastatic cancer have been established using nanoparticles (NPs). NPs have been shown to exhibit a high capacity to precisely transport therapeutic chemicals to both primary and secondary cancers [<xref ref-type="bibr" rid="CR25">25</xref>]. Additionally, NPs can facilitate the development of personalized vaccines, tailored for individual patient populations [<xref ref-type="bibr" rid="CR26">26</xref>], to target tumor metastasis [<xref ref-type="bibr" rid="CR27">27</xref>]. This is because NPs greatly improve the drug delivery capabilities of cancer vaccines. These capabilities are rooted in the optimization of the nanometer size or physicochemical performance of the nanomaterial carriers through modifying the nanomaterials with targeting molecules or co-encapsulating them with immunostimulators. Moreover, beyond improving the precision of cancer vaccines, NPs can be applied to stimulate the immune system [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par73">Nanovaccines, a novel generation of vaccines utilizing NPs ranging from 50 to 200&#160;nm in diameter as carriers and/or adjuvants [<xref ref-type="bibr" rid="CR29">29</xref>], can effectively prime tumor-specific immunity to prevent distant organ metastasis, including in the lymph nodes (LNs) [<xref ref-type="bibr" rid="CR30">30</xref>], lung [<xref ref-type="bibr" rid="CR31">31</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref>], liver [<xref ref-type="bibr" rid="CR34">34</xref>] and bones [<xref ref-type="bibr" rid="CR35">35</xref>]. Nanovaccines co-deliver anti-tumor antigens and immunologic adjuvants to antigen-presenting cells (APCs) [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] Nanocarriers with adjuvant effects augment the strength, breadth, and durability of immune responses to vaccines by efficiently facilitating key steps of the vaccination process, including the recognition, encapsulation, release, transport, and presentation of antigens to T lymphocytes [<xref ref-type="bibr" rid="CR38">38</xref>]. For example, NP-based vaccines have been demonstrated to increase CD8&#8201;+&#8201;T-cell activation and cross-presentation drastically by at least 55-fold when compared with soluble antigens [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par74">As anti-metastasis strategies evolve and novel nanovaccines emerge, attention toward anti-metastasis nanovaccines and nanovaccine-based strategies that target the metastatic cascade will increase in anti-cancer investigations and practice in the future. Therefore, this review focuses on advances in basic immunology and delves into design strategies for anti-metastasis nanovaccines. Recent developments and advantages of nanovaccines for anti-metastasis therapy are comprehensively reviewed across both&#160;preclinical&#160;and&#160;clinical&#160;settings, with a particular focus on individualized anti-metastasis nanovaccines.</p></sec><sec id="Sec2"><title>Mechanisms underlying enhanced tumor immune activation by nanovaccines in cancer metastatic cascades</title><sec id="Sec3"><title>Interplay between <italic toggle="yes">cancer</italic> vaccines and metastasis</title><sec id="Sec4"><title><italic toggle="yes">Cancer</italic> metastatic cascades</title><p id="Par75">Cancer metastasis is a multistep process that is characterized by the following cascade of events: local invasion, intravasation, extravasation, micrometastatic colony formation, and cell proliferation [<xref ref-type="bibr" rid="CR10">10</xref>]. In essence, progression of cancer can be categorized into three primary stages: (1) primary tumor; (2) metastasizing dissemination involving CTCs, and (3) metastatic colonization involving pre-metastatic niches and disseminated tumor cell settlement and colonization. CTCs travel primarily through two main routes, i.e., circulation within the blood vessels and through the lymphatic vessels to the blood vessels [<xref ref-type="bibr" rid="CR40">40</xref>]. Notably, cancer cells have the ability to migrate to nearby LNs through the lymphatic arteries, thereby avoiding immune monitoring and facilitating the establishment of secondary tumors [<xref ref-type="bibr" rid="CR41">41</xref>]. We propose that tumors have far-reaching consequences, mostly fueled by local and systemic immunosuppression involving several immunological components [<xref ref-type="bibr" rid="CR42">42</xref>] such as regulatory T cells (Tregs), macrophages, Myeloid-derived suppressor cells, and neutrophils [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par76">Tumor metastasis is a complex process, and the complexity can be mediated partly by the activation and regulation of different signaling pathways [<xref ref-type="bibr" rid="CR45">45</xref>]. Nanovaccines can intervene in pathways that are involved in cancer metastatic cascades and have been shown to inhibit hypoxia-inducible factors (HIFs) [<xref ref-type="bibr" rid="CR46">46</xref>], transforming growth factor <italic toggle="yes">&#946;</italic> (TGF-<italic toggle="yes">&#946;</italic>) [<xref ref-type="bibr" rid="CR47">47</xref>], and the Wnt/<italic toggle="yes">&#946;</italic>-catenin pathway [<xref ref-type="bibr" rid="CR48">48</xref>], and to activate the cGAS-STING cascade [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and the SHP-1/JAK2/STAT3 signaling pathway [<xref ref-type="bibr" rid="CR50">50</xref>]. The pathways can influence epithelial&#8211;mesenchymal transition (EMT), cell stemness, the tumor hypoxic microenvironment, and anti-tumor immunity in vitro and in vivo, eventually impacting metastasis (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Signaling pathways intervened by nanovaccines in tumor metastatic cascades</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13045_2024_1628_Fig2_HTML.jpg"/></fig></p><p id="Par77">Overall, during a metastasis cascade, the interruption of immunosuppressive components and relevant signaling pathways in any one of the steps leads to hypoxia-inducible factors (HIFs) [<xref ref-type="bibr" rid="CR46">46</xref>], transforming growth factor <italic toggle="yes">&#946;</italic> (TGF-<italic toggle="yes">&#946;</italic>) metastasis failure. This insight has prompted numerous trials aimed at activating immune responses to combat tumor metastasis (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p></sec><sec id="Sec5"><title>Cancer vaccination cascade</title><p id="Par78">The cancer vaccine cascade can be encapsulated in five processes, which are as follows: antigen delivery aimed at LNs, antigen/adjuvant co-encapsulation, specific antigen identification, antigen internalization and release, and antigen cross-presentation for T-cell cross-priming [<xref ref-type="bibr" rid="CR51">51</xref>]. Macrophages, dendritic cells (DCs), B cells, natural killer (NK) cells, CD4&#8201;+&#8201;T cells, and CD8&#8201;+&#8201;T cells are the immune cells primarily involved in these critical cascades (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par79">Immune responses are primed by tumor vaccines, which target APCs with adjuvants and antigens. APCs [<xref ref-type="bibr" rid="CR52">52</xref>], including macrophages and DCs, are the primary adaptive and innate immune system mediators [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR54">54</xref>] As DCs potentially regulate immunity and immunological tolerance, they are crucial to the design of nanovaccines and should be considered to lie at the core of the immune system [<xref ref-type="bibr" rid="CR55">55</xref>]. Specifically, APCs, especially DCs, are the main immune cells that absorb the complete components of a vaccine when it is administered to a patient. Following stimulation by the adjuvant, such APCs use major histocompatibility complex class I/II (MHC I/II) to display antigens on their surface. When APCs are activated, they tend to translocate to secondary lymphoid organs, including the spleen or LNs, where they cause APC maturation [<xref ref-type="bibr" rid="CR56">56</xref>]. This outcome culminates in the activation of the adaptive immune system, which primarily consists of T and B cells. Through the application of a peptide-bound MHC, CD8&#8201;+&#8201;T cells eradicate tumor cells directly, whereas B cells require CD4&#8201;+&#8201;T cells for sufficient activation and antibody production, which results in antibody-mediated secondary tumor cell death [<xref ref-type="bibr" rid="CR14">14</xref>]. Cancer vaccines effectively facilitate T-cell differentiation from na&#239;ve CD8&#8201;+&#8201;T cells into cytotoxic T lymphocytes (CTLs) and differentiate na&#239;ve CD4&#8201;+&#8201;T cells into CD4&#8201;+&#8201;T helper type 1 (Th1) or Th2 cells [<xref ref-type="bibr" rid="CR57">57</xref>]. Th1 cells generate cytokines, including interleukin-2 (IL-2) and interferon-&#947; (IFN-&#947;), to promote CTL activation and the growth of cellular immunity [<xref ref-type="bibr" rid="CR57">57</xref>]. Th2 interact with B cells and aid in their full activation through CD40&#8211;CD40L interaction [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par80">Collectively, such results suggest that the immunosuppressive TME is responsible for metastasis. Numerous immune interactions between cancer vaccination and tumor metastasis indicate a potential therapeutic strategy against metastasis by leveraging cancer vaccines to reverse the immunosuppressive TME.</p></sec></sec><sec id="Sec6"><title>Targeting <italic toggle="yes">cancer</italic> metastasis using nanovaccines in precision medicine</title><p id="Par81">Cancer vaccines intended to limit metastasis have not been able to effectively reach LNs due to the significant heterogeneity and low immunogenicity of tumors, coupled with instability in circulation and the poor in vivo targeting ability of associated antigens. Recently, nanostrategies have emerged among the most promising approaches for addressing such specific barriers in vaccine delivery and considering the individual stages of solid tumor metastasis. Nanostrategies offer several advantages, including protection against enzymatic degradation, modified circulation time, solubility and bioavailability of various hydrophobic antigens, and increased&#160;tumor-targeting&#160;affinity. Such attributes collectively maximize immune stimulation (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Advantages of nanotechnology in vaccine delivery. NP delivery systems yield effective vaccine formulations. Additionally, these systems protect bioactive encapsulated payloads, co-delivering antigens and adjuvants in a unified formulation and targeting specific cell subsets via functional surface ligands. The inherent small size of these systems allows for them to efficiently reach the LNs, thus facilitating antigen presentation and enhancing the activation of immune cells, such as B cells, NK cells, CD4&#8201;+&#8201;T cells, and CD8&#8201;+&#8201;T cells</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13045_2024_1628_Fig3_HTML.jpg"/></fig></p><sec id="Sec7"><title>Antigens</title><p id="Par82">In general, tumor antigens are divided into peptide [<xref ref-type="bibr" rid="CR58">58</xref>], messenger RNA (mRNA)- [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>] DNA-, and protein-based antigens, depending on their composition [<xref ref-type="bibr" rid="CR28">28</xref>]. Single-stranded mRNA functions as a template for protein translation [<xref ref-type="bibr" rid="CR61">61</xref>]. mRNA vaccines rival the best available conventional vaccines due to their low side effects, as well as their rapid and cost-effective development potential [<xref ref-type="bibr" rid="CR62">62</xref>]. The rationale behind the design of an mRNA cancer vaccination platform is to deliver the transcript(s) of interest, encoding one or more tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs), into the host cell (typically APC) cytoplasm [<xref ref-type="bibr" rid="CR63">63</xref>]. The recent discovery, identification, and usage of TSAs and TAAs facilitate mRNA-based personalized cancer vaccine treatment applications [<xref ref-type="bibr" rid="CR64">64</xref>]. mRNA-encoded neoantigens with precise and potent anti-tumor immunity have become a key focus in the personalized vaccine campaign.</p><p id="Par83">The identification of suitable tumor-specific immunogenic antigens is crucial for eliciting specific CD8&#8201;+&#8201;CTL immunity against tumors. Cancer cell membranes contain the distinct TAA and TSA profiles of a particular patient, facilitating their application to the production of vaccines that do not necessitate antigen manufacturing or sequencing to meet tailored therapy goals [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par84">Utilizing cancer cell materials such as lysates and membranes as antigen libraries holds promise in precision medicine applications. For example, personalized F-PEI/ovalbumin (OVA) NPs can be prepared by simply mixing a protein antigen fluoropolymer with a model antigen (OVA) or tumor cell membrane antigen from surgically resected tumors. Through the toll-like receptor 4 (TLR4)-mediated signaling cascade, the F-PEI/OVA NPs drive DC maturation and facilitate antigen delivery into the cytosol of DCs, which in turn activates OVA-specific T-cell responses, ultimately preventing metastases [<xref ref-type="bibr" rid="CR66">66</xref>]. Autologous tumor cell lysates, presenting a comprehensive range of personal epitopes without the need for complex ex vivo processes such as sequencing, purification, and extraction, hold potential for developing personalized nanovaccines to prevent tumor metastasis [<xref ref-type="bibr" rid="CR67">67</xref>]. Such personalized in situ nanovaccines&#160;activate a multistep cascade of anti-tumor immune responses involving antigen cross-presentation, DC maturation, NK cells, and tumor-related macrophage repolarization along with CTL infiltration [<xref ref-type="bibr" rid="CR67">67</xref>]. To generate synergistic anti-tumor immune responses, nanoplatforms that are concurrently loaded with numerous different tumor antigens have been established, thereby abrogating metastasis [<xref ref-type="bibr" rid="CR32">32</xref>&#8211;<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par85">Selecting the appropriate antigens for tumor vaccines is crucial due to the remarkable impact of antigens on the safety and efficacy of a vaccine [<xref ref-type="bibr" rid="CR68">68</xref>]. Priority is given to antigens that are expressed specifically in tumor cells, with minimal or no expression in normal cells, in order to enhance the targeting of the vaccine and minimize potential side effects [<xref ref-type="bibr" rid="CR69">69</xref>]. Examples include TSAs and TAAs [<xref ref-type="bibr" rid="CR70">70</xref>]. Immunogenicity is another important consideration, and antigens are selected based on their ability to elicit an immune response in the host. This includes antigens that can activate T and B cells and produce specific antibodies [<xref ref-type="bibr" rid="CR71">71</xref>]. Regarding expression frequency, antigens that are highly expressed in a majority of tumor cells in patients have the ability to improve the therapeutic efficacy of the vaccine [<xref ref-type="bibr" rid="CR72">72</xref>]. Antigens should also be highly stable in tumor cells to ensure that they do not easily mutate or degrade during treatment [<xref ref-type="bibr" rid="CR73">73</xref>]. The HLA-binding affinity of the antigen is also an important indicator to be considered [<xref ref-type="bibr" rid="CR74">74</xref>]. The clinical relevance of the antigens should also be considered, and antigens that are associated with tumor progression, prognosis, or patient survival should be selected. Some antigens may undergo alterations during tumor progression or treatment, making antigen variability an important criterion to consider. Antigens should not be affected easily by the immune evasion mechanisms of tumor cells; particularly, those that are less likely to become ineffective due to mechanisms such as downregulation of MHC molecule expression should be selected [<xref ref-type="bibr" rid="CR75">75</xref>]. Regarding more practical considerations, selecting antigens that are easy to obtain and identify from tumor tissue or blood for clinical application and research is critical.</p><p id="Par86">Single-target vaccines may exhibit reduced efficacy due to tumor heterogeneity and antigen variability. Thus, strategies that utilize multi-target antigens are gradually gaining attention [<xref ref-type="bibr" rid="CR76">76</xref>]. Multi-target antigen tumor vaccines can stimulate a broader immune response by targeting multiple tumor antigens, thereby enhancing the opportunities to recognize and attack tumor cells [<xref ref-type="bibr" rid="CR76">76</xref>]. Tumor cells may evade immune surveillance by altering their surface antigens, and the multi-target strategy can overcome the tumor&#8217;s escape mechanisms, reducing the risk of immune evasion [<xref ref-type="bibr" rid="CR77">77</xref>]. Multi-target vaccines have the potential to perform better in different TMEs and adapt to the individualized needs of different patients. Additionally, targeting multiple antigens can enhance immune memory and promote long-term anti-tumor&#160;immunity [<xref ref-type="bibr" rid="CR77">77</xref>].</p><p id="Par87">Several mRNA vaccines exploit a multi-target design, thereby generating a stronger immune response. For instance, a personalized mRNA vaccine, autogene cevumeran (BNT122), has been developed for pancreatic cancer treatment in a phase I clinical trial [<xref ref-type="bibr" rid="CR78">78</xref>]. The vaccine operates by using mRNA to express 20 neoantigens derived from patients with pancreatic ductal adenocarcinoma (PDAC), administered via intravenous injection using lipid NPs (LNPs). Following treatment with this mRNA vaccine, the T cells in some patients with pancreatic cancer were activated for up to 3 years, and the immune response induced by the vaccine was linked to a decreased risk of recurrence. Various treatment options for PDAC have shown limited efficacy and high recurrence rates, attributed to low mutation rates in PDAC, which lead to few neoantigens and weak antigenicity. However, recent evidence suggests that a majority of PDAC cases contain more neoantigens than predicted previously. Therefore, the strategy of delivering neoantigens to patients may stimulate neoantigen-specific T cells, thereby improving treatment outcome.</p></sec><sec id="Sec8"><title>Adjuvant</title><p id="Par88">The capacity of formulations based on NPs to co-deliver immunostimulatory adjuvants and antigenic components is another benefit [<xref ref-type="bibr" rid="CR26">26</xref>]. This is crucial for appropriate immune activation given the spatial co-localization of the adjuvant and antigen to ensure uniform distribution to immune cells; overall, nanovaccine capacity facilitates a prompt and complete stimulation of antigen-specific immunity [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>]. By decreasing antigen dosages, shortening vaccination intervals, and boosting vaccine responses, adjuvants can influence the quantitative immune response [<xref ref-type="bibr" rid="CR81">81</xref>]. Adjuvants achieve excellent immune-active effects by influencing antigen storage, presentation, and targeting, as well as the internalization of antigens into DCs and regulation of immune pathways [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. Historically, on the basis of oil emulsions or aluminum salts (alum), adjuvants that have been encapsulated in the NP core or NPs themselves can possess inherent stimulatory properties (self-adjuvanting) [<xref ref-type="bibr" rid="CR29">29</xref>]. For instance, alum, a common adjuvant, relies on the injection site catalyzing inflammatory cell death and the generation of inflammatory cytokines in draining LNs for immune activation [<xref ref-type="bibr" rid="CR84">84</xref>].</p><p id="Par89">Adjuvants are typically classified as immunomodulatory agents and delivery systems. Immunostimulatory adjuvants include ligands for natural or synthetic pattern recognition receptor (PRR) agonists, cytokines, and natural polysaccharides. A majority of immunostimulatory adjuvants target PRRs, namely, nucleotide oligomerization domain-like receptors, retinoic acid-inducible gene-like receptors, C-type lectin receptors, cytosolic DNA receptors, scavenger receptors [<xref ref-type="bibr" rid="CR85">85</xref>], and ligands for TLRs [<xref ref-type="bibr" rid="CR29">29</xref>]. TLR ligands include cytosine&#8211;phosphate&#8211;guanosine oligonucleotides (CpG), poly (I: C) (TLR3 ligand), and stimulators of interferon gene (STING)&#160;agonists [<xref ref-type="bibr" rid="CR86">86</xref>].</p><p id="Par90">Owing to their capacity to transfer antigens into the cytosol, nanovaccines based on fluoropolymer have notably exhibited more efficacy in inducing anti-tumor immune responses when compared with that of vaccines employing traditional immune adjuvants, such as alum and CpG, facilitating antigen cross-presentation [<xref ref-type="bibr" rid="CR66">66</xref>]. Overall, immune activation, DC maturation, and tumor antigen release are all increased by the application of adjuvants that function as immune promoters.</p><p id="Par91">An effective adjuvant should meet the following criteria: high chemical purity, clear configuration, no induction of autoimmune responses, ability to activate vaccines, and promote strong humoral and T-cell immune responses [<xref ref-type="bibr" rid="CR87">87</xref>]. The adjuvant should be suitable for classification as a supplementary vaccine, enhancing immune memory or long-term immunity while remaining stable under varying conditions of time, storage, temperature, and pH [<xref ref-type="bibr" rid="CR88">88</xref>]. Additionally, the adjuvant should be biocompatible, biodegradable, safe, sterile, cost-effective, and easy to handle and store [<xref ref-type="bibr" rid="CR89">89</xref>].</p><p id="Par92">The selection of vaccine adjuvants, in addition to meeting basic standards, must primarily consider their effectiveness, specifically their ability to work in conjunction with the vaccine to achieve the optimal anti-tumor efficacy and therapeutic outcomes [<xref ref-type="bibr" rid="CR69">69</xref>]. To further improve the efficiency of tumor antigen cross-presentation and T lymphocyte activation and enhance the anti-tumor effects of nanovaccines, researchers are continuously developing new tumor vaccine adjuvants. For instance, the use of freely soluble STING agonists as immune adjuvants in tumor vaccine design presents challenges such as poor delivery efficiency to lymphoid organs and an inability to enhance the cytoplasmic release of antigens. These issues lead to suboptimal clinical efficacy for physically mixed formulations of tumor antigens and immune adjuvants. In response to these challenges, Chen et al. developed a novel ionizable iron nanoadjuvant library, which specifically amplifies the activation of STING signals in draining LNs, providing a new strategy for personalized tumor vaccine therapy [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec><sec id="Sec9"><title>Superior circulation life</title><p id="Par93">One of the main advantages of NP-based vaccines is their ability to safeguard the bioactivity of payloads that are enclosed. This outcome is important because of the bodily presence of several different types of enzymes that can degrade bioactive cargo and biomolecules in the circulatory system. Neoantigens and antigen peptides can be conjugated to a nanocarrier to encapsulate them, protecting the bioactivity and materials of the encapsulated payloads from host interactions during delivery [<xref ref-type="bibr" rid="CR90">90</xref>]. To increase the circulation of NPs, bioactive nanovaccines, for example, are coated with a polyethylene glycol (PEG) shell, which may be shed in response to a TME that is slightly acidic [<xref ref-type="bibr" rid="CR91">91</xref>].</p></sec><sec id="Sec10"><title>Specific targeting abilities</title><p id="Par94">NP uptake may be induced specifically and efficiently through the active targeting of particular cell types and introduction of functional surface ligands, which is an effective strategy for improving vaccine efficacy [<xref ref-type="bibr" rid="CR65">65</xref>]. Tumor cell-targeting moieties on the NP surface include antibodies, carbohydrates, peptides, integrin ligands, glucose, transferrin 3, folic acid, and other ligands [<xref ref-type="bibr" rid="CR23">23</xref>]. Advancements in technology have led to the incorporation of multiple targeting modalities into a single NP, further enhancing their targeting abilities [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par95">In the LNs and peripheral tissues, including skin and muscle, an abundance of immature DCs exists. MHC II accumulates in endosomes for antigen presentation, whereas MHC II and CD86 are both expressed at low levels by immature DCs in LNs. Such DCs are still able to present and absorb antigens, react to antigens in LNs, and mature in the field. DCs that dwell in the LNs are potential targets for vaccines. Additionally, these vaccines can provide anti-tumor immunological responses when adjuvants and antigens are administered to LNs. To induce DC maturity and migration to the draining LNs, where DCs can interact with and stimulate T cell response, biomimetic NPs, for example, target peripheral immature DCs through biomolecules [<xref ref-type="bibr" rid="CR92">92</xref>]. The advantages of existing cancer vaccination therapies have been hampered severely by the inadequate activation of the innate immune system in APCs and poor cytosolic transport of tumor antigens. Additionally, effective cytosolic delivery may be improved by designing NPs, potentially and significantly enhancing vaccine efficacy [<xref ref-type="bibr" rid="CR39">39</xref>]. Robust anti-tumor responses in this phase depend on DCs delivering antigens cytosolically and cross-presenting them through the MHC I antigen-presenting pathway [<xref ref-type="bibr" rid="CR66">66</xref>]. Conversely, the delivery of specific antigenic material into the cytosol circumvents endogenous cross-presentation systems and facilitates CD8&#8201;+&#8201;T-cell activation.</p><p id="Par96">Nanovaccines can also target specific organs, tissues [<xref ref-type="bibr" rid="CR93">93</xref>], or cell types [<xref ref-type="bibr" rid="CR94">94</xref>]. The surface protein corona and polymer composition, along with their organ-specific affinity, are important determinants of the in vivo destiny of polymersomes. For example, in mouse models of melanoma, acute myeloid leukemia, and melanoma lung metastasis, the spleen-targeted polymersome PH9-Aln-8020 has been employed as a systemic nanocarrier to co-deliver adjuvants and antigens, greatly increasing splenic immune responses [<xref ref-type="bibr" rid="CR95">95</xref>].</p><p id="Par97">Overall, NPs increase the cross-presentation, immunogenicity, and protection of antigens, as well as improve cellular and metastatic targeting abilities while enabling the controlled release of payloads. Such a multifaceted approach provides a robust platform for cancer vaccines to bolster systemic immune responses and reduce side effects, aiding in the development of more specialized medicines, including multidrug treatments. Overall, the enhancement of the local activity and specificity of NP delivery systems can improve the efficacy of precision medicine treatments, expanding their benefits to a wider population and ultimately improving overall patient outcomes.</p></sec></sec></sec><sec id="Sec11"><title>Nanovaccine designs aimed toward overcoming metastasis</title><p id="Par98">The use of NPs in personalized medicine is intended to harness detailed genomic information about the patient, account for existing comorbidities, and consider environmental exposures. These insights are then channeled toward the development of customized treatment. This approach aims to enhance drug specificity and optimize dosing, ensuring the accurate delivery of therapeutic agents to specific sites within the body. Conventional tumor therapeutic strategies host several limitations, whereas personalized nanoplatforms ensure the precise treatment of the metastatic cascade.</p><p id="Par99">To develop precise anti-metastasis nanovaccines, selecting suitable NP platforms tailored to specific needs is crucial. Here, we present a summary of the main characteristics, nanostructural aspects, and therapeutic and diagnostic benefits of several NP platforms that show promise for facilitating the development of anti-metastasis nanovaccines (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>, Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Halting and counteracting cancer metastasis through nanovaccines. Summary of promising NP platforms for the development of anti-metastasis nanovaccines, including organic, inorganic, semi-biogenic, and biogenic nanocarriers. Targeting the entire metastatic cascade, multiple individual anti-metastasis approaches have been created using multiple phase-specific nanovaccines. These vaccines target and remodel the microenvironment in primary tumors, as well as intercepting circulating tumor cells and remodeling the microenvironment in distant metastatic organs</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13045_2024_1628_Fig4_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Nanoparticle platforms beneficial for nanovaccine construction</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Classifications</th><th align="left" colspan="1" rowspan="1">Sub-classification</th><th align="left" colspan="1" rowspan="1">Nanoplatforms</th><th align="left" colspan="1" rowspan="1">Material properties</th><th align="left" colspan="1" rowspan="1">Advantages</th><th align="left" colspan="1" rowspan="1">Disadvantages</th><th align="left" colspan="1" rowspan="1">Refs.</th></tr></thead><tbody><tr><td align="left" rowspan="12" colspan="1">Synthetic nanocarriers</td><td align="left" rowspan="6" colspan="1">Organic nanoparticle platform</td><td align="left" colspan="1" rowspan="1">Dendrimer</td><td align="left" colspan="1" rowspan="1">High surface area; small nano-size, controllable biodegradation; functionally integratable</td><td align="left" colspan="1" rowspan="1">High payloads of drugs and imaging agents; controlled drug release</td><td align="left" colspan="1" rowspan="1">Difficult to purify or low yield</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR96">96</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Micelles</td><td align="left" colspan="1" rowspan="1">Biodegradable; functionally integratable</td><td align="left" colspan="1" rowspan="1">Multidrug co-loading and co-delivery; controlled drug release</td><td align="left" colspan="1" rowspan="1">Poor stability</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR103">103</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid-based NPs</td><td align="left" colspan="1" rowspan="1">Biocompatibility; stability; small nano-size; surface charge</td><td align="left" colspan="1" rowspan="1">Enhanced cellular uptake of vaccine components; stimulating innate immune responses; versatility; ease of manufacturing</td><td align="left" colspan="1" rowspan="1">Biological barriers; potential toxicity; immunogenicity; limited payload capacity</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR111">111</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid&#8211;polymer hybrid nanoparticles</td><td align="left" colspan="1" rowspan="1">Structural stability; tunable size and surface characteristics; payload flexibility; biocompatibility; sustained-release; protection of payload</td><td align="left" colspan="1" rowspan="1">Enhanced cellular uptake of vaccine components; Modulation of immune responses; improved stability and shelf Life; customizable formulations; potential for co-delivery; versatility in antigen presentation</td><td align="left" colspan="1" rowspan="1">Complex formulation and manufacturing; potential toxicity; immune recognition and clearance; storage and stability concerns; limited payload capacity; cost-effectiveness and widespread accessibility of vaccines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR120">120</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Nanogel</td><td align="left" colspan="1" rowspan="1">Surface functionalization; charge and zeta potential; softness and flexibility; long-term stability in suspension; controlled degradation</td><td align="left" colspan="1" rowspan="1">Encapsulation capability; non-toxicity; low immunogenicity; efficient cellular uptake; pH or enzyme-sensitive release; protection of antigens; enhanced circulation time; enhanced immune activation; surface functionalization; safety profile; controlled release</td><td align="left" colspan="1" rowspan="1">Complex production processes; batch variability; unintended immune responses; clearance by the immune system; limited penetration in solid tumors</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR125">125</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">RNA nanovaccines</td><td align="left" colspan="1" rowspan="1">RNA as a template; nanoparticle formulation; nucleotide sequence variability;</td><td align="left" colspan="1" rowspan="1">Innate immune stimulation; rapid development; customizable antigens; adaptability to variants; reduced production time; no risk of integration into host genome</td><td align="left" colspan="1" rowspan="1">Stability challenges; cold chain requirements; potential side effects; limited long-term stability</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR139">139</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">Inorganic nanocarriers</td><td align="left" colspan="1" rowspan="1">DNA nanovaccines</td><td align="left" colspan="1" rowspan="1">DNA as a genetic template; nanoparticle formulation; customizable antigens; innate immune stimulation</td><td align="left" colspan="1" rowspan="1">Rapid development; adaptability to variants; customizable genetic information; no cold chain requirements; safety profile</td><td align="left" colspan="1" rowspan="1">Limited transfection efficiency; risk of genomic integration; immune tolerance;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR144">144</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Gold (Au)</td><td align="left" colspan="1" rowspan="1">Biochemically insert; structurally expandable; functionally integratable</td><td align="left" colspan="1" rowspan="1">NIR-photothermal therapy; drug delivery, controlled release; NIR-photothermal imaging; NIR-photoacoustic imaging;CT imaging; two-photon luminescence imaging; optical coherence tomography imaging</td><td align="left" colspan="1" rowspan="1">Biocompatibility and toxicity; biodegradability; immunogenicity; synthesis complexity; cost; limited payload capacity</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR151">151</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Superparamagnetic iron oxide nanoparticles (SPIONs)</td><td align="left" colspan="1" rowspan="1">Magnetic properties; biocompatibility; size tunability; surface functionalization; stability</td><td align="left" colspan="1" rowspan="1">Targeted delivery; enhanced cellular uptake; imaging capabilities; theranostic potential; prolonged antigen presentation; heat generation for hyperthermia; reduced dose requirements</td><td align="left" colspan="1" rowspan="1">Potential toxicity; immunogenicity; biodistribution and clearance; risk of aggregation; synthesis complexity; potential for oxidative stress; cost</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR165">165</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Mesoporous silica (or silicon) nanoparticles (MSNs)</td><td align="left" colspan="1" rowspan="1">Porosity and surface area; tunable pore size; biocompatibility; surface functionalization; stability</td><td align="left" colspan="1" rowspan="1">High loading capacity; controlled release; enhanced stability of payload; customizable surface; biodegradability; adjuvant delivery</td><td align="left" colspan="1" rowspan="1">Potential toxicity; immunogenicity; synthesis complexity; cost</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR170">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Carbon nanoparticles</td><td align="left" colspan="1" rowspan="1">Versatility; high surface area; electrical conductivity; biocompatibility; tailorable surface chemistry</td><td align="left" colspan="1" rowspan="1">High payload capacity; stimulatory effects; stability; customizable surface; ease of functionalization</td><td align="left" colspan="1" rowspan="1">Potential toxicity; immunogenicity; biodistribution concerns; synthesis complexity;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR178">178</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Organic&#8211;inorganic hybrid NPs</td><td align="left" colspan="1" rowspan="1">Combine organic and inorganic NPs</td><td align="left" colspan="1" rowspan="1">Core&#8211;shell or composite structures; shape diversity; enhanced surface-to-volume ratio; tailorable chemical composition</td><td align="left" colspan="1" rowspan="1">Efficient encapsulation and protection of antigens; controlled release; targeted delivery to immune cells; simultaneous delivery of adjuvants; optimizable size for immune activation; surface functionalization; immunostimulatory properties</td><td align="left" colspan="1" rowspan="1">Complexity of design; batch-to-batch variability; inorganic component toxicity; clearance issues; unintended immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR180">180</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">Semi-biogenic nanocarriers</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Cell membrane-coated nanocarriers</td><td align="left" colspan="1" rowspan="1">Cell membrane composition; nanocarrier core</td><td align="left" colspan="1" rowspan="1">Biocompatibility; mimicking native cell properties; enhanced targeting and homing; reduced immunogenicity; stability and stealth properties; potential for immune modulation</td><td align="left" colspan="1" rowspan="1">Complexity of production; limited cargo capacity; batch-to-batch variability; biodegradability</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR185">185</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Virus-like particles</td><td align="left" colspan="1" rowspan="1">Protein composition; no genetic material</td><td align="left" colspan="1" rowspan="1">Safer than live vaccines; mimicry of viral structure; effective antigen presentation; broad applicability; induction of both humoral and cellular immunity; stability</td><td align="left" colspan="1" rowspan="1">Complex manufacturing process; potential batch-to-batch variability; limited induction of mucosal immunity; may require booster shots:</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR188">188</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Endogenous protein-based nanocarriers</td><td align="left" colspan="1" rowspan="1">Protein composition; structural stability:</td><td align="left" colspan="1" rowspan="1">Biocompatibility; reduced immunogenicity; native antigen presentation; diverse protein options; potential for multifunctionality; versatility</td><td align="left" colspan="1" rowspan="1">Potential for immune responses; Complexity of production; batch-to-batch variability; limited payload capacity;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR190">190</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">Biogenic nanosystems</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Exosome</td><td align="left" colspan="1" rowspan="1">Lipid bilayer composition; nanometer size; surface proteins; endogenous origin</td><td align="left" colspan="1" rowspan="1">Biocompatibility and rare immunogenicity; cellular targeting; antigen presentation; cargo diversity</td><td align="left" colspan="1" rowspan="1">Heterogeneity; limited payload capacity; biodistribution and clearance; immunosuppressive properties</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR301">301</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Outer membrane vesicles</td><td align="left" colspan="1" rowspan="1">Lipid bilayer structure; protein composition; nanometer size</td><td align="left" colspan="1" rowspan="1">Antigen presentation; bacterial membrane mimicry; stimulate both innate and adaptive immunity; bacterial source variety</td><td align="left" colspan="1" rowspan="1">Potential reactogenicity; heterogeneity; limited payload capacity; limited efficacy against intracellular pathogens</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR302">302</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Whole-cell nanovaccine</td><td align="left" colspan="1" rowspan="1">Cellular structure; diversity of antigens; nanometer size</td><td align="left" colspan="1" rowspan="1">Broad antigen presentation; cross-reactivity; adjuvant effects; memory immune responses; simplified formulation</td><td align="left" colspan="1" rowspan="1">Potential reactogenicity; risk of autoimmunity; limited control over antigen composition; risk of infection</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR303">303</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Artificial antigen-presenting cells</td><td align="left" colspan="1" rowspan="1">Polymeric or nanoparticle structure; surface modifications; incorporation of antigens and signaling molecules</td><td align="left" colspan="1" rowspan="1">Enhanced antigen presentation; customizable design; consistent antigen presentation; tunable immune response; inclusion of co-stimulatory signals; induction of memory responses</td><td align="left" colspan="1" rowspan="1">Biocompatibility and safety concerns; complex production processes; limited understanding of immune interactions; risk of immunogenicity</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR304">304</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Neoantigen/adjuvant nanovaccine</td><td align="left" colspan="1" rowspan="1">Nanoscale size; patient's cancer mutations; nature of adjuvants; biodegradability;</td><td align="left" colspan="1" rowspan="1">Personalized approach; induction of robust immunity; reduced toxicity; memory Immune responses; versatility</td><td align="left" colspan="1" rowspan="1">Complex production; heterogeneity; limited availability of neoantigens; tumor escape mutations; immune suppression in the tumor microenvironment</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR131">131</xref>]</td></tr></tbody></table></table-wrap></p><sec id="Sec12"><title>Synthetic NANOCARRIERS</title><sec id="Sec13"><title>Organic NP platforms</title><p id="Par100"><italic toggle="yes">Dendrimers:</italic> Dendrimers are intricate, highly branched polymers known for their dense molecular architecture and a multitude of functional end groups. They are composed of a central core molecule that gives rise to several branches, forming a distinct and hierarchical architecture [<xref ref-type="bibr" rid="CR96">96</xref>&#8211;<xref ref-type="bibr" rid="CR98">98</xref>]. These branches comprise monomers or repetitive units joined chemically in a controlled manner. Combining hydrophilic and hydrophobic medications, contrast agents, antibodies, peptides, and genes can be administered with dendrimers via physical encapsulation or environmentally responsive chemical bonding (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). This facilitates efficient delivery to tumor sites, leveraging high permeability, prolonged retention, or targeted delivery factors. Finally, drug release is achieved through carrier swelling or the cleavage of sensitive chemical bonds. The inherent flexibility of dendrimers allows for the development of molecular vaccines that exhibit extreme specificity and predictability. Additionally, the immune-stimulating (adjuvant) qualities of dendrimers highlight their use as potential substrates for various medicinal applications, including vaccine development.</p><p id="Par101">Symmetrically branching dendrimers and asymmetrical MAP systems have been studied and developed in the context of their usage as vaccinations [<xref ref-type="bibr" rid="CR99">99</xref>]. For example, polyamidoamine dendrimer modified with guanidinobenzoic acid was found by Xu et al. to be an efficient protein carrier, facilitating the delivery of protein antigens and the efficient presentation of antigens (i.e., by DCs) for cross-presentation [<xref ref-type="bibr" rid="CR100">100</xref>]. By applying GD2 or GD3 glycomimetic analogs to a dendrimer core, Tong et al. created a synthetic vaccine that stimulates specific humoral and cellular responses. This vaccine was shown to be effective against several malignancies that express GD2 or GD3 [<xref ref-type="bibr" rid="CR101">101</xref>]. Furthermore, a programmed cell death ligand 1 (PD-L1) antibody-conjugated PAMAM dendrimer nanosystem has been applied toward the enhancement of PD-1/PD-L1 pathway-based immunotherapy, effectively preventing breast cancer (BC) [<xref ref-type="bibr" rid="CR102">102</xref>].</p><p id="Par102"><italic toggle="yes">Micelles:</italic> Micelles are self-assembled aggregates of surfactants or amphiphilic polymer molecules that are driven by thermodynamic forces. Consequently, micelles have a relatively sizable hydrophobic core, which aids in the encapsulation and transport of hydrophobic drugs (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR103">103</xref>&#8211;<xref ref-type="bibr" rid="CR105">105</xref>]. Micelle-based delivery systems are remarkably versatile in their ability to carry various payloads, including DNA, proteins, peptides, medicines, and small interfering RNA (siRNA) [<xref ref-type="bibr" rid="CR106">106</xref>&#8211;<xref ref-type="bibr" rid="CR108">108</xref>].</p><p id="Par103">A recent study demonstrated the use of a polyethyleneimine-based self-assembled polymeric micelle delivery system for the injection of mRNA vaccines [<xref ref-type="bibr" rid="CR109">109</xref>]. Additionally, through the targeted delivery of immune-stimulating chemicals and tumor antigens, micelles hold promise to boost the effectiveness of cancer vaccines and to provoke robust immune reactions against tumors. Moreover, Ren et al. described a method formulated from block copolymers that have been chemically tailored with a hydrophobic, self-degradable linkage for delivering short peptide antigens to DCs. Following alteration, the micelles rapidly and efficiently bonded with the adjuvants and antigens in an aqueous solution through covalent bonds. Intracellular glutathione cleaved the polymer disulfide bond upon uptake by APCs, resulting in the release of pristine antigens and the increased expression of co-stimulatory molecules. In human papilloma virus, E6/E7 subcutaneous, and lung metastatic tumor models and murine B16OVA tumor models, the generated antigen-specific CD8<sup>+</sup> T lymphocytes demonstrated potent tumor cell-killing effectiveness. Overall, vaccine trafficking can be observed by delivering vaccines to LNs [<xref ref-type="bibr" rid="CR110">110</xref>].</p><p id="Par104"><italic toggle="yes">Lipid-based NPs:</italic> Liposomes are a type of spherical, self-enclosing vesicles that possess an aqueous core surrounded by a lipid bilayer membrane. The distinctive architecture of liposomes allows for the simultaneous encapsulation and delivery of agents of varying sizes, particularly hydrophilic and hydrophobic drugs, which are enclosed within the core and the shell, respectively (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR111">111</xref>]. Myocet (liposomal doxorubicin) is an excellent example of such an NP, which, when used in combination with cyclophosphamide, has received clearance for addressing the treatment of metastatic BC in Europe and Canada [<xref ref-type="bibr" rid="CR112">112</xref>]. Another example is Vyxeos (liposomal daunorubicin and cytarabine), which was designed to treat acute myeloid leukemia and is available in Europe and the US [<xref ref-type="bibr" rid="CR113">113</xref>]. Moreover, liposomes exhibit significant flexibility and deformability, allowing them to permeate the barrier of stacked corneocytes, which can be 10&#8211;20-mm thick [<xref ref-type="bibr" rid="CR111">111</xref>].</p><p id="Par105">Despite advancements in vaccine adjuvants, the development of suitable vaccinations for cancer treatment remains a challenge. Owing to their versatility, liposomes have been demonstrated to be highly effective as adjuvants and delivery systems. Additionally, they are expected to find expanded applications in this context. Notably, LNP technology facilitated mRNA vaccines in combating the SARS-CoV-2 epidemic [<xref ref-type="bibr" rid="CR114">114</xref>]. However, in the context of cancer treatment, its application warrants further exploration. AS015, a liposomal adjuvant produced by GSK, has been used as an adjuvant for MAGE-A3-positive melanoma immunotherapy [<xref ref-type="bibr" rid="CR115">115</xref>]. Arabi et al. reported a novel cancer vaccination approach using C3 liposomes to deliver the MUC1 antigen and immunostimulatory compounds to APCs. Their findings demonstrate enhanced immune responses to MUC1, particularly when combined with TLR agonists, suggesting the feasibility of antigen-specific cancer immunotherapy [<xref ref-type="bibr" rid="CR116">116</xref>].</p><p id="Par106"><italic toggle="yes">Lipid&#8211;Polymer Hybrid NPs:</italic> Polymeric (such as dendrimers and micelles) and LNPs for the delivery of anti-cancer agents, especially in the field of cancer vaccines, have specific advantages associated with their use, as previously discussed. Lipid&#8211;polymer hybrid NPs (LPHNPs) consist of three primary components: a hydrophilic polymeric shell on the outside, a central lipid layer, and an interior polymer core [<xref ref-type="bibr" rid="CR117">117</xref>]. Treatments and antigens, such as nucleic acids or peptides, could be effectively enclosed within a polymer core. The central lipid layer serves as a protective barrier during preparation, preventing the leakage of chemicals. It functions as a molecular fence, restricting the inward flow of water and preventing the breakdown of the polymer, thereby enabling the continuous release of the encapsulated substance [<xref ref-type="bibr" rid="CR118">118</xref>]. The external hydrophilic polymeric shell typically consists of PEG, which enhances steric stability, and extends the in vivo half-life of the LNPs, thus facilitating their ability to target specific ligands [<xref ref-type="bibr" rid="CR119">119</xref>]. Furthermore, LPHNPs demonstrate higher in vivo cellular delivery effectiveness than NPs and liposomes. Designed to offer stability, high cargo loading, enhanced biocompatibility and medication half-life, rate-limiting controlled release, and therapeutic effectiveness while minimizing drawbacks, LPHNPs offer a promising approach for cancer therapy [<xref ref-type="bibr" rid="CR120">120</xref>].</p><p id="Par107">The use of CD44-targeting LPHNPs for the delivery of vaccines within tumors has been explored extensively. One example is the development of the CD44-targeting DOTAP-poly (lactic-co-glycolic acid) (PLGA) nanovaccine, which aims to elicit a robust immunological response primarily through cell-mediated mechanisms. However, the approach has been associated with significant cytotoxicity, raising concerns about its safety profile. Additionally, this particle formulation has been linked to a site-specific OVA antigen release of 80%. LPHNPs coated with hyaluronic acid have been shown to facilitate the controlled release of both drugs and antigens from NPs [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]. Zhu et al. designed mannose-functionalized lipid-hybrid polymersomes (MAN-IMO-PS) for the co-delivery of the OVA antigen both inside and outside the lipid layer. These polymersomes encapsulate the TLR7/8 agonist imiquimod within the hydrophobic membrane, while the TLR4 agonist monophosphoryl lipid A is incorporated into the lipid layer. The objective of this adaptable nanovaccine was to enhance vaccination efficacy by concurrently triggering immunological responses. Upon effective internalization by DCs through TLR4 ligation and mannose targeting, MAN-IMO-PS markedly increased cytokine production and cross-presentation [<xref ref-type="bibr" rid="CR123">123</xref>].</p><p id="Par108"><italic toggle="yes">Nanogel:</italic> As reported by Soni et al. [<xref ref-type="bibr" rid="CR124">124</xref>], nanogels (NGs) are three-dimensional nanoscale hydrogel materials that consist of cross-linked swellable polymer networks capable of retaining a significant amount of water without dissolving in the aqueous environment. The gel-like properties of NGs enable them to swell when exposed to physiological fluids. This characteristic provides flexibility, enabling them to closely approach the target site and improve the dispersion of pharmaceuticals and other healing substances. Furthermore, NGs can be designed to release drugs in response to specific physiological conditions [<xref ref-type="bibr" rid="CR125">125</xref>]. NG-based cancer vaccines have shown great potential as customizable immune carriers. They improve the pharmacokinetics of antigens and adjuvants, as well as provide a larger surface area, enhancing antigen interaction with APCs and enabling the introduction of other immunomodulatory signals to enhance immune system reaction. NG-based vaccines have shown positive results in clinical and animal studies. Personalized cancer vaccines based on NGs are highly promising for inducing strong and lasting anti-tumor responses in cancer immunotherapy.</p><p id="Par109">NG and nanocomplex formulations have been used as cancer vaccine platforms. Researchers have engineered a versatile nanogel-based vaccine designed to provoke a strong and enduring immune reaction. They have integrated CCL21a with ExoGM-CSF&#8201;+&#8201;Ce6 (which are tumor cell-derived exosomes loaded with GM-CSF mRNA and featuring the sonosensitizer chlorin e6 [Ce6]. on their exterior) and then combined this with nanoclay and gelatin methacryloyl to create a hydrogel known as CCL21a/ExoGM-CSF&#8201;+&#8201;Ce6 @nanoGel. With these dual programmed components, the innovative modular nanogel vaccine effectively suppresses tumor progression and spread by redirecting metastatic cancer cells from the tumor-draining lymph nodes (TdLN) to the nanogel, neutralizing the entrapped tumor cells and triggering a long-lasting and potent immunotherapeutic response in a synchronized fashion [<xref ref-type="bibr" rid="CR126">126</xref>].</p><p id="Par110">A self-immolative NG vaccine has been designed for traceless intracellular release and subsequent immune system activation. This NG is constructed from three cytosine-rich oligonucleotide building blocks that self-assemble into a precisely sized NG scaffold. Concurrently, the acid-labile linkers undergo hydrolytic cleavage, liberating the conjugated agonists and antigenic peptides in their native, unmodified forms [<xref ref-type="bibr" rid="CR127">127</xref>].</p><p id="Par111">An NP complex consisting of cholesteryl pullulan and the NY-ESO-1 antigen protein (CHP-NY-ESO-1) exhibits multiple epitope peptides to both MHC class I and II pathways, which triggers responses in CD8<sup>+</sup> and CD4<sup>+</sup> T cells. Takeshi et al. carried out a phase 1 clinical trial involving the administration of CHP-NY-ESO-1 (a cancer vaccine) alongside poly-ICLC (an immune-stimulating adjuvant for the vaccine) to patients suffering from advanced or recurrent esophageal cancer. The trial resulted in all participants (100%) developing antibody responses after a median of 2.5 vaccine doses [<xref ref-type="bibr" rid="CR128">128</xref>].</p><p id="Par112">Neoantigen/Adjuvant Nanovaccines: Neoantigens are unique proteins or peptides resulting from non-synonymous gene mutations in tumor cells that offer distinct antigenic properties and high reactivity to the immune system [<xref ref-type="bibr" rid="CR129">129</xref>]. Owing to their specificity, potential for personalization, and immune responsiveness, neoantigens have emerged as crucial targets in tumor immunotherapies, especially in therapeutic vaccines [<xref ref-type="bibr" rid="CR130">130</xref>]. Tumor neoantigens are effective at activating a patient&#8217;s immune system and eliciting anti-tumor immune responses [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. Such advantages encompass the enhancement of antigen stability, precise targeting of LNs, and facilitation of APC uptake, alongside facilitating lysosome elude and cross-presentation of antigens. The transportation of substances such as PLGA, aluminum NPs, or mesoporous silicon vectors can enhance the immunogenicity of neoantigen peptides significantly [<xref ref-type="bibr" rid="CR132">132</xref>&#8211;<xref ref-type="bibr" rid="CR135">135</xref>].</p><p id="Par113">Nucleic Acid Nanovaccines:Over the last 10&#160;years, vaccines based on nucleic acids have emerged as promising contenders to conventional subunit vaccines and those derived from live or attenuated viruses. Vaccines based on nucleic acids have several advantages, including being simple to manufacture, safe, and adaptable, and having the capacity to provoke both antibody-mediated and cell-mediated immune reactions [<xref ref-type="bibr" rid="CR136">136</xref>, <xref ref-type="bibr" rid="CR137">137</xref>]. Despite such benefits, developing nucleic acid-based cancer immunotherapy vaccines has encountered several challenges. However, advancements in cancer nanovaccine technology utilizing nanobiomaterials provide viable approaches for enhancing the efficacy of nucleic acid treatments.</p><p id="Par114"><italic toggle="yes">Nanobiomaterial-based RNA Cancer Nanovaccines:</italic> Nanobiomaterials play a dual role in RNA cancer nanovaccines by serving as gene carriers for tumor antigen expression and as immune adjuvants that activate APCs through interactions with PRRs [<xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR139">139</xref>]. In recent years, advancements have been made in RNA cancer nanovaccines utilizing nanobiomaterials, which have shown promise as replacements for conventional immunizations. These improvements are credited to their capacity to protect RNA molecules against degradation by ribonucleases, diminish the immunogenicity of RNA, and enhance RNA transport into APCs for antigen production [<xref ref-type="bibr" rid="CR140">140</xref>&#8211;<xref ref-type="bibr" rid="CR142">142</xref>]. For instance, Zhang et al. have engineered a biomimetic nanovaccine edited with long noncoding RNA in combination with anti-TIM-3 to bolster immune checkpoint blockade (ICB) immunotherapy. This approach facilitated simultaneous enhancement of antigen cross-presentation and alleviation of T-cell suppression, thereby strengthening treatment efficacy [<xref ref-type="bibr" rid="CR143">143</xref>].</p><p id="Par115"><italic toggle="yes">Nanobiomaterial-based DNA Cancer Nanovaccines:</italic> DNA vaccines utilize plasmid DNA-encoding antigen sequences, which are injected into the body and are often combined with electroporation and transduction. Cells at the site of injection are incorporated into the nucleus, where the antigen is translated and then recognized by the body to mount an immune reaction. However, the method has drawbacks, including low efficiency and a risk of mutation due to DNA insertion. In contrast, mRNA vaccines do not need to enter cells; however, mRNA is not stable and is degraded easily, requiring more effective preparation and storage methods.</p><p id="Par116">Third-generation DNA vaccines comprise closed circular DNA plasmids housing antigen-coding sequences and immunomodulatory molecules. These plasmids prompt transfected cells to produce the desired antigens, thus triggering immune responses [<xref ref-type="bibr" rid="CR144">144</xref>]. DNA vaccines offer numerous advantages, such as being easy to produce, safe, stable at room temperature for transport, and cost-effective, in addition to exhibiting reduced risk of hypersensitivity reactions and replication interference. Furthermore, they provide an opportunity to immunize against multiple pathogens using a single vaccine [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec14"><title>Inorganic NPs</title><p id="Par117"><italic toggle="yes">Gold:</italic> Gold NPs (AuNPs) possess two highly appealing characteristics for application in biomedicine. First, they offer multivalent surface coordination, allowing for simple surface conjugation using amines, carboxylates, and thiolates with medications and target compounds. This synchronization has been shown to facilitate accurate drug delivery and regulated drug release [<xref ref-type="bibr" rid="CR145">145</xref>&#8211;<xref ref-type="bibr" rid="CR148">148</xref>]. Second, photothermal treatment (PTT) effectively leverages the surface plasmon resonance phenomenon of AuNPs. By adjusting the surfaces, sizes, and shapes of these NPs, the plasmon absorption wavelengths could be adjusted to target the near-infrared (NIR) spectrum, increasing their suitability for NIR-PTT applications.</p><p id="Par118">AuNPs, which are biocompatible and straightforward to produce, represent an alternative type of nanocarrier for vaccine delivery. Using seed-mediated growth techniques, AuNPs can be manufactured in various sizes (i.e., 1&#8211;150&#160;nm) and shapes (i.e., spheres, rods, and cubes). Moreover, the surface of AuNPs can be chemically bound to stabilizers (i.e., surfactants) or absorbed, allowing for additional surface modifications with ligands or other compounds [<xref ref-type="bibr" rid="CR149">149</xref>]. Notably, the size and structure of AuNPs affect the generation of antibodies and the release of cytokines, among other immune responses [<xref ref-type="bibr" rid="CR150">150</xref>&#8211;<xref ref-type="bibr" rid="CR152">152</xref>].</p><p id="Par119">For instance, Cai et al. developed an innovative composite material consisting of Fe<sub>3</sub>O<sub>4</sub> supported by gold nanoparticles derived from biogenic lignin to evaluate its effectiveness against human lung cancer. This material was also studied in its role in the catalytic reduction of aromatic nitro compounds [<xref ref-type="bibr" rid="CR153">153</xref>]. In contrast, Zhang et al. used human serum albumin (HSA@AuNPs) to establish a self-generated AuNP template. Specifically, peptides were administered via HSA@AuNPs, thereby enhancing the immune response and integrated PTT using immunotherapy. Furthermore, under NIR irradiation, studies performed both in vitro and in vivo have demonstrated that nanoparticles can facilitate the conversion of light into heat, resulting in tumor ablation and boosting anti-tumor immunity. In conclusion, such NPs can enhance the product yield, reduce flux, boost interactant transition efficiency, and insulate hazardous agents, all of which lay a foundation for a novel, easy-to-use method for the environmentally sustainable synthesis of nanovaccines [<xref ref-type="bibr" rid="CR154">154</xref>].</p><p id="Par120"><italic toggle="yes">Superparamagnetic Iron Oxide NPs:</italic> Iron oxide cores, which make up superparamagnetic iron oxide NPs (SPIONs), can be directed to a specific spot with the use of external magnets. Superparamagnetism, irreversibility in high fields, elevated saturation fields, extra anisotropy contributions, and loops that shift after field cooling are among their fascinating properties [<xref ref-type="bibr" rid="CR155">155</xref>]. These properties render SPIONs advantageous as a platform for nanomedicine. These benefits include superparamagnetism for magnetic targeting, magnetothermal action for hyperthermia therapy, and good biodegradability (because of their acid-soluble nature) [<xref ref-type="bibr" rid="CR156">156</xref>&#8211;<xref ref-type="bibr" rid="CR162">162</xref>].</p><p id="Par121">In the context of cancer vaccines, OVA-bound SPIONs (with a size and zeta potential of approximately 200&#160;nm and&#8201;&#8722;&#8201;22&#160;mV, respectively) have been reported as effective vaccine delivery platforms and immune potentiators, as evidenced by their ability to induce cytokine production and activate immune cells [<xref ref-type="bibr" rid="CR163">163</xref>]. Additionally, SPIONs can serve as platforms for the magnetic guidance of immune cells, including T cells, to a target area. Ortega et al. developed SPIONs coated with dextran (6&#160;kDa), 3-aminopropyl-triethoxysilane, or dimercaptosuccinic acid. These SPIONs exhibited a zeta potential and size between&#8201;&#8722;&#8201;34 and 38&#160;mV and 82 and 120&#160;nm, respectively. When subjected to an external magnetic field, they aided in the in vivo migration of T cells [<xref ref-type="bibr" rid="CR164">164</xref>]. Furthermore, because of their adaptability and modular design, SPIONs exhibit extensive multifunctionality. Moreover, they have shown great safety, biocompatibility, and the capacity to transport drugs (i.e., in the context of chemotherapy and immune checkpoint inhibitors) while also possessing magnetic properties that facilitate their application in the context of magnetic hyperthermia and magnetic resonance imaging [<xref ref-type="bibr" rid="CR165">165</xref>]. Copolymers that are acid-ionizable are combined with SPIONs and MSA-2 to form iron-based nanoadjuvants that stimulate STING activation in the lymph nodes. The top-performing iron nanoadjuvant (PEIM) efficiently delivers the model antigen OVA to CD169<sup>+</sup> antigen-presenting cells (APCs) and enhances cross-presentation of the antigen. This leads to a substantial 55-fold enhancement in the frequency of antigen-specific CD8<sup>+</sup> cytotoxic T lymphocyte responses compared to the use of soluble antigen alone. Immunization with the PEIM@OVA nanovaccine generates powerful and enduring anti-tumor immunity, preventing the metastasis of lung tumors and eradicating already-established tumors [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par122"><italic toggle="yes">Mesoporous Silica (or Silicon) NPs:</italic> Mesoporous silica (or silicon) NPs (MSNs) are spherical NPs with several pores separated by a solid framework [<xref ref-type="bibr" rid="CR166">166</xref>]. They offer a range of unique advantages. First, they feature extensive mesoporosity, with adjustable pore sizes (ranging from 2 to 20&#160;nm), allowing for precise control over drug release. Second, a sizable drug payload is made possible by their huge pore capacity and high surface area. Third, the MSNs&#8217; particle size could be customized (from 10 to 1000&#160;nm), and it is simple to functionalize their surfaces to enable precise medication distribution. Finally, MSNs possess flexible nanostructures and excellent biocompatibility and biodegradability, as shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR167">167</xref>&#8211;<xref ref-type="bibr" rid="CR170">170</xref>].</p><p id="Par123">H-XL-MSNs, created by coating poly(ethyleneimine) solution-coated core&#8211;shell MSNs, exhibit high loading efficiency for proteins and enhanced DC activation. H-XL-MSNs have shown promise as a potential cancer vaccine, resulting in enhanced tumor growth suppression and higher mouse survival rates [<xref ref-type="bibr" rid="CR171">171</xref>]. Another study investigated employing MSNs with exceptionally large pores (XL-MSNs) to directly activate host DCs for cancer vaccines, thereby circumventing various limitations of current DC-based cancer vaccines. Antigen proteins and TLR 9 agonists can be loaded more efficiently using XL-MSNs, thereby enhancing DC activation and antigen presentation and stimulating antigen-specific CTLs. The high memory T-cell count of the resultant vaccination has demonstrated the ability to curb tumor growth and avert relapses in mouse model [<xref ref-type="bibr" rid="CR172">172</xref>]. Incorporating photothermal and mildly immunostimulatory porous silicon@Au nanocomposites as the particulate core of a biomimetic nanovaccine boosts its biosafety and therapeutic efficacy in immunotherapy against solid tumors. This innovative nanovaccine, serving as a PTT agent, when combined with other immunotherapies, markedly inhibits the expansion and metastasis of established solid tumors by provoking anti-tumor immune reactions and counteracting their suppressive microenvironments [<xref ref-type="bibr" rid="CR173">173</xref>].</p><p id="Par124">Many treatment combinations are being considered for boosting the effectiveness of cancer immunotherapy. Specifically, immune checkpoint inhibitors and TME reprogramming, such as M2-to-M1-like macrophage restoring the polarity of tumor-associated macrophages, show promise in enhancing the effectiveness of approved immunotherapies.</p><p id="Par125"><italic toggle="yes">Carbon NPs:</italic> Carbon NPs (CNPs), which include carbon dots, mesoporous CNPs, nanographene oxide, and carbon nanotubes, all provide two unique benefits in nanomedicine: [<xref ref-type="bibr" rid="CR1">1</xref>]. Outstanding surface area: these NPs provide an exceptionally high surface area, facilitating the efficient delivery of drugs and therapeutics [<xref ref-type="bibr" rid="CR2">2</xref>]. Effective absorption of NIR light: CNPs exhibit efficient NIR optical absorption capabilities, making them suitable for imaging and NIR-PTT. This allows low-energy NIR lasers to generate substantial thermal energy because of their high photothermal conversion efficiencies [<xref ref-type="bibr" rid="CR174">174</xref>&#8211;<xref ref-type="bibr" rid="CR177">177</xref>]. The unique molecular structure of CNPs, characterized by alternating polycyclic aromatic hydrocarbons with only six-membered carbon rings, enables carbon nanotubes and nanographene oxide to absorb significant amounts of several photosensitizers, including doxorubicin, CPT, and porphyrins, as well as aromatic molecular medications. This is achieved through non-covalent <italic toggle="yes">&#960;</italic>&#8211;<italic toggle="yes">&#960;</italic> stacking interactions, resulting in an exceptional drug-loading capacity [<xref ref-type="bibr" rid="CR178">178</xref>].</p><p id="Par126">Wang et al. created novel oral vaccine adjuvants using hydrophobic CNPs (C1) with silica and sucrose. Characterized by their size (470&#160;nm) and large mesopores and macropores [40&#8211;60&#160;nm), these adjuvants are highly suitable for carrying antigens. For example, eliciting a potent mucosal immune response, observed in intestinal, salivary, and vaginal secretions, was demonstrated via an immunoglobulin G titer to reach levels comparable to those following oral immunization, after the injection of an antigen mixed with Freund's complete adjuvant with bovine serum albumin loaded in C1. Moreover, it induced both Th1- and Th2-mediated responses, indicating its potential utility in vaccine adjuvant design to enhance immune modulation [<xref ref-type="bibr" rid="CR179">179</xref>].</p></sec><sec id="Sec15"><title>Organic&#8211;inorganic Hybrid NPs</title><p id="Par127">Organic&#8211;inorganic hybrid NPs take advantage of the structural stability and versatile functionalities of inorganic materials while incorporating the flexibility and tunability of organic components, creating systems with enhanced performance compared to their purely organic or inorganic counterparts [<xref ref-type="bibr" rid="CR180">180</xref>]. Considering properties, these NPs are gaining popularity in the development of cancer vaccines, acting as platforms for delivery of antigens or adjuvants to provoke strong immune reactions.</p><p id="Par128">A recent study [<xref ref-type="bibr" rid="CR181">181</xref>] reported an organic&#8211;inorganic hybrid NP-based in situ cancer vaccine, which achieved outstanding cancer immunotherapy by simultaneously neutralizing reactive oxygen species and triggering the STING pathway in DCs. This vaccine triggers the STING signaling pathway via the combined action of Mn2&#8201;+&#8201;and SN38, while also neutralizing existing H<sub>2</sub>O<sub>2</sub> in the TME and Mn<sup>2+</sup>-catalyzed hydroxyl radicals (&#8226;OH) through the antioxidant properties of diselenide and polyphenol. This strategy effectively activates dendritic cells (DCs), shields them from oxidative stress, and subsequently leads to significant activation of downstream T-cells and the establishment of systemic anti-tumor immunity.</p><p id="Par129">Chen et al. [<xref ref-type="bibr" rid="CR182">182</xref>] designed organic&#8211;inorganic hybrid hollow MSNs as a vaccine delivery platform, incorporating dopamine surface modification to enhance the ability to regulate biodegradation and drug delivery. The molecular backbone, featuring disulfide bonds, enabled stepwise degradation within the reductive TME. The organic&#8211;inorganic hybrid hollow MSNs exhibited an effective sustained-release profile, significantly suppressed tumor cell proliferation, and achieved notable anti-tumor effects in vivo via dual-reaction release mechanisms triggered by the TME. Zhuang et al. [<xref ref-type="bibr" rid="CR183">183</xref>] engineered lipid-enveloped zinc phosphate hybrid nanoparticles to encapsulate peptides (TRP2180-188/ HGP10025-33) along with toll-like receptor 4 agonists. The lipid-coated zinc phosphate hybrid NP vaccine, measuring 30&#160;nm with an outer lipid layer, demonstrated anti-tumor immunity by boosting the secretion of cytokines and enhancing the CD8<sup>+</sup> T-cell response in vitro. The vaccine's anti-tumor efficacy was confirmed further through its performance in prophylactic, therapeutic, and metastatic melanoma tumor models, outperforming both free antigens and single peptide-loaded nanovaccines.</p></sec></sec><sec id="Sec16"><title>Semi-biogenic nanocarriers</title><p id="Par130">Semi-synthetic nanocarriers partially blend biogenic and synthetic components. When designed effectively, these semi-synthetic nanocarriers can inherit certain attributes of biogenic nanocarriers, including biocompatibility and minimal toxicity. Simultaneously, they can incorporate the capabilities of synthetic NPs, such as their ability to be readily and consistently manufactured on a large scale. Within this context, we will explore three categories of semi-synthetic nanocarriers, concentrating particularly on nanocarriers derived from endogenous protein, VLPs, and nanocarriers coated with cell membranes.</p><sec id="Sec17"><title>Cell Membrane-coated nanocarriers</title><p id="Par131">Cell membrane-coated nanocarriers consist of a synthetic core, typically composed of inorganic or organic materials enveloped within a natural cell membrane. This design combines elements of artificial synthesis and biological origin, hence earning the description &#8220;semi-biogenic.&#8221; Recently, these nanocarriers, which mimic the properties of cell membranes, have emerged as promising platforms for medication delivery [<xref ref-type="bibr" rid="CR184">184</xref>, <xref ref-type="bibr" rid="CR185">185</xref>]. The process involves extracting desired cell membranes, which are then used to coat NP surfaces or construct nanocarriers. Notably, the potential for cancer nanovaccines is rooted in the ability of NPs (i.e., coated with cancer cell membranes) to encapsulate a broad spectrum of antigens from cancer cell membranes. Furthermore, a strong anti-cancer immune response that resembles the reactions observed during bacterial infections could be triggered by blending an adjuvant with cell membrane antigens and specific ligands. Nanovaccines based on cell membrane camouflage exhibit significant therapeutic applicability; this outcome can be attributed to the fact that these vaccines are based on the use of the cancer cells of an individual patient as a source, simplifying the modification of adjuvants and cell membrane materials.</p><p id="Par132">Fang et al. used the tumor cell line MDA-MB-435, which is known for its homotypic aggregation in vivo, to demonstrate thecancer-homing capabilities of NPs coated with cancer cell membranes. Applying a cell membrane to NPs augmented cellular adherence to the source cells significantly when compared with that of conventional NPs. Reduced particle binding was observed in red blood cell NPs, explained by the increased particle&#8211;cell adhesion to the homotypic cell membrane. MDA-MB-435 cancer cell membrane-coated NPs showed a somewhat higher affinity for human foreskin fibroblasts than bare PLGA cores, highlighting the cancer cell specificity of NPs [<xref ref-type="bibr" rid="CR186">186</xref>]. Taken together, these studies underline the considerable potential of cell membrane-coated NPs in nanovaccines.</p><p id="Par133">ZIF-8 NPs containing epirubicin, glucose oxidase, and hemin were coated with calreticulin produced through tumor cell membrane overexpression to create mEHGZ, a self-amplified biomimetic nanosystem. When this nanosystem was used in conjunction with an anti-PD-L1 antibody, lung metastasis and tumor growth were significantly inhibited [<xref ref-type="bibr" rid="CR187">187</xref>].</p></sec><sec id="Sec18"><title>VLPs</title><p id="Par134">VLPs represent another category of semi-synthetic nanocarriers with considerable promise as cancer nanovaccines. VLPs possess a structural resemblance to viruses but do not contain viral genetic material, making them non-contagious. These nanocarriers self-assemble from structural viral proteins expressed in vitro. VLPs are particularly appealing as nanovaccines because of their adaptability to tailored engineering, enabling the precise manipulation of both VLPs and antigens present on their surfaces. Moreover, the design of repetitive antigenic structures in VLPs facilitates efficient immune activation. VLPs are internalized efficiently by APCs, and when engineered with specific antigens, they can initiate enduring adaptive immune responses [<xref ref-type="bibr" rid="CR188">188</xref>].</p><p id="Par135">S100A9, a notable inflammatory regulator, is essential for the development of polymorphonuclear neutrophil leukocyte (PMNs) in the lungs and plays a role in the advancement and spread of cancer. A vaccine against S100A9 (generated from VLPs) was designed by Chung et al. The vaccine decreased lung tumor nodules drastically following intravenous challenge or post-surgical excision of the main tumor in metastatic mouse models of BC and melanoma. Mechanistically, the vaccinations induced the lungs and sera to contain lower amounts of S100A9. This reduction then drove an increased in the expression of immunostimulatory cytokines, including IL-12 and IFN-&#947;. The cytokines exhibited anti-tumor properties while simultaneously decreasing levels of immunosuppressive cytokines; this outcome manifested as changes in the levels of TGF-<italic toggle="yes">&#946;</italic> and IL-10 [<xref ref-type="bibr" rid="CR189">189</xref>].</p></sec><sec id="Sec19"><title>Endogenous protein-based nanocarriers</title><p id="Par136">Endogenous protein-based nanocarriers utilize proteins sourced from within an organism, typically synthesized as intracellular or extracellular proteins. The preparation methods for these nanocarriers involve the extraction or synthesis of endogenous proteins from an organism, leveraging their natural biocompatibility and functional properties [<xref ref-type="bibr" rid="CR190">190</xref>]. The constructed protein&#8211;drug nanocomplexes for vaccine delivery tend to be in a size range ideal for promoting effective lymphatic drainage and intracellular absorption. This property is particularly desirable for promoting vaccine delivery to APCs and lymphoid organs. This immunomodulatory effect translates into remarkable therapeutic outcomes in cancer and viral diseases.</p></sec></sec><sec id="Sec20"><title>Biogenic nanosystems</title><p id="Par137">Nanomaterials derived from diverse biological sources, including cells, are collectively termed biogenic nanocarriers. These carriers are often regarded as inherently &#8220;self,&#8221; exhibiting significant biodegradability, biocompatibility, and minimal toxicity. Biogenic nanocarriers encompass exosomes, outer membrane vesicles (OMVs), whole-cell nanovaccines, artificial APCs (aAPCs), and neoantigen nanovaccines.</p><sec id="Sec21"><title>Exosomes</title><p id="Par138">Exosomes are naturally occurring NPs. These small membrane vesicles, typically measuring 30&#8211;150&#160;nm in size, derive from late endosomes within various cell types and are discharged into the extracellular environment, retaining the properties of the original cells [<xref ref-type="bibr" rid="CR191">191</xref>, <xref ref-type="bibr" rid="CR192">192</xref>]. They are characterized by a cup-shaped structure with a lipid bilayer [<xref ref-type="bibr" rid="CR192">192</xref>, <xref ref-type="bibr" rid="CR193">193</xref>]. Their composition and natural origin render exosomes non-cytotoxic and endow them with a remarkable ability for precise homing to target sites, overcoming biological barriers encountered in vivo&#8212;a challenge faced by many exogenous NPs [<xref ref-type="bibr" rid="CR194">194</xref>]. However, the use of exosomes in cancer vaccines remains challenging. For instance, the production and purification of tumor-derived exosomes in sufficient quantities for clinical use are technically demanding. Furthermore, tumor-derived exosomes can carry immunosuppressive molecules that induce immune tolerance rather than an anti-tumor response.</p><p id="Par139">Researchers isolated DC-derived exosomes (DEX) and engineered them with a hepatocellular carcinoma (HCC)-targeting peptide (P47-P), an &#945;-fetoprotein epitope (AFP212-A2), and a functional domain of high-mobility group nucleosome-binding protein 1 (N1ND-N), which serves as an immunoadjuvant for dendritic cell recruitment and activation. These components were incorporated using an exosomal anchor peptide to create a "trigger" DEX vaccine (DEX<sub>P&amp;A2&amp;N</sub>). This engineered DEX vaccine specifically enhanced the recruitment, accumulation, and activation of DCs in mice with orthotopic HCC tumors, leading to improved cross-presentation of tumor neoantigens and a robust de novo T-cell response [<xref ref-type="bibr" rid="CR195">195</xref>].</p></sec><sec id="Sec22"><title>Outer membrane vesicles</title><p id="Par140">OMVs are nanostructures that range in size from approximately 20 to 250&#160;nm and originate from the budding or blebbing o shedding of the bacterial cell envelope [<xref ref-type="bibr" rid="CR196">196</xref>]. These vesicles encapsulate a diverse range of components, yielding complex arrangements of antigenic materials (i.e., proteins that occur in the cytoplasm, inner membrane, and the outer membrane). OMV development is influenced by multiple factors, including the lipid composition of the outer membrane and the presence of envelope-crosslinking proteins. Moreover, factors in the environment like temperature and nutrient accessibility may alter the rate at which OMVs are produced. Although OMVs contain virulence factors, the precise mechanisms governing the selective incorporation of these factors into OMVs remain to be fully elucidated. OMVs function as decoys to evade antibiotics and phages, respond to stress, and scavenge nutrients in bacteria following their release from the bacterial cell membrane.</p></sec><sec id="Sec23"><title>Whole-cell nanovaccines</title><p id="Par141">The considerable heterogeneity within tumors presents a challenge in utilizing single-antigen immunotherapy for cancer treatment. Vast antigenic variety can lead to immune evasion because tumor cells can continue to grow and multiply even when they express little of the targeted antigen. Moreover, tumors may lose their ability to express immunogenic antigens, rendering CTLs produced by immunization with a single antigen useless [<xref ref-type="bibr" rid="CR197">197</xref>]. The use of the entire population of cancer cells as a source of antigenic material has been proposed as a viable solution to this challenge [<xref ref-type="bibr" rid="CR198">198</xref>].</p><p id="Par142">Based on the abovementioned studies, several research teams have combined the benefits of NP delivery systems with the advantages of using tumor cell lysates as antigenic materials. Occasionally, lysate-loaded NPs, either with or without adjuvants, have been used to increase DC uptake and antigen presentation in vitro, especially in cell-based immunotherapies [<xref ref-type="bibr" rid="CR199">199</xref>&#8211;<xref ref-type="bibr" rid="CR201">201</xref>].</p></sec><sec id="Sec24"><title>Artificial APCs</title><p id="Par143">To guarantee the development of anti-tumor responses, vaccination techniques that directly deliver tumor antigen materials are employed. Nevertheless, many of these antigens are highly similar to those found in healthy cells and exhibit low immunogenicity. Therefore, it can be challenging to elicit immune responses with adequate strength to inhibit tumor growth. Recent developments in aAPC technology have attempted to avoid the requirement for endogenous antigen presentation instead of depending on the activation of APCs to elicit T-cell education with the appropriate specificities. These synthetic NPs, called aAPCs, are produced to mimic every signal needed to stimulate T cells [<xref ref-type="bibr" rid="CR202">202</xref>].</p><p id="Par144">aAPCs offer advantages over natural APCs, including the fact that&#160;their release can be controlled, they are highly targeted and customizable, and they exhibit consistent performance without relying on the body's natural antigen-processing mechanisms [<xref ref-type="bibr" rid="CR203">203</xref>]. aAPCs can precisely activate T cells and reduce off-target effects, and they offer flexibility in genetic engineering to express specific co-stimulatory molecules or cytokines [<xref ref-type="bibr" rid="CR204">204</xref>]. However, aAPCs find it challenging to mimic the intricate immune signals and the microenvironment that natural APCs provide, and they might be limited in overcoming the immune evasion tactics of tumors. Additionally, they could encounter issues with standardizing production, potential toxicity, and the absence of sustained cytokine release, which is vital for the long-term survival and function of T-cells.</p><p id="Par145">The generation of aAPCs involves the incorporation of two crucial components. MHC, which confers antigen specificity and binds to the matching T-cell receptor on effector T cells, presents a peptide epitope as part of its first component. For T cells to successfully activate and proliferate, a molecule that provides co-stimulatory signals, like CD80 or CD86, must be engaged simultaneously with the T cells. aAPCs are used to induce tumor-specific responses by mimicking the actions of natural APCs. This eliminates the need to administer antigens and adjuvants, which usually necessitate further processing by the body&#8217;s innate immune system [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR202">202</xref>].</p></sec></sec></sec><sec id="Sec25"><title>Blocking and combating cancer metastasis using nanovaccines</title><p id="Par146">With the aim of transcending the traditional, one-size-fits-all approach to medicine, personalized nanovaccines can be tailored for each stage of the metastatic cascade. These nanovaccines can be customized according to patient-specific metastatic processes, thereby improving therapeutic effectiveness and minimizing side effects (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). In this section, these strategies are discussed in further detail.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Summary of nanovaccines for tumor metastasis and their immune-enhancing mechanisms in preclinical studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Metastatic stages</th><th align="left" colspan="1" rowspan="1">Formulations/Metastatic site</th><th align="left" colspan="1" rowspan="1">Name</th><th align="left" colspan="1" rowspan="1">Antigen used</th><th align="left" colspan="1" rowspan="1">Immune adjuvant</th><th align="left" colspan="1" rowspan="1">Tumor model</th><th align="left" colspan="1" rowspan="1">Combined treatment</th><th align="left" colspan="1" rowspan="1">Injection route</th><th align="left" colspan="1" rowspan="1">Immune-enhancing mechanisms</th><th align="left" colspan="1" rowspan="1">Refs.</th></tr></thead><tbody><tr><td align="left" rowspan="11" colspan="1">Primary tumor</td><td align="left" colspan="1" rowspan="1">Peptide</td><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Listeria-Ova</italic> or OVA peptide</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">B16-OVA melanoma tumor</td><td align="left" colspan="1" rowspan="1">ICB</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">Promotes central memory T-cell formation rather than tissue-resident memory generation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR207">207</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">herpes simplex virus</td><td align="left" colspan="1" rowspan="1">AdC68-gDMelapoly</td><td align="left" colspan="1" rowspan="1">CD8<sup>+</sup>T-cell epitopes, mTrp-1, hgp100, and mBrafV600E fused into herpes simplex virus glycoprotein</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">mouse model of melanoma</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Intramuscularly</td><td align="left" colspan="1" rowspan="1">Reprogramming cells within tumors to increase fatty acid metabolism, providing T cells access to glucose in the TME</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR208">208</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CaCO<sub>3</sub> biomineralized Salmonella (Sal)</td><td align="left" colspan="1" rowspan="1">Sal@CaCO<sub>3</sub></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">Salmonella</italic></td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">mouse model of melanoma</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">Inducing cancer cells' immunogenic cell death and promoting the gap junction formation between tumor cells and (DCs) to promote antigen presentation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR210">210</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA</td><td align="left" colspan="1" rowspan="1">mPLA/mRNA</td><td align="left" colspan="1" rowspan="1">MAGE-A1 mRNA</td><td align="left" colspan="1" rowspan="1">mPLA</td><td align="left" colspan="1" rowspan="1">mouse model of lung</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Nasal administration</td><td align="left" colspan="1" rowspan="1">Immune cell activation, IFN- &#947;/IL-12 cytokine secretion, and natural killer cell-mediated antibody-dependent cellular cytotoxicity</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR217">217</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DNA</td><td align="left" colspan="1" rowspan="1">Tem 1-TT</td><td align="left" colspan="1" rowspan="1">TEM1</td><td align="left" colspan="1" rowspan="1">tetanus toxoid (TT)</td><td align="left" colspan="1" rowspan="1">mouse model of lung and colon</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Intramuscularly</td><td align="left" colspan="1" rowspan="1">Reduced tumor vascularity, increased infiltration of CD3<sup>+</sup> T cells into the tumor; elicited CD8<sup>+</sup> cytotoxic T-cell responses against murine tumor-specific antigens</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR305">305</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid-based NPs</td><td align="left" colspan="1" rowspan="1">FAP<sub>PEP</sub>-SLNPs</td><td align="left" colspan="1" rowspan="1">&#945;FAP</td><td align="left" colspan="1" rowspan="1">CpG</td><td align="left" colspan="1" rowspan="1">E.G7-OVA Lymphoma model, MC38 colorectal tumor</td><td align="left" colspan="1" rowspan="1">Doxorubicin</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">Depleting FAP<sup>+</sup> CAFs and thereby reducing ECM production in the TME while causing little appreciable adverse effects. Increased drug accumulation and resulted in a synergistic anti-tumor efficacy when combine with Doxorubicin</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR240">240</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein</td><td align="left" colspan="1" rowspan="1">TRXtr-Vimentin</td><td align="left" colspan="1" rowspan="1">Vimentin</td><td align="left" colspan="1" rowspan="1">CpG</td><td align="left" colspan="1" rowspan="1">Dog with transitional cell carcinoma of the bladder were recruited within their own veterinary practice. B16F10 melanoma mouse model</td><td align="left" colspan="1" rowspan="1">meloxicam</td><td align="left" colspan="1" rowspan="1">Recruited; Subcutaneously</td><td align="left" colspan="1" rowspan="1">extracellular vimentin contributes to immune suppression and functions as a vascular immune checkpoint molecule</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR248">248</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">whole lysates based CCSC</td><td align="left" colspan="1" rowspan="1">MUC1/CCSC</td><td align="left" colspan="1" rowspan="1">MUC1</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">SW620 colorectal tumor</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">delay of tumor growth, increased cytotoxicity, antibody production, and generation of memory B cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR254">254</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid calcium phosphate (LCP) nanoparticles</td><td align="left" colspan="1" rowspan="1">Frax NE/ BRAF</td><td align="left" colspan="1" rowspan="1">modified BRAFV600E peptide</td><td align="left" colspan="1" rowspan="1">CpG</td><td align="left" colspan="1" rowspan="1">BPD6 desmoplastic melanoma model</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">abrogating tumor-associated immune suppression and promoting infiltration of immune cells such as CTLs, NK cells and memory T cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR257">257</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OMV</td><td align="left" colspan="1" rowspan="1">SpC-OMVs&#8201;+&#8201;SpT-peptides</td><td align="left" colspan="1" rowspan="1">OMV</td><td align="left" colspan="1" rowspan="1">OMV</td><td align="left" colspan="1" rowspan="1">MB49 Transitional cell carcinoma model</td><td align="left" colspan="1" rowspan="1">ICB</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">reducing tumor growth by enhancing IFN-&#947;-CD8<sup>+</sup>&#160;T-cell responses and increasing the number of CD8<sup>+</sup>&#160;memory cells and antigen-specific T cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR306">306</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cytokine</td><td align="left" colspan="1" rowspan="1">3xTx vaccine</td><td align="left" colspan="1" rowspan="1">3xTx</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">melanoma or head and neck carcinoma models</td><td align="left" colspan="1" rowspan="1">Radiotherapy; ICB</td><td align="left" colspan="1" rowspan="1">Intratumoral Injection</td><td align="left" colspan="1" rowspan="1">NK cells promote CTLA4<sup>+</sup> Treg apoptosis in non-targeted tumors. This is dependent on NK cell expression of CD8, which is upregulated downstream of KLRK1</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR307">307</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Post-surgical tumor metastases</td><td align="left" colspan="1" rowspan="1">Polymer</td><td align="left" colspan="1" rowspan="1">F-PEI/OVA</td><td align="left" colspan="1" rowspan="1">OVA, cancer cell membrane</td><td align="left" colspan="1" rowspan="1">F<sub>13</sub>-PEI</td><td align="left" colspan="1" rowspan="1">B16-OVA melanoma tumor, CT26 colon tumors 4T1 breast tumor (mice)</td><td align="left" colspan="1" rowspan="1">ICB</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">Induced DC maturation and antigen cross-presentation, OVA-specific T-cell responses (in vitro), immunological memory responses, decreased CD4<sup>+</sup>Foxp3<sup>+</sup> T regulatory cells</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">Secondary metastases</td><td align="left" colspan="1" rowspan="1">Lung</td><td align="left" colspan="1" rowspan="1">PEIM@OVA, PEIM@Mem</td><td align="left" colspan="1" rowspan="1">OVA, tumor cell membranes</td><td align="left" colspan="1" rowspan="1">PEIM</td><td align="left" colspan="1" rowspan="1">B16-OVA melanoma, MC38 colorectal tumor</td><td align="left" colspan="1" rowspan="1">ICB</td><td align="left" colspan="1" rowspan="1">Subcutaneous</td><td align="left" colspan="1" rowspan="1">Activate STING/IFN-I cascade, stimulate APCs activation and antigen cross-presentation for priming CD8<sup>+</sup> CTL response</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR39">39</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">porous silicon@Au</td><td align="left" colspan="1" rowspan="1">CCM@(PSiNPs@Au)</td><td align="left" colspan="1" rowspan="1">Tumor cell membranes</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">4T1 cancer cells</td><td align="left" colspan="1" rowspan="1">ICB</td><td align="left" colspan="1" rowspan="1">Subcutaneous injection near the inguinal lymph nodes of their left hind legs</td><td align="left" colspan="1" rowspan="1">Activate the antigen presentation of DCs for priming CTLs</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR308">308</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lung</td><td align="left" colspan="1" rowspan="1">virus&#173;like particles</td><td align="left" colspan="1" rowspan="1">Virus</td><td align="left" colspan="1" rowspan="1">CPMV and Q<italic toggle="yes">&#946;</italic></td><td align="left" colspan="1" rowspan="1">B16F10 and 4T1&#173;Luc-lung metastatic Model</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Subcutaneous</td><td align="left" colspan="1" rowspan="1">reduce the levels of S100A9 within the lungs, thereby increasing the expression of immunostimulatory cytokines with anti-tumor function (IL-12 and IFN&#947;) while reducing levels of immunosuppressive cytokines (IL-10 and TGF<italic toggle="yes">&#946;</italic>)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR189">189</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ovarian</td><td align="left" colspan="1" rowspan="1">Neoantigen vaccine</td><td align="left" colspan="1" rowspan="1">Neoantigen of personalized patients</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">metastatic ovarian cancer patients</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Subcutaneous</td><td align="left" colspan="1" rowspan="1">riggers cytotoxic lymphocytes expressing polyclonal TCR against cancer</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR309">309</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lymph node</td><td align="left" colspan="1" rowspan="1">Tu-NP<sub>FN</sub> and Ln-NP<sub>R848</sub></td><td align="left" colspan="1" rowspan="1">situ antigen generation</td><td align="left" colspan="1" rowspan="1">R848</td><td align="left" colspan="1" rowspan="1">4T1 cancer cells</td><td align="left" colspan="1" rowspan="1">ICB</td><td align="left" colspan="1" rowspan="1">Subcutaneous</td><td align="left" colspan="1" rowspan="1">promoted the uptake and maturation of dendritic cells to initiate potent anti-cancer immune responses</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR79">79</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Lung</td><td align="left" colspan="1" rowspan="1">LN-IMQ</td><td align="left" colspan="1" rowspan="1">UT-Ags, PTX-Ags and PTX&#8201;+&#8201;Carb-Ags</td><td align="left" colspan="1" rowspan="1">LN</td><td align="left" colspan="1" rowspan="1">4T1-bearing mouse</td><td align="left" colspan="1" rowspan="1">ICB</td><td align="left" colspan="1" rowspan="1">intravenous injection</td><td align="left" colspan="1" rowspan="1">triggered the anti-tumor ability of macrophages, mobilized T-cell immunity, and promoted the secretion of anti-tumor cytokines</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR132">132</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Lymph node</td><td align="left" colspan="1" rowspan="1">TPOP</td><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">OMs</td><td align="left" colspan="1" rowspan="1">subcutaneous mouse colorectal cancer model and melanoma model</td><td align="left" colspan="1" rowspan="1">pretreatment with doxorubicin</td><td align="left" colspan="1" rowspan="1">intratumoral injection</td><td align="left" colspan="1" rowspan="1">manipulate TIDC lipid metabolism and inhibit de novo synthesis of fatty acids, thus improving the ability of TIDCs to cross-present by reducing their lipid accumulation</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR209">209</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Lung</td><td align="left" colspan="1" rowspan="1">LDHs-cGAMP</td><td align="left" colspan="1" rowspan="1">BSA-Cy5</td><td align="left" colspan="1" rowspan="1">LDH</td><td align="left" colspan="1" rowspan="1">hepa1-6 liver cancer</td><td align="left" colspan="1" rowspan="1">RFA</td><td align="left" colspan="1" rowspan="1">intratumorally inject</td><td align="left" colspan="1" rowspan="1">inducing a stronger IFN-I response, changed the tumor immune microenvironment and promoted the response efficiency of&#945;PD-L1 immunotherapy</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR280">280</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Primary tumor/lung metastasis</td><td align="left" colspan="1" rowspan="1">Lymphocytic choriomeningitis virus</td><td align="left" colspan="1" rowspan="1">LCMV-TRP2</td><td align="left" colspan="1" rowspan="1">melanoma-associated self-antigen TRP2</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">mouse model of melanoma</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Applying DMBA in acetone onto the shaved back for primary melanoma; subcutaneously into the flank or intravenously for the lung metastasis</td><td align="left" colspan="1" rowspan="1">induce effective antigen-specific CD8<sup>+</sup> T-cell responses, renders previously &#8220;cold&#8221; tumors open to immune infiltration and reprograms tumor microenvironment to &#8220;hot.&#8221;</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR216">216</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Primary tumor/lung metastasis</td><td align="left" colspan="1" rowspan="1">Peptide</td><td align="left" colspan="1" rowspan="1">CTAs Peptide</td><td align="left" colspan="1" rowspan="1">Cancer&#8211;testis antigens (CTAs) (Siglece and Lin28a)</td><td align="left" colspan="1" rowspan="1">Poly(I:C)</td><td align="left" colspan="1" rowspan="1">4T1 triple&#173;negative breast cancer model</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Subcutaneously</td><td align="left" colspan="1" rowspan="1">increased T-cell anti-tumor immunity and reduced primary tumor growth</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR310">310</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ICB</italic> immune checkpoint blockade, <italic toggle="yes">OMVs</italic> outer membrane vesicles, <italic toggle="yes">CAFs</italic> cancer associated fibroblasts, <italic toggle="yes">ECM</italic> extracellular matrix, <italic toggle="yes">TME</italic> tumor microenvironment; <italic toggle="yes">NPs</italic> nanoparticles, <italic toggle="yes">CCSC</italic> colorectal cancer stem cells, <italic toggle="yes">APC</italic> antigen-presenting cells, <italic toggle="yes">CTLs</italic> cytotoxic T lymphocytes</p></table-wrap-foot></table-wrap></p><sec id="Sec26"><title>Utilizing nanomedicines to prevent and combat metastasis initiation from the primary tumor: remodeling the microenvironment in primary tumors</title><p id="Par147">The complex ecosystem known as the TME, which includes a variety of cell types, stromal components, and other physical characteristics, envelops cancer cells (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>). It is essential for the growth and spread of cancer. Considering that specific approaches can inadvertently harm healthy tissues, personalized nanovaccines show potential in the context of facilitating controlled drug release while ensuring minimal side effects. Additionally, nanovaccines can be designed to safely carry a wide array of different active agents while being optimized to target specific factors in the primary tumor TME. In the following discussion, we outline the key components of the TME that contribute to cancer metastasis and discuss how personalized nanovaccines can be used to counteract each of them.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Preventing and battling initial tumor metastasis with nanovaccines. Nanovaccines designed with the different NP platforms summarized in Sect.&#160;"<xref rid="Sec11" ref-type="sec">Nanovaccine designs aimed toward overcoming metastasis</xref>" could target specific factors in the primary tumor TME, thus exerting a precise anti-tumor effect. These specific factors individually contribute to the initiation of metastasis; they are as follows: metabolic microenvironment, immune microenvironment, vasculature, extracellular matrix, stromal cells, epithelial&#8211;mesenchymal transition, cancer stem cells, and the physical structure of the TME</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="13045_2024_1628_Fig5_HTML.jpg"/></fig></p><sec id="Sec27"><title>Modulating the metabolic microenvironment</title><p id="Par148">Hypoxia and acidosis are critical interdependent elements that contribute to the metabolic TME and establish favorable conditions for tumor growth. As tumors expand, the oxygen supply from nearby blood vessels becomes inadequate and is depleted gradually, giving rise to a hypoxic microenvironment. To maintain an oxygen balance, the HIFs HIF-1 and HIF-2 activate HIF signaling, which enhances oxygen delivery and synchronizes the cellular response to oxygen levels. Nearly all stages of the metastatic process, including invasion, EMT, and angiogenesis, involve active HIF signaling [<xref ref-type="bibr" rid="CR205">205</xref>, <xref ref-type="bibr" rid="CR206">206</xref>].</p><p id="Par149">Numerous studies have delved into the connection between immune cells fatty acid metabolism and immunological capacity, suggesting potential overlaps between cancer therapeutic vaccines and medications that target immune cell fatty acid metabolism in the TME. Although enhanced fatty acid oxidation in T cells improves spare respiratory capacity, increases peptide vaccine memory ability, and promotes anti-tumor immunity, the overexpression of PGC-1&#945; increases CD8 central memory T-cell development [<xref ref-type="bibr" rid="CR207">207</xref>]. Remarkably, in a mouse model of melanoma, the co-administration of a cancer vaccine and a PPAR&#945; agonist inhibited tumor growth. As tumor and stromal cells have an increased need for fatty acids, there is a greater chance that T cells may use glucose, which will improve anti-tumor immunity [<xref ref-type="bibr" rid="CR208">208</xref>]. Qin and colleagues developed an in situ nanovaccine (TPOP) that leverages nanoparticles to modulate lipid metabolism and activate the innate immune system. Combined with immune checkpoint inhibitors, TPOP was able to substantially impede the growth of distant tumors by eliciting robust systemic anti-tumor immunity [<xref ref-type="bibr" rid="CR209">209</xref>].</p><p id="Par150">The modulation of the acidic microenvironment has the potential to reduce the metastatic propensity of tumor cells. Guo et al. introduced a novel bacteria-based autologous cancer vaccine. The vaccine produces an in situ cancer vaccine and modulates the systemic immune response by employing <italic toggle="yes">Salmonella</italic> biomineralized with CaCO<sub>3</sub> [<xref ref-type="bibr" rid="CR210">210</xref>]. The CaCO<sub>3</sub> shell of this vaccine decomposes in acidic environments, reducing tumor acidity and facilitating the release of <italic toggle="yes">Salmonella</italic>. Therefore, this bio-vaccine exhibits exceptional effectiveness against cancers that are primary or metastatic.</p></sec><sec id="Sec28"><title>Reprogramming the tumor immune microenvironment</title><p id="Par151">The tumor immune microenvironment (TIME) is an intricate web made up of different parts within a tumor that inhibit the immune response to cancer and facilitate tumor immune evasion [<xref ref-type="bibr" rid="CR211">211</xref>]. Patients with immunologically &#8220;hot&#8221; tumors have a higher likelihood of responding well to immunotherapies, resulting in improved survival rates. However, a majority of cancers are regarded as immunologically &#8220;cold,&#8221; and the efficacy of immunotherapies in treating patients is comparatively low [<xref ref-type="bibr" rid="CR212">212</xref>, <xref ref-type="bibr" rid="CR213">213</xref>]. Consequently, there is intense interest in innovative vaccination strategies aimed at reprogramming the TIME to render tumors &#8220;hot.&#8221;</p><p id="Par152">Within the TIME, immunosuppressive cells release a plethora of inhibitory signals such as TGF-<italic toggle="yes">&#946;</italic>, vascular endothelial growth factor (VEGF), and PD-L1. These signals decrease the immune reaction against cancerous growths by acting either directly or indirectly on effector T cells [<xref ref-type="bibr" rid="CR214">214</xref>]. Addressing the challenges posed by these immunosuppressive mechanisms within the TIME is imperative for developing effective cancer immunotherapy strategies.</p><p id="Par153">Vaccination can reverse the suppressive TME and subsequently activate CD8<sup>+</sup> T cells, thereby transforming a cold TME into a hot TME. For example, the tumor vaccine vector TA-Met@MS triggers a metabolic switch from glycolysis to fatty acid oxidation. This photothermal metabolic manipulation boosts the longevity of T cells and encourages the maturation of memory CD8<sup>+</sup> T cells, thereby prolonging the effectiveness of vaccine [<xref ref-type="bibr" rid="CR215">215</xref>]. Several nanovaccines have demonstrated the ability to successfully reprogram the TME. Purde et al. studied employment of viral vector-based cancer vaccines encoding a self-antigen associated with tumors (TRP2) in preclinical mouse models to cure existing melanomas. By effectively priming T cells, this method converts previously cold tumors into immune-infiltrated ones and sets the TME in a hot state [<xref ref-type="bibr" rid="CR216">216</xref>]. With the aid of the TLR4 agonist mPLA, which promoted DC maturation, Ma et al. engineered an mPLA/mRNA tumor vaccine (mLPR) to redirect M2 macrophages towards the M1 phenotype, cross-activate innate and adaptive immune responses in vivo, and facilitate the delivery of mRNA into the cytoplasm to amplify the immune response [<xref ref-type="bibr" rid="CR217">217</xref>]. Moreover, the inactivated probiotic strain <italic toggle="yes">Escherichia coli</italic> Nissle 1917 has been recently modified to incorporate tumor antigens along with <italic toggle="yes">&#946;</italic>-glucan, a stimulator of trained immunity, in the creation of a personalized cancer vaccine. This vaccine, known as BG/OVA@EcN, induces trained immunity through subcutaneous injection of the model antigen OVA. This injection prompts macrophages at the injection sites to phagocytose the vaccine. Trained macrophages recruit DCs to aid in the phagocytosis of BG/OVA@EcN, leading to DC maturation and T-cell activation [<xref ref-type="bibr" rid="CR218">218</xref>].</p><p id="Par154">Immunotherapy, in conjunction with customized nanomedicine, shows great promise in yielding improved anti-cancer outcomes. For example, Kadam et al. have shown that ICB enhances the action of therapeutic cancer vaccines. Therefore, patients with lung cancer may benefit from CCL21-DC tumor lysate vaccination treatment in addition to PD-1 inhibition [<xref ref-type="bibr" rid="CR219">219</xref>].</p></sec><sec id="Sec29"><title>Targeting the tumor vasculature</title><p id="Par155">As tumor growth accelerates, the establishment of a vascular network becomes crucial for providing nutrition to tumor cells. To fulfill the escalating demand for proliferation, tumor cells secrete a variety of angiogenic agents that promote the quick development of immature vasculature, such as VEGF. This newly formed vasculature is known for its convoluted and leaky nature, which results in the significant intravasation of cancer cells, with higher blood vessel density correlating with increased tumor metastasis incidence [<xref ref-type="bibr" rid="CR220">220</xref>].</p><p id="Par156">Many nanosystems have shown impressive anti-angiogenic and -tumor activity [<xref ref-type="bibr" rid="CR221">221</xref>, <xref ref-type="bibr" rid="CR222">222</xref>]. On the contrary, anti-angiogenesis-driven hypoxia could increase tumor aggressiveness, thereby catalyzing metastasis [<xref ref-type="bibr" rid="CR223">223</xref>, <xref ref-type="bibr" rid="CR224">224</xref>]. Given this scenario, rather than inhibition, the normalization of vasculature should be viewed as a more suitable paradigm for addressing metastasis [<xref ref-type="bibr" rid="CR225">225</xref>]. The doses of anti-angiogenic drugs should be closely monitored to accomplish this goal, and they should be used in conjunction with cytotoxic treatment modalities such photodynamic therapy and chemotherapy. One study showed that CD248 may be targeted immunologically to produce an anti-tumor vascular response using a DNA-based vaccine, providing a unique tool for cancer diagnostics and treatment [<xref ref-type="bibr" rid="CR226">226</xref>].</p></sec><sec id="Sec30"><title>Modulating the extracellular matrix</title><p id="Par157">Matricellular proteins, glycoproteins, fibrous proteins, and enzymes make up the intricate three-dimensional network known as the extracellular matrix (ECM) [<xref ref-type="bibr" rid="CR227">227</xref>]. The onset of angiogenesis and metastasis in primary cancers is significantly influenced by the ECM [<xref ref-type="bibr" rid="CR228">228</xref>]. As cancer progresses, tumor cells continuously remodel their ECM. One well-recognized alteration in the ECM is the increased deposition of collagen, which controls the migration and polarity of cells and is intimately related to metastasis [<xref ref-type="bibr" rid="CR229">229</xref>, <xref ref-type="bibr" rid="CR230">230</xref>]. Nanovaccines can effectively regulate the ECM. Hu et al. constructed PEG/PEI/pSpam1 NPs, in which Spam1 could express hyaluronidase. It was discovered that PEG/PEI/pSpam1 NPs could produce high hyaluronidase expression at the tumor location, which further broke down the tumor ECM and encouraged immune cell infiltration [<xref ref-type="bibr" rid="CR231">231</xref>].</p><p id="Par158">Among the various ECM components, matrix metalloproteinases (MMPs), which are overexpressed proteases that facilitate tumor migration by directly breaking down the ECM, are considered ideal targets for the treatment of metastasis. Therefore, over the past two decades, synthetic inhibitors of MMPs (MMPIs) have been studied for use against various types of cancer [<xref ref-type="bibr" rid="CR232">232</xref>]. For example, a hyaluronic acid-paclitaxel prodrug was used to synthesize marimastat, a broad-spectrum MMPI with limited water solubility, into NPs for the treatment of metastatic cancer [<xref ref-type="bibr" rid="CR233">233</xref>].</p></sec><sec id="Sec31"><title>Targeting tumor stromal cells</title><p id="Par159">Cancer-associated fibroblasts (CAFs) are a heterogeneous population of activated fibroblasts found within the primary TME plays vital roles in multiple pathways that facilitate the growth and dissemination of tumors. The increased release of cytokines and growth factors, including TGF-<italic toggle="yes">&#946;</italic>, CXCL12, and IL-6, has been observed in CAFs, and these substances have been shown to improve the invasion and migration of tumor cells [<xref ref-type="bibr" rid="CR234">234</xref>&#8211;<xref ref-type="bibr" rid="CR236">236</xref>]. CAFs have emerged as a key target for intervention since they are among the most prevalent elements of the tumor stroma.</p><p id="Par160">Zhao et al. showed that a localized reduction in CAFs can change the TME and increase the efficacy of chemotherapeutic drugs [<xref ref-type="bibr" rid="CR237">237</xref>]. Notably, despite the effectiveness of this method, tumor cells may continue to invade or migrate if they are not completely eradicated [<xref ref-type="bibr" rid="CR238">238</xref>]. To mitigate potential risks associated with tumor growth and metastasis, an siRNA was developed to silence CXCL12, a factor that sustains the active phenotype of CAFs. The nanosystem, named PNP/siCXCL12/mAb, specifically targeted CAFs [<xref ref-type="bibr" rid="CR239">239</xref>]. Remarkably, PNP/siCXCL12/mAb significantly decreased CXCL12 expression by 64.4%, resulting in suppressed angiogenesis, migration, and tumor invasion. Importantly, in the major organs, relatively little tumor fluorescence was observed, indicating a strong suppression of metastasis. In a separate investigation, a cancer nanovaccine was designed to target CAFs expressing fibroblast activation protein (FAP) &#945;. By reducing FAP-expressing CAFs, this study demonstrated a substantial suppression of tumor growth across various malignancies. It also identified immunodominant FAP-specific epitope peptides and established a vaccine based on NPs that displayed the selected epitope peptides. Furthermore, when paired with chemotherapeutic medications, the nanovaccines targeting FAP-expressing CAFs may have synergistic anti-tumor activity, indicating their potential utility as a "commercially available" pan-tumor vaccination as well as a platform for different combination therapies [<xref ref-type="bibr" rid="CR240">240</xref>].</p></sec><sec id="Sec32"><title>Targeting the EMT</title><p id="Par161">Tumor cells undergo an EMT, which allows them to migrate toward arteries, thus subsequently penetrating into the bloodstream. Tumor cells at the beginning of invasive cancers typically express more mesenchymal markers and fewer intercellular adhesions and epithelial markers [<xref ref-type="bibr" rid="CR241">241</xref>]. Eventually, these cancerous cells change into mesenchymal phenotypes, which are characterized by increased contractility and motility as well as the increased production of markers associated with metastasis, such as VEGF and MMPs [<xref ref-type="bibr" rid="CR242">242</xref>, <xref ref-type="bibr" rid="CR243">243</xref>]. Numerous substances, such as WNT, HIF-1a, TGF-<italic toggle="yes">&#946;</italic>, and some cytotoxic medications, can cause EMT [<xref ref-type="bibr" rid="CR244">244</xref>&#8211;<xref ref-type="bibr" rid="CR247">247</xref>]. Therefore, targeting EMT holds promise in the context of preventing the initiation of metastasis.</p><p id="Par162">For instance, ZnAs@SiO2 NPs, designed by Huang et al. [<xref ref-type="bibr" rid="CR50">50</xref>], inhibited stemness while elevating levels of SHP-1. Simultaneously, they inhibited the JAK2/STAT3 pathway. This enabled the NPs to regulate the underlying gene networks. As mentioned previously, several chemotherapy drugs, such paclitaxel and doxorubicin, can induce EMT, which raises the possibility of metastasis. Zhou et al. used hydroxyethyl starch&#8211;polylactide NPs to co-deliver doxorubicin and a TGF-<italic toggle="yes">&#946;</italic> receptor inhibitor in order to lessen these negative effects [<xref ref-type="bibr" rid="CR47">47</xref>]. With this method, pulmonary metastasis was inhibited, and primary tumors were concurrently suppressed. By effectively blocking the active TGF-<italic toggle="yes">&#946;</italic> pathway, the concomitantly delivered TGF-<italic toggle="yes">&#946;</italic> receptor inhibitor decelerated the EMT process. In contrast, the uneven distribution of could worsen EMT and metastasis. Additionally, van Beijnum et al. created anti-vimentin vaccines by cloning sequences that code for vimentin from dogs and mice into the pET21a expression vector. These vaccines were then produced using <italic toggle="yes">Escherichia coli</italic> [<xref ref-type="bibr" rid="CR248">248</xref>]. Targeting vimentin with the anti-vimentin vaccine (TRXtr-Vim) was found to elicit immunity and positively impact EMT-regulated processes, including angiogenesis and metastasis.</p></sec><sec id="Sec33"><title>Targeting <italic toggle="yes">cancer</italic> stem cells</title><p id="Par163">Owing to their multipotency, cancer stem cells (CSCs) generate new tumors and self-renew. The shift from an invasive mesenchymal phenotype to another that significantly enhances metastatic spread sometimes occurs along with the acquisition of stem-like features [<xref ref-type="bibr" rid="CR249">249</xref>]. Only a small percentage of CTCs survive the metastatic dissemination phase and form micrometastases. Such micrometastases exhibit CSC traits and serve as seeds for colonization at secondary sites [<xref ref-type="bibr" rid="CR249">249</xref>, <xref ref-type="bibr" rid="CR250">250</xref>]. Therefore, it is essential to target and eradicate CSCs to eradicate original tumors and prevent them from spreading.</p><p id="Par164">Li et al. created NPs that specifically target integrin &#945;5; they did this toblock the Wnt/<italic toggle="yes">&#946;</italic>-catenin pathway, which is essential for the development and sustenance of stem cells [<xref ref-type="bibr" rid="CR48">48</xref>]. These NPs demonstrated improved uptake and retention after systemic delivery. This strategy reduced <italic toggle="yes">&#946;</italic>-catenin levels and curbed both primary and metastatic cancers. Notably, some chemotherapeutic drugs have been found to enhance stemness and metastasis through a "backdoor" mechanism facilitated by COX-2/PGE2 pathway [<xref ref-type="bibr" rid="CR251">251</xref>]. To address this aspect, doxorubicin was co-delivered with a particular COX-2 inhibitor, which improved the overall anti-tumor efficacy and prevented doxorubicin from inducing the growth of cancer stem-like cells [<xref ref-type="bibr" rid="CR252">252</xref>]. This combination of treatments effectively reduced pulmonary metastasis by 67% and slowed the growth of the main tumor by 91%. Moreover, it has been demonstrated that CSC-based tumor vaccines exhibit strong anti-tumor properties [<xref ref-type="bibr" rid="CR253">253</xref>]. A recent study assessed the immunogenicity and protective effectiveness of CSC immunization against colorectal cancer in a mouse model using cells with high MUC1 expression. The CSC vaccine demonstrated a notable impact on tumor growth by selectively targeting CSCs, leading to reduced levels of CD133<sup>+</sup> and ALDH<sup>+</sup> cells within the tumors. In addition, increased NK cytotoxicity, perforin and granzyme B production, IFN-&#947; secretion, memory B-cell activation, and anti-MUC1 antibody production were observed following CSC vaccination [<xref ref-type="bibr" rid="CR254">254</xref>].</p><p id="Par165">In summary, developing nanocarriers to enhance CSC-targeting therapies holds promise for preventing metastatic dissemination and colonization.</p></sec><sec id="Sec34"><title>Targeting physical traits in the TME</title><p id="Par166">The mechanical TME is a crucial aspect of cancer biology that influences disease progression. It refers to the physical characteristics of a tumor, such as its structure, stiffness, pressure, and the impact of mechanical forces within the tumor [<xref ref-type="bibr" rid="CR255">255</xref>]. Changes in these mechanical properties can significantly affect tumor growth and adaptation to the environment. They may also affect how well cancers respond to therapy. Certain studies have highlighted a correlation between increased liver tumor tissue hardness and resistance to immunotherapy in patients with colorectal cancer, crediting abnormal vascular distribution as a contributing factor. Leveraging anti-angiogenic therapies with immunotherapy opens up a promising treatment route for solid tumors and calls for the further exploration of the macroscopic influence of tumor matrix stiffness and mechanical forces in the TME on immunotherapies [<xref ref-type="bibr" rid="CR256">256</xref>].</p><p id="Par167">Nanovaccines offer potential solutions to address these challenges in the TME. For example, a study described the development of a nanoemulsion to deliver the anti-fibrotic agent fraxinellone to tumor-associated fibroblasts (TAFs) in desmoplastic melanoma. TAFs and tumor cells efficiently uptake the fraxinellone nanoemulsion, with a particle size of approximately 145&#160;nm, at the tumor site, r leading to a substantial decrease in TAFs and stromal deposition. By boosting the quantity of NK cells and cytotoxic T cells while decreasing the quantity of regulatory B cells and myeloid-derived suppressor cells, this strategy simultaneously alters the TIME [<xref ref-type="bibr" rid="CR257">257</xref>].</p></sec></sec><sec id="Sec35"><title>Intercepting CTCs using nanovaccines</title><p id="Par168">CTCs are cancer cells that have separated from the primary tumor and have entered into the bloodstream and lymphatic systems, where they circulate [<xref ref-type="bibr" rid="CR258">258</xref>]. Upon detachment from primary tumors, metastatic tumor cells embark on a protracted voyage through the lymphatic system and/or bloodstream before arriving at a new location. Blood vessel circulation and lymphatic vessel-to-blood vessel circulation are the two main pathways through which CTCs migrate [<xref ref-type="bibr" rid="CR258">258</xref>]. Within this category, there are two distinct pathways: scirculation from the sentinel lymph node to blood vessels and from distant lymph nodes to blood vessels.</p><p id="Par169">Many methods have been investigated for CTC enrichment and detection. Filtration, density gradient separation, and immunomagnetic separation are examples of enrichment techniques, whereas direct microscopy, fluorescently activated cell sorting cytometric procedures, manual immunocytometry, and PCR-based approaches are examples of detection techniques [<xref ref-type="bibr" rid="CR259">259</xref>]. Currently, the Cell Search system (Veridex, LLC, Warren, NJ, USA), which combines flow cytometry and immunomagnetic separation, is commercialized. This technology is suitable for the identification and evaluation of CTCs in patients with metastatic cancer [<xref ref-type="bibr" rid="CR260">260</xref>, <xref ref-type="bibr" rid="CR261">261</xref>].</p><p id="Par170">Compared with their spherical counterparts, NP with high aspect ratios and low surface curvatures&#8212;such as those that are rod-, discoid-, or worm-shaped&#8212;are better suited for evading phagocytosis, leading to longer circulating lifetimes and higher tumor accumulation [<xref ref-type="bibr" rid="CR262">262</xref>, <xref ref-type="bibr" rid="CR263">263</xref>]. Furthermore, in a mouse model of lung metastasis derived from 4T1 cells, nanoparticles made of PEG&#8211;PLA encapsulating paclitaxel and modified with a peptide (K237) that targets tumor neovessels and an EpCAM aptamer (Ep23) were described to concurrently impair the primary tumor and capture and eliminate CTCs, particularly those that overexpressed EpCAM on their surface [<xref ref-type="bibr" rid="CR264">264</xref>]. Mitchell et al. devised a technique wherein E-selectin was adhered onto the surface of liposomes filled with doxorubicin and rendered immobile inside a microtube apparatus. This method enables the selective targeting, collection, and elimination of CTCs [<xref ref-type="bibr" rid="CR265">265</xref>].</p></sec><sec id="Sec36"><title>Combating secondary metastatic tumors with nanomedicines: remodeling the microenvironment in distant metastatic organs</title><sec id="Sec37"><title>Modulating the PMN via nanovaccines: inhibiting metastatic colonization</title><p id="Par171">As depicted in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>, although CTCs possess significant metastatic potential, their presence alone is insufficient to establish metastasis. To effectively enable the seeding of surviving CTCs at distant sites, the primary TME initiates a series of changes before tumor cell dissemination. During this process, tumor-derived factors and extracellular vesicles are secreted, collectively altering the PMN to form an environment conducive to hosting metastatic sites [<xref ref-type="bibr" rid="CR266">266</xref>, <xref ref-type="bibr" rid="CR267">267</xref>].</p><p id="Par172">These changes in the PMN include increased vascular permeability, the recruitment of myeloid cells, the upregulation of MMP-9 in the ECM, the overexpression of inflammatory molecules, and the induction of hypoxia [<xref ref-type="bibr" rid="CR266">266</xref>, <xref ref-type="bibr" rid="CR268">268</xref>, <xref ref-type="bibr" rid="CR269">269</xref>]. These factors work in synergy to construct an environment characterized by immunosuppression and inflammation, which in turn facilitates the extravasation, invasion, and colonization of CTCs (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par173">A promising strategy to hinder the later stages of the metastatic cascade involves targeting the PMN, rendering it less suitable for CTCs. This approach has the potential to disrupt the formation of metastases and represents an ideal protocol for metastasis inhibition.</p><p id="Par174">Recent reports on the modulation of the PMN have demonstrated promising therapeutic outcomes, underscoring the potential of the PMN as a target for treating tumor metastasis [<xref ref-type="bibr" rid="CR270">270</xref>&#8211;<xref ref-type="bibr" rid="CR272">272</xref>]. This highlights the growing recognition of the PMN as a valuable focal point in the battle against metastatic disease. Growing evidence indicates that S100A9, a critical inflammatory regulator, contributes to the formation of the PMN, particularly in the lungs. Researchers have devised a vaccine targeting S100A9 using VLPs and plant viruses, demonstrating the efficacy of S100A9 vaccine candidates in inhibiting the dissemination of metastatic disease and tumor seeding in the lungs [<xref ref-type="bibr" rid="CR189">189</xref>]. Lu et al [<xref ref-type="bibr" rid="CR273">273</xref>]. showed that exosomes derived from &#945;-fetoprotein-expressing DCs (DEX<sub>AFP</sub>) can be used to create a novel class of vaccines intended for customized immunotherapy. This outcome can be attributed to the possibility that DEX<sub>AFP</sub> can alter the TME in HCC mice and elicit strong antigen-specific anti-cancer immune responses. The ES-exo/GM-CSF vaccine, which is produced from murine ESCs modified to create GM-CSF, has been shown in a recent mouse-model-based study to offer protection against metastasized lung cancers (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>) [<xref ref-type="bibr" rid="CR274">274</xref>].</p><p id="Par175">Combining personalized nanovaccines with ICB also shows promise in the treatment of the PMN. For example, Zhou et al [<xref ref-type="bibr" rid="CR275">275</xref>]. developed a hydrogel-based toolkit to be used as a cancer vaccine to treat postoperative BC. This innovative approach integrates CXCR4 inhibition, immunogenicity activation, and PD-L1 blockade strategies. The hydrogel toolkit effectively inhibits local residual tumor cell &#8220;seeds,&#8221; as well as produces an abscopal effect by disrupting the PMN &#8220;soil.&#8221;<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Targeting circulating tumor cells (CTCs) and secondary tumors through nanovaccines. In the last stage of the metastatic cascade, CTCs attempt to transit through the blood or lymphatic vessels, colonizing distant sites as disseminated tumor cells. The basis of nanomedicine lies in halting this process. Specifically, personalized nanovaccines may modulate the polymorphonuclear neutrophil leukocyte (PMN), thus rendering it less suitable for CTCs. Alternatively, these vaccines may directly target established metastasis. Specifically, nanovaccines are designed to: (1) target extracellular vesicles, as with DEXAFP and ES-exo/GM-CSF; (2) target inflammatory molecules and hypoxia factors, as with virus-like particles (VLPs), plant viruses, and the hydrogel toolbox combined with PD-L1 blockade; and (3) target the immune environment, as with Tu-NPFN, Ln-NPR848, and OMPN. Nanovaccines with active targeting could be important for driving innovation in personalized medicine, as they allow for the treatment of patients using optimal and site-specific subtypes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="13045_2024_1628_Fig6_HTML.jpg"/></fig></p><p id="Par176">In the last stage of the metastatic cascade, CTCs attempt to transit through the blood or lymphatic vessels, colonizing distant sites as disseminated tumor cells. The basis of nanomedicine lies in halting this process. Specifically, personalized nanovaccines may modulate the polymorphonuclear neutrophil leukocyte (PMN), thus rendering it less suitable for CTCs. Alternatively, these vaccines may directly target established metastasis. Specifically, nanovaccines are designed to: [<xref ref-type="bibr" rid="CR1">1</xref>]. target extracellular vesicles, as with DEX<sub>AFP</sub> and ES-exo/GM-CSF; [<xref ref-type="bibr" rid="CR2">2</xref>]. target inflammatory molecules and hypoxia factors, as with virus-like particles (VLPs), plant viruses, and the hydrogel toolbox combined with PD-L1 blockade; and [<xref ref-type="bibr" rid="CR3">3</xref>]. target the immune environment, as with Tu-NPFN, Ln-NPR848, and OMPN. Nanovaccines with active targeting could be important for driving innovation in personalized medicine, as they allow for the treatment of patients using optimal and site-specific subtypes.</p></sec><sec id="Sec38"><title>Targeting established metastasis with nanovaccines</title><p id="Par177">Tumor cells look for places that are conducive to colonization as they travel throughout the body. The liver, brain, lungs, LNs, and bone are the most desirable organs for tumor colonization [<xref ref-type="bibr" rid="CR276">276</xref>]. However, because of their inherent characteristics, certain organs and systems may present challenges for targeted drug delivery. An example is the metastasis to the central nervous system (CNS), where the blood&#8211;brain barrier hinders the passage of numerous therapeutic drugs from penetrating the affected area. Notably, tailored NPs have demonstrated an amazing capacity to move payloads across the blood&#8211;brain barrier [<xref ref-type="bibr" rid="CR23">23</xref>]. A CXCL13-modified nanocapsule was created by Wen et al. to encapsulate the anti-cancer antibody rituximab, which was later found in the CNS at low concentrations [<xref ref-type="bibr" rid="CR277">277</xref>]. The permeability of rituximab across the blood&#8211;brain barrier was significantly enhanced by the cholinergic analogs of the polymer shell, resulting in its concentration being increased in the CNS, culminating in the effective treatment of brain lymphomas.</p><p id="Par178">In addition to addressing brain metastasis, tackling lymphatic metastasis presents challenges; these challenges can largely be attributed to the unique anatomy of the lymphatic system. Smaller NPs can exploit this feature [<xref ref-type="bibr" rid="CR278">278</xref>]. Liu et al. developed acidity-responsive, clustered NPs with adjustable diameters [<xref ref-type="bibr" rid="CR279">279</xref>]. Initially sized at 100&#160;nm and shrinking to 5&#160;nm upon reaching the tumor site, these NPs facilitated the following processes: prolonged circulation and enhanced penetration into solid tumors, diffusion into interstitial fluid, and intravasation into tumor lymphatics. In contrast, Jin et al. proposed an innovative approach involving the synergistic application of two nanomedicines, Tu-NPFN and Ln-NPR848. Under the guidance of an alternating magnetic field, Tu-NPFN produced many antigens. Concurrently, Ln-NPR848 encapsulated the adjuvant R848, directing some of the produced antigens toward the synthesis of in situ nanovaccines and their targeted distribution to LNs. Remarkably, in conjunction with an anti-CTLA4 antibody, the therapy demonstrated notable efficacy in completely eradicating distant tumors in certain mice while simultaneously demonstrating evidence of an immunological memory effect that prevented tumor dissemination [<xref ref-type="bibr" rid="CR79">79</xref>]. Another study introduced a multifunctional nanovaccine, OMPN, created using a simple one-pot method that included elements such as OVA, MnO<sub>2</sub>, and polydopamine. This nanovaccine demonstrated significant anti-cancer efficacy against orthotopic melanoma and was efficient in preventing the spread in a mouse model of liver metastasis of tumor recurrence [<xref ref-type="bibr" rid="CR34">34</xref>]. Importantly, magnetic resonance image tracking of the interaction between nanovaccines and DCs in the inguinal LNs indicated effective DC activation and an immunological response.</p><p id="Par179">An ionized iron nanoadjuvant can be self-assembled with model antigen OVA to build a tumor nanovaccine. During the activation of STING signaling, the nanovaccine could effectively promote the cytoplasmic delivery of the antigen, thus achieving efficient antigen cross-presentation. This system demonstrated a nearly 170-fold enhancement in the antigen-specific CD8<sup>+</sup> T lymphocyte response, along with significant tumor growth and inhibition prevention&#160;in a B160VA melanoma mouse model. In addition to producing a long-lasting anti-tumor immunological memory effect, the combination of nanovaccine and ICB therapy dramatically reduced the postoperative recurrence and distal metastasis of B16OVA and MC38 tumors [<xref ref-type="bibr" rid="CR39">39</xref>]. In addition, LN-IMQ monotherapy resulted in complete tumor regression in 6 out of 8 4T1-bearing mice, with the cured mice showing resistance to secondary tumor challenges. LN-IMQ also reduced the incidence of lung metastases and proved effective against advanced metastatic disease [<xref ref-type="bibr" rid="CR132">132</xref>]. A general concept for tailored personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy has been reported. The fluoropolymer-based nanovaccine can trigger anti-tumor immune responses with excellent efficiency. The combination of nanovaccines and immune checkpoint inhibitors can effectively suppress distant tumor growth and metastasis after surgery [<xref ref-type="bibr" rid="CR66">66</xref>]. In addition, an advanced in situ nanovaccine was developed using layered double hydroxides to carry cGAMP (a STING agonist) and adsorb TAAs, designed to enhance the anti-tumor immune response triggered by radiofrequency ablation. After treatment with the nanovaccine, there was a&#160;marked increase in CTLs and activated DCs in the tumors and LNs, resulting in a marked suppression of primary, distant, and metastatic lesions of liver cancer [<xref ref-type="bibr" rid="CR280">280</xref>]. Furthermore, an in situ nanovaccine (TPOP) based on innate immunostimulatory NPs and lipid metabolism regulation can reportedly capture tumor antigens and cause specific recognition and uptake by TIDC through a systemic anti-tumor immune response. When paired with immune checkpoint inhibitors, TPOP can significantly inhibit the growth of distant tumors [<xref ref-type="bibr" rid="CR209">209</xref>].</p><p id="Par180">In many patients, the presence of tumor cells may remain unnoticed until they have already spread throughout the body or even established secondary colonies. Consequently, although the strategies discussed earlier can aid in preventing or delaying the progression of established metastases, they may not achieve complete eradication. To effectively address established metastases, therapeutic agents must possess the capacity to eliminate tumor cells rather than merely inhibit their growth.</p></sec></sec></sec><sec id="Sec39"><title>Anti-metastatic nanovaccines and nanovaccine-based combination immunotherapies in clinical trials</title><p id="Par181">To date, only a few nanovaccines have progressed into clinical trials for the treatment of cancer metastasis. This limited translation into clinical settings is primarily because of the challenges associated with large-scale manufacturing and quality control of complex nanobiomaterials. Nonetheless, several phase I/II clinical trials have demonstrated promising clinical translation potential for various types of nanovaccines in treating metastatic solid cancers, including BC, glioblastoma, gastric cancer, colorectal cancer, prostate cancer, cervical cancer, endometrial cancer, uveal melanoma,&#160;pancreatic&#160;cancer, non-small cell lung cancer, and other solid cancers (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Tumor nanovaccines for metastasis and recurrence in clinical trials in the past 5&#160;years</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Classifications</th><th align="left" colspan="1" rowspan="1">Nanoplatforms</th><th align="left" colspan="1" rowspan="1">Name</th><th align="left" colspan="1" rowspan="1">Active component</th><th align="left" colspan="1" rowspan="1">Design and arms</th><th align="left" colspan="1" rowspan="1">Cancer type</th><th align="left" colspan="1" rowspan="1">Primary objective</th><th align="left" colspan="1" rowspan="1">Results</th><th align="left" colspan="1" rowspan="1">Phases</th><th align="left" colspan="1" rowspan="1">NCT Number (status)/ Refs.</th></tr></thead><tbody><tr><td align="left" rowspan="30" colspan="1">Biomimetic nanovaccine</td><td align="left" colspan="1" rowspan="1">Whole-cell vaccine</td><td align="left" colspan="1" rowspan="1">Mixed vaccine</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Control vs. mix&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Metastatic colorectal cancer</td><td align="left" colspan="1" rowspan="1">Relief degree of tumors</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03357276">NCT03357276</ext-link> (Completed)</td></tr><tr><td align="left" rowspan="3" colspan="1">Gene-modified tumor cell</td><td align="left" rowspan="3" colspan="1">Allogeneic GM-CSF-secreting breast cancer vaccine</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Allogeneic GM-CSF-secreting breast cancer&#160;vaccine&#8201;+&#8201;Trastuzumab&#8201;+&#8201;Cyclophosphamide</td><td align="left" colspan="1" rowspan="1">HER-2/neu-overexpressing metastatic BC</td><td align="left" colspan="1" rowspan="1">Adverse events, clinical benefit</td><td align="left" colspan="1" rowspan="1">Overall median PFS and OS were 7&#160;months and 42&#160;months, respectively; the 5-year survival rate was 30% [<xref ref-type="bibr" rid="CR6">6</xref> of <xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00399529">NCT00399529</ext-link> (Completed) [<xref ref-type="bibr" rid="CR311">311</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Cyclophosphamide&#8201;+&#8201;Vaccine vs. -Cyclophosphamide&#8201;+&#8201;zVaccine&#8201;+&#8201;Trastuzumab</td><td align="left" colspan="1" rowspan="1">Metastatic HER2-negative breast cancer</td><td align="left" colspan="1" rowspan="1">Toxicity, clinical benefit</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00971737">NCT00971737</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Trastuzumab&#8201;+&#8201;Cyclophosphamide&#8201;+&#8201;vaccine</td><td align="left" colspan="1" rowspan="1">High risk/metastatic&#160;HER-2/Neu- overexpressing BC</td><td align="left" colspan="1" rowspan="1">Safety</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00847171">NCT00847171</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">Genetically modified autologous DCs</td><td align="left" colspan="1" rowspan="1">Anti-HER2/HER3 DC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Anti-HER2/HER3 dendritic cell vaccine&#8201;+&#8201;Pembrolizumab</td><td align="left" colspan="1" rowspan="1">Brain metastatic malignancy, metastatic TNBC</td><td align="left" colspan="1" rowspan="1">CNS, ORR</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348747">NCT04348747</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen DC&#160;vaccine</td><td align="left" colspan="1" rowspan="1">NA DC&#160;vaccine</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Neoantigen DC&#160;vaccine&#8201;+&#8201;Nivolumab</td><td align="left" colspan="1" rowspan="1">Liver&#160;metastases&#160;from CRC</td><td align="left" colspan="1" rowspan="1">Relapse free survival, immune response</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04912765">NCT04912765</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Antigen-loaded DC-based&#160;vaccines</td><td align="left" colspan="1" rowspan="1">Dendritic Cells for endometrial cancer</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Dendritic Cells for endometrial cancer</td><td align="left" colspan="1" rowspan="1">Metastaticendometrial&#160;cancer</td><td align="left" colspan="1" rowspan="1">Immunologic efficacy</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04212377">NCT04212377</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">CAR-DC&#160;Vaccine</td><td align="left" colspan="1" rowspan="1">KRAS-EphA-2-CAR-DC</td><td align="left" colspan="1" rowspan="1">Autologous EphA2-targeting CAR-DC&#160;vaccine&#160;loaded with KRAS mutant peptide</td><td align="left" colspan="1" rowspan="1">KRAS-EphA-2-CAR-DC&#8201;+&#8201;Anti-PD-1/CTLA4 antibody</td><td align="left" colspan="1" rowspan="1">Metastatic solid tumors</td><td align="left" colspan="1" rowspan="1">Safety, efficacy, immune response</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05631899">NCT05631899</ext-link> (Recruiting)</td></tr><tr><td align="left" rowspan="12" colspan="1">DC-based vaccines</td><td align="left" colspan="1" rowspan="1">Dendritic cell vaccination</td><td align="left" colspan="1" rowspan="1">Autologous DCs pulsed with lysate derived from an allogeneic stem-like cell line</td><td align="left" colspan="1" rowspan="1">Dendritic cell vaccination&#8201;&#177;&#8201;bevacizumab</td><td align="left" colspan="1" rowspan="1">Recurrent glioblastoma with minimal residual tumor</td><td align="left" colspan="1" rowspan="1">Safety, tolerability</td><td align="left" colspan="1" rowspan="1">mPFS 3.23&#160;months, 6-month PFS 24%, mOS 11.97&#160;months</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02010606">NCT02010606</ext-link> (Completed) [<xref ref-type="bibr" rid="CR283">283</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DC IKKb</td><td align="left" colspan="1" rowspan="1">IKKb-matured, RNA-loaded DCs</td><td align="left" colspan="1" rowspan="1">DC IKKb</td><td align="left" colspan="1" rowspan="1">Metastasized uveal melanoma</td><td align="left" colspan="1" rowspan="1">Safety, Tolerability, DLTS, MTD</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04335890">NCT04335890</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">MesoPher/Mitazalimab</td><td align="left" colspan="1" rowspan="1">DCs Loaded With Allogeneic&#160;Tumor&#160;Lysate (MesoPher) and a CD40 Agonist (Mitazalimab)</td><td align="left" colspan="1" rowspan="1">MesoPher/Mitazalimab</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;pancreatic&#160;cancer</td><td align="left" colspan="1" rowspan="1">DLTs</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05650918">NCT05650918</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">PEP-DC&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Autologous dendritic cell&#160;vaccine&#160;loaded with personalized peptides</td><td align="left" colspan="1" rowspan="1">PEP-DC vaccine&#8201;+&#8201;cyclophosphamide</td><td align="left" colspan="1" rowspan="1">Metastatic NSCLC</td><td align="left" colspan="1" rowspan="1">AEs</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05195619">NCT05195619</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">HER2-pulsed dendritic cell&#160;vaccine</td><td align="left" colspan="1" rowspan="1">DC1&#160;vaccine</td><td align="left" colspan="1" rowspan="1">DC1&#160;vaccine&#8201;+&#8201;Trastuzumab&#8201;+&#8201;Pepinemab&#8201;+&#8201;T-cell therapy</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;HER2&#8201;+&#8201;BC</td><td align="left" colspan="1" rowspan="1">MTD</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05378464">NCT05378464</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">DC/PANVAC</td><td align="left" colspan="1" rowspan="1">autologous&#160;DCs modified with&#160;PANVAC</td><td align="left" colspan="1" rowspan="1">Bcl-Xl_42-CAF09b&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Prostate&#160;cancer&#160;with lymph node&#160;metastases</td><td align="left" colspan="1" rowspan="1">Safety</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03412786">NCT03412786</ext-link>(Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA tumor antigen-pulsed DCs</td><td align="left" colspan="1" rowspan="1">mRNA-pulsed autologous DCs</td><td align="left" colspan="1" rowspan="1">mRNA-pulsed autologous DCs</td><td align="left" colspan="1" rowspan="1">Advanced cancer patients with brain metastases</td><td align="left" colspan="1" rowspan="1">Adverse events</td><td align="left" colspan="1" rowspan="1">Favorable overall survival, without obvious autoimmune adverse events</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02808416">NCT02808416</ext-link> (Completed) [<xref ref-type="bibr" rid="CR282">282</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;DC1-TBVA&#160;vaccine</td><td align="left" colspan="1" rowspan="1">DC vaccine incorporating tumor blood vessel antigen-derived peptides</td><td align="left" colspan="1" rowspan="1">Gemcitabine hydrochloride (GEM)&#8201;+&#8201;&#945;DC1-TBVA&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Metastatic breast cancer</td><td align="left" colspan="1" rowspan="1">Safety, clinical response</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02479230">NCT02479230</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">Prodencel</td><td align="left" colspan="1" rowspan="1">autologous dendritic cell vaccine</td><td align="left" colspan="1" rowspan="1">Prodencel; an autologous dendritic cell therapeutic tumor vaccine</td><td align="left" colspan="1" rowspan="1">mCRPC</td><td align="left" colspan="1" rowspan="1">Safety</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05533203">NCT05533203</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">MIDRIX4-LUNG</td><td align="left" colspan="1" rowspan="1">Tetravalent autologous dendritic cell vaccine</td><td align="left" colspan="1" rowspan="1">Intra-patient dose escalation of intravenous MIDRIX4-LUNG autologous DC vaccine</td><td align="left" colspan="1" rowspan="1">Metastatic NSCLC</td><td align="left" colspan="1" rowspan="1">Toxicity, maximal tolerated dose</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04082182">NCT04082182</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Multiepitope DC&#160;Vaccine</td><td align="left" colspan="1" rowspan="1">Autologous DCs</td><td align="left" colspan="1" rowspan="1">Therapeutic autologous dendritic cells&#8201;+&#8201;trastuzumab&#8201;+&#8201;vinorelbine</td><td align="left" colspan="1" rowspan="1">Locally recurrent or metastatic BC</td><td align="left" colspan="1" rowspan="1">Efficacy, toxicity</td><td align="left" colspan="1" rowspan="1">Safe and can induce immune responses</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00266110">NCT00266110</ext-link> (Completed)[<xref ref-type="bibr" rid="CR312">312</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">BPX101</td><td align="left" colspan="1" rowspan="1">PSMA- targeting autologous DC</td><td align="left" colspan="1" rowspan="1">BPX-201&#8201;+&#8201;AP1903</td><td align="left" colspan="1" rowspan="1">Metastatic prostate cancer</td><td align="left" colspan="1" rowspan="1">Safety, tolerability</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01823978">NCT01823978</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">T cell-based vaccine</td><td align="left" colspan="1" rowspan="1">Allogeneic HPV-specific T Cells</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Allogeneic bone marrow transplant, CD8-depleted donor lymphocyte infusion (DLI) per dose escalation scheme</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;HPV16&#8201;+&#8201;cancer</td><td align="left" colspan="1" rowspan="1">Safety, MTD</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04713046">NCT04713046</ext-link> (Not yet recruiting)</td></tr><tr><td align="left" rowspan="9" colspan="1">Neoantigen vaccines</td><td align="left" colspan="1" rowspan="1">PNVAC</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">PNVAC&#8201;+&#8201;adjuvant ISA 51 (subcutaneously) following adjuvant chemotherapy (capecitabine/S1&#8201;+&#8201;oxaliplatin or S-1&#8201;+&#8201;docetaxel)</td><td align="left" colspan="1" rowspan="1">Post-surgical resection/ recurrence of stage IIIB/IIIC/IVA GC</td><td align="left" colspan="1" rowspan="1">Safety, immune response</td><td align="left" colspan="1" rowspan="1">Higher one- and two-year survival rates 96.6% (28/29), 82.4% (14/17)) than historical record)</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">ChiCTR1800017319/[<xref ref-type="bibr" rid="CR295">295</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">EVAX-01-CAF09b</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">EVAX-01-CAF09b&#8201;+&#8201;Anti-PD-1 or Anti-PD-L1</td><td align="left" colspan="1" rowspan="1">Metastatic solid&#160;tumors</td><td align="left" colspan="1" rowspan="1">Adverse events</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03715985">NCT03715985</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">OVM-200</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">OVM-200</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;NSCLC, ovarian&#160;Cancer, prostate&#160;Cancer</td><td align="left" colspan="1" rowspan="1">Safety, tolerability</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05104515">NCT05104515</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">VB10.NEO</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">VB10.NEO&#8201;+&#8201;Atezolizumab</td><td align="left" colspan="1" rowspan="1">Metastatic solid&#160;tumors</td><td align="left" colspan="1" rowspan="1">AEs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05018273">NCT05018273</ext-link>(Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Neoantigen DNA&#160;vaccine</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Neoantigen DNA&#160;vaccine&#8201;+&#8201;Ipilimumab/Nivolumab</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;hormone-sensitive prostate&#160;cancer</td><td align="left" colspan="1" rowspan="1">Safety, tolerability, immune response</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03532217">NCT03532217</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">AlloStim&#174;</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AlloStim vs. AlloStim&#8201;+&#8201;cryoablation</td><td align="left" colspan="1" rowspan="1">Metastati colorectal&#160;cancer</td><td align="left" colspan="1" rowspan="1">Safety</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02380443">NCT02380443</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">GVAX</td><td align="left" colspan="1" rowspan="1">Allogeneic colon cancer cell vaccine administered with a GM-CSF producing bystander cell line</td><td align="left" colspan="1" rowspan="1">GVAX&#8201;+&#8201;Cyclophosphamide</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;colorectal&#160;cancer</td><td align="left" colspan="1" rowspan="1">Toxicity</td><td align="left" colspan="1" rowspan="1">The six of nine&#160;patients who underwent curative metastasectomy survived longer than 36&#160;months, and four of these six patients were without disease recurrence</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00656123">NCT00656123</ext-link> (Completed) [<xref ref-type="bibr" rid="CR313">313</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GVAX pancreas&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Granulocyte&#8211;macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells</td><td align="left" colspan="1" rowspan="1">Cyclophosphamide/GVAX&#8201;+&#8201;CRS-207 vs. CRS-207 vs. standard chemotherapy</td><td align="left" colspan="1" rowspan="1">Metastatic pancreatic cancer</td><td align="left" colspan="1" rowspan="1">OS</td><td align="left" colspan="1" rowspan="1">The combination of Cy/GVAX&#8201;+&#8201;CRS-207 did not improve survival; no treatment-related deaths occurred</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02004262">NCT02004262</ext-link> (completed)[<xref ref-type="bibr" rid="CR314">314</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">GRT-C901/GRT-R902</td><td align="left" colspan="1" rowspan="1">Patient-specific neoantigen&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Control vs. GRT-C901/GRT-R902&#8201;+&#8201;Atezolizumab/Ipilimumab&#8201;+&#8201;fluoropyrimidine/bevacizumab vs. fluoropyrimidine/bevacizumab</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;colorectal&#160;cancer</td><td align="left" colspan="1" rowspan="1">ctDNA, PFS</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II/III</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05141721">NCT05141721</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" rowspan="10" colspan="1">Peptide vaccines</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Vigil&#8482;&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Autologous whole-cell vaccine, Vigil&#8482;</td><td align="left" colspan="1" rowspan="1">Placebo vs. Vigil&#8482;&#160;Vaccine</td><td align="left" colspan="1" rowspan="1">Colorectal carcinoma with liver&#160;metastases</td><td align="left" colspan="1" rowspan="1">Immune analysis, percent of patients who progressed or survived after treatment</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01505166">NCT01505166</ext-link> (Terminated)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">IMU-131</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">IMU-131&#8201;+&#8201;Chemotherapy or Pembrolizumab</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas</td><td align="left" colspan="1" rowspan="1">ORR, AEs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05311176">NCT05311176</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">AE37</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">AE37&#8201;+&#8201;Pembrolizumab</td><td align="left" colspan="1" rowspan="1">mTNBC</td><td align="left" colspan="1" rowspan="1">Adverse events, ORR</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04024800">NCT04024800</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Multi-peptide cancer vaccine</td><td align="left" colspan="1" rowspan="1">PVX-410</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">PVX-410&#8201;+&#8201;Pembrolizumab&#8201;+&#8201;Chemotherapy</td><td align="left" colspan="1" rowspan="1">Metastatic TNBC</td><td align="left" colspan="1" rowspan="1">PFS</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04634747">NCT04634747</ext-link> (Not yet recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Synthetic long peptides</td><td align="left" colspan="1" rowspan="1">ISA101b&#160;Vaccine</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Cemiplimab&#8201;+&#8201;ISA101b&#160;Vaccine</td><td align="left" colspan="1" rowspan="1">Metastatic HPV 16 cervical&#160;cancer</td><td align="left" colspan="1" rowspan="1">ORR</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04646005">NCT04646005</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Multi-peptide vaccine</td><td align="left" colspan="1" rowspan="1">PolyPEPI1018</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">PolyPEPI1018&#8201;+&#8201;Atezolizumab</td><td align="left" colspan="1" rowspan="1">mCRC</td><td align="left" colspan="1" rowspan="1">Adverse events</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05243862">NCT05243862</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Multi-peptide vaccine</td><td align="left" colspan="1" rowspan="1">PolyPEPI1018</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">PolyPEPI1018&#8201;+&#8201;TAS-102</td><td align="left" colspan="1" rowspan="1">mCRC</td><td align="left" colspan="1" rowspan="1">Adverse events</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05130060">NCT05130060</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">SurVaxM</td><td align="left" colspan="1" rowspan="1">Survivin long peptide&#160;vaccine</td><td align="left" colspan="1" rowspan="1">SVN53-67/M57-KLH peptide&#160;vaccine&#8201;+&#8201;sargramostim&#8201;+&#8201;octreotide acetate</td><td align="left" colspan="1" rowspan="1">Survivin positive metastatic pancreatic neuroendocrine&#160;tumor</td><td align="left" colspan="1" rowspan="1">safety, tolerability, toxicity</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03879694">NCT03879694</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">A recombinant protein</td><td align="left" colspan="1" rowspan="1">dHER2&#8201;+&#8201;AS15&#160;cancer&#160;vaccine</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">dHER2&#8201;+&#8201;AS15 ASCI vs. dHER2&#8201;+&#8201;AS15 ASCI&#8201;+&#8201;Lapatinib</td><td align="left" colspan="1" rowspan="1">Metastatic breast cancer</td><td align="left" colspan="1" rowspan="1">Safety</td><td align="left" colspan="1" rowspan="1">No cardiotoxicity; immunogenic with promising long-term survival in those with HER2-overexpressing breast cancers</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00952692">NCT00952692</ext-link> (Completed)[<xref ref-type="bibr" rid="CR315">315</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">UCPVax</td><td align="left" colspan="1" rowspan="1">Universal&#160;cancer&#160;peptide-based vaccination</td><td align="left" colspan="1" rowspan="1">UCPVax</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;NSCLC</td><td align="left" colspan="1" rowspan="1">DLT, dose-related immunogenicity</td><td align="left" colspan="1" rowspan="1">The 1-year PFS and the median OS were 17.2% and 11.6&#160;months in immune responders (P&#8201;=&#8201;0.015)</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02818426">NCT02818426</ext-link> (Active, not recruiting)[<xref ref-type="bibr" rid="CR316">316</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DNA&#160;vaccines</td><td align="left" colspan="1" rowspan="1">Plasmid&#160;DNA&#160;vaccine</td><td align="left" colspan="1" rowspan="1">pTVG-HP, pTVG-AR</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">pTVG-HP&#8201;+&#8201;Pembrolizumab vs. pTVG-AR&#8201;+&#8201;pTVG-HP&#8201;+&#8201;Pembrolizumab</td><td align="left" colspan="1" rowspan="1">Metastaticprostate&#160;cancer</td><td align="left" colspan="1" rowspan="1">PFS</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04090528">NCT04090528</ext-link> (Recruiting)</td></tr><tr><td align="left" rowspan="9" colspan="1">Viral&#160;vaccine</td><td align="left" colspan="1" rowspan="1">Modified vaccinia Ankara (MVA) virus</td><td align="left" colspan="1" rowspan="1">MVA-BN-Brachyury</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">MVA-BN-Brachyury</td><td align="left" colspan="1" rowspan="1">Metastatic or unresectable locally advanced malignant solid tumors</td><td align="left" colspan="1" rowspan="1">DLT</td><td align="left" colspan="1" rowspan="1">Safe, tolerable</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04134312">NCT04134312</ext-link>(Complete) [<xref ref-type="bibr" rid="CR285">285</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Autologous, cell-based, HPV therapeutic cancer vaccine</td><td align="left" colspan="1" rowspan="1">SQZ-eAPC-HPV</td><td align="left" colspan="1" rowspan="1">Autologous, cell-based, HPV therapeutic cancer vaccine</td><td align="left" colspan="1" rowspan="1">SQZ-eAPC-HPV vs. SQZ-eAPC-HPV&#8201;+&#8201;ICBs</td><td align="left" colspan="1" rowspan="1">HPV16&#8201;+&#8201;metastatic solid&#160;tumors</td><td align="left" colspan="1" rowspan="1">AEs, DLTs</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05357898">NCT05357898</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Autologous PBMCs modified to present HPV16 antigens</td><td align="left" colspan="1" rowspan="1">SQZ-PBMC-HPV</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">SQZ-PBMC-HPV&#8201;+&#8201;nivolumab/ipilimumab/atezolizumab</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;solid&#160;tumors</td><td align="left" colspan="1" rowspan="1">AEs, ORR, PFS, OS</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04084951">NCT04084951</ext-link> (Completed)</td></tr><tr><td align="left" colspan="1" rowspan="1">autologous RBCs</td><td align="left" colspan="1" rowspan="1">SQZ-AAC-HPV</td><td align="left" colspan="1" rowspan="1">autologous RBCs engineered to deliver synthetic long peptides (SLP) of HPV16 E6, E7 and the adjuvant, poly I:C</td><td align="left" colspan="1" rowspan="1">SQZ-AAC-HPV vs. SQZ-AAC-HPV&#8201;+&#8201;nivolumab and/or ipilimumab</td><td align="left" colspan="1" rowspan="1">Metastatic HPV16&#8201;+&#8201;solid tumors</td><td align="left" colspan="1" rowspan="1">AEs, DLT</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04892043">NCT04892043</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Arenavirus Pichinde virus/arenavirus lymphocytic choriomeningitis virus</td><td align="left" colspan="1" rowspan="1">HB-302/HB-301</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">HB-302/HB-301 Alternating 2-Vector Therapy</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;prostate&#160;cancer</td><td align="left" colspan="1" rowspan="1">DLT, AEs, ORR</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05553639">NCT05553639</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">A modified measles virus</td><td align="left" colspan="1" rowspan="1">MV-s-NAP</td><td align="left" colspan="1" rowspan="1">Measles virus derivative expressing the helicobacter pylori neutrophil-activating protein</td><td align="left" colspan="1" rowspan="1">MV-s-NAP</td><td align="left" colspan="1" rowspan="1">Metastatic BC</td><td align="left" colspan="1" rowspan="1">Safety, toxicity</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04521764">NCT04521764</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Poxviral-based vaccine</td><td align="left" colspan="1" rowspan="1">BN-CV301&#160;vaccine</td><td align="left" colspan="1" rowspan="1">A recombinant poxviral vaccine targeting MUC1 and CEA with co-stimulatory molecules</td><td align="left" colspan="1" rowspan="1">SX-682 followed by BinTraFusp Alfa&#8201;+&#8201;CV301</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;solid&#160;tumors</td><td align="left" colspan="1" rowspan="1">DLT, AEs</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04574583">NCT04574583</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Virus-based vaccine</td><td align="left" colspan="1" rowspan="1">ETBX-021</td><td align="left" colspan="1" rowspan="1">A modified adenovirus 5 that is inserted into the HER2 gene</td><td align="left" colspan="1" rowspan="1">ETBX-021</td><td align="left" colspan="1" rowspan="1">Metastatic HER2-low BC</td><td align="left" colspan="1" rowspan="1">MTD, DLTs, AEs,</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02751528">NCT02751528</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Adenovirus&#160;vaccine</td><td align="left" colspan="1" rowspan="1">AdMA3 vaccine</td><td align="left" colspan="1" rowspan="1">Adenovirus vaccine with transgenic MAGE-A3 insertion</td><td align="left" colspan="1" rowspan="1">MG1MA3 virus vs. AdMA3 vaccine&#160;vs. AdMA3&#8201;+&#8201;MG1MA3</td><td align="left" colspan="1" rowspan="1">Metastatic MAGE-A3-expressing solid tumors</td><td align="left" colspan="1" rowspan="1">Toxicity, ORR</td><td align="left" colspan="1" rowspan="1">Feasible, induce anti-tumor immune response</td><td align="left" colspan="1" rowspan="1">I/II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02285816">NCT02285816</ext-link> (Active, not recruiting) [<xref ref-type="bibr" rid="CR317">317</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">Lipid nanoparticle</td><td align="left" colspan="1" rowspan="1">mRNA Lipid NPs</td><td align="left" colspan="1" rowspan="1">mRNA-2752</td><td align="left" colspan="1" rowspan="1">mRNA encoding human OX40L, IL-23, and IL-36&#947;</td><td align="left" colspan="1" rowspan="1">mRNA-2752 alone vs. mRNA-2752&#8201;+&#8201;Durvalumab</td><td align="left" colspan="1" rowspan="1">Relapsed/refractory solid tumor</td><td align="left" colspan="1" rowspan="1">Safety, tolerability, immune response</td><td align="left" colspan="1" rowspan="1">Elicit anti-tumor T cells</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link> (Recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Pegylated liposome</td><td align="left" colspan="1" rowspan="1">Pegylated liposomal doxorubicin</td><td align="left" colspan="1" rowspan="1">Doxorubicin</td><td align="left" colspan="1" rowspan="1">Chemo only vs. Chemo&#8201;+&#8201;ipilimumab&#8201;+&#8201;nivolumab</td><td align="left" colspan="1" rowspan="1">Metastatic BC</td><td align="left" colspan="1" rowspan="1">Toxicity, PFS</td><td align="left" colspan="1" rowspan="1">Induce a Type I interferon immune response</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03409198">NCT03409198</ext-link> (Active, not recruiting)</td></tr><tr><td align="left" colspan="1" rowspan="1">Polymeric nanoparticles</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">NLG207 (CRLX101)</td><td align="left" colspan="1" rowspan="1">Camptothecin</td><td align="left" colspan="1" rowspan="1">CRLX101&#8201;+&#8201;Enzalutamide</td><td align="left" colspan="1" rowspan="1">mCRPC</td><td align="left" colspan="1" rowspan="1">Anti-tumor activity</td><td align="left" colspan="1" rowspan="1">Study was closed for toxicity, two of the four patients experienced DLTs</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03531827">NCT03531827</ext-link> (Terminated) [<xref ref-type="bibr" rid="CR293">293</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Inorganic</td><td align="left" colspan="1" rowspan="1">allogenic large multivalent immunogen (LMI) vaccines in silica particles</td><td align="left" colspan="1" rowspan="1">LMI&#160;Vaccine&#160;With IL-2</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">LMI Vaccination&#8201;+&#8201;IL-2</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;BC</td><td align="left" colspan="1" rowspan="1">Disease response</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">II</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00784524">NCT00784524</ext-link> (Terminated)</td></tr><tr><td align="left" colspan="1" rowspan="1">Exosomal&#160;vaccines</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Chimeric exosomal&#160;tumor&#160;vaccines</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">Chimeric exosomal tumor&#160;vaccines</td><td align="left" colspan="1" rowspan="1">Metastatic&#160;BC</td><td align="left" colspan="1" rowspan="1">Clinical response rate, OS, safety</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05559177">NCT05559177</ext-link> (Recruiting)</td></tr></tbody></table><table-wrap-foot><p>BC breast cancer, <italic toggle="yes">DCs</italic> dendritic cells, <italic toggle="yes">CNS</italic> central nervous system symptoms, <italic toggle="yes">RR</italic> relative risk, <italic toggle="yes">TNBC</italic> triple-negative breast cancer, <italic toggle="yes">CRC</italic> colorectal cancer, <italic toggle="yes">DLTS</italic> dose-limiting toxicity, <italic toggle="yes">MTD</italic> maximum tolerated dose, <italic toggle="yes">AEs</italic> adverse events, <italic toggle="yes">NSCLC</italic> non-small cell lung cancer, <italic toggle="yes">ORR</italic> objective response rate, <italic toggle="yes">PFS</italic> progression-free survival, <italic toggle="yes">OS</italic> overall survival</p></table-wrap-foot></table-wrap></p><sec id="Sec40"><title>Nanovaccine monotherapy</title><p id="Par182">DCs exert critical effects in the initiation of the primary response and the induction of an anti-metastasis-specific immune response. DC vaccine therapies are developed to elicit tumor-specific cytotoxic T-cell responses. DC-derived exosome-based nanovaccines have shown favorable safety profiles in phase I clinical trials of patients with metastatic melanoma [<xref ref-type="bibr" rid="CR281">281</xref>]. Moreover, mRNA tumor antigen-pulsed DCs induce TAA-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses without severe autoimmune adverse events and are associated with favorable overall survival [<xref ref-type="bibr" rid="CR282">282</xref>]. In a single-institution phase I trial involving 25 patients with recurrent glioblastoma&#160;multiforme, an autologous DC vaccine loaded with a lysate from an allogeneic stem-like cell line demonstrated safety and tolerability, with a six-month progression-free survival (PFS) rate of 24%, a median survival of 11.97&#160;months, and a median PFS of 3.23&#160;months, showing favorable outcomes compared to historical controls [<xref ref-type="bibr" rid="CR283">283</xref>].</p><p id="Par183">Besides TAAs and TSAs, CIGB-247, a multiple-TME-targeting vaccine that uses a variant of human VEGF mixed with the bacteria-derived adjuvant VSSP, was demonstrated to be safe and immunogenic for metastatic disease in a clinical trial [<xref ref-type="bibr" rid="CR284">284</xref>]. For instance, a recent phase I study has been completed utilizing DCs pulsed with tumor blood vessel antigens (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02479230">NCT02479230</ext-link>).</p><p id="Par184">Bavarian Nordic (BN)-brachyury represents a novel prime&#8211;boost therapeutic tumor immunotherapy approach. It comprises a modified vaccinia Ankara (MVA)-vector vaccine followed by an FPV-vector booster vaccine, both targeting the transcription factor brachyury [<xref ref-type="bibr" rid="CR285">285</xref>]. In a phase I open-label trial of the intravenous administration of the MVA-BN-brachyury-TRICOM vaccine among patients with advanced cancer, the maximal administered dose was 10<sup>9</sup>&#160;infectious units every three weeks for three doses [<xref ref-type="bibr" rid="CR286">286</xref>]. This dose was recommended as phase II dose because of its safety and tolerability.</p><p id="Par185">Nanovaccines have been shown to be safe and effective in the treatment of cancer, indicating good biocompatibility and few side effects. Overall, these outcomes warrant investment into their continued development in the context of general oncology.</p></sec><sec id="Sec41"><title>Nanovaccine-based combination therapy</title><p id="Par186">Suppressing tumors by inducing an anti-tumor immune response typically requires a considerable amount of time, making it challenging to completely eradicate progressive primary tumors solely through host anti-tumor immunity. Hence, the integration of nanovaccine-based immunotherapy with other complementary therapies (e.g., chemotherapy, PTT, and photodynamic therapy) can result in a synergistic response against metastasis [<xref ref-type="bibr" rid="CR108">108</xref>].</p><p id="Par187">Therapeutic mRNA vaccine technology has promoted the development of personalized neoantigen vaccines by facilitating the rapid development of personalized vaccines that express a wide array of new antigens and activate APCs. Additionally, these vaccines can be delivered using clinically validated LNPs. In a small phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04161755">NCT04161755</ext-link>) of an mRNA pancreatic cancer vaccine, a personalized mRNA vaccine strategy was developed, namely, autogene cevumeran (BNT122). This strategy facilitates the expression of 20 new antigens of patients with PDAC, using LNPs for intravenous administration. The personalized mRNA vaccine, when combined with mFOLFIRINOX regimen and anti-PD-L1 antibody, resulted in 50% of pancreatic cancer patients who underwent tumor resection not showing signs of recurrence after 18&#160;months; in addition, these patients showed no side effects [<xref ref-type="bibr" rid="CR287">287</xref>].</p><p id="Par188">After 30&#160;years of failed attempts, this is the first successful trial of a pancreatic cancer mRNA vaccine. Although this innovation is still in its early stages, it is important to acknowledge it as a great milestone that shows great promise in yielding novel and highly effective anti-cancer treatments. The mRNA vaccine technology enables the rapid development, large-scale production, and delivery of vaccines without significantly delayed treatment of rapidly progressive pancreatic cancer.</p><p id="Par189">Another innovative personalized cancer vaccine based on mRNA, mRNA-4157/V940, consists of a single mRNA encoding 34 tumor neoantigens. Theoretically, this vaccine should be capable of eliciting both MHC class I and MHC class II presentation pathways. The design of this vaccine is rooted in its high specificity for the genomic information of an individual patient. In the phase IIb KEYNOTE-942/mRNA-4157-P201 clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03897881">NCT03897881</ext-link>), the mRNA vaccine was combined with the anti-PD-1 therapy KEYTRUDA&#174; for adjuvant treatment of completely resected stage III/IV melanoma patients; overall, 157 patients have thus far been recruited for this trial. Compared to KEYTRUDA alone, the use of mRNA-4157/V940 in combination with KEYTRUDA for adjuvant treatment has been shown to reduce the risk of recurrence or death by 44% [<xref ref-type="bibr" rid="CR288">288</xref>].</p><p id="Par190">A pivotal phase III clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05933577">NCT05933577</ext-link>) has been initiated to evaluate the efficacy and safety of the tumor neoantigen mRNA vaccine (mRNA-4157) combined with the PD-1 inhibitor KEYTRUDA as am adjuvant therapy for high-risk cutaneous melanoma patients who have undergone surgical resection (stage IIB&#8211;IV). Additionally, in the past 2&#160;years, trials combining mRNA-4157 with KEYTRUDA have been conducted for renal cell carcinoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06307431">NCT06307431</ext-link>, phase II), non-small cell lung cancer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06077760">NCT06077760</ext-link>, phase III), cutaneous squamous cell carcinoma (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06295809">NCT06295809</ext-link>, phase II/III), and bladder cancer (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06305767">NCT06305767</ext-link>, phase II).</p><p id="Par191">Nanovaccines have been combined with the aim of creating or re-establishing a TME that favors the generation of anti-tumor immune responses, offering promising clinical translation potential. For example, HER 3 overexpression in triple-negative and HER 2-positive brain metastatic breast cancer is a resistance factor to HER 2-targeted therapy as well as a driver of CNS metastasis. Therefore, a phase II clinical study is currently exploring the combination of the HER 2 / HER 3-targeting &#945; DC1 vaccine with pembrolizumab in patients with asymptomatic brain metastases derived from triple-negative or HER 2-positive breast cancer. Similarly, a phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03739931">NCT03739931</ext-link>) is evaluating mRNA-2752, which encodes human OX40L, IL-23, and IL-36&#947; and is loaded into LNPs; this approach is intended to manage recurring or treatment-resistant solid tumors. Notably, unlike other tumor types that elicit anti-tumor T cells, the efficacy of mRNA-2752 combined with ICB has not been explored in the treatment of colorectal cancer [<xref ref-type="bibr" rid="CR289">289</xref>].</p><p id="Par192">The ASPIRE nanovaccine is crafted from genetically modified nanovesicles that originate from the cell membranes of dendritic cells infected with adenovirus. This innovative vaccine combines antigen self-presentation with the reversal of immunosuppression. By utilizing a programmed approach to attach specific components, it markedly improves the delivery of antigens to lymphoid organs. The nanovaccine generates extensive T-cell responses that can eradicate existing tumors and offers a powerful vaccine formulation that can effectively activate both naive and exhausted T cells for cancer immunotherapy [<xref ref-type="bibr" rid="CR290">290</xref>].</p><p id="Par193">In vivo, the topical TLR-7 agonist imiquimod activates DCs, enhancing antigen processing and presentation through type 1 interferon secretion. This activation upregulates immune co-stimulatory molecules in tumors, leading to cancer growth inhibition [<xref ref-type="bibr" rid="CR291">291</xref>]. The combination of imiquimod and systemic albumin-bound paclitaxel has shown to effectively reduce disease progression in treatment-resistant breast cancer of the chest wall while exhibiting manageable toxicity. Importantly, pre-existing levels of cells that indicate T-cell exhaustion or systemic immunosuppression may act as markers to identify patients likely to respond favorably to the treatment.</p><p id="Par194">Enzalutamide, an androgen receptor antagonist, is the standard therapy option against metastatic prostate cancer [<xref ref-type="bibr" rid="CR292">292</xref>]. A single-arm phase II study was conducted on patients with progressive, metastatic, castration-resistant prostate cancer who had already progressed on enzalutamide. In this study, a combination treatment of 1&#160;mg/m of CRLX101, a NP topoisomerase I inhibitor containing camptothecin, was administered [<xref ref-type="bibr" rid="CR293">293</xref>]. However, the study was terminated because of toxicity, with two of the four patients experienced dose-limiting toxicities.</p><p id="Par195">Primary tumors have been shown to secrete high levels of granulocyte CSF, driving epigenetic changes in bone marrow granulocyte monocyte precursor cells. This trend culminates in the disruption of the immune system, with APCs being most impacted. Consequently, nanovaccines targeting metastases are rendered ineffective [<xref ref-type="bibr" rid="CR294">294</xref>]. Debulking surgery can reverse tumor-growth-driven changes in the immune system; specifically, this approach corrects the dysfunction of APCs, thereby restoring the effectiveness of nanovaccines. These findings highlight the importance of the holistic consideration of the immune environment affected by tumor growth when designing and evaluating tumor nanovaccines. Combining primary tumor resection with NanoVac emerges as a promising and radical treatment for widely metastatic tumors [<xref ref-type="bibr" rid="CR294">294</xref>]. In a phase I clinical trial (ChiCTR1800017319), researchers developed and assessed the safety and feasibility of a personalized neoantigen nanovaccine (PNVAC) platform targeting tumors. The focus of this trial was to use the PNVAC to slow the progression of gastric cancer in high-risk patients with gastric/gastroesophageal junction cancer after receiving adjuvant chemotherapy following surgery [<xref ref-type="bibr" rid="CR295">295</xref>]. The trial demonstrated markedly improved 1- and 2-year disease-free survival rates compared to previously published outcomes. In another clinical study, patients received treatment with a PVNAC combined with PD-1 monoclonal antibody and/or anti-angiogenic drugs (ChiCTR1900022986). The PVNAC was shown to be safe and well-tolerated. Clinical responses were observed in combination with PD-1 monoclonal antibody and anti-angiogenic drugs, and neoantigen-specific T-cell responses were detected following vaccination.&#160;In terms of its mechanism, the PNVAC triggers CD4&#8201;+&#8201;and CD8&#8201;+&#8201;T-cell responses, along with the presence of antigen-experienced memory T cells that can still be detected 1&#160;year after the administration of the vaccine.</p><p id="Par196">The careful timing of administration is essential to avoid interference between the combined treatments. Overall, clinical trials evaluating nanovaccines for the treatment of metastatic cancer have failed to yield convincing results. Moreover, there is a scarcity of phase III trials involving patients with metastatic disease.</p></sec></sec><sec id="Sec42"><title>Challenges and future perspectives</title><p id="Par197">Nanovaccines demonstrate significant anti-metastasis effects in animal tumor models, offering advantages such as safety and reduced side effects. However, several challenges still need to be addressed prior to their clinical translation.</p><p id="Par198">First, the vast heterogeneity of biological barriers in patients with metastatic cancers presents a challenge in effectively evaluating NP platforms across diverse populations. This diversity may obscure the potential success of these platforms in treating specific subgroups. To tackle this issue, there is a need for increased stratified trials and customized nanovaccines [<xref ref-type="bibr" rid="CR23">23</xref>]. However, the development of personalized vaccines requires the challenging task of efficiently and accurately identifying patient-specific antigens, underscoring the importance of enhancing the integration of biotechniques and computer simulation methods for antigen sequencing and identification. Cancer cell membranes derived from the tumor of an individual patient could be used to coat NPs, with the aim of ensuring the use of an optimal set of antigens for training the immune system.</p><p id="Par199">The large-scale production of nanovaccines with acceptable batch-to-batch differences remains a significant challenge. This challenge can be attributed to the currently volatile nature of these vaccines and their inherently high manufacturing costs. For example, tumor immunotherapy using autologous APCs is expensive and time consuming [<xref ref-type="bibr" rid="CR12">12</xref>]. For efficient large-scale production, nanobiomaterials require several key traits, including biodegradability, biocompatibility, and biostability. Additionally, their preparation methods should be well established and reliable. For example, the biocompatibility and biodegradability of nanocarriers, particularly inorganic nanocarriers, require further investigation [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, we should strive to find an efficient and economical method for up-scaling nanovaccine production. Furthermore, balancing functional complexity and structural simplicity in vaccine design is necessary for successful clinical applications. Simpler nanobiomaterials are more conducive to clinical translation. LNPs with straightforward compositions and established production methods appear promising for future human testing [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par200">Challenges also persist in chemistry, manufacturing, and control processes. For instance, ensuring that cellular components are free of heat and pathogen contamination while eliminating denatured proteins is crucial to prevent potential immune responses against endogenous antigens. In addition, antigen/adjuvant leakage and the scaled-up production of biomimetic nanovaccines are significant hurdles in clinical translation [<xref ref-type="bibr" rid="CR296">296</xref>]. Thus, establishing a quality control standard during chemistry, manufacturing, and control research is imperative [<xref ref-type="bibr" rid="CR296">296</xref>].</p><p id="Par201">The combined use of nanovaccines and immune checkpoint inhibitors has a complementary mechanism in tumor immunotherapy [<xref ref-type="bibr" rid="CR297">297</xref>, <xref ref-type="bibr" rid="CR298">298</xref>]. Combining vaccines with immune checkpoint inhibitors could potentially lead to a synergistic effect, enhancing the immune response against tumors [<xref ref-type="bibr" rid="CR299">299</xref>]. However, immune checkpoint inhibitors can activate both tumor-specific T cells and other non-specific T cells, which may lead to side effects such as cytokine storms. Ideally, the focus should be on eliminating inhibitory signals specifically targeting the activated tumor-specific T cells while preserving the inhibitory signals for other self-antigens. It would be most effective to selectively activate only those T cells that are able to recognize this specific group of antigens. However, this could increase the cost of drug development, thus highlighting the need for further investigation and consideration in future research.</p><p id="Par202">In addition, the complete response rate for the strategy of combining a vaccine with immune checkpoint inhibitors remains unresolved. Liu et al. described a genetically engineered cell membrane nanocesicle antigen self-presentation and immunosuppression reversal (ASPIRE) strategy that may disrupt the general vaccine development routine, improve the efficiency of antigen presentation through antigen self-presentation, and drive CD8 T cell-led immunity against tumors with a strong CTL immune response [<xref ref-type="bibr" rid="CR290">290</xref>].</p><p id="Par203">The outcomes of nanovaccines with immunotherapy are also influenced by previous treatment history, specific tumor biology, and systemic effects of cancer on the immune system, which often cannot be predicted accurately by pre-clinical studies. Difficulty in assessing the limitations of preclinical models and the "over-interpretation" of preclinical data may lead to a lack of sufficient biological basis for combinatorial therapies. Pre-identified biomarkers could enhance the effectiveness of combinatorial therapies [<xref ref-type="bibr" rid="CR300">300</xref>].</p><p id="Par204">Overall, the investigation of NPs for vaccine delivery remains in its infancy, and numerous challenges remain for researchers to overcome. These challenges include understanding the mechanisms by which physiochemical properties determine the anti-tumor effect through their impact on NP biodistribution and targeting ability, maintaining consistent characteristics during manufacturing, and integrating nanovaccines with other therapeutic modalities to achieve more effective results. These challenges limit the clinical translation of nanovaccines and underscore the need for further extensive research.</p><p id="Par205">Nanovaccines encapsulate antigens and adjuvants into nanocarriers, effectively enhancing the stability, durability, and immunogenicity of vaccines. Nanovaccines can be channeled toward addressing tumor metastasis by enhancing the immune memory effect of the immune system. Additionally, these vaccines can facilitate precise treatment, since they can be designed on the basis of the immune characteristics of an individual patient and the specificity of the tumor, thereby achieving personalized treatment, improving treatment outcomes, and reducing side effects. Nanovaccines show great potential in their applicability toward the treatment of cancer metastasis, as they have thus far been shown to improve treatment outcomes and reduce treatment risks. Considering the continuous development and improvement of nanotechnology, nanovaccines are expected to yield a wide range of applications and breakthroughs in the context of cancer treatment.</p></sec><sec id="Sec43"><title>Conclusions</title><p id="Par206">Personalized anti-metastatic nanovaccines are unique in their ability to precisely target specific groups of cancerous cells, significantly setting them apart from traditional anti-cancer nanomedicines. Nanocarriers of various sizes, compositions, and physical parameters have been used to develop a range of nanovaccine strategies that target different stages of metastasis, thus preventing its progression. To develop precise anti-metastasis nanovaccines, the selection of appropriate NP platforms meeting specific requirements is crucial. This review has highlighted various promising NP platforms for developing anti-metastasis nanovaccines, including synthetic, semi-biogenic, and biogenic nanosystems, and emphasizes their physical and pharmacological properties in enhancing the efficacy of cancer vaccines against metastasis. Additionally, we have discussed the latest trends in combining nanovaccines with cancer immunotherapy to address various steps in the metastatic cascade, drawing insights from both preclinical and clinical research.</p><p id="Par207">The design of personalized nanovaccines is based on the consideration of the crucial role of NPs in vaccine stability, antigen recognition, and delivery. These NPs can exhibit high tumor penetration, aid in the effective delivery of vaccine components to the lymphatic system and provide a suitable environment to enhance immune responses. The strategies discussed in this review can be used to combat the complex primary TME, modulate the metabolic microenvironment, reprogram the TIME, and target various cell types and stromal components within the TME. Furthermore, nanovaccines have the potential to intercept CTCs and combat secondary tumors by reshaping the microenvironment in distant metastatic organs, including modulating the PMN and targeting established metastases.</p><p id="Par208">Although personalized nanovaccines hold promise in the treatment of solid cancer metastasis, challenges persist, including low clinical response rates. To overcome these challenges, researchers are continuously improving the design of nanocarriers, exploring more effective combinations of antigens and adjuvants, and integrating personalized nanovaccines with other cancer treatment methods to enhance therapeutic outcomes. The strategic development of nanovaccines will facilitate the precise administration of different antigens, adjuvants, and immune-regulatory substances, greatly transcending the capabilities of traditional vaccination methods. Thus, nanovaccines emerge as a promising strategy for both suppressing primary tumors and preventing tumor metastasis by enhancing long-term anti-cancer immune responses. The development of personalized nanovaccines holds even greater promise for patients with cancer in the future.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>aAPC</term><def><p id="Par2">Artificial APC</p></def></def-item><def-item><term>APC</term><def><p id="Par3">Antigen-presenting cell</p></def></def-item><def-item><term>AuNP</term><def><p id="Par4">Gold nanoparticle</p></def></def-item><def-item><term>ASPIRE</term><def><p id="Par5">Antigen self-presentation and immunosuppression reversal</p></def></def-item><def-item><term>BC</term><def><p id="Par6">Breast cancer</p></def></def-item><def-item><term>BN</term><def><p id="Par7">Bavarian Nordic</p></def></def-item><def-item><term>CAF</term><def><p id="Par8">Cancer-associated fibroblast</p></def></def-item><def-item><term>CNP</term><def><p id="Par9">Carbon nanoparticle</p></def></def-item><def-item><term>CNS</term><def><p id="Par10">Central nervous system</p></def></def-item><def-item><term>CpG</term><def><p id="Par11">Cytosine&#8211;phosphate&#8211;guanosine oligonucleotides</p></def></def-item><def-item><term>CSC</term><def><p id="Par12">Cancer stem cell</p></def></def-item><def-item><term>CTC</term><def><p id="Par13">Circulating tumor cell</p></def></def-item><def-item><term>CTL</term><def><p id="Par14">Cytotoxic T lymphocyte</p></def></def-item><def-item><term>DC</term><def><p id="Par15">Dendritic cell</p></def></def-item><def-item><term>DEX<sub>AFP</sub></term><def><p id="Par16">Fetoprotein-expressing dendritic cell</p></def></def-item><def-item><term>ECM</term><def><p id="Par17">Extracellular matrix</p></def></def-item><def-item><term>EMT</term><def><p id="Par18">Epithelial&#8211;mesenchymal transition</p></def></def-item><def-item><term>FAP</term><def><p id="Par19">Fibroblast activation protein</p></def></def-item><def-item><term>GM-CSF</term><def><p id="Par20">Granulocyte-macrophage colony-stimulating factor</p></def></def-item><def-item><term>HCC</term><def><p id="Par21">Hepatocellular carcinoma</p></def></def-item><def-item><term>HIF</term><def><p id="Par22">Hypoxia-inducible factor</p></def></def-item><def-item><term>HSA</term><def><p id="Par23">Human serum albumin</p></def></def-item><def-item><term>ICB</term><def><p id="Par24">Immune checkpoint blockade</p></def></def-item><def-item><term>IFN</term><def><p id="Par25">Interferon</p></def></def-item><def-item><term>IL-2</term><def><p id="Par26">Interleukin-2</p></def></def-item><def-item><term>LNP</term><def><p id="Par27">Lipid nanoparticle</p></def></def-item><def-item><term>LN</term><def><p id="Par28">Lymph node</p></def></def-item><def-item><term>LPHNP</term><def><p id="Par29">Lipid&#8211;polymer hybrid nanoparticle</p></def></def-item><def-item><term>MAN-IMO-PS</term><def><p id="Par30">Mannose-functionalized lipid-hybrid polymersomes</p></def></def-item><def-item><term>MHC</term><def><p id="Par31">Histocompatibility complex class</p></def></def-item><def-item><term>mLPR</term><def><p id="Par32">MPLA/mRNA tumor vaccine</p></def></def-item><def-item><term>MMPI</term><def><p id="Par33">Matrix metalloproteinase inhibitor</p></def></def-item><def-item><term>MMP</term><def><p id="Par34">Matrix metalloproteinase</p></def></def-item><def-item><term>MSN</term><def><p id="Par35">Mesoporous silica (or silicon) nanoparticle</p></def></def-item><def-item><term>MVA</term><def><p id="Par36">Modified vaccinia Ankara</p></def></def-item><def-item><term>NG</term><def><p id="Par37">Nanogel</p></def></def-item><def-item><term>NIR</term><def><p id="Par38">Near-infrared</p></def></def-item><def-item><term>NK</term><def><p id="Par39">Natural killer</p></def></def-item><def-item><term>NP</term><def><p id="Par40">Nanoparticle</p></def></def-item><def-item><term>OMV</term><def><p id="Par41">Outer membrane vesicle</p></def></def-item><def-item><term>OVA</term><def><p id="Par42">Ovalbumin</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par43">Programmed cell death ligand 1</p></def></def-item><def-item><term>PDAC</term><def><p id="Par44">Pancreatic ductal adenocarcinoma</p></def></def-item><def-item><term>PEG</term><def><p id="Par45">Polyethylene glycol</p></def></def-item><def-item><term>PFS</term><def><p id="Par46">Progression-free survival</p></def></def-item><def-item><term>PLGA</term><def><p id="Par47">Poly (lactic-co-glycolic acid)</p></def></def-item><def-item><term>PMN</term><def><p id="Par48">Polymorphonuclear neutrophil leukocyte</p></def></def-item><def-item><term>PNVAC</term><def><p id="Par49">Personalized neoantigen nanovaccine</p></def></def-item><def-item><term>PRR</term><def><p id="Par50">Pattern recognition receptor</p></def></def-item><def-item><term>PTT</term><def><p id="Par51">Photothermal treatment</p></def></def-item><def-item><term>siRNA</term><def><p id="Par52">Small interfering RNA</p></def></def-item><def-item><term>SPION</term><def><p id="Par53">Superparamagnetic iron oxide nanoparticle</p></def></def-item><def-item><term>STING</term><def><p id="Par54">Stimulators of interferon gene</p></def></def-item><def-item><term>TAA</term><def><p id="Par55">Tumor-associated antigen</p></def></def-item><def-item><term>TAF</term><def><p id="Par56">Tumor-associated fibroblast</p></def></def-item><def-item><term>TGF</term><def><p id="Par57">Transforming growth factor</p></def></def-item><def-item><term>Th1</term><def><p id="Par58">T helper type 1</p></def></def-item><def-item><term>Th2</term><def><p id="Par59">T helper type 2</p></def></def-item><def-item><term>TIME</term><def><p id="Par60">Tumor immune microenvironment</p></def></def-item><def-item><term>TLR4</term><def><p id="Par61">Toll-like receptor 4</p></def></def-item><def-item><term>TME</term><def><p id="Par62">Tumor microenvironment</p></def></def-item><def-item><term>Treg</term><def><p id="Par63">Regulatory T cell</p></def></def-item><def-item><term>TRP2</term><def><p id="Par64">Tumor-associated self-antigen</p></def></def-item><def-item><term>TSA</term><def><p id="Par65">Tumor-specific antigen</p></def></def-item><def-item><term>VEGF</term><def><p id="Par66">Vascular endothelial growth factor</p></def></def-item><def-item><term>VLP</term><def><p id="Par67">Virus-like particle</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Tang Feng, Jia Hu have contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We sincerely appreciate Zhirong Zhang from the Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry of Sichuan University, and Yang Yang from the Animal Experimental Center of West China Hospital for their assistance and suggestions.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Lingling Zhu and Jirui Wen: Conceptualization. Tang Feng and Jia Hu: Investigation, Writing &#8211; Original Draft, Visualization. Lingling Zhu, Guowei Che, Qinghua Zhou and Zhiyong Qian: Writing &#8211; Review &amp; Editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by grants from the National Natural Science Foundation of China (No. 82202989, No. 32401087); Sichuan Science and Technology Program (No. 2023YFS0163, No. 2023NSFSC1742); and Sichuan Province Science and Technology Activities Funding for Returned Overseas Scholars (awarded to Lingling Zhu) for financial support.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par209">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par210">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fares</surname><given-names>J</given-names></name><name name-style="western"><surname>Fares</surname><given-names>MY</given-names></name><name name-style="western"><surname>Khachfe</surname><given-names>HH</given-names></name><name name-style="western"><surname>Salhab</surname><given-names>HA</given-names></name><name name-style="western"><surname>Fares</surname><given-names>Y</given-names></name></person-group><article-title>Molecular principles of metastasis: a hallmark of cancer revisited</article-title><source>Signal Transduct Target Ther</source><year>2020</year><volume>5</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-0134-x</pub-id><pub-id pub-id-type="pmid">32296047</pub-id><pub-id pub-id-type="pmcid">PMC7067809</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28.<pub-id pub-id-type="pmid">32296047</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-0134-x</pub-id><pub-id pub-id-type="pmcid">PMC7067809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chua</surname><given-names>D</given-names></name><name name-style="western"><surname>Tan</surname><given-names>NS</given-names></name></person-group><article-title>Reactive oxygen species: a volatile driver of field cancerization and metastasis</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s12943-019-0961-y</pub-id><pub-id pub-id-type="pmid">30927919</pub-id><pub-id pub-id-type="pmcid">PMC6441160</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Liao Z, Chua D, Tan NS. Reactive oxygen species: a volatile driver of field cancerization and metastasis. Mol Cancer. 2019;18:65.<pub-id pub-id-type="pmid">30927919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-019-0961-y</pub-id><pub-id pub-id-type="pmcid">PMC6441160</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castaneda</surname><given-names>M</given-names></name><name name-style="western"><surname>den Hollander</surname><given-names>P</given-names></name><name name-style="western"><surname>Kuburich</surname><given-names>NA</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Mani</surname><given-names>SA</given-names></name></person-group><article-title>Mechanisms of cancer metastasis</article-title><source>Semin Cancer Biol</source><year>2022</year><volume>87</volume><fpage>17</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2022.10.006</pub-id><pub-id pub-id-type="pmid">36354098</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Castaneda M, den Hollander P, Kuburich NA, Rosen JM, Mani SA. Mechanisms of cancer metastasis. Semin Cancer Biol. 2022;87:17&#8211;31.<pub-id pub-id-type="pmid">36354098</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2022.10.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganesh</surname><given-names>K</given-names></name><name name-style="western"><surname>Massagu&#233;</surname><given-names>J</given-names></name></person-group><article-title>Targeting metastatic cancer</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>34</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01195-4</pub-id><pub-id pub-id-type="pmid">33442008</pub-id><pub-id pub-id-type="pmcid">PMC7895475</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ganesh K, Massagu&#233; J. Targeting metastatic cancer. Nat Med. 2021;27:34&#8211;44.<pub-id pub-id-type="pmid">33442008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-01195-4</pub-id><pub-id pub-id-type="pmcid">PMC7895475</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGinnis</surname><given-names>CS</given-names></name><name name-style="western"><surname>Miao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Superville</surname><given-names>D</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W</given-names></name><name name-style="western"><surname>Goga</surname><given-names>A</given-names></name><name name-style="western"><surname>Reticker-Flynn</surname><given-names>NE</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>J</given-names></name><name name-style="western"><surname>Satpathy</surname><given-names>AT</given-names></name></person-group><article-title>The temporal progression of lung immune remodeling during breast cancer metastasis</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><issue>6</issue><fpage>1018</fpage><lpage>1031.e6</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2024.05.004</pub-id><pub-id pub-id-type="pmid">38821060</pub-id><pub-id pub-id-type="pmcid">PMC11255555</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">McGinnis CS, Miao Z, Superville D, Yao W, Goga A, Reticker-Flynn NE, Winkler J, Satpathy AT. The temporal progression of lung immune remodeling during breast cancer metastasis. Cancer Cell. 2024;42(6):1018-1031.e6. 10.1016/j.ccell.2024.05.004.<pub-id pub-id-type="pmid">38821060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2024.05.004</pub-id><pub-id pub-id-type="pmcid">PMC11255555</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>NM</given-names></name><name name-style="western"><surname>Chadwick</surname><given-names>TB</given-names></name><name name-style="western"><surname>Parker</surname><given-names>BS</given-names></name></person-group><article-title>The complexity of immune evasion mechanisms throughout the metastatic cascade</article-title><source>Nat Immunol</source><year>2024</year><volume>25</volume><fpage>1793</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1038/s41590-024-01960-4</pub-id><pub-id pub-id-type="pmid">39285252</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Haynes NM, Chadwick TB, Parker BS. The complexity of immune evasion mechanisms throughout the metastatic cascade. Nat Immunol. 2024;25:1793&#8211;808.<pub-id pub-id-type="pmid">39285252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-024-01960-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuengkham</surname><given-names>H</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><name name-style="western"><surname>Shin</surname><given-names>IW</given-names></name><name name-style="western"><surname>Lim</surname><given-names>YT</given-names></name></person-group><article-title>Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy</article-title><source>Adv Mater</source><year>2019</year><volume>31</volume><fpage>e1803322</fpage><pub-id pub-id-type="doi">10.1002/adma.201803322</pub-id><pub-id pub-id-type="pmid">30773696</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Phuengkham H, Ren L, Shin IW, Lim YT. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy. Adv Mater. 2019;31: e1803322.<pub-id pub-id-type="pmid">30773696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201803322</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis</article-title><source>Chin Med J (Engl)</source><year>2023</year><volume>136</volume><fpage>2787</fpage><lpage>2801</lpage><pub-id pub-id-type="pmid">37442772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000002525</pub-id><pub-id pub-id-type="pmcid">PMC10686602</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Zhu L, Wu J, Gao H, Wang T, Xiao G, Hu C, Lin Q, Zhou Q. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis. Chin Med J (Engl). 2023;136:2787&#8211;801.<pub-id pub-id-type="pmid">37442772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000002525</pub-id><pub-id pub-id-type="pmcid">PMC10686602</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>D</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L</given-names></name></person-group><article-title>Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside</article-title><source>Exp Hematol Oncol</source><year>2024</year><volume>13</volume><fpage>72</fpage><pub-id pub-id-type="doi">10.1186/s40164-024-00539-x</pub-id><pub-id pub-id-type="pmid">39085965</pub-id><pub-id pub-id-type="pmcid">PMC11292955</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, Xu X, Nie Y, Fan D, Wu K, Xia L. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13:72.<pub-id pub-id-type="pmid">39085965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40164-024-00539-x</pub-id><pub-id pub-id-type="pmcid">PMC11292955</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Nanomedicine-based immunotherapy for the treatment of cancer metastasis</article-title><source>Adv Mater</source><year>2019</year><volume>31</volume><fpage>e1904156</fpage><pub-id pub-id-type="doi">10.1002/adma.201904156</pub-id><pub-id pub-id-type="pmid">31566275</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Zhang P, Zhai Y, Cai Y, Zhao Y, Li Y. Nanomedicine-based immunotherapy for the treatment of cancer metastasis. Adv Mater. 2019;31: e1904156.<pub-id pub-id-type="pmid">31566275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201904156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy</article-title><source>Chem Soc Rev</source><year>2016</year><volume>45</volume><fpage>6250</fpage><lpage>6269</lpage><pub-id pub-id-type="doi">10.1039/C6CS00458J</pub-id><pub-id pub-id-type="pmid">27333329</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Liang C, Xu L, Song G, Liu Z. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy. Chem Soc Rev. 2016;45:6250&#8211;69.<pub-id pub-id-type="pmid">27333329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c6cs00458j</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liew</surname><given-names>SS</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Pu</surname><given-names>K</given-names></name></person-group><article-title>Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines</article-title><source>Adv Mater</source><year>2022</year><volume>34</volume><fpage>e2103790</fpage><pub-id pub-id-type="doi">10.1002/adma.202103790</pub-id><pub-id pub-id-type="pmid">34651344</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Liu J, Liew SS, Wang J, Pu K. Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines. Adv Mater. 2022;34: e2103790.<pub-id pub-id-type="pmid">34651344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202103790</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>AC</given-names></name><name name-style="western"><surname>Goubier</surname><given-names>A</given-names></name><name name-style="western"><surname>Kohrt</surname><given-names>HE</given-names></name></person-group><article-title>A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial</article-title><source>J Immunother Cancer</source><year>2015</year><volume>3</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s40425-015-0093-x</pub-id><pub-id pub-id-type="pmid">26579225</pub-id><pub-id pub-id-type="pmcid">PMC4647658</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Tan AC, Goubier A, Kohrt HE. A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer. 2015;3:48.<pub-id pub-id-type="pmid">26579225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-015-0093-x</pub-id><pub-id pub-id-type="pmcid">PMC4647658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>WH</given-names></name><name name-style="western"><surname>Su</surname><given-names>JY</given-names></name><name name-style="western"><surname>Li</surname><given-names>YM</given-names></name></person-group><article-title>Rational design of T-Cell- and B-Cell-based therapeutic cancer vaccines</article-title><source>Acc Chem Res</source><year>2022</year><volume>55</volume><fpage>2660</fpage><lpage>2671</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.2c00360</pub-id><pub-id pub-id-type="pmid">36048514</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Li WH, Su JY, Li YM. Rational design of T-Cell- and B-Cell-based therapeutic cancer vaccines. Acc Chem Res. 2022;55:2660&#8211;71.<pub-id pub-id-type="pmid">36048514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.2c00360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tagliamonte</surname><given-names>M</given-names></name><name name-style="western"><surname>Cavalluzzo</surname><given-names>B</given-names></name><name name-style="western"><surname>Mauriello</surname><given-names>A</given-names></name><name name-style="western"><surname>Ragone</surname><given-names>C</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>FM</given-names></name><name name-style="western"><surname>Tornesello</surname><given-names>ML</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>L</given-names></name></person-group><article-title>Molecular mimicry and cancer vaccine development</article-title><source>Mol Cancer</source><year>2023</year><volume>22</volume><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01776-0</pub-id><pub-id pub-id-type="pmid">37101139</pub-id><pub-id pub-id-type="pmcid">PMC10131527</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, Buonaguro L. Molecular mimicry and cancer vaccine development. Mol Cancer. 2023;22:75.<pub-id pub-id-type="pmid">37101139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01776-0</pub-id><pub-id pub-id-type="pmcid">PMC10131527</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viswanath</surname><given-names>DI</given-names></name><name name-style="western"><surname>Liu</surname><given-names>HC</given-names></name><name name-style="western"><surname>Huston</surname><given-names>DP</given-names></name><name name-style="western"><surname>Chua</surname><given-names>CYX</given-names></name><name name-style="western"><surname>Grattoni</surname><given-names>A</given-names></name></person-group><article-title>Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines</article-title><source>Biomaterials</source><year>2022</year><volume>280</volume><fpage>121297</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121297</pub-id><pub-id pub-id-type="pmid">34902729</pub-id><pub-id pub-id-type="pmcid">PMC8725170</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Viswanath DI, Liu HC, Huston DP, Chua CYX, Grattoni A. Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. Biomaterials. 2022;280: 121297.<pub-id pub-id-type="pmid">34902729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.121297</pub-id><pub-id pub-id-type="pmcid">PMC8725170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G</given-names></name><name name-style="western"><surname>Ding</surname><given-names>B</given-names></name></person-group><article-title>A DNA nanodevice-based vaccine for cancer immunotherapy</article-title><source>Nat Mater</source><year>2021</year><volume>20</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0793-6</pub-id><pub-id pub-id-type="pmid">32895504</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Liu S, Jiang Q, Zhao X, Zhao R, Wang Y, Wang Y, Liu J, Shang Y, Zhao S, Wu T, Zhang Y, Nie G, Ding B. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2021;20:421&#8211;30.<pub-id pub-id-type="pmid">32895504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41563-020-0793-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Q</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Development of individualized anti-metastasis strategies by engineering nanomedicines</article-title><source>Chem Soc Rev</source><year>2015</year><volume>44</volume><fpage>6258</fpage><lpage>6286</lpage><pub-id pub-id-type="doi">10.1039/C4CS00511B</pub-id><pub-id pub-id-type="pmid">26056688</pub-id><pub-id pub-id-type="pmcid">PMC4540626</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">He Q, Guo S, Qian Z, Chen X. Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev. 2015;44:6258&#8211;86.<pub-id pub-id-type="pmid">26056688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c4cs00511b</pub-id><pub-id pub-id-type="pmcid">PMC4540626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerstberger</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ganesh</surname><given-names>K</given-names></name></person-group><source>Metastasis Cell</source><year>2023</year><volume>186</volume><fpage>1564</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">37059065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.03.003</pub-id><pub-id pub-id-type="pmcid">PMC10511214</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Gerstberger S, Jiang Q, Ganesh K. Metastasis Cell. 2023;186:1564&#8211;79.<pub-id pub-id-type="pmid">37059065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.03.003</pub-id><pub-id pub-id-type="pmcid">PMC10511214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name></person-group><article-title>Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets</article-title><source>Semin Cancer Biol</source><year>2020</year><volume>60</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.08.012</pub-id><pub-id pub-id-type="pmid">31421262</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14&#8211;27.<pub-id pub-id-type="pmid">31421262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2019.08.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>G</given-names></name><name name-style="western"><surname>Pothuraju</surname><given-names>R</given-names></name><name name-style="western"><surname>Kanchan</surname><given-names>RK</given-names></name><name name-style="western"><surname>Batra</surname><given-names>SK</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>JA</given-names></name></person-group><article-title>Chemokines network in bone metastasis: vital regulators of seeding and soiling</article-title><source>Semin Cancer Biol</source><year>2022</year><volume>86</volume><fpage>457</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2022.02.003</pub-id><pub-id pub-id-type="pmid">35124194</pub-id><pub-id pub-id-type="pmcid">PMC9744380</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sharma G, Pothuraju R, Kanchan RK, Batra SK, Siddiqui JA. Chemokines network in bone metastasis: vital regulators of seeding and soiling. Semin Cancer Biol. 2022;86:457&#8211;72.<pub-id pub-id-type="pmid">35124194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2022.02.003</pub-id><pub-id pub-id-type="pmcid">PMC9744380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name></person-group><article-title>Tumor organoids: applications in cancer modeling and potentials in precision medicine</article-title><source>J Hematol Oncol</source><year>2022</year><volume>15</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01278-4</pub-id><pub-id pub-id-type="pmid">35551634</pub-id><pub-id pub-id-type="pmcid">PMC9103066</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Xu H, Jiao D, Liu A, Wu K. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol. 2022;15:58.<pub-id pub-id-type="pmid">35551634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-022-01278-4</pub-id><pub-id pub-id-type="pmcid">PMC9103066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Billingsley</surname><given-names>MM</given-names></name><name name-style="western"><surname>Haley</surname><given-names>RM</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>ME</given-names></name><name name-style="western"><surname>Peppas</surname><given-names>NA</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R</given-names></name></person-group><article-title>Engineering precision nanoparticles for drug delivery</article-title><source>Nat Rev Drug Discov</source><year>2021</year><volume>20</volume><fpage>101</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101&#8211;24.<pub-id pub-id-type="pmid">33277608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-020-0090-8</pub-id><pub-id pub-id-type="pmcid">PMC7717100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>VU</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Chugh</surname><given-names>AR</given-names></name><name name-style="western"><surname>O'Quinn</surname><given-names>R</given-names></name><name name-style="western"><surname>Fradley</surname><given-names>MG</given-names></name><name name-style="western"><surname>Raghavendra</surname><given-names>M</given-names></name><name name-style="western"><surname>Dent</surname><given-names>S</given-names></name><name name-style="western"><surname>Barac</surname><given-names>A</given-names></name><name name-style="western"><surname>Lenihan</surname><given-names>D</given-names></name></person-group><article-title>Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>77</volume><fpage>2693</fpage><lpage>2716</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.04.009</pub-id><pub-id pub-id-type="pmid">34045027</pub-id><pub-id pub-id-type="pmcid">PMC8091379</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Rao VU, Reeves DJ, Chugh AR, O&#8217;Quinn R, Fradley MG, Raghavendra M, Dent S, Barac A, Lenihan D. Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:2693&#8211;716.<pub-id pub-id-type="pmid">34045027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0735-1097(21)04048-1</pub-id><pub-id pub-id-type="pmcid">PMC8091379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name></person-group><article-title>Nanotherapeutics for antimetastatic treatment</article-title><source>Trends Cancer</source><year>2020</year><volume>6</volume><fpage>645</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.05.001</pub-id><pub-id pub-id-type="pmid">32448754</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Yang F, Zhao Z, Sun B, Chen Q, Sun J, He Z, Luo C. Nanotherapeutics for antimetastatic treatment. Trends Cancer. 2020;6:645&#8211;59.<pub-id pub-id-type="pmid">32448754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2020.05.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Kroll</surname><given-names>AV</given-names></name><name name-style="western"><surname>Holay</surname><given-names>M</given-names></name><name name-style="western"><surname>Fang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Biomimetic nanotechnology toward personalized vaccines</article-title><source>Adv Mater</source><year>2020</year><volume>32</volume><fpage>e1901255</fpage><pub-id pub-id-type="doi">10.1002/adma.201901255</pub-id><pub-id pub-id-type="pmid">31206841</pub-id><pub-id pub-id-type="pmcid">PMC6918015</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhou J, Kroll AV, Holay M, Fang RH, Zhang L. Biomimetic nanotechnology toward personalized vaccines. Adv Mater. 2020;32: e1901255.<pub-id pub-id-type="pmid">31206841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201901255</pub-id><pub-id pub-id-type="pmcid">PMC6918015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>CK</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>CG</given-names></name><name name-style="western"><surname>Kralisch</surname><given-names>D</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>LJ</given-names></name></person-group><article-title>Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences</article-title><source>J Contr Release: Off J Controlled Release Soc</source><year>2018</year><volume>285</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.07.011</pub-id><pub-id pub-id-type="pmid">30008371</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chung CK, Da Silva CG, Kralisch D, Chan A, Ossendorp F, Cruz LJ. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. J Contr Release: Off J Controlled Release Soc. 2018;285:56&#8211;66.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.07.011</pub-id><pub-id pub-id-type="pmid">30008371</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Sui</surname><given-names>J</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G</given-names></name></person-group><article-title>Nanoparticle cancer vaccines: design considerations and recent advances</article-title><source>Asian J Pharm Sci</source><year>2020</year><volume>15</volume><fpage>576</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2019.10.006</pub-id><pub-id pub-id-type="pmid">33193861</pub-id><pub-id pub-id-type="pmcid">PMC7610208</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Liu J, Miao L, Sui J, Hao Y, Huang G. Nanoparticle cancer vaccines: design considerations and recent advances. Asian J Pharm Sci. 2020;15:576&#8211;90.<pub-id pub-id-type="pmid">33193861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajps.2019.10.006</pub-id><pub-id pub-id-type="pmcid">PMC7610208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lo</surname><given-names>PC</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>JF</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name></person-group><article-title>Self-adjuvanting cancer nanovaccines</article-title><source>J Nanobiotechnol</source><year>2022</year><volume>20</volume><fpage>345</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01545-z</pub-id><pub-id pub-id-type="pmcid">PMC9316869</pub-id><pub-id pub-id-type="pmid">35883176</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Liao Z, Huang J, Lo PC, Lovell JF, Jin H, Yang K. Self-adjuvanting cancer nanovaccines. J Nanobiotechnol. 2022;20:345.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-022-01545-z</pub-id><pub-id pub-id-type="pmcid">PMC9316869</pub-id><pub-id pub-id-type="pmid">35883176</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tan</surname><given-names>K</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name></person-group><article-title>Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions</article-title><source>J Nanobiotechnol</source><year>2023</year><volume>21</volume><fpage>212</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-01977-1</pub-id><pub-id pub-id-type="pmcid">PMC10327386</pub-id><pub-id pub-id-type="pmid">37415161</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Li Y, Li S, Jiang Z, Tan K, Meng Y, Zhang D, Ma X. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions. J Nanobiotechnol. 2023;21:212.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-01977-1</pub-id><pub-id pub-id-type="pmcid">PMC10327386</pub-id><pub-id pub-id-type="pmid">37415161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HY</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M</given-names></name><name name-style="western"><surname>Choo</surname><given-names>YW</given-names></name><name name-style="western"><surname>Go</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>SP</given-names></name><name name-style="western"><surname>Song</surname><given-names>SY</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>HS</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BS</given-names></name></person-group><article-title>Immunomodulatory lipocomplex functionalized with photosensitizer-embedded cancer cell membrane inhibits tumor growth and metastasis</article-title><source>Nano Lett</source><year>2019</year><volume>19</volume><fpage>5185</fpage><lpage>5193</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b01571</pub-id><pub-id pub-id-type="pmid">31298024</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kim HY, Kang M, Choo YW, Go SH, Kwon SP, Song SY, Sohn HS, Hong J, Kim BS. Immunomodulatory lipocomplex functionalized with photosensitizer-embedded cancer cell membrane inhibits tumor growth and metastasis. Nano Lett. 2019;19:5185&#8211;93.<pub-id pub-id-type="pmid">31298024</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.9b01571</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G</given-names></name></person-group><article-title>Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><fpage>2041</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22308-8</pub-id><pub-id pub-id-type="pmid">33824314</pub-id><pub-id pub-id-type="pmcid">PMC8024398</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Cheng K, Zhao R, Li Y, Qi Y, Wang Y, Zhang Y, Qin H, Qin Y, Chen L, Li C, Liang J, Li Y, Xu J, Han X, Anderson GJ, Shi J, Ren L, Zhao X, Nie G. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via plug-and-display technology. Nat Commun. 2021;12:2041.<pub-id pub-id-type="pmid">33824314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-22308-8</pub-id><pub-id pub-id-type="pmcid">PMC8024398</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q</given-names></name><name name-style="western"><surname>Song</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liang</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Dong</surname><given-names>A</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses</article-title><source>Biomaterials</source><year>2020</year><volume>230</volume><fpage>119649</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119649</pub-id><pub-id pub-id-type="pmid">31791843</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Liu X, Feng Z, Wang C, Su Q, Song H, Zhang C, Huang P, Liang XJ, Dong A, Kong D, Wang W. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses. Biomaterials. 2020;230: 119649.<pub-id pub-id-type="pmid">31791843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.119649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Slater</surname><given-names>NKH</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name></person-group><article-title>An MRI-trackable therapeutic nanovaccine preventing cancer liver metastasis</article-title><source>Biomaterials</source><year>2021</year><volume>274</volume><fpage>120893</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120893</pub-id><pub-id pub-id-type="pmid">34029913</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Xiao B, Li D, Xu H, Zhou X, Xu X, Qian Y, Yu F, Hu H, Zhou Z, Liu X, Gao J, Slater NKH, Shen Y, Tang J. An MRI-trackable therapeutic nanovaccine preventing cancer liver metastasis. Biomaterials. 2021;274: 120893.<pub-id pub-id-type="pmid">34029913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.120893</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adjei</surname><given-names>IM</given-names></name><name name-style="western"><surname>Temples</surname><given-names>MN</given-names></name><name name-style="western"><surname>Brown</surname><given-names>SB</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>B</given-names></name></person-group><article-title>Targeted nanomedicine to treat bone metastasis</article-title><source>Pharmaceutics</source><year>2018</year><volume>10</volume><issue>4</issue><fpage>205</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics10040205</pub-id><pub-id pub-id-type="pmid">30366428</pub-id><pub-id pub-id-type="pmcid">PMC6320768</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Adjei IM, Temples MN, Brown SB, Sharma B. Targeted nanomedicine to treat bone metastasis. Pharmaceutics. 2018;10(4):205. 10.3390/pharmaceutics10040205.<pub-id pub-id-type="pmid">30366428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics10040205</pub-id><pub-id pub-id-type="pmcid">PMC6320768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>Lymph node-targeting nanovaccines for cancer immunotherapy</article-title><source>J Control Release</source><year>2022</year><volume>351</volume><fpage>102</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.015</pub-id><pub-id pub-id-type="pmid">36115556</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Wang Q, Wang Z, Sun X, Jiang Q, Sun B, He Z, Zhang S, Luo C, Sun J. Lymph node-targeting nanovaccines for cancer immunotherapy. J Control Release. 2022;351:102&#8211;22.<pub-id pub-id-type="pmid">36115556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.09.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>X</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kong</surname><given-names>M</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma</article-title><source>ACS Nano</source><year>2015</year><volume>9</volume><fpage>6918</fpage><lpage>6933</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b01042</pub-id><pub-id pub-id-type="pmid">26153897</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Guo Y, Wang D, Song Q, Wu T, Zhuang X, Bao Y, Kong M, Qi Y, Tan S, Zhang Z. Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma. ACS Nano. 2015;9:6918&#8211;33.<pub-id pub-id-type="pmid">26153897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.5b01042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Nanobiomaterial-based vaccination immunotherapy of cancer</article-title><source>Biomaterials</source><year>2021</year><volume>270</volume><fpage>120709</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120709</pub-id><pub-id pub-id-type="pmid">33581608</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Chen F, Wang Y, Gao J, Saeed M, Li T, Wang W, Yu H. Nanobiomaterial-based vaccination immunotherapy of cancer. Biomaterials. 2021;270: 120709.<pub-id pub-id-type="pmid">33581608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.120709</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Hou</surname><given-names>B</given-names></name><name name-style="western"><surname>Lai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name></person-group><article-title>Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer</article-title><source>Adv Mater</source><year>2023</year><volume>35</volume><fpage>e2209910</fpage><pub-id pub-id-type="doi">10.1002/adma.202209910</pub-id><pub-id pub-id-type="pmid">36576344</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Chen F, Li T, Zhang H, Saeed M, Liu X, Huang L, Wang X, Gao J, Hou B, Lai Y, Ding C, Xu Z, Xie Z, Luo M, Yu H. Acid-ionizable iron nanoadjuvant augments STING activation for personalized vaccination immunotherapy of cancer. Adv Mater. 2023;35: e2209910.<pub-id pub-id-type="pmid">36576344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202209910</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohme</surname><given-names>M</given-names></name><name name-style="western"><surname>Riethdorf</surname><given-names>S</given-names></name><name name-style="western"><surname>Pantel</surname><given-names>K</given-names></name></person-group><article-title>Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape</article-title><source>Nat Rev Clin Oncol</source><year>2017</year><volume>14</volume><fpage>155</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.144</pub-id><pub-id pub-id-type="pmid">27644321</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14:155&#8211;67.<pub-id pub-id-type="pmid">27644321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrclinonc.2016.144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>du Bois</surname><given-names>H</given-names></name><name name-style="western"><surname>Heim</surname><given-names>TA</given-names></name><name name-style="western"><surname>Lund</surname><given-names>AW</given-names></name></person-group><article-title>Tumor-draining lymph nodes: at the crossroads of metastasis and immunity</article-title><source>Sci Immunol</source><year>2021</year><volume>6</volume><issue>63</issue><fpage>eabg3551</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.abg3551</pub-id><pub-id pub-id-type="pmid">34516744</pub-id><pub-id pub-id-type="pmcid">PMC8628268</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">du Bois H, Heim TA, Lund AW. Tumor-draining lymph nodes: at the crossroads of metastasis and immunity. Sci Immunol. 2021;6(63):eabg3551. 10.1126/sciimmunol.abg3551.<pub-id pub-id-type="pmid">34516744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abg3551</pub-id><pub-id pub-id-type="pmcid">PMC8628268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patras</surname><given-names>L</given-names></name><name name-style="western"><surname>Shaashua</surname><given-names>L</given-names></name><name name-style="western"><surname>Matei</surname><given-names>I</given-names></name><name name-style="western"><surname>Lyden</surname><given-names>D</given-names></name></person-group><article-title>Immune determinants of the pre-metastatic niche</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>546</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.02.018</pub-id><pub-id pub-id-type="pmid">36917952</pub-id><pub-id pub-id-type="pmcid">PMC10170403</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Patras L, Shaashua L, Matei I, Lyden D. Immune determinants of the pre-metastatic niche. Cancer Cell. 2023;41:546&#8211;72.<pub-id pub-id-type="pmid">36917952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2023.02.018</pub-id><pub-id pub-id-type="pmcid">PMC10170403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Cao</surname><given-names>T</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis</article-title><source>Acta Pharm Sin B</source><year>2023</year><volume>13</volume><fpage>2464</fpage><lpage>2482</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.03.004</pub-id><pub-id pub-id-type="pmid">37425034</pub-id><pub-id pub-id-type="pmcid">PMC10326251</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Zhu L, Yu X, Cao T, Deng H, Tang X, Lin Q, Zhou Q. Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis. Acta Pharm Sin B. 2023;13:2464&#8211;82.<pub-id pub-id-type="pmid">37425034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.03.004</pub-id><pub-id pub-id-type="pmcid">PMC10326251</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Juan</surname><given-names>W</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name><name name-style="western"><surname>Chenggong</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name></person-group><article-title>Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis</article-title><source>Chinese Med J</source><year>2023</year><pub-id pub-id-type="doi">10.1097/CM9.0000000000002525</pub-id><pub-id pub-id-type="pmcid">PMC10686602</pub-id><pub-id pub-id-type="pmid">37442772</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Zhu L, Juan W, Gao H, Wang T, Xiao G, Chenggong H, Lin Q, Zhou Q. Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis. Chinese Med J. 2023. 10.1097/CM9.0000000000002525.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CM9.0000000000002525</pub-id><pub-id pub-id-type="pmcid">PMC10686602</pub-id><pub-id pub-id-type="pmid">37442772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D</given-names></name><name name-style="western"><surname>Shao</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives</article-title><source>Signal Transduct Target Ther</source><year>2024</year><volume>9</volume><fpage>192</fpage><pub-id pub-id-type="doi">10.1038/s41392-024-01885-2</pub-id><pub-id pub-id-type="pmid">39090094</pub-id><pub-id pub-id-type="pmcid">PMC11294630</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z, Chai Y, Song J, Tang W, Wang X. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct Target Ther. 2024;9:192.<pub-id pub-id-type="pmid">39090094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-024-01885-2</pub-id><pub-id pub-id-type="pmcid">PMC11294630</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>CS</given-names></name><name name-style="western"><surname>Deng</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D</given-names></name><name name-style="western"><surname>Mu</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XG</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: where do we stand?</article-title><source>Acta Biomater</source><year>2021</year><volume>125</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2021.02.030</pub-id><pub-id pub-id-type="pmid">33639310</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Yuan CS, Deng ZW, Qin D, Mu YZ, Chen XG, Liu Y. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: where do we stand? Acta Biomater. 2021;125:1&#8211;28.<pub-id pub-id-type="pmid">33639310</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2021.02.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C</given-names></name><name name-style="western"><surname>Jia</surname><given-names>H</given-names></name><name name-style="western"><surname>Bao</surname><given-names>B</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy</article-title><source>J Control Release</source><year>2018</year><volume>275</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.02.026</pub-id><pub-id pub-id-type="pmid">29471038</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Zhou Q, Li Y, Zhu Y, Yu C, Jia H, Bao B, Hu H, Xiao C, Zhang J, Zeng X, Wan Y, Xu H, Li Z, Yang X. Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. J Control Release. 2018;275:67&#8211;77.<pub-id pub-id-type="pmid">29471038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.02.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HP</given-names></name><name name-style="western"><surname>Reichel</surname><given-names>D</given-names></name><name name-style="western"><surname>Bae</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EY</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>In vivo beta-catenin attenuation by the integrin alpha5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis</article-title><source>Biomaterials</source><year>2019</year><volume>188</volume><fpage>160</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.10.019</pub-id><pub-id pub-id-type="pmid">30352320</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Li Y, Xiao Y, Lin HP, Reichel D, Bae Y, Lee EY, Jiang Y, Huang X, Yang C, Wang Z. In vivo beta-catenin attenuation by the integrin alpha5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis. Biomaterials. 2019;188:160&#8211;72.<pub-id pub-id-type="pmid">30352320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2018.10.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Q</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Du</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ran</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D</given-names></name></person-group><article-title>Smart responsive Fe/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation</article-title><source>J Nanobiotechnology</source><year>2024</year><volume>22</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s12951-024-02354-2</pub-id><pub-id pub-id-type="pmid">38448959</pub-id><pub-id pub-id-type="pmcid">PMC10918897</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Du Q, Luo Y, Xu L, Du C, Zhang W, Xu J, Liu Y, Liu B, Chen S, Wang Y, Wang Z, Ran H, Wang J, Guo D. Smart responsive Fe/Mn nanovaccine triggers liver cancer immunotherapy via pyroptosis and pyroptosis-boosted cGAS-STING activation. J Nanobiotechnology. 2024;22:95.<pub-id pub-id-type="pmid">38448959</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-024-02354-2</pub-id><pub-id pub-id-type="pmcid">PMC10918897</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Mei</surname><given-names>C</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Su</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pang</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H</given-names></name></person-group><article-title>ZnAs@SiO(2) nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>4391</fpage><lpage>4408</lpage><pub-id pub-id-type="doi">10.7150/thno.32462</pub-id><pub-id pub-id-type="pmid">31285768</pub-id><pub-id pub-id-type="pmcid">PMC6599649</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, Mei C, Yan Y, Jin H, Gao J, Su Z, Pang P, Li D, Shan H. ZnAs@SiO(2) nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. Theranostics. 2019;9:4391&#8211;408.<pub-id pub-id-type="pmid">31285768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.32462</pub-id><pub-id pub-id-type="pmcid">PMC6599649</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Umeshappa</surname><given-names>CS</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name></person-group><article-title>Nanovaccine-based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy</article-title><source>Small</source><year>2021</year><volume>17</volume><fpage>e2006000</fpage><pub-id pub-id-type="doi">10.1002/smll.202006000</pub-id><pub-id pub-id-type="pmid">33768693</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Qin L, Zhang H, Zhou Y, Umeshappa CS, Gao H. Nanovaccine-based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy. Small. 2021;17: e2006000.<pub-id pub-id-type="pmid">33768693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202006000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Biomaterial&#8208;based in situ cancer vaccines</article-title><source>Adv Mater</source><year>2023</year><volume>36</volume><issue>43</issue><fpage>e2210452</fpage><pub-id pub-id-type="doi">10.1002/adma.202210452</pub-id><pub-id pub-id-type="pmid">36649567</pub-id><pub-id pub-id-type="pmcid">PMC10408245</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Bo Y, Wang H. Biomaterial&#8208;based in situ cancer vaccines. Adv Mater. 2023;36(43):e2210452. 10.1002/adma.202210452.<pub-id pub-id-type="pmid">36649567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202210452</pub-id><pub-id pub-id-type="pmcid">PMC10408245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>CR</given-names></name><name name-style="western"><surname>De Palma</surname><given-names>M</given-names></name></person-group><article-title>Engineering dendritic cell vaccines to improve cancer immunotherapy</article-title><source>Nat Commun</source><year>2019</year><volume>10</volume><fpage>5408</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13368-y</pub-id><pub-id pub-id-type="pmid">31776331</pub-id><pub-id pub-id-type="pmcid">PMC6881351</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10:5408.<pub-id pub-id-type="pmid">31776331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-13368-y</pub-id><pub-id pub-id-type="pmcid">PMC6881351</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>T</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C</given-names></name></person-group><article-title>A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>6936</fpage><lpage>6949</lpage><pub-id pub-id-type="doi">10.7150/thno.58173</pub-id><pub-id pub-id-type="pmid">34093863</pub-id><pub-id pub-id-type="pmcid">PMC8171104</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Liang X, Li L, Li X, He T, Gong S, Zhu S, Zhang M, Wu Q, Gong C. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. Theranostics. 2021;11:6936&#8211;49.<pub-id pub-id-type="pmid">34093863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.58173</pub-id><pub-id pub-id-type="pmcid">PMC8171104</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wculek</surname><given-names>SK</given-names></name><name name-style="western"><surname>Cueto</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Mujal</surname><given-names>AM</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I</given-names></name><name name-style="western"><surname>Krummel</surname><given-names>MF</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D</given-names></name></person-group><article-title>Dendritic cells in cancer immunology and immunotherapy</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><fpage>7</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0210-z</pub-id><pub-id pub-id-type="pmid">31467405</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7&#8211;24.<pub-id pub-id-type="pmid">31467405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-019-0210-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>N</given-names></name><name name-style="western"><surname>Xu</surname><given-names>FJ</given-names></name></person-group><article-title>Rough nanovaccines boost antitumor immunity through the enhancement of vaccination cascade and immunogenic cell death induction</article-title><source>Small methods</source><year>2023</year><volume>7</volume><fpage>e2201595</fpage><pub-id pub-id-type="doi">10.1002/smtd.202201595</pub-id><pub-id pub-id-type="pmid">36869418</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Zhao X, Zhang J, Chen B, Ding X, Zhao N, Xu FJ. Rough nanovaccines boost antitumor immunity through the enhancement of vaccination cascade and immunogenic cell death induction. Small methods. 2023;7: e2201595.<pub-id pub-id-type="pmid">36869418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202201595</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Leng</surname><given-names>X</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name></person-group><article-title>Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy</article-title><source>Nano Lett</source><year>2019</year><volume>19</volume><fpage>4237</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b00030</pub-id><pub-id pub-id-type="pmid">30868883</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Zhang L, Wu S, Qin Y, Fan F, Zhang Z, Huang C, Ji W, Lu L, Wang C, Sun H, Leng X, Kong D, Zhu D. Targeted codelivery of an antigen and dual agonists by hybrid nanoparticles for enhanced cancer immunotherapy. Nano Lett. 2019;19:4237&#8211;49.<pub-id pub-id-type="pmid">30868883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.9b00030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name><name name-style="western"><surname>You</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yao</surname><given-names>R</given-names></name><name name-style="western"><surname>Tong</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>A nanovaccine based on adjuvant peptide FK-13 and l-phenylalanine poly (ester amide) enhances CD8+ T cell-mediated antitumor immunity</article-title><source>Adv Sci</source><year>2023</year><volume>10</volume><issue>20</issue><fpage>2300418</fpage><pub-id pub-id-type="doi">10.1002/advs.202300418</pub-id><pub-id pub-id-type="pmcid">PMC10369282</pub-id><pub-id pub-id-type="pmid">37162249</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Xie C, You X, Zhang H, Li J, Wang L, Liu Y, Wang Z, Yao R, Tong T, Li M, Wang X. A nanovaccine based on adjuvant peptide FK-13 and l-phenylalanine poly (ester amide) enhances CD8+ T cell-mediated antitumor immunity. Adv Sci. 2023;10(20):2300418.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202300418</pub-id><pub-id pub-id-type="pmcid">PMC10369282</pub-id><pub-id pub-id-type="pmid">37162249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Ji</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xing</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name></person-group><article-title>Ultrasound responsive nanovaccine armed with engineered cancer cell membrane and RNA to prevent foreseeable metastasis</article-title><source>Adv Sci</source><year>2023</year><volume>10</volume><issue>19</issue><fpage>e2301107</fpage><pub-id pub-id-type="doi">10.1002/advs.202301107</pub-id><pub-id pub-id-type="pmcid">PMC10323640</pub-id><pub-id pub-id-type="pmid">37097746</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Sun W, Ji P, Zhou T, Li Z, Xing C, Zhang L, Wei M, Yang G, Yuan L. Ultrasound responsive nanovaccine armed with engineered cancer cell membrane and RNA to prevent foreseeable metastasis. Adv Sci. 2023;10(19):e2301107. 10.1002/advs.202301107.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202301107</pub-id><pub-id pub-id-type="pmcid">PMC10323640</pub-id><pub-id pub-id-type="pmid">37097746</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>In Situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy</article-title><source>Nano Lett</source><year>2021</year><volume>21</volume><fpage>2224</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c05039</pub-id><pub-id pub-id-type="pmid">33594887</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, Yu S, Nie G, Wang H. In Situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy. Nano Lett. 2021;21:2224&#8211;31.<pub-id pub-id-type="pmid">33594887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.0c05039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Porter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA vaccines - a new era in vaccinology</article-title><source>Nat Rev Drug Discov</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261&#8211;79.<pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorentzen</surname><given-names>CL</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>JB</given-names></name><name name-style="western"><surname>Met</surname><given-names>&#214;</given-names></name><name name-style="western"><surname>Svane</surname><given-names>IM</given-names></name></person-group><article-title>Clinical advances and ongoing trials on mRNA vaccines for cancer treatment</article-title><source>Lancet Oncol</source><year>2022</year><volume>23</volume><fpage>e450</fpage><lpage>e458</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00372-2</pub-id><pub-id pub-id-type="pmid">36174631</pub-id><pub-id pub-id-type="pmcid">PMC9512276</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Lorentzen CL, Haanen JB, Met &#214;, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23:e450&#8211;8.<pub-id pub-id-type="pmid">36174631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(22)00372-2</pub-id><pub-id pub-id-type="pmcid">PMC9512276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccine for cancer immunotherapy</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20:41.<pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>She</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><name name-style="western"><surname>Lou</surname><given-names>C</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>mRNA vaccine in cancer therapy: current advance and future outlook</article-title><source>Clin Transl Med</source><year>2023</year><volume>13</volume><fpage>e1384</fpage><pub-id pub-id-type="doi">10.1002/ctm2.1384</pub-id><pub-id pub-id-type="pmid">37612832</pub-id><pub-id pub-id-type="pmcid">PMC10447885</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, She Q, Tan J, Lou C, Liao Z, Li X. mRNA vaccine in cancer therapy: current advance and future outlook. Clin Transl Med. 2023;13: e1384.<pub-id pub-id-type="pmid">37612832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ctm2.1384</pub-id><pub-id pub-id-type="pmcid">PMC10447885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>L</given-names></name><name name-style="western"><surname>Teng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy</article-title><source>Nanoscale</source><year>2023</year><volume>15</volume><fpage>6432</fpage><lpage>6455</lpage><pub-id pub-id-type="doi">10.1039/D2NR07071E</pub-id><pub-id pub-id-type="pmid">36916703</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Meng L, Teng Z, Yang S, Wang N, Guan Y, Chen X, Liu Y. Biomimetic nanoparticles for DC vaccination: a versatile approach to boost cancer immunotherapy. Nanoscale. 2023;15:6432&#8211;55.<pub-id pub-id-type="pmid">36916703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2nr07071e</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Pei</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy</article-title><source>Nat Nanotechnol</source><year>2020</year><volume>15</volume><fpage>1043</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-00781-4</pub-id><pub-id pub-id-type="pmid">33139933</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L, Pei P, Wang C, Wu H, Dong Z, Chao Y, Wang C, Yang K, Peng R, Cheng Y, Liu Z. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020;15:1043&#8211;52.<pub-id pub-id-type="pmid">33139933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-020-00781-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>W</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Ferroptosis and necroptosis produced autologous tumor cell lysates co-delivering with combined immnoadjuvants as personalized in situ nanovaccines for antitumor immunity</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>14475</fpage><lpage>14493</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c00901</pub-id><pub-id pub-id-type="pmid">37466500</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Shi W, Feng W, Li S, Cui Y, Liu S, Jiang H, Liu Y, Zhang H. Ferroptosis and necroptosis produced autologous tumor cell lysates co-delivering with combined immnoadjuvants as personalized in situ nanovaccines for antitumor immunity. ACS Nano. 2023;17:14475&#8211;93.<pub-id pub-id-type="pmid">37466500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c00901</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guasp</surname><given-names>P</given-names></name><name name-style="western"><surname>Reiche</surname><given-names>C</given-names></name><name name-style="western"><surname>Sethna</surname><given-names>Z</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>VP</given-names></name></person-group><article-title>RNA vaccines for cancer: principles to practice</article-title><source>Cancer Cell</source><year>2024</year><volume>42</volume><fpage>1163</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2024.05.005</pub-id><pub-id pub-id-type="pmid">38848720</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Guasp P, Reiche C, Sethna Z, Balachandran VP. RNA vaccines for cancer: principles to practice. Cancer Cell. 2024;42:1163&#8211;84.<pub-id pub-id-type="pmid">38848720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2024.05.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>N</given-names></name><name name-style="western"><surname>Chavda</surname><given-names>V</given-names></name><name name-style="western"><surname>Singh</surname><given-names>TRR</given-names></name><name name-style="western"><surname>Thorat</surname><given-names>ND</given-names></name><name name-style="western"><surname>Vora</surname><given-names>LK</given-names></name></person-group><article-title>Cancer nanovaccines: nanomaterials and clinical perspectives</article-title><source>Small</source><year>2024</year><volume>20</volume><fpage>e2401631</fpage><pub-id pub-id-type="doi">10.1002/smll.202401631</pub-id><pub-id pub-id-type="pmid">38693099</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Desai N, Chavda V, Singh TRR, Thorat ND, Vora LK. Cancer nanovaccines: nanomaterials and clinical perspectives. Small. 2024;20: e2401631.<pub-id pub-id-type="pmid">38693099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202401631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Research progress of neoantigens in gynecologic cancers</article-title><source>Int Immunopharmacol</source><year>2022</year><volume>112</volume><fpage>109236</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2022.109236</pub-id><pub-id pub-id-type="pmid">36113318</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Song Y, Zhang Y. Research progress of neoantigens in gynecologic cancers. Int Immunopharmacol. 2022;112: 109236.<pub-id pub-id-type="pmid">36113318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2022.109236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bennett</surname><given-names>NR</given-names></name><name name-style="western"><surname>Zwick</surname><given-names>DB</given-names></name><name name-style="western"><surname>Courtney</surname><given-names>AH</given-names></name><name name-style="western"><surname>Kiessling</surname><given-names>LL</given-names></name></person-group><article-title>Multivalent antigens for promoting B and T cell activation</article-title><source>ACS Chem Biol</source><year>2015</year><volume>10</volume><fpage>1817</fpage><lpage>1824</lpage><pub-id pub-id-type="doi">10.1021/acschembio.5b00239</pub-id><pub-id pub-id-type="pmid">25970017</pub-id><pub-id pub-id-type="pmcid">PMC4669068</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Bennett NR, Zwick DB, Courtney AH, Kiessling LL. Multivalent antigens for promoting B and T cell activation. ACS Chem Biol. 2015;10:1817&#8211;24.<pub-id pub-id-type="pmid">25970017</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acschembio.5b00239</pub-id><pub-id pub-id-type="pmcid">PMC4669068</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zainal</surname><given-names>NS</given-names></name><name name-style="western"><surname>Chai</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Dickie</surname><given-names>J</given-names></name><name name-style="western"><surname>Gan</surname><given-names>CP</given-names></name><name name-style="western"><surname>Zulaziz</surname><given-names>N</given-names></name><name name-style="western"><surname>Lye</surname><given-names>BKW</given-names></name><name name-style="western"><surname>Sutavani</surname><given-names>RV</given-names></name><name name-style="western"><surname>Ottensmeier</surname><given-names>CH</given-names></name><name name-style="western"><surname>King</surname><given-names>EV</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>MT</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>SMB</given-names></name><name name-style="western"><surname>Lau</surname><given-names>SH</given-names></name><name name-style="western"><surname>Kallarakkal</surname><given-names>TG</given-names></name><name name-style="western"><surname>Mun</surname><given-names>KS</given-names></name><name name-style="western"><surname>Zain</surname><given-names>RB</given-names></name><name name-style="western"><surname>Abdul Rahman</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Cheong</surname><given-names>SC</given-names></name><name name-style="western"><surname>Savelyeva</surname><given-names>N</given-names></name><name name-style="western"><surname>Lim</surname><given-names>KP</given-names></name></person-group><article-title>DNA vaccines targeting novel cancer-associated antigens frequently expressed in head and neck cancer enhance the efficacy of checkpoint inhibitor</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>763086</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.763086</pub-id><pub-id pub-id-type="pmid">34733290</pub-id><pub-id pub-id-type="pmcid">PMC8559892</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Wang C, Zainal NS, Chai SJ, Dickie J, Gan CP, Zulaziz N, Lye BKW, Sutavani RV, Ottensmeier CH, King EV, Abraham MT, Ismail SMB, Lau SH, Kallarakkal TG, Mun KS, Zain RB, Abdul Rahman ZA, Thomas GJ, Cheong SC, Savelyeva N, Lim KP. DNA vaccines targeting novel cancer-associated antigens frequently expressed in head and neck cancer enhance the efficacy of checkpoint inhibitor. Front Immunol. 2021;12:763086. 10.3389/fimmu.2021.763086.<pub-id pub-id-type="pmid">34733290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.763086</pub-id><pub-id pub-id-type="pmcid">PMC8559892</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blass</surname><given-names>E</given-names></name><name name-style="western"><surname>Ott</surname><given-names>PA</given-names></name></person-group><article-title>Advances in the development of personalized neoantigen-based therapeutic cancer vaccines</article-title><source>Nat Rev Clin Oncol</source><year>2021</year><volume>18</volume><fpage>215</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00460-2</pub-id><pub-id pub-id-type="pmid">33473220</pub-id><pub-id pub-id-type="pmcid">PMC7816749</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18:215&#8211;29.<pub-id pub-id-type="pmid">33473220</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-020-00460-2</pub-id><pub-id pub-id-type="pmcid">PMC7816749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>W</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R</given-names></name></person-group><article-title>The future of cancer vaccines against colorectal cancer</article-title><source>Expert Opin Biol Ther</source><year>2024</year><volume>24</volume><fpage>269</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1080/14712598.2024.2341744</pub-id><pub-id pub-id-type="pmid">38644655</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Jia W, Shen X, Guo Z, Cheng X, Zhao R. The future of cancer vaccines against colorectal cancer. Expert Opin Biol Ther. 2024;24:269&#8211;84.<pub-id pub-id-type="pmid">38644655</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14712598.2024.2341744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dersh</surname><given-names>D</given-names></name><name name-style="western"><surname>Holly</surname><given-names>J</given-names></name><name name-style="western"><surname>Yewdell</surname><given-names>JW</given-names></name></person-group><article-title>A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion</article-title><source>Nat Rev Immunol</source><year>2021</year><volume>21</volume><fpage>116</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0390-6</pub-id><pub-id pub-id-type="pmid">32820267</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Dersh D, Holly J, Yewdell JW. A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion. Nat Rev Immunol. 2021;21:116&#8211;28.<pub-id pub-id-type="pmid">32820267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0390-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>LX</given-names></name><name name-style="western"><surname>Xie</surname><given-names>XX</given-names></name><name name-style="western"><surname>Liu</surname><given-names>DQ</given-names></name><name name-style="western"><surname>Xu</surname><given-names>ZP</given-names></name><name name-style="western"><surname>Liu</surname><given-names>RT</given-names></name></person-group><article-title>Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy</article-title><source>Biomaterials</source><year>2018</year><volume>174</volume><fpage>54</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.05.015</pub-id><pub-id pub-id-type="pmid">29778982</pub-id></element-citation><mixed-citation id="mc-CR76" publication-type="journal">Zhang LX, Xie XX, Liu DQ, Xu ZP, Liu RT. Efficient co-delivery of neo-epitopes using dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy. Biomaterials. 2018;174:54&#8211;66.<pub-id pub-id-type="pmid">29778982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2018.05.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donaldson</surname><given-names>B</given-names></name><name name-style="western"><surname>Al-Barwani</surname><given-names>F</given-names></name><name name-style="western"><surname>Pelham</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Young</surname><given-names>K</given-names></name><name name-style="western"><surname>Ward</surname><given-names>VK</given-names></name><name name-style="western"><surname>Young</surname><given-names>SL</given-names></name></person-group><article-title>Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer</article-title><source>J Immunother Cancer</source><year>2017</year><volume>5</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s40425-017-0270-1</pub-id><pub-id pub-id-type="pmid">28806910</pub-id><pub-id pub-id-type="pmcid">PMC5556368</pub-id></element-citation><mixed-citation id="mc-CR77" publication-type="journal">Donaldson B, Al-Barwani F, Pelham SJ, Young K, Ward VK, Young SL. Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer. J Immunother Cancer. 2017;5:69.<pub-id pub-id-type="pmid">28806910</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40425-017-0270-1</pub-id><pub-id pub-id-type="pmcid">PMC5556368</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>LA</given-names></name><name name-style="western"><surname>Sethna</surname><given-names>Z</given-names></name><name name-style="western"><surname>Soares</surname><given-names>KC</given-names></name><name name-style="western"><surname>Olcese</surname><given-names>C</given-names></name><name name-style="western"><surname>Pang</surname><given-names>N</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>E</given-names></name><name name-style="western"><surname>Lihm</surname><given-names>J</given-names></name><name name-style="western"><surname>Ceglia</surname><given-names>N</given-names></name><name name-style="western"><surname>Guasp</surname><given-names>P</given-names></name><name name-style="western"><surname>Chu</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>AK</given-names></name><name name-style="western"><surname>Waters</surname><given-names>T</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>J</given-names></name><name name-style="western"><surname>Amisaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Zebboudj</surname><given-names>A</given-names></name><name name-style="western"><surname>Odgerel</surname><given-names>Z</given-names></name><name name-style="western"><surname>Payne</surname><given-names>G</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Muller</surname><given-names>F</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>I</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>M</given-names></name><name name-style="western"><surname>Dobrin</surname><given-names>A</given-names></name><name name-style="western"><surname>Sadelain</surname><given-names>M</given-names></name><name name-style="western"><surname>Luksza</surname><given-names>M</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>N</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Basturk</surname><given-names>O</given-names></name><name name-style="western"><surname>Gonen</surname><given-names>M</given-names></name><name name-style="western"><surname>Katz</surname><given-names>S</given-names></name><name name-style="western"><surname>Do</surname><given-names>RK</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>AS</given-names></name><name name-style="western"><surname>Momtaz</surname><given-names>P</given-names></name><name name-style="western"><surname>Park</surname><given-names>W</given-names></name><name name-style="western"><surname>Sugarman</surname><given-names>R</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>AM</given-names></name><name name-style="western"><surname>Won</surname><given-names>E</given-names></name><name name-style="western"><surname>Desai</surname><given-names>A</given-names></name><name name-style="western"><surname>Wei</surname><given-names>AC</given-names></name><name name-style="western"><surname>D'Angelica</surname><given-names>MI</given-names></name><name name-style="western"><surname>Kingham</surname><given-names>TP</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I</given-names></name><name name-style="western"><surname>Merghoub</surname><given-names>T</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>JD</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Tureci</surname><given-names>O</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>BD</given-names></name><name name-style="western"><surname>Jarnagin</surname><given-names>WR</given-names></name><name name-style="western"><surname>Drebin</surname><given-names>J</given-names></name><name name-style="western"><surname>O'Reilly</surname><given-names>EM</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>VP</given-names></name></person-group><article-title>Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer</article-title><source>Nature</source><year>2023</year><volume>618</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></element-citation><mixed-citation id="mc-CR78" publication-type="journal">Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Muller F, Rhee I, Yadav M, Dobrin A, Sadelain M, Luksza M, Cohen N, Tang L, Basturk O, Gonen M, Katz S, Do RK, Epstein AS, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D&#8217;Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Tureci O, Greenbaum BD, Jarnagin WR, Drebin J, O&#8217;Reilly EM, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144&#8211;50.<pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>CF</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>In Situ programming of nanovaccines for lymph node-targeted delivery and cancer immunotherapy</article-title><source>ACS Nano</source><year>2022</year><volume>16</volume><fpage>15226</fpage><lpage>15236</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c06560</pub-id><pub-id pub-id-type="pmid">36018240</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Jin L, Yang D, Song Y, Li D, Xu W, Zhu Y, Xu CF, Lu Y, Yang X. In Situ programming of nanovaccines for lymph node-targeted delivery and cancer immunotherapy. ACS Nano. 2022;16:15226&#8211;36.<pub-id pub-id-type="pmid">36018240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c06560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meng</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hao</surname><given-names>K</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy</article-title><source>Biomaterials</source><year>2022</year><volume>289</volume><fpage>121794</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121794</pub-id><pub-id pub-id-type="pmid">36113330</pub-id></element-citation><mixed-citation id="mc-CR80" publication-type="journal">Zhang S, Feng Y, Meng M, Li Z, Li H, Lin L, Xu C, Chen J, Hao K, Tang Z, Tian H, Chen X. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy. Biomaterials. 2022;289: 121794.<pub-id pub-id-type="pmid">36113330</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2022.121794</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>B</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>PA</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J</given-names></name></person-group><article-title>MnOx nanospikes as nanoadjuvants and immunogenic cell death drugs with enhanced antitumor immunity and antimetastatic effect</article-title><source>Angew Chem Int Ed</source><year>2020</year><volume>59</volume><issue>38</issue><fpage>16381</fpage><lpage>16384</lpage><pub-id pub-id-type="doi">10.1002/anie.202005111</pub-id><pub-id pub-id-type="pmid">32484598</pub-id></element-citation><mixed-citation id="mc-CR81" publication-type="journal">Ding B, Zheng P, Jiang F, Zhao Y, Wang M, Chang M, Ma PA, Lin J. MnOx nanospikes as nanoadjuvants and immunogenic cell death drugs with enhanced antitumor immunity and antimetastatic effect. Angew Chem Int Ed. 2020;59(38):16381&#8211;4.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202005111</pub-id><pub-id pub-id-type="pmid">32484598</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L</given-names></name><name name-style="western"><surname>Ou</surname><given-names>M</given-names></name></person-group><article-title>Vaccine-like nanomedicine for cancer immunotherapy</article-title><source>J Control Release</source><year>2023</year><volume>355</volume><fpage>760</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.02.015</pub-id><pub-id pub-id-type="pmid">36822241</pub-id></element-citation><mixed-citation id="mc-CR82" publication-type="journal">Yi Y, Yu M, Li W, Zhu D, Mei L, Ou M. Vaccine-like nanomedicine for cancer immunotherapy. J Control Release. 2023;355:760&#8211;78.<pub-id pub-id-type="pmid">36822241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.02.015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>G</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy</article-title><source>Biomaterials</source><year>2020</year><volume>235</volume><fpage>119795</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.119795</pub-id><pub-id pub-id-type="pmid">32014739</pub-id></element-citation><mixed-citation id="mc-CR83" publication-type="journal">Zhou S, Huang Y, Chen Y, Liu S, Xu M, Jiang T, Song Q, Jiang G, Gu X, Gao X, Chen J. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy. Biomaterials. 2020;235: 119795.<pub-id pub-id-type="pmid">32014739</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2020.119795</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lerner</surname><given-names>MI</given-names></name><name name-style="western"><surname>Mikhaylov</surname><given-names>G</given-names></name><name name-style="western"><surname>Tsukanov</surname><given-names>AA</given-names></name><name name-style="western"><surname>Lozhkomoev</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gutmanas</surname><given-names>E</given-names></name><name name-style="western"><surname>Gotman</surname><given-names>I</given-names></name><name name-style="western"><surname>Bratovs</surname><given-names>A</given-names></name><name name-style="western"><surname>Turk</surname><given-names>V</given-names></name><name name-style="western"><surname>Turk</surname><given-names>B</given-names></name><name name-style="western"><surname>Psakhye</surname><given-names>SG</given-names></name><name name-style="western"><surname>Vasiljeva</surname><given-names>O</given-names></name></person-group><article-title>Crumpled aluminum hydroxide nanostructures as a microenvironment dysregulation agent for cancer treatment</article-title><source>Nano Lett</source><year>2018</year><volume>18</volume><fpage>5401</fpage><lpage>5410</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.8b01592</pub-id><pub-id pub-id-type="pmid">30070485</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Lerner MI, Mikhaylov G, Tsukanov AA, Lozhkomoev AS, Gutmanas E, Gotman I, Bratovs A, Turk V, Turk B, Psakhye SG, Vasiljeva O. Crumpled aluminum hydroxide nanostructures as a microenvironment dysregulation agent for cancer treatment. Nano Lett. 2018;18:5401&#8211;10.<pub-id pub-id-type="pmid">30070485</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.8b01592</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Si</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Song</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy</article-title><source>Adv Mater</source><year>2021</year><volume>33</volume><fpage>e2007293</fpage><pub-id pub-id-type="doi">10.1002/adma.202007293</pub-id><pub-id pub-id-type="pmid">33448050</pub-id></element-citation><mixed-citation id="mc-CR85" publication-type="journal">Zhang Y, Ma S, Liu X, Xu Y, Zhao J, Si X, Li H, Huang Z, Wang Z, Tang Z, Song W, Chen X. Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy. Adv Mater. 2021;33: e2007293.<pub-id pub-id-type="pmid">33448050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202007293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Ventura</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Fang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Nanodelivery of STING agonists against cancer and infectious diseases</article-title><source>Mol Aspects Med</source><year>2022</year><volume>83</volume><fpage>101007</fpage><pub-id pub-id-type="doi">10.1016/j.mam.2021.101007</pub-id><pub-id pub-id-type="pmid">34353637</pub-id><pub-id pub-id-type="pmcid">PMC8792206</pub-id></element-citation><mixed-citation id="mc-CR86" publication-type="journal">Zhou J, Ventura CJ, Fang RH, Zhang L. Nanodelivery of STING agonists against cancer and infectious diseases. Mol Aspects Med. 2022;83: 101007.<pub-id pub-id-type="pmid">34353637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mam.2021.101007</pub-id><pub-id pub-id-type="pmcid">PMC8792206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habib</surname><given-names>A</given-names></name><name name-style="western"><surname>Anjum</surname><given-names>KM</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>R</given-names></name><name name-style="western"><surname>Jaffar</surname><given-names>G</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>MS</given-names></name><name name-style="western"><surname>Taj</surname><given-names>MU</given-names></name><name name-style="western"><surname>Zainab</surname><given-names>SW</given-names></name><name name-style="western"><surname>Umair</surname><given-names>M</given-names></name><name name-style="western"><surname>Zohaib</surname><given-names>M</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>T</given-names></name></person-group><article-title>Vaccine adjuvants: selection criteria, mechanism of action associated with immune responses and future directions</article-title><source>Iran J Immunol</source><year>2023</year><volume>20</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">36917475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22034/iji.2023.94097.2284</pub-id></element-citation><mixed-citation id="mc-CR87" publication-type="journal">Habib A, Anjum KM, Iqbal R, Jaffar G, Ashraf Z, Khalid MS, Taj MU, Zainab SW, Umair M, Zohaib M, Khalid T. Vaccine adjuvants: selection criteria, mechanism of action associated with immune responses and future directions. Iran J Immunol. 2023;20:1&#8211;15.<pub-id pub-id-type="pmid">36917475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.22034/iji.2023.94097.2284</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Ni</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Materials engineering strategies for cancer vaccine adjuvant development</article-title><source>Chem Soc Rev</source><year>2023</year><volume>52</volume><fpage>2886</fpage><lpage>2910</lpage><pub-id pub-id-type="doi">10.1039/D2CS00647B</pub-id><pub-id pub-id-type="pmid">37014050</pub-id></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Zhang X, Yang B, Ni Q, Chen X. Materials engineering strategies for cancer vaccine adjuvant development. Chem Soc Rev. 2023;52:2886&#8211;910.<pub-id pub-id-type="pmid">37014050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2cs00647b</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tian</surname><given-names>X</given-names></name></person-group><article-title>Vaccine adjuvants: mechanisms and platforms</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01557-7</pub-id><pub-id pub-id-type="pmid">37468460</pub-id><pub-id pub-id-type="pmcid">PMC10356842</pub-id></element-citation><mixed-citation id="mc-CR89" publication-type="journal">Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Ther. 2023;8:283.<pub-id pub-id-type="pmid">37468460</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01557-7</pub-id><pub-id pub-id-type="pmcid">PMC10356842</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>F</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name></person-group><article-title>In situ antigen-capturing nanochaperone toward personalized nanovaccine for cancer immunotherapy</article-title><source>Small</source><year>2022</year><volume>18</volume><fpage>e2203100</fpage><pub-id pub-id-type="doi">10.1002/smll.202203100</pub-id><pub-id pub-id-type="pmid">35843873</pub-id></element-citation><mixed-citation id="mc-CR90" publication-type="journal">Li X, Zhang Y, Wu X, Chen J, Yang M, Ma F, Shi L. In situ antigen-capturing nanochaperone toward personalized nanovaccine for cancer immunotherapy. Small. 2022;18:e2203100.<pub-id pub-id-type="pmid">35843873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202203100</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q</given-names></name><name name-style="western"><surname>Song</surname><given-names>T</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>N</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name></person-group><article-title>Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy</article-title><source>Bioact Mater</source><year>2022</year><volume>16</volume><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">35386322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.03.008</pub-id><pub-id pub-id-type="pmcid">PMC8958467</pub-id></element-citation><mixed-citation id="mc-CR91" publication-type="journal">Xie X, Feng Y, Zhang H, Su Q, Song T, Yang G, Li N, Wei X, Li T, Qin X, Li S, Wu C, Zhang X, Wang G, Liu Y, Yang H. Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. Bioact Mater. 2022;16:107&#8211;19.<pub-id pub-id-type="pmid">35386322</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.03.008</pub-id><pub-id pub-id-type="pmcid">PMC8958467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>ES</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JM</given-names></name><name name-style="western"><surname>Son</surname><given-names>S</given-names></name><name name-style="western"><surname>Ko</surname><given-names>H</given-names></name><name name-style="western"><surname>Um</surname><given-names>W</given-names></name><name name-style="western"><surname>Song</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JA</given-names></name><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name></person-group><article-title>Recent advances in polymeric nanomedicines for cancer immunotherapy</article-title><source>Adv Healthcare Mater</source><year>2019</year><volume>8</volume><fpage>e1801320</fpage><pub-id pub-id-type="doi">10.1002/adhm.201801320</pub-id><pub-id pub-id-type="pmid">30666822</pub-id></element-citation><mixed-citation id="mc-CR92" publication-type="journal">Lee ES, Shin JM, Son S, Ko H, Um W, Song SH, Lee JA, Park JH. Recent advances in polymeric nanomedicines for cancer immunotherapy. Adv Healthcare Mater. 2019;8: e1801320.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201801320</pub-id><pub-id pub-id-type="pmid">30666822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>R</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name></person-group><article-title>A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine</article-title><source>Sci Adv</source><year>2021</year><volume>7</volume><issue>35</issue><fpage>6326</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abi6326</pub-id><pub-id pub-id-type="pmcid">PMC8386930</pub-id><pub-id pub-id-type="pmid">34433569</pub-id></element-citation><mixed-citation id="mc-CR93" publication-type="journal">Zhai Y, He X, Li Y, Han R, Ma Y, Gao P, Qian Z, Gu Y, Li S. A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine. Sci Adv. 2021;7(35):6326.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abi6326</pub-id><pub-id pub-id-type="pmcid">PMC8386930</pub-id><pub-id pub-id-type="pmid">34433569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaps</surname><given-names>L</given-names></name><name name-style="western"><surname>Limeres</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>P</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>M</given-names></name><name name-style="western"><surname>Zeyn</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fraude</surname><given-names>S</given-names></name><name name-style="western"><surname>Cacicedo</surname><given-names>ML</given-names></name><name name-style="western"><surname>Galle</surname><given-names>PR</given-names></name><name name-style="western"><surname>Gehring</surname><given-names>S</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M</given-names></name></person-group><article-title>Liver cell type-specific targeting by nanoformulations for therapeutic applications</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>14</issue><fpage>11869</fpage><pub-id pub-id-type="doi">10.3390/ijms241411869</pub-id><pub-id pub-id-type="pmid">37511628</pub-id><pub-id pub-id-type="pmcid">PMC10380755</pub-id></element-citation><mixed-citation id="mc-CR94" publication-type="journal">Kaps L, Limeres MJ, Schneider P, Svensson M, Zeyn Y, Fraude S, Cacicedo ML, Galle PR, Gehring S, Bros M. Liver cell type-specific targeting by nanoformulations for therapeutic applications. Int J Mol Sci. 2023;24(14):11869.<pub-id pub-id-type="pmid">37511628</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms241411869</pub-id><pub-id pub-id-type="pmcid">PMC10380755</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><name name-style="western"><surname>An</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name></person-group><article-title>Tuning the organ tropism of polymersome for spleen-selective nanovaccine delivery to boost cancer immunotherapy</article-title><source>Adv Mater</source><year>2023</year><volume>35</volume><issue>41</issue><fpage>2301686</fpage><pub-id pub-id-type="doi">10.1002/adma.202301686</pub-id><pub-id pub-id-type="pmid">37165781</pub-id></element-citation><mixed-citation id="mc-CR95" publication-type="journal">Gu W, An J, Li Y, Yang Y, Wang S, Shan H, Li S, Li H, Liu G, Li K, Yin Y. Tuning the organ tropism of polymersome for spleen-selective nanovaccine delivery to boost cancer immunotherapy. Adv Mater. 2023;35(41):2301686.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202301686</pub-id><pub-id pub-id-type="pmid">37165781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Ferreiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Abelairas</surname><given-names>MA</given-names></name><name name-style="western"><surname>Criado</surname><given-names>A</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>IJ</given-names></name><name name-style="western"><surname>Mosquera</surname><given-names>J</given-names></name></person-group><article-title>Dendrimers: exploring their wide structural variety and applications</article-title><source>Polymers</source><year>2023</year><volume>15</volume><issue>22</issue><fpage>4369</fpage><pub-id pub-id-type="doi">10.3390/polym15224369</pub-id><pub-id pub-id-type="pmid">38006093</pub-id><pub-id pub-id-type="pmcid">PMC10674315</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">P&#233;rez-Ferreiro M, Abelairas MA, Criado A, G&#243;mez IJ, Mosquera J. Dendrimers: exploring their wide structural variety and applications. Polymers. 2023;15(22):4369.<pub-id pub-id-type="pmid">38006093</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/polym15224369</pub-id><pub-id pub-id-type="pmcid">PMC10674315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Afzal</surname><given-names>O</given-names></name><name name-style="western"><surname>Altamimi</surname><given-names>AS</given-names></name><name name-style="western"><surname>Nadeem</surname><given-names>MS</given-names></name><name name-style="western"><surname>Alzarea</surname><given-names>SI</given-names></name><name name-style="western"><surname>Almalki</surname><given-names>WH</given-names></name><name name-style="western"><surname>Tariq</surname><given-names>A</given-names></name><name name-style="western"><surname>Mubeen</surname><given-names>B</given-names></name><name name-style="western"><surname>Murtaza</surname><given-names>BN</given-names></name><name name-style="western"><surname>Iftikhar</surname><given-names>S</given-names></name><name name-style="western"><surname>Riaz</surname><given-names>N</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>I</given-names></name></person-group><article-title>Nanoparticles in drug delivery: from history to therapeutic applications</article-title><source>Nanomaterials</source><year>2022</year><volume>12</volume><issue>24</issue><fpage>4494</fpage><pub-id pub-id-type="doi">10.3390/nano12244494</pub-id><pub-id pub-id-type="pmid">36558344</pub-id><pub-id pub-id-type="pmcid">PMC9781272</pub-id></element-citation><mixed-citation id="mc-CR97" publication-type="journal">Afzal O, Altamimi AS, Nadeem MS, Alzarea SI, Almalki WH, Tariq A, Mubeen B, Murtaza BN, Iftikhar S, Riaz N, Kazmi I. Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials. 2022;12(24):4494.<pub-id pub-id-type="pmid">36558344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano12244494</pub-id><pub-id pub-id-type="pmcid">PMC9781272</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knauer</surname><given-names>N</given-names></name><name name-style="western"><surname>Pashkina</surname><given-names>E</given-names></name><name name-style="western"><surname>Aktanova</surname><given-names>A</given-names></name><name name-style="western"><surname>Boeva</surname><given-names>O</given-names></name><name name-style="western"><surname>Arkhipova</surname><given-names>V</given-names></name><name name-style="western"><surname>Barkovskaya</surname><given-names>M</given-names></name><name name-style="western"><surname>Meschaninova</surname><given-names>M</given-names></name><name name-style="western"><surname>Karpus</surname><given-names>A</given-names></name><name name-style="western"><surname>Majoral</surname><given-names>JP</given-names></name><name name-style="western"><surname>Kozlov</surname><given-names>V</given-names></name><name name-style="western"><surname>Apartsin</surname><given-names>E</given-names></name></person-group><article-title>Effects of cationic dendrimers and their complexes with microRNAs on immunocompetent cells</article-title><source>Pharmaceutics</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>148</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15010148</pub-id><pub-id pub-id-type="pmid">36678776</pub-id><pub-id pub-id-type="pmcid">PMC9862986</pub-id></element-citation><mixed-citation id="mc-CR98" publication-type="journal">Knauer N, Pashkina E, Aktanova A, Boeva O, Arkhipova V, Barkovskaya M, Meschaninova M, Karpus A, Majoral JP, Kozlov V, Apartsin E. Effects of cationic dendrimers and their complexes with microRNAs on immunocompetent cells. Pharmaceutics. 2022;15(1):148.<pub-id pub-id-type="pmid">36678776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15010148</pub-id><pub-id pub-id-type="pmcid">PMC9862986</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>RJ</given-names></name></person-group><article-title>Dendrimers in vaccine delivery: recent progress and advances</article-title><source>Biomaterials</source><year>2022</year><volume>280</volume><fpage>121303</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121303</pub-id><pub-id pub-id-type="pmid">34871877</pub-id></element-citation><mixed-citation id="mc-CR99" publication-type="journal">Chowdhury S, Toth I, Stephenson RJ. Dendrimers in vaccine delivery: recent progress and advances. Biomaterials. 2022;280: 121303.<pub-id pub-id-type="pmid">34871877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.121303</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Chao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy</article-title><source>Biomaterials</source><year>2019</year><volume>207</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.03.037</pub-id><pub-id pub-id-type="pmid">30947117</pub-id></element-citation><mixed-citation id="mc-CR100" publication-type="journal">Xu J, Wang H, Xu L, Chao Y, Wang C, Han X, Dong Z, Chang H, Peng R, Cheng Y, Liu Z. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy. Biomaterials. 2019;207:1&#8211;9.<pub-id pub-id-type="pmid">30947117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.03.037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tong</surname><given-names>W</given-names></name><name name-style="western"><surname>Maira</surname><given-names>M</given-names></name><name name-style="western"><surname>Roychoudhury</surname><given-names>R</given-names></name><name name-style="western"><surname>Galan</surname><given-names>A</given-names></name><name name-style="western"><surname>Brahimi</surname><given-names>F</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>M</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>AM</given-names></name><name name-style="western"><surname>Josephy</surname><given-names>S</given-names></name><name name-style="western"><surname>Pirvulescu</surname><given-names>I</given-names></name><name name-style="western"><surname>Moffett</surname><given-names>S</given-names></name><name name-style="western"><surname>Saragovi</surname><given-names>HU</given-names></name></person-group><article-title>Vaccination with tumor-ganglioside glycomimetics activates a selective immunity that affords cancer therapy</article-title><source>Cell Chem Biol</source><year>2019</year><volume>26</volume><issue>1013&#8211;1026</issue><fpage>e1014</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.03.018</pub-id><pub-id pub-id-type="pmid">31105061</pub-id></element-citation><mixed-citation id="mc-CR101" publication-type="journal">Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU. Vaccination with tumor-ganglioside glycomimetics activates a selective immunity that affords cancer therapy. Cell Chem Biol. 2019;26(1013&#8211;1026):e1014.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.03.018</pub-id><pub-id pub-id-type="pmid">31105061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>A PD-L1 antibody-conjugated PAMAM dendrimer nanosystem for simultaneously inhibiting glycolysis and promoting immune response in fighting breast cancer</article-title><source>Adv Mater</source><year>2023</year><volume>35</volume><fpage>e2305215</fpage><pub-id pub-id-type="doi">10.1002/adma.202305215</pub-id><pub-id pub-id-type="pmid">37522451</pub-id></element-citation><mixed-citation id="mc-CR102" publication-type="journal">Zhang P, Li Z, Cao W, Tang J, Xia Y, Peng L, Ma J. A PD-L1 antibody-conjugated PAMAM dendrimer nanosystem for simultaneously inhibiting glycolysis and promoting immune response in fighting breast cancer. Adv Mater. 2023;35: e2305215.<pub-id pub-id-type="pmid">37522451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202305215</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Hao</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>Advances in polymeric micelles: responsive and targeting approaches for cancer immunotherapy in the tumor microenvironment</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><issue>11</issue><fpage>2622</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15112622</pub-id><pub-id pub-id-type="pmid">38004600</pub-id><pub-id pub-id-type="pmcid">PMC10675796</pub-id></element-citation><mixed-citation id="mc-CR103" publication-type="journal">Cheng L, Yu J, Hao T, Wang W, Wei M, Li G. Advances in polymeric micelles: responsive and targeting approaches for cancer immunotherapy in the tumor microenvironment. Pharmaceutics. 2023;15(11):2622.<pub-id pub-id-type="pmid">38004600</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15112622</pub-id><pub-id pub-id-type="pmcid">PMC10675796</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghani</surname><given-names>L</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Ehsan</surname><given-names>M</given-names></name><name name-style="western"><surname>Lan</surname><given-names>B</given-names></name><name name-style="western"><surname>Poulsen</surname><given-names>IH</given-names></name><name name-style="western"><surname>Dev</surname><given-names>C</given-names></name><name name-style="western"><surname>Katsube</surname><given-names>S</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>B</given-names></name><name name-style="western"><surname>Guan</surname><given-names>L</given-names></name><name name-style="western"><surname>Loland</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Im</surname><given-names>W</given-names></name><name name-style="western"><surname>Chae</surname><given-names>PS</given-names></name></person-group><article-title>Melamine-cored glucosides for membrane protein solubilization and stabilization: importance of water-mediated intermolecular hydrogen bonding in detergent performance</article-title><source>Chem Sci</source><year>2023</year><volume>14</volume><fpage>13014</fpage><lpage>13024</lpage><pub-id pub-id-type="doi">10.1039/D3SC03543C</pub-id><pub-id pub-id-type="pmid">38023530</pub-id><pub-id pub-id-type="pmcid">PMC10664503</pub-id></element-citation><mixed-citation id="mc-CR104" publication-type="journal">Ghani L, Kim S, Ehsan M, Lan B, Poulsen IH, Dev C, Katsube S, Byrne B, Guan L, Loland CJ, Liu X, Im W, Chae PS. Melamine-cored glucosides for membrane protein solubilization and stabilization: importance of water-mediated intermolecular hydrogen bonding in detergent performance. Chem Sci. 2023;14:13014&#8211;24.<pub-id pub-id-type="pmid">38023530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3sc03543c</pub-id><pub-id pub-id-type="pmcid">PMC10664503</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>D</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name></person-group><article-title>Nanotechnology-based drug delivery systems for Honokiol: enhancing therapeutic potential and overcoming limitations</article-title><source>Int J Nanomedicine</source><year>2023</year><volume>18</volume><fpage>6639</fpage><lpage>6665</lpage><pub-id pub-id-type="doi">10.2147/IJN.S431409</pub-id><pub-id pub-id-type="pmid">38026538</pub-id><pub-id pub-id-type="pmcid">PMC10656744</pub-id></element-citation><mixed-citation id="mc-CR105" publication-type="journal">Yang J, Shang J, Yang L, Wei D, Wang X, Deng Q, Zhong Z, Ye Y, Zhou M. Nanotechnology-based drug delivery systems for Honokiol: enhancing therapeutic potential and overcoming limitations. Int J Nanomedicine. 2023;18:6639&#8211;65.<pub-id pub-id-type="pmid">38026538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S431409</pub-id><pub-id pub-id-type="pmcid">PMC10656744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsabahy</surname><given-names>M</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>NG</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S</given-names></name><name name-style="western"><surname>Hamad</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wooley</surname><given-names>KL</given-names></name></person-group><article-title>Morphologic design of sugar-based polymer nanoparticles for delivery of antidiabetic peptides</article-title><source>J Control Release</source><year>2021</year><volume>334</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.04.006</pub-id><pub-id pub-id-type="pmid">33845056</pub-id></element-citation><mixed-citation id="mc-CR106" publication-type="journal">Elsabahy M, Song Y, Eissa NG, Khan S, Hamad MA, Wooley KL. Morphologic design of sugar-based polymer nanoparticles for delivery of antidiabetic peptides. J Control Release. 2021;334:1&#8211;10.<pub-id pub-id-type="pmid">33845056</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.04.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaur</surname><given-names>J</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>V</given-names></name><name name-style="western"><surname>Singh</surname><given-names>SK</given-names></name><name name-style="western"><surname>Gulati</surname><given-names>M</given-names></name><name name-style="western"><surname>Kapoor</surname><given-names>B</given-names></name><name name-style="western"><surname>Chellappan</surname><given-names>DK</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>G</given-names></name><name name-style="western"><surname>Dureja</surname><given-names>H</given-names></name><name name-style="western"><surname>Anand</surname><given-names>K</given-names></name><name name-style="western"><surname>Dua</surname><given-names>K</given-names></name><name name-style="western"><surname>Khatik</surname><given-names>GL</given-names></name><name name-style="western"><surname>Gowthamarajan</surname><given-names>K</given-names></name></person-group><article-title>Harnessing amphiphilic polymeric micelles for diagnostic and therapeutic applications: Breakthroughs and bottlenecks</article-title><source>J Control Release</source><year>2021</year><volume>334</volume><fpage>64</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.04.014</pub-id><pub-id pub-id-type="pmid">33887283</pub-id></element-citation><mixed-citation id="mc-CR107" publication-type="journal">Kaur J, Mishra V, Singh SK, Gulati M, Kapoor B, Chellappan DK, Gupta G, Dureja H, Anand K, Dua K, Khatik GL, Gowthamarajan K. Harnessing amphiphilic polymeric micelles for diagnostic and therapeutic applications: Breakthroughs and bottlenecks. J Control Release. 2021;334:64&#8211;95.<pub-id pub-id-type="pmid">33887283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.04.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Attenuating uncontrolled inflammation by radical trapping chiral polymer micelles</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>12127</fpage><lpage>12139</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c12356</pub-id><pub-id pub-id-type="pmid">37352508</pub-id></element-citation><mixed-citation id="mc-CR108" publication-type="journal">Li Y, Wang J, Li Y, Luo J, Liu F, Chen T, Ji Y, Yang H, Wang Z, Zhao Y. Attenuating uncontrolled inflammation by radical trapping chiral polymer micelles. ACS Nano. 2023;17:12127&#8211;39.<pub-id pub-id-type="pmid">37352508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c12356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name></person-group><article-title>Self-assembled polymeric micelle as a novel mRNA delivery carrier</article-title><source>J Control Release</source><year>2021</year><volume>338</volume><fpage>537</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.08.061</pub-id><pub-id pub-id-type="pmid">34481924</pub-id><pub-id pub-id-type="pmcid">PMC8411660</pub-id></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Ren J, Cao Y, Li L, Wang X, Lu H, Yang J, Wang S. Self-assembled polymeric micelle as a novel mRNA delivery carrier. J Control Release. 2021;338:537&#8211;47.<pub-id pub-id-type="pmid">34481924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.08.061</pub-id><pub-id pub-id-type="pmcid">PMC8411660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>JF</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Anticancer vaccination with immunogenic micelles that capture and release pristine CD8(+) T-cell epitopes and adjuvants</article-title><source>ACS Appl Mater Interfaces</source><year>2022</year><volume>14</volume><fpage>2510</fpage><lpage>2521</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c18117</pub-id><pub-id pub-id-type="pmid">34986639</pub-id></element-citation><mixed-citation id="mc-CR110" publication-type="journal">Ren H, Li J, Liu G, Sun Y, Yang X, Jiang Z, Zhang J, Lovell JF, Zhang Y. Anticancer vaccination with immunogenic micelles that capture and release pristine CD8(+) T-cell epitopes and adjuvants. ACS Appl Mater Interfaces. 2022;14:2510&#8211;21.<pub-id pub-id-type="pmid">34986639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.1c18117</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaghmur</surname><given-names>A</given-names></name><name name-style="western"><surname>&#216;stergaard</surname><given-names>J</given-names></name><name name-style="western"><surname>Mu</surname><given-names>H</given-names></name></person-group><article-title>Lipid nanoparticles for targeted delivery of anticancer therapeutics: recent advances in development of siRNA and lipoprotein-mimicking nanocarriers</article-title><source>Adv Drug Deliv Rev</source><year>2023</year><volume>203</volume><fpage>115136</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.115136</pub-id><pub-id pub-id-type="pmid">37944644</pub-id></element-citation><mixed-citation id="mc-CR111" publication-type="journal">Yaghmur A, &#216;stergaard J, Mu H. Lipid nanoparticles for targeted delivery of anticancer therapeutics: recent advances in development of siRNA and lipoprotein-mimicking nanocarriers. Adv Drug Deliv Rev. 2023;203:115136.<pub-id pub-id-type="pmid">37944644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2023.115136</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>S</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>N</given-names></name><name name-style="western"><surname>Juozaityte</surname><given-names>E</given-names></name><name name-style="western"><surname>Erdkamp</surname><given-names>F</given-names></name><name name-style="western"><surname>Pluzanska</surname><given-names>A</given-names></name><name name-style="western"><surname>Azarnia</surname><given-names>N</given-names></name><name name-style="western"><surname>Lee</surname><given-names>LW</given-names></name></person-group><article-title>Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer</article-title><source>Ann Oncol</source><year>2004</year><volume>15</volume><fpage>1527</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdh393</pub-id><pub-id pub-id-type="pmid">15367414</pub-id></element-citation><mixed-citation id="mc-CR112" publication-type="journal">Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, Lee LW. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15:1527&#8211;34.<pub-id pub-id-type="pmid">15367414</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdh393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lancet</surname><given-names>JE</given-names></name><name name-style="western"><surname>Uy</surname><given-names>GL</given-names></name><name name-style="western"><surname>Newell</surname><given-names>LF</given-names></name><name name-style="western"><surname>Lin</surname><given-names>TL</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>EK</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>RK</given-names></name><name name-style="western"><surname>Strickland</surname><given-names>SA</given-names></name><name name-style="western"><surname>Hogge</surname><given-names>D</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>SR</given-names></name><name name-style="western"><surname>Bixby</surname><given-names>D</given-names></name><name name-style="western"><surname>Kolitz</surname><given-names>JE</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Wieduwilt</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>DH</given-names></name><name name-style="western"><surname>Faderl</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y-L</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>J</given-names></name></person-group><article-title>Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary</article-title><source>AML.</source><year>2020</year><volume>38</volume><fpage>7510</fpage><lpage>7510</lpage></element-citation><mixed-citation id="mc-CR113" publication-type="journal">Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby D, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, Chang Y-L, Cortes J. Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary. AML. 2020;38:7510&#8211;7510.</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H</given-names></name></person-group><article-title>COVID-19 vaccine development: milestones, lessons and prospects</article-title><source>Signal Transduct Target Ther</source><year>2022</year><volume>7</volume><fpage>146</fpage><pub-id pub-id-type="doi">10.1038/s41392-022-00996-y</pub-id><pub-id pub-id-type="pmid">35504917</pub-id><pub-id pub-id-type="pmcid">PMC9062866</pub-id></element-citation><mixed-citation id="mc-CR114" publication-type="journal">Li M, Wang H, Tian L, Pang Z, Yang Q, Huang T, Fan J, Song L, Tong Y, Fan H. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022;7:146.<pub-id pub-id-type="pmid">35504917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-00996-y</pub-id><pub-id pub-id-type="pmcid">PMC9062866</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dreno</surname><given-names>B</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>JF</given-names></name><name name-style="western"><surname>Smithers</surname><given-names>BM</given-names></name><name name-style="western"><surname>Santinami</surname><given-names>M</given-names></name><name name-style="western"><surname>Jouary</surname><given-names>T</given-names></name><name name-style="western"><surname>Gutzmer</surname><given-names>R</given-names></name><name name-style="western"><surname>Levchenko</surname><given-names>E</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>P</given-names></name><name name-style="western"><surname>Grob</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Korovin</surname><given-names>S</given-names></name><name name-style="western"><surname>Drucis</surname><given-names>K</given-names></name><name name-style="western"><surname>Grange</surname><given-names>F</given-names></name><name name-style="western"><surname>Machet</surname><given-names>L</given-names></name><name name-style="western"><surname>Hersey</surname><given-names>P</given-names></name><name name-style="western"><surname>Krajsova</surname><given-names>I</given-names></name><name name-style="western"><surname>Testori</surname><given-names>A</given-names></name><name name-style="western"><surname>Conry</surname><given-names>R</given-names></name><name name-style="western"><surname>Guillot</surname><given-names>B</given-names></name><name name-style="western"><surname>Kruit</surname><given-names>WHJ</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>JM</given-names></name></person-group><article-title>MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial</article-title><source>Lancet Oncol</source><year>2018</year><volume>19</volume><fpage>916</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30254-7</pub-id><pub-id pub-id-type="pmid">29908991</pub-id></element-citation><mixed-citation id="mc-CR115" publication-type="journal">Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Kirkwood JM. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:916&#8211;29.<pub-id pub-id-type="pmid">29908991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(18)30254-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>A</given-names></name><name name-style="western"><surname>Aria</surname><given-names>S</given-names></name><name name-style="western"><surname>Maniaci</surname><given-names>B</given-names></name><name name-style="western"><surname>Mann</surname><given-names>K</given-names></name><name name-style="western"><surname>Martinson</surname><given-names>H</given-names></name><name name-style="western"><surname>Kullberg</surname><given-names>M</given-names></name></person-group><article-title>Enhancing T Cell and antibody response in Mucin-1 transgenic mice through co-delivery of tumor-associated Mucin-1 antigen and TLR agonists in C3-liposomes</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><issue>12</issue><fpage>2774</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15122774</pub-id><pub-id pub-id-type="pmid">38140114</pub-id><pub-id pub-id-type="pmcid">PMC10747059</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Arabi A, Aria S, Maniaci B, Mann K, Martinson H, Kullberg M. Enhancing T Cell and antibody response in Mucin-1 transgenic mice through co-delivery of tumor-associated Mucin-1 antigen and TLR agonists in C3-liposomes. Pharmaceutics. 2023;15(12):2774.<pub-id pub-id-type="pmid">38140114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15122774</pub-id><pub-id pub-id-type="pmcid">PMC10747059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pradyuth</surname><given-names>KS</given-names></name><name name-style="western"><surname>Salunkhe</surname><given-names>SA</given-names></name><name name-style="western"><surname>Singh</surname><given-names>AK</given-names></name><name name-style="western"><surname>Chitkara</surname><given-names>D</given-names></name><name name-style="western"><surname>Mittal</surname><given-names>A</given-names></name></person-group><article-title>Belinostat loaded lipid-polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model</article-title><source>J Mater Chem B</source><year>2023</year><volume>11</volume><fpage>10859</fpage><lpage>10872</lpage><pub-id pub-id-type="doi">10.1039/D3TB01317K</pub-id><pub-id pub-id-type="pmid">37938124</pub-id></element-citation><mixed-citation id="mc-CR117" publication-type="journal">Pradyuth KS, Salunkhe SA, Singh AK, Chitkara D, Mittal A. Belinostat loaded lipid-polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model. J Mater Chem B. 2023;11:10859&#8211;72.<pub-id pub-id-type="pmid">37938124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3tb01317k</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andretto</surname><given-names>V</given-names></name><name name-style="western"><surname>Repellin</surname><given-names>M</given-names></name><name name-style="western"><surname>Pujol</surname><given-names>M</given-names></name><name name-style="western"><surname>Almouazen</surname><given-names>E</given-names></name><name name-style="western"><surname>Sidi-Boumedine</surname><given-names>J</given-names></name><name name-style="western"><surname>Granjon</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Remaut</surname><given-names>K</given-names></name><name name-style="western"><surname>Jordheim</surname><given-names>LP</given-names></name><name name-style="western"><surname>Briancon</surname><given-names>S</given-names></name><name name-style="western"><surname>Keil</surname><given-names>IS</given-names></name><name name-style="western"><surname>Vascotto</surname><given-names>F</given-names></name><name name-style="western"><surname>Walzer</surname><given-names>KC</given-names></name><name name-style="western"><surname>Sahin</surname><given-names>U</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H</given-names></name><name name-style="western"><surname>Kryza</surname><given-names>D</given-names></name><name name-style="western"><surname>Lollo</surname><given-names>G</given-names></name></person-group><article-title>Hybrid core-shell particles for mRNA systemic delivery</article-title><source>J Control Release</source><year>2023</year><volume>353</volume><fpage>1037</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.11.042</pub-id><pub-id pub-id-type="pmid">36442614</pub-id></element-citation><mixed-citation id="mc-CR118" publication-type="journal">Andretto V, Repellin M, Pujol M, Almouazen E, Sidi-Boumedine J, Granjon T, Zhang H, Remaut K, Jordheim LP, Briancon S, Keil IS, Vascotto F, Walzer KC, Sahin U, Haas H, Kryza D, Lollo G. Hybrid core-shell particles for mRNA systemic delivery. J Control Release. 2023;353:1037&#8211;49.<pub-id pub-id-type="pmid">36442614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.11.042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajana</surname><given-names>N</given-names></name><name name-style="western"><surname>Mounika</surname><given-names>A</given-names></name><name name-style="western"><surname>Chary</surname><given-names>PS</given-names></name><name name-style="western"><surname>Bhavana</surname><given-names>V</given-names></name><name name-style="western"><surname>Urati</surname><given-names>A</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>D</given-names></name><name name-style="western"><surname>Singh</surname><given-names>SB</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>NK</given-names></name></person-group><article-title>Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer</article-title><source>J Control Release</source><year>2022</year><volume>352</volume><fpage>1024</fpage><lpage>1047</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.11.009</pub-id><pub-id pub-id-type="pmid">36379278</pub-id></element-citation><mixed-citation id="mc-CR119" publication-type="journal">Rajana N, Mounika A, Chary PS, Bhavana V, Urati A, Khatri D, Singh SB, Mehra NK. Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer. J Control Release. 2022;352:1024&#8211;47.<pub-id pub-id-type="pmid">36379278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120</label><citation-alternatives><element-citation id="ec-CR120" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gajbhiye</surname><given-names>KR</given-names></name><name name-style="western"><surname>Salve</surname><given-names>R</given-names></name><name name-style="western"><surname>Narwade</surname><given-names>M</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>A</given-names></name><name name-style="western"><surname>Kesharwani</surname><given-names>P</given-names></name><name name-style="western"><surname>Gajbhiye</surname><given-names>V</given-names></name></person-group><article-title>Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics</article-title><source>Mol Cancer</source><year>2023</year><volume>22</volume><fpage>160</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01849-0</pub-id><pub-id pub-id-type="pmid">37784179</pub-id><pub-id pub-id-type="pmcid">PMC10546754</pub-id></element-citation><mixed-citation id="mc-CR120" publication-type="journal">Gajbhiye KR, Salve R, Narwade M, Sheikh A, Kesharwani P, Gajbhiye V. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics. Mol Cancer. 2023;22:160.<pub-id pub-id-type="pmid">37784179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01849-0</pub-id><pub-id pub-id-type="pmcid">PMC10546754</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR121"><label>121</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name></person-group><article-title>Encapsulation of Poly I: C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors</article-title><source>Int J Pharm</source><year>2018</year><volume>553</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2018.10.054</pub-id><pub-id pub-id-type="pmid">30393151</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Liu C, Chu X, Yan M, Qi J, Liu H, Gao F, Gao R, Ma G, Ma Y. Encapsulation of Poly I: C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors. Int J Pharm. 2018;553:327&#8211;37.<pub-id pub-id-type="pmid">30393151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2018.10.054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy</article-title><source>Drug Des Devel Ther</source><year>2019</year><volume>13</volume><fpage>2043</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S202818</pub-id><pub-id pub-id-type="pmid">31388296</pub-id><pub-id pub-id-type="pmcid">PMC6607984</pub-id></element-citation><mixed-citation id="mc-CR122" publication-type="journal">Shao Y, Luo W, Guo Q, Li X, Zhang Q, Li J. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. Drug Des Devel Ther. 2019;13:2043&#8211;55.<pub-id pub-id-type="pmid">31388296</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S202818</pub-id><pub-id pub-id-type="pmcid">PMC6607984</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C</given-names></name><name name-style="western"><surname>Fan</surname><given-names>F</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H</given-names></name><name name-style="western"><surname>Leng</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination</article-title><source>Biomaterials</source><year>2019</year><volume>206</volume><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.03.012</pub-id><pub-id pub-id-type="pmid">30925286</pub-id></element-citation><mixed-citation id="mc-CR123" publication-type="journal">Zhu D, Hu C, Fan F, Qin Y, Huang C, Zhang Z, Lu L, Wang H, Sun H, Leng X, Wang C, Kong D, Zhang L. Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination. Biomaterials. 2019;206:25&#8211;40.<pub-id pub-id-type="pmid">30925286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.03.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soni</surname><given-names>KS</given-names></name><name name-style="western"><surname>Desale</surname><given-names>SS</given-names></name><name name-style="western"><surname>Bronich</surname><given-names>TK</given-names></name></person-group><article-title>Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation</article-title><source>J Control Release</source><year>2016</year><volume>240</volume><fpage>109</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.11.009</pub-id><pub-id pub-id-type="pmid">26571000</pub-id><pub-id pub-id-type="pmcid">PMC4862943</pub-id></element-citation><mixed-citation id="mc-CR124" publication-type="journal">Soni KS, Desale SS, Bronich TK. Nanogels: an overview of properties, biomedical applications and obstacles to clinical translation. J Control Release. 2016;240:109&#8211;26.<pub-id pub-id-type="pmid">26571000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2015.11.009</pub-id><pub-id pub-id-type="pmcid">PMC4862943</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muraoka</surname><given-names>D</given-names></name><name name-style="western"><surname>Harada</surname><given-names>N</given-names></name><name name-style="western"><surname>Shiku</surname><given-names>H</given-names></name><name name-style="western"><surname>Akiyoshi</surname><given-names>K</given-names></name></person-group><article-title>Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance</article-title><source>J Control Release</source><year>2022</year><volume>347</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.05.004</pub-id><pub-id pub-id-type="pmid">35526613</pub-id></element-citation><mixed-citation id="mc-CR125" publication-type="journal">Muraoka D, Harada N, Shiku H, Akiyoshi K. Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. J Control Release. 2022;347:175&#8211;82.<pub-id pub-id-type="pmid">35526613</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.05.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>P</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ji</surname><given-names>G</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G</given-names></name></person-group><article-title>Modular hydrogel vaccine for programmable and coordinate elicitation of cancer immunotherapy</article-title><source>Adv Sci</source><year>2023</year><volume>10</volume><issue>22</issue><fpage>e2301789</fpage><pub-id pub-id-type="doi">10.1002/advs.202301789</pub-id><pub-id pub-id-type="pmcid">PMC10401092</pub-id><pub-id pub-id-type="pmid">37222047</pub-id></element-citation><mixed-citation id="mc-CR126" publication-type="journal">Ji P, Sun W, Zhang S, Xing Y, Wang C, Wei M, Li Q, Ji G, Yang G. Modular hydrogel vaccine for programmable and coordinate elicitation of cancer immunotherapy. Adv Sci. 2023;10(22):e2301789. 10.1002/advs.202301789.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202301789</pub-id><pub-id pub-id-type="pmcid">PMC10401092</pub-id><pub-id pub-id-type="pmid">37222047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ying</surname><given-names>JY</given-names></name></person-group><article-title>A self-immolative DNA nanogel vaccine toward cancer immunotherapy</article-title><source>Nano Lett</source><year>2023</year><volume>23</volume><fpage>9778</fpage><lpage>9787</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.3c02449</pub-id><pub-id pub-id-type="pmid">37877690</pub-id></element-citation><mixed-citation id="mc-CR127" publication-type="journal">Hu Y, Gao S, Lu H, Tan S, Chen F, Ke Y, Ying JY. A self-immolative DNA nanogel vaccine toward cancer immunotherapy. Nano Lett. 2023;23:9778&#8211;87.<pub-id pub-id-type="pmid">37877690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.3c02449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishikawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Kageyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Miyahara</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okayama</surname><given-names>T</given-names></name><name name-style="western"><surname>Kokura</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Sato</surname><given-names>E</given-names></name><name name-style="western"><surname>Yagita</surname><given-names>H</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shiku</surname><given-names>H</given-names></name></person-group><article-title>Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients</article-title><source>Cancer Immunol Immunother</source><year>2021</year><volume>70</volume><fpage>3081</fpage><lpage>3091</lpage><pub-id pub-id-type="doi">10.1007/s00262-021-02892-w</pub-id><pub-id pub-id-type="pmid">33751208</pub-id><pub-id pub-id-type="pmcid">PMC10991152</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, Sato E, Yagita H, Itoh Y, Shiku H. Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunol Immunother. 2021;70:3081&#8211;91.<pub-id pub-id-type="pmid">33751208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-021-02892-w</pub-id><pub-id pub-id-type="pmcid">PMC10991152</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lu</surname><given-names>MM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bai</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Gu</surname><given-names>JY</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>WZ</given-names></name></person-group><article-title>Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges</article-title><source>Biomark Res</source><year>2023</year><volume>11</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.1186/s40364-023-00534-0</pub-id><pub-id pub-id-type="pmid">38037114</pub-id><pub-id pub-id-type="pmcid">PMC10690996</pub-id></element-citation><mixed-citation id="mc-CR129" publication-type="journal">Pang Z, Lu MM, Zhang Y, Gao Y, Bai JJ, Gu JY, Xie L, Wu WZ. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11:104.<pub-id pub-id-type="pmid">38037114</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-023-00534-0</pub-id><pub-id pub-id-type="pmcid">PMC10690996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shyr</surname><given-names>C-R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L-C</given-names></name><name name-style="western"><surname>Chien</surname><given-names>H-S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C-P</given-names></name></person-group><article-title>Immunotherapeutic agents for intratumoral immunotherapy</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><issue>11</issue><fpage>1717</fpage><pub-id pub-id-type="doi">10.3390/vaccines11111717</pub-id><pub-id pub-id-type="pmid">38006049</pub-id><pub-id pub-id-type="pmcid">PMC10674963</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Shyr C-R, Liu L-C, Chien H-S, Huang C-P. Immunotherapeutic agents for intratumoral immunotherapy. Vaccines. 2023;11(11):1717. 10.3390/vaccines11111717.<pub-id pub-id-type="pmid">38006049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11111717</pub-id><pub-id pub-id-type="pmcid">PMC10674963</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargrave</surname><given-names>A</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>A</given-names></name><name name-style="western"><surname>Tunio</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>SNM</given-names></name></person-group><article-title>Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><issue>11</issue><fpage>1633</fpage><pub-id pub-id-type="doi">10.3390/vaccines11111633</pub-id><pub-id pub-id-type="pmid">38005965</pub-id><pub-id pub-id-type="pmcid">PMC10675687</pub-id></element-citation><mixed-citation id="mc-CR131" publication-type="journal">Hargrave A, Mustafa AS, Hanif A, Tunio JH, Hanif SNM. Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines. Vaccines. 2023;11(11):1633. 10.3390/vaccines11111633.<pub-id pub-id-type="pmid">38005965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11111633</pub-id><pub-id pub-id-type="pmcid">PMC10675687</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Min</surname><given-names>Y</given-names></name></person-group><article-title>Stimuli-responsive nanoadjuvant rejuvenates robust immune responses to sensitize cancer immunotherapy</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>21455</fpage><lpage>21469</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c06233</pub-id><pub-id pub-id-type="pmid">37897704</pub-id></element-citation><mixed-citation id="mc-CR132" publication-type="journal">Huang R, Zhou P, Chen B, Zhu Y, Chen X, Min Y. Stimuli-responsive nanoadjuvant rejuvenates robust immune responses to sensitize cancer immunotherapy. ACS Nano. 2023;17:21455&#8211;69.<pub-id pub-id-type="pmid">37897704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c06233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>L</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Q</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>W</given-names></name></person-group><article-title>Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy</article-title><source>Int J Pharm</source><year>2021</year><volume>608</volume><fpage>121091</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121091</pub-id><pub-id pub-id-type="pmid">34555477</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Liang Z, Cui X, Yang L, Hu Q, Li D, Zhang X, Han L, Shi S, Shen Y, Zhao W, Ju Q, Deng X, Wu Y, Sheng W. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy. Int J Pharm. 2021;608: 121091.<pub-id pub-id-type="pmid">34555477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2021.121091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>L</given-names></name></person-group><article-title>Advances in mRNA-based cancer vaccines</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><issue>10</issue><fpage>1599</fpage><pub-id pub-id-type="doi">10.3390/vaccines11101599</pub-id><pub-id pub-id-type="pmid">37897001</pub-id><pub-id pub-id-type="pmcid">PMC10611059</pub-id></element-citation><mixed-citation id="mc-CR134" publication-type="journal">Ni L. Advances in mRNA-based cancer vaccines. Vaccines. 2023;11(10):1599. 10.3390/vaccines11101599.<pub-id pub-id-type="pmid">37897001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11101599</pub-id><pub-id pub-id-type="pmcid">PMC10611059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richard</surname><given-names>G</given-names></name><name name-style="western"><surname>Princiotta</surname><given-names>MF</given-names></name><name name-style="western"><surname>Bridon</surname><given-names>D</given-names></name><name name-style="western"><surname>Martin</surname><given-names>WD</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>GD</given-names></name><name name-style="western"><surname>De Groot</surname><given-names>AS</given-names></name></person-group><article-title>Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy</article-title><source>Expert Rev Vaccines</source><year>2022</year><volume>21</volume><fpage>173</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1080/14760584.2022.2012456</pub-id><pub-id pub-id-type="pmid">34882038</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Richard G, Princiotta MF, Bridon D, Martin WD, Steinberg GD, De Groot AS. Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Rev Vaccines. 2022;21:173&#8211;84.<pub-id pub-id-type="pmid">34882038</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14760584.2022.2012456</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>P</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name></person-group><article-title>Advances, opportunities and challenges in developing therapeutic cancer vaccines</article-title><source>Crit Rev Oncol Hematol</source><year>2023</year><volume>193</volume><fpage>104198</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2023.104198</pub-id><pub-id pub-id-type="pmid">37949152</pub-id></element-citation><mixed-citation id="mc-CR136" publication-type="journal">Duan Z, Yang D, Yuan P, Dai X, Chen G, Wu D. Advances, opportunities and challenges in developing therapeutic cancer vaccines. Crit Rev Oncol Hematol. 2023;193: 104198.<pub-id pub-id-type="pmid">37949152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2023.104198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>In situ vaccination with an injectable nucleic acid hydrogel for synergistic cancer immunotherapy</article-title><source>Angew Chem Int Ed</source><year>2024</year><volume>63</volume><issue>4</issue><fpage>e202315282</fpage><pub-id pub-id-type="doi">10.1002/anie.202315282</pub-id><pub-id pub-id-type="pmid">38032360</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Wang F, Xie M, Huang Y, Liu Y, Liu X, Zhu L, Zhu X, Guo Y, Zhang C. In situ vaccination with an injectable nucleic acid hydrogel for synergistic cancer immunotherapy. Angew Chem Int Ed. 2024;63(4):e202315282.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202315282</pub-id><pub-id pub-id-type="pmid">38032360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>WQ</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><name name-style="western"><surname>Hou</surname><given-names>JC</given-names></name><name name-style="western"><surname>Coghi</surname><given-names>PS</given-names></name><name name-style="western"><surname>Fan</surname><given-names>XX</given-names></name></person-group><article-title>Overcoming suppressive tumor microenvironment by vaccines in solid tumor</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><issue>2</issue><fpage>394</fpage><pub-id pub-id-type="doi">10.3390/vaccines11020394</pub-id><pub-id pub-id-type="pmid">36851271</pub-id><pub-id pub-id-type="pmcid">PMC9964970</pub-id></element-citation><mixed-citation id="mc-CR138" publication-type="journal">Xie YJ, Liu WQ, Li D, Hou JC, Coghi PS, Fan XX. Overcoming suppressive tumor microenvironment by vaccines in solid tumor. Vaccines. 2023;11(2):394.<pub-id pub-id-type="pmid">36851271</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11020394</pub-id><pub-id pub-id-type="pmcid">PMC9964970</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X</given-names></name></person-group><article-title>RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy</article-title><source>Hum Vaccin Immunother</source><year>2021</year><volume>17</volume><fpage>2995</fpage><lpage>2998</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.1921524</pub-id><pub-id pub-id-type="pmid">33945399</pub-id><pub-id pub-id-type="pmcid">PMC8381784</pub-id></element-citation><mixed-citation id="mc-CR139" publication-type="journal">Zhang H, Xia X. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy. Hum Vaccin Immunother. 2021;17:2995&#8211;8.<pub-id pub-id-type="pmid">33945399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2021.1921524</pub-id><pub-id pub-id-type="pmcid">PMC8381784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>G&#243;mez-Aguado</surname><given-names>I</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Castej&#243;n</surname><given-names>J</given-names></name><name name-style="western"><surname>Vicente-Pascual</surname><given-names>M</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Gasc&#243;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Solin&#237;s</surname><given-names>M&#193;</given-names></name><name name-style="western"><surname>del Pozo-Rodr&#237;guez</surname><given-names>A</given-names></name></person-group><article-title>Nanomedicines to deliver mRNA: state of the art and future perspectives</article-title><source>Nanomaterials</source><year>2020</year><volume>10</volume><issue>2</issue><fpage>364</fpage><pub-id pub-id-type="doi">10.3390/nano10020364</pub-id><pub-id pub-id-type="pmid">32093140</pub-id><pub-id pub-id-type="pmcid">PMC7075285</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">G&#243;mez-Aguado I, Rodr&#237;guez-Castej&#243;n J, Vicente-Pascual M, Rodr&#237;guez-Gasc&#243;n A, Solin&#237;s M&#193;, del Pozo-Rodr&#237;guez A. Nanomedicines to deliver mRNA: state of the art and future perspectives. Nanomaterials. 2020;10(2):364.<pub-id pub-id-type="pmid">32093140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano10020364</pub-id><pub-id pub-id-type="pmcid">PMC7075285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>MM</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name></person-group><article-title>An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><issue>3</issue><fpage>244</fpage><pub-id pub-id-type="doi">10.3390/vaccines9030244</pub-id><pub-id pub-id-type="pmid">33799516</pub-id><pub-id pub-id-type="pmcid">PMC8001631</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Rahman MM, Zhou N, Huang J. An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo. Vaccines. 2021;9(3):244.<pub-id pub-id-type="pmid">33799516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9030244</pub-id><pub-id pub-id-type="pmcid">PMC8001631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoo</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Lim</surname><given-names>YT</given-names></name></person-group><article-title>Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy</article-title><source>J Control Release</source><year>2022</year><volume>343</volume><fpage>564</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.01.047</pub-id><pub-id pub-id-type="pmid">35124126</pub-id></element-citation><mixed-citation id="mc-CR142" publication-type="journal">Yoo YJ, Lee CH, Park SH, Lim YT. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy. J Control Release. 2022;343:564&#8211;83.<pub-id pub-id-type="pmid">35124126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.01.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F</given-names></name><name name-style="western"><surname>Tan</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>LncRNA-edited biomimetic nanovaccines combined with anti-TIM-3 for augmented immune checkpoint blockade immunotherapy</article-title><source>J Control Release</source><year>2023</year><volume>361</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.08.022</pub-id><pub-id pub-id-type="pmid">37591462</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Zhang Y, Liu F, Tan L, Li X, Dai Z, Cheng Q, Liu J, Wang Y, Huang L, Wang L, Wang Z. LncRNA-edited biomimetic nanovaccines combined with anti-TIM-3 for augmented immune checkpoint blockade immunotherapy. J Control Release. 2023;361:671&#8211;80.<pub-id pub-id-type="pmid">37591462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.08.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TL</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name></person-group><article-title>Enhanced cancer DNA vaccine via direct transfection to host dendritic cells recruited in injectable scaffolds</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>11623</fpage><lpage>11636</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c04188</pub-id><pub-id pub-id-type="pmid">32808762</pub-id></element-citation><mixed-citation id="mc-CR144" publication-type="journal">Nguyen TL, Yin Y, Choi Y, Jeong JH, Kim J. Enhanced cancer DNA vaccine via direct transfection to host dendritic cells recruited in injectable scaffolds. ACS Nano. 2020;14:11623&#8211;36.<pub-id pub-id-type="pmid">32808762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c04188</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alnaimi</surname><given-names>A</given-names></name><name name-style="western"><surname>Al-Hamry</surname><given-names>A</given-names></name><name name-style="western"><surname>Makableh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Adiraju</surname><given-names>A</given-names></name><name name-style="western"><surname>Kanoun</surname><given-names>O</given-names></name></person-group><article-title>Gold nanoparticles-MWCNT based aptasensor for early diagnosis of prostate cancer</article-title><source>Biosensors</source><year>2022</year><volume>12</volume><issue>12</issue><fpage>1130</fpage><pub-id pub-id-type="doi">10.3390/bios12121130</pub-id><pub-id pub-id-type="pmid">36551097</pub-id><pub-id pub-id-type="pmcid">PMC9776393</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Alnaimi A, Al-Hamry A, Makableh Y, Adiraju A, Kanoun O. Gold nanoparticles-MWCNT based aptasensor for early diagnosis of prostate cancer. Biosensors. 2022;12(12):1130. 10.3390/bios12121130.<pub-id pub-id-type="pmid">36551097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/bios12121130</pub-id><pub-id pub-id-type="pmcid">PMC9776393</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonz&#225;lez-Ballesteros</surname><given-names>N</given-names></name><name name-style="western"><surname>Maietta</surname><given-names>I</given-names></name><name name-style="western"><surname>Rey-M&#233;ndez</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Arg&#252;elles</surname><given-names>MC</given-names></name><name name-style="western"><surname>Lastra-Valdor</surname><given-names>M</given-names></name><name name-style="western"><surname>Cavazza</surname><given-names>A</given-names></name><name name-style="western"><surname>Grimaldi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bigi</surname><given-names>F</given-names></name><name name-style="western"><surname>Sim&#243;n-V&#225;zquez</surname><given-names>R</given-names></name></person-group><article-title>Gold nanoparticles synthesized by an aqueous extract of codium tomentosum as potential antitumoral enhancers of gemcitabine</article-title><source>Mar Drugs</source><year>2022</year><volume>21</volume><issue>1</issue><fpage>20</fpage><pub-id pub-id-type="doi">10.3390/md21010020</pub-id><pub-id pub-id-type="pmid">36662193</pub-id><pub-id pub-id-type="pmcid">PMC9865996</pub-id></element-citation><mixed-citation id="mc-CR146" publication-type="journal">Gonz&#225;lez-Ballesteros N, Maietta I, Rey-M&#233;ndez R, Rodr&#237;guez-Arg&#252;elles MC, Lastra-Valdor M, Cavazza A, Grimaldi M, Bigi F, Sim&#243;n-V&#225;zquez R. Gold nanoparticles synthesized by an aqueous extract of codium tomentosum as potential antitumoral enhancers of gemcitabine. Mar Drugs. 2022;21(1):20.<pub-id pub-id-type="pmid">36662193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/md21010020</pub-id><pub-id pub-id-type="pmcid">PMC9865996</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bui</surname><given-names>B</given-names></name><name name-style="western"><surname>Pi</surname><given-names>J</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P</given-names></name></person-group><article-title>Real-time SERS monitoring anticancer drug release along with SERS/MR imaging for pH-sensitive chemo-phototherapy</article-title><source>Acta Pharm Sin B</source><year>2023</year><volume>13</volume><fpage>1303</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.08.024</pub-id><pub-id pub-id-type="pmid">36970207</pub-id><pub-id pub-id-type="pmcid">PMC10031148</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Huang X, Sheng B, Tian H, Chen Q, Yang Y, Bui B, Pi J, Cai H, Chen S, Zhang J, Chen W, Zhou H, Sun P. Real-time SERS monitoring anticancer drug release along with SERS/MR imaging for pH-sensitive chemo-phototherapy. Acta Pharm Sin B. 2023;13:1303&#8211;17.<pub-id pub-id-type="pmid">36970207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.08.024</pub-id><pub-id pub-id-type="pmcid">PMC10031148</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name></person-group><article-title>Plasmonic nanocavity-modulated electrochemiluminescence sensor for gastric cancer exosomal miRNA detection</article-title><source>Biosens Bioelectron</source><year>2023</year><volume>245</volume><fpage>115847</fpage><pub-id pub-id-type="doi">10.1016/j.bios.2023.115847</pub-id><pub-id pub-id-type="pmid">37995625</pub-id></element-citation><mixed-citation id="mc-CR148" publication-type="journal">Wang P, Liang Z, Li Z, Wang D, Ma Q. Plasmonic nanocavity-modulated electrochemiluminescence sensor for gastric cancer exosomal miRNA detection. Biosens Bioelectron. 2023;245: 115847.<pub-id pub-id-type="pmid">37995625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bios.2023.115847</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L</given-names></name></person-group><article-title>The basic properties of gold nanoparticles and their applications in tumor diagnosis and treatment</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>7</issue><fpage>2480</fpage><pub-id pub-id-type="doi">10.3390/ijms21072480</pub-id><pub-id pub-id-type="pmid">32260051</pub-id><pub-id pub-id-type="pmcid">PMC7178173</pub-id></element-citation><mixed-citation id="mc-CR149" publication-type="journal">Bai X, Wang Y, Song Z, Feng Y, Chen Y, Zhang D, Feng L. The basic properties of gold nanoparticles and their applications in tumor diagnosis and treatment. Int J Mol Sci. 2020;21(7):2480.<pub-id pub-id-type="pmid">32260051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms21072480</pub-id><pub-id pub-id-type="pmcid">PMC7178173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Pastor</surname><given-names>R</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gimeno</surname><given-names>M</given-names></name><name name-style="western"><surname>de Martino</surname><given-names>A</given-names></name><name name-style="western"><surname>Man</surname><given-names>YKS</given-names></name><name name-style="western"><surname>Hallden</surname><given-names>G</given-names></name><name name-style="western"><surname>Quintanilla</surname><given-names>M</given-names></name><name name-style="western"><surname>de la Fuente</surname><given-names>JM</given-names></name><name name-style="western"><surname>Martin-Duque</surname><given-names>P</given-names></name></person-group><article-title>Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy</article-title><source>Acta Biomater</source><year>2021</year><volume>134</volume><fpage>593</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2021.07.047</pub-id><pub-id pub-id-type="pmid">34325075</pub-id></element-citation><mixed-citation id="mc-CR150" publication-type="journal">Gonzalez-Pastor R, Hernandez Y, Gimeno M, de Martino A, Man YKS, Hallden G, Quintanilla M, de la Fuente JM, Martin-Duque P. Coating an adenovirus with functionalized gold nanoparticles favors uptake, intracellular trafficking and anti-cancer therapeutic efficacy. Acta Biomater. 2021;134:593&#8211;604.<pub-id pub-id-type="pmid">34325075</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2021.07.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>XY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Ashby</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name><name name-style="western"><surname>Fan</surname><given-names>YF</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ZS</given-names></name></person-group><article-title>Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer</article-title><source>Drug Discov Today</source><year>2021</year><volume>26</volume><fpage>1284</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2021.01.030</pub-id><pub-id pub-id-type="pmid">33549529</pub-id></element-citation><mixed-citation id="mc-CR151" publication-type="journal">Liu XY, Wang JQ, Ashby CR Jr, Zeng L, Fan YF, Chen ZS. Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discov Today. 2021;26:1284&#8211;92.<pub-id pub-id-type="pmid">33549529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2021.01.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152</label><citation-alternatives><element-citation id="ec-CR152" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perzanowska</surname><given-names>O</given-names></name><name name-style="western"><surname>Majewski</surname><given-names>M</given-names></name><name name-style="western"><surname>Strenkowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Glowala</surname><given-names>P</given-names></name><name name-style="western"><surname>Czarnocki-Cieciura</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazur</surname><given-names>M</given-names></name><name name-style="western"><surname>Kowalska</surname><given-names>J</given-names></name><name name-style="western"><surname>Jemielity</surname><given-names>J</given-names></name></person-group><article-title>Nucleotide-decorated AuNPs as probes for nucleotide-binding proteins</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>15741</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-94983-y</pub-id><pub-id pub-id-type="pmid">34344911</pub-id><pub-id pub-id-type="pmcid">PMC8333360</pub-id></element-citation><mixed-citation id="mc-CR152" publication-type="journal">Perzanowska O, Majewski M, Strenkowska M, Glowala P, Czarnocki-Cieciura M, Mazur M, Kowalska J, Jemielity J. Nucleotide-decorated AuNPs as probes for nucleotide-binding proteins. Sci Rep. 2021;11:15741.<pub-id pub-id-type="pmid">34344911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-94983-y</pub-id><pub-id pub-id-type="pmcid">PMC8333360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR153"><label>153</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Karmakar</surname><given-names>B</given-names></name><name name-style="western"><surname>Babalghith</surname><given-names>AO</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>GE</given-names></name><name name-style="western"><surname>AlSalem</surname><given-names>HS</given-names></name><name name-style="western"><surname>El-Kott</surname><given-names>AF</given-names></name><name name-style="western"><surname>Shati</surname><given-names>AA</given-names></name><name name-style="western"><surname>Alfaifi</surname><given-names>MY</given-names></name><name name-style="western"><surname>Elbehairi</surname><given-names>SEI</given-names></name></person-group><article-title>Decorated Au NPs on lignin coated magnetic nanoparticles: Investigation of its catalytic application in the reduction of aromatic nitro compounds and its performance against human lung cancer</article-title><source>Int J Biol Macromol</source><year>2022</year><volume>223</volume><fpage>1067</fpage><lpage>1082</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2022.10.268</pub-id><pub-id pub-id-type="pmid">36368366</pub-id></element-citation><mixed-citation id="mc-CR153" publication-type="journal">Cai Y, Karmakar B, Babalghith AO, Batiha GE, AlSalem HS, El-Kott AF, Shati AA, Alfaifi MY, Elbehairi SEI. Decorated Au NPs on lignin coated magnetic nanoparticles: Investigation of its catalytic application in the reduction of aromatic nitro compounds and its performance against human lung cancer. Int J Biol Macromol. 2022;223:1067&#8211;82.<pub-id pub-id-type="pmid">36368366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2022.10.268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>HSA-templated self-generation of gold nanoparticles for tumor vaccine delivery and combinational therapy</article-title><source>J Mater Chem B</source><year>2022</year><volume>10</volume><fpage>8750</fpage><lpage>8759</lpage><pub-id pub-id-type="doi">10.1039/D2TB01483A</pub-id><pub-id pub-id-type="pmid">36254821</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Zhang D, Liu P, Qin X, Cheng L, Wang F, Xiong X, Huang C, Zhang Z. HSA-templated self-generation of gold nanoparticles for tumor vaccine delivery and combinational therapy. J Mater Chem B. 2022;10:8750&#8211;9.<pub-id pub-id-type="pmid">36254821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d2tb01483a</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kodama</surname><given-names>RH</given-names></name></person-group><article-title>Magnetic nanoparticles</article-title><source>J Magn Magn Mater</source><year>1999</year><volume>200</volume><fpage>359</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/S0304-8853(99)00347-9</pub-id></element-citation><mixed-citation id="mc-CR155" publication-type="journal">Kodama RH. Magnetic nanoparticles. J Magn Magn Mater. 1999;200:359&#8211;72.</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darroudi</surname><given-names>M</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>M</given-names></name><name name-style="western"><surname>Rezayi</surname><given-names>M</given-names></name><name name-style="western"><surname>Khazaei</surname><given-names>M</given-names></name></person-group><article-title>An overview and bibliometric analysis on the colorectal cancer therapy by magnetic functionalized nanoparticles for the responsive and targeted drug delivery</article-title><source>J Nanobiotechnology</source><year>2021</year><volume>19</volume><fpage>399</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-01150-6</pub-id><pub-id pub-id-type="pmid">34844632</pub-id><pub-id pub-id-type="pmcid">PMC8630862</pub-id></element-citation><mixed-citation id="mc-CR156" publication-type="journal">Darroudi M, Gholami M, Rezayi M, Khazaei M. An overview and bibliometric analysis on the colorectal cancer therapy by magnetic functionalized nanoparticles for the responsive and targeted drug delivery. J Nanobiotechnology. 2021;19:399.<pub-id pub-id-type="pmid">34844632</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-021-01150-6</pub-id><pub-id pub-id-type="pmcid">PMC8630862</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korakaki</surname><given-names>E</given-names></name><name name-style="western"><surname>Simos</surname><given-names>YV</given-names></name><name name-style="western"><surname>Karouta</surname><given-names>N</given-names></name><name name-style="western"><surname>Spyrou</surname><given-names>K</given-names></name><name name-style="western"><surname>Zygouri</surname><given-names>P</given-names></name><name name-style="western"><surname>Gournis</surname><given-names>DP</given-names></name><name name-style="western"><surname>Tsamis</surname><given-names>KI</given-names></name><name name-style="western"><surname>Stamatis</surname><given-names>H</given-names></name><name name-style="western"><surname>Dounousi</surname><given-names>E</given-names></name><name name-style="western"><surname>Vezyraki</surname><given-names>P</given-names></name><name name-style="western"><surname>Peschos</surname><given-names>D</given-names></name></person-group><article-title>Effect of highly hydrophilic superparamagnetic iron oxide nanoparticles on macrophage function and survival</article-title><source>J Funct Biomat</source><year>2023</year><volume>14</volume><issue>10</issue><fpage>514</fpage><pub-id pub-id-type="doi">10.3390/jfb14100514</pub-id><pub-id pub-id-type="pmcid">PMC10607831</pub-id><pub-id pub-id-type="pmid">37888179</pub-id></element-citation><mixed-citation id="mc-CR157" publication-type="journal">Korakaki E, Simos YV, Karouta N, Spyrou K, Zygouri P, Gournis DP, Tsamis KI, Stamatis H, Dounousi E, Vezyraki P, Peschos D. Effect of highly hydrophilic superparamagnetic iron oxide nanoparticles on macrophage function and survival. J Funct Biomat. 2023;14(10):514.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jfb14100514</pub-id><pub-id pub-id-type="pmcid">PMC10607831</pub-id><pub-id pub-id-type="pmid">37888179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158</label><citation-alternatives><element-citation id="ec-CR158" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Butch</surname><given-names>CJ</given-names></name></person-group><article-title>Coating influence on inner shell water exchange: An underinvestigated major contributor to SPIONs relaxation properties</article-title><source>Nanomedicine</source><year>2023</year><volume>54</volume><fpage>102713</fpage><pub-id pub-id-type="doi">10.1016/j.nano.2023.102713</pub-id><pub-id pub-id-type="pmid">37839694</pub-id></element-citation><mixed-citation id="mc-CR158" publication-type="journal">Peng Y, Li Y, Li L, Xie M, Wang Y, Butch CJ. Coating influence on inner shell water exchange: An underinvestigated major contributor to SPIONs relaxation properties. Nanomedicine. 2023;54: 102713.<pub-id pub-id-type="pmid">37839694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2023.102713</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR159"><label>159</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfister</surname><given-names>F</given-names></name><name name-style="western"><surname>Dorrie</surname><given-names>J</given-names></name><name name-style="western"><surname>Schaft</surname><given-names>N</given-names></name><name name-style="western"><surname>Buchele</surname><given-names>V</given-names></name><name name-style="western"><surname>Unterweger</surname><given-names>H</given-names></name><name name-style="western"><surname>Carnell</surname><given-names>LR</given-names></name><name name-style="western"><surname>Schreier</surname><given-names>P</given-names></name><name name-style="western"><surname>Stein</surname><given-names>R</given-names></name><name name-style="western"><surname>Kubankova</surname><given-names>M</given-names></name><name name-style="western"><surname>Guck</surname><given-names>J</given-names></name><name name-style="western"><surname>Hackstein</surname><given-names>H</given-names></name><name name-style="western"><surname>Alexiou</surname><given-names>C</given-names></name><name name-style="western"><surname>Janko</surname><given-names>C</given-names></name></person-group><article-title>Human T cells loaded with superparamagnetic iron oxide nanoparticles retain antigen-specific TCR functionality</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1223695</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1223695</pub-id><pub-id pub-id-type="pmid">37662937</pub-id><pub-id pub-id-type="pmcid">PMC10470061</pub-id></element-citation><mixed-citation id="mc-CR159" publication-type="journal">Pfister F, Dorrie J, Schaft N, Buchele V, Unterweger H, Carnell LR, Schreier P, Stein R, Kubankova M, Guck J, Hackstein H, Alexiou C, Janko C. Human T cells loaded with superparamagnetic iron oxide nanoparticles retain antigen-specific TCR functionality. Front Immunol. 2023;14:1223695.<pub-id pub-id-type="pmid">37662937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1223695</pub-id><pub-id pub-id-type="pmcid">PMC10470061</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sell</surname><given-names>M</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>AR</given-names></name><name name-style="western"><surname>Escudeiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Esteves</surname><given-names>B</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>AR</given-names></name><name name-style="western"><surname>Trindade</surname><given-names>T</given-names></name><name name-style="western"><surname>Cruz-Lopes</surname><given-names>L</given-names></name></person-group><article-title>Application of nanoparticles in cancer treatment: a concise review</article-title><source>Nanomaterials</source><year>2023</year><volume>13</volume><issue>21</issue><fpage>2887</fpage><pub-id pub-id-type="doi">10.3390/nano13212887</pub-id><pub-id pub-id-type="pmid">37947732</pub-id><pub-id pub-id-type="pmcid">PMC10650201</pub-id></element-citation><mixed-citation id="mc-CR160" publication-type="journal">Sell M, Lopes AR, Escudeiro M, Esteves B, Monteiro AR, Trindade T, Cruz-Lopes L. Application of nanoparticles in cancer treatment: a concise review. Nanomaterials. 2023;13(21):2887.<pub-id pub-id-type="pmid">37947732</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano13212887</pub-id><pub-id pub-id-type="pmcid">PMC10650201</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161</label><citation-alternatives><element-citation id="ec-CR161" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verimli</surname><given-names>N</given-names></name><name name-style="western"><surname>Gorali</surname><given-names>SI</given-names></name><name name-style="western"><surname>Abisoglu</surname><given-names>B</given-names></name><name name-style="western"><surname>Altan</surname><given-names>CL</given-names></name><name name-style="western"><surname>Sucu</surname><given-names>BO</given-names></name><name name-style="western"><surname>Karatas</surname><given-names>E</given-names></name><name name-style="western"><surname>Tulek</surname><given-names>A</given-names></name><name name-style="western"><surname>Bayraktaroglu</surname><given-names>C</given-names></name><name name-style="western"><surname>Beker</surname><given-names>MC</given-names></name><name name-style="western"><surname>Erdem</surname><given-names>SS</given-names></name></person-group><article-title>Development of light and pH-dual responsive self-quenching theranostic SPION to make EGFR overexpressing micro tumors glow and destroy</article-title><source>J Photochem Photobiol B</source><year>2023</year><volume>248</volume><fpage>112797</fpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2023.112797</pub-id><pub-id pub-id-type="pmid">37862898</pub-id></element-citation><mixed-citation id="mc-CR161" publication-type="journal">Verimli N, Gorali SI, Abisoglu B, Altan CL, Sucu BO, Karatas E, Tulek A, Bayraktaroglu C, Beker MC, Erdem SS. Development of light and pH-dual responsive self-quenching theranostic SPION to make EGFR overexpressing micro tumors glow and destroy. J Photochem Photobiol B. 2023;248: 112797.<pub-id pub-id-type="pmid">37862898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jphotobiol.2023.112797</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR162"><label>162</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zschiesche</surname><given-names>L</given-names></name><name name-style="western"><surname>Janko</surname><given-names>C</given-names></name><name name-style="western"><surname>Friedrich</surname><given-names>B</given-names></name><name name-style="western"><surname>Frey</surname><given-names>B</given-names></name><name name-style="western"><surname>Band</surname><given-names>J</given-names></name><name name-style="western"><surname>Lyer</surname><given-names>S</given-names></name><name name-style="western"><surname>Alexiou</surname><given-names>C</given-names></name><name name-style="western"><surname>Unterweger</surname><given-names>H</given-names></name></person-group><article-title>Biocompatibility of Dextran-Coated 30 nm and 80 nm Sized SPIONs towards monocytes, dendritic cells and lymphocytes</article-title><source>Nanomaterials</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>14</fpage><pub-id pub-id-type="doi">10.3390/nano13010014</pub-id><pub-id pub-id-type="pmid">36615924</pub-id><pub-id pub-id-type="pmcid">PMC9823599</pub-id></element-citation><mixed-citation id="mc-CR162" publication-type="journal">Zschiesche L, Janko C, Friedrich B, Frey B, Band J, Lyer S, Alexiou C, Unterweger H. Biocompatibility of Dextran-Coated 30 nm and 80 nm Sized SPIONs towards monocytes, dendritic cells and lymphocytes. Nanomaterials. 2022;13(1):14.<pub-id pub-id-type="pmid">36615924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano13010014</pub-id><pub-id pub-id-type="pmcid">PMC9823599</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>W</given-names></name></person-group><article-title>Iron oxide nanoparticles-based vaccine delivery for cancer treatment</article-title><source>Mol Pharm</source><year>2018</year><volume>15</volume><fpage>1791</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b01103</pub-id><pub-id pub-id-type="pmid">29570298</pub-id></element-citation><mixed-citation id="mc-CR163" publication-type="journal">Zhao Y, Zhao X, Cheng Y, Guo X, Yuan W. Iron oxide nanoparticles-based vaccine delivery for cancer treatment. Mol Pharm. 2018;15:1791&#8211;9.<pub-id pub-id-type="pmid">29570298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.7b01103</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164</label><citation-alternatives><element-citation id="ec-CR164" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanz-Ortega</surname><given-names>L</given-names></name><name name-style="western"><surname>Portilla</surname><given-names>Y</given-names></name><name name-style="western"><surname>Perez-Yague</surname><given-names>S</given-names></name><name name-style="western"><surname>Barber</surname><given-names>DF</given-names></name></person-group><article-title>Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8(+) T cells does not improve their tumour infiltration in a mouse model of cancer but promotes the retention of these cells in tumour-draining lymph nodes</article-title><source>J Nanobiotechnology</source><year>2019</year><volume>17</volume><fpage>87</fpage><pub-id pub-id-type="doi">10.1186/s12951-019-0520-0</pub-id><pub-id pub-id-type="pmid">31387604</pub-id><pub-id pub-id-type="pmcid">PMC6683429</pub-id></element-citation><mixed-citation id="mc-CR164" publication-type="journal">Sanz-Ortega L, Portilla Y, Perez-Yague S, Barber DF. Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8(+) T cells does not improve their tumour infiltration in a mouse model of cancer but promotes the retention of these cells in tumour-draining lymph nodes. J Nanobiotechnology. 2019;17:87.<pub-id pub-id-type="pmid">31387604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-019-0520-0</pub-id><pub-id pub-id-type="pmcid">PMC6683429</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR165"><label>165</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dias</surname><given-names>AM</given-names></name><name name-style="western"><surname>Courteau</surname><given-names>A</given-names></name><name name-style="western"><surname>Bellaye</surname><given-names>PS</given-names></name><name name-style="western"><surname>Kohli</surname><given-names>E</given-names></name><name name-style="western"><surname>Oudot</surname><given-names>A</given-names></name><name name-style="western"><surname>Doulain</surname><given-names>PE</given-names></name><name name-style="western"><surname>Petitot</surname><given-names>C</given-names></name><name name-style="western"><surname>Walker</surname><given-names>PM</given-names></name><name name-style="western"><surname>Decr&#233;au</surname><given-names>R</given-names></name><name name-style="western"><surname>Collin</surname><given-names>B</given-names></name></person-group><article-title>Superparamagnetic iron oxide nanoparticles for immunotherapy of cancers through macrophages and magnetic hyperthermia</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><issue>11</issue><fpage>2388</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14112388</pub-id><pub-id pub-id-type="pmid">36365207</pub-id><pub-id pub-id-type="pmcid">PMC9694944</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Dias AM, Courteau A, Bellaye PS, Kohli E, Oudot A, Doulain PE, Petitot C, Walker PM, Decr&#233;au R, Collin B. Superparamagnetic iron oxide nanoparticles for immunotherapy of cancers through macrophages and magnetic hyperthermia. Pharmaceutics. 2022;14(11):2388.<pub-id pub-id-type="pmid">36365207</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics14112388</pub-id><pub-id pub-id-type="pmcid">PMC9694944</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fathy</surname><given-names>MM</given-names></name><name name-style="western"><surname>Yassin</surname><given-names>FM</given-names></name><name name-style="western"><surname>Elshemey</surname><given-names>WM</given-names></name><name name-style="western"><surname>Fahmy</surname><given-names>HM</given-names></name></person-group><article-title>Insight on the dependence of the drug delivery applications of mesoporous silica nanoparticles on their physical properties</article-title><source>SILICON</source><year>2022</year><volume>15</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/s12633-022-01962-7</pub-id></element-citation><mixed-citation id="mc-CR166" publication-type="journal">Fathy MM, Yassin FM, Elshemey WM, Fahmy HM. Insight on the dependence of the drug delivery applications of mesoporous silica nanoparticles on their physical properties. SILICON. 2022;15:61&#8211;70.</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#193;lvarez</surname><given-names>E</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>B</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>D</given-names></name><name name-style="western"><surname>Doadrio</surname><given-names>AL</given-names></name><name name-style="western"><surname>Colilla</surname><given-names>M</given-names></name><name name-style="western"><surname>Izquierdo-Barba</surname><given-names>I</given-names></name></person-group><article-title>Nanoantibiotics based in mesoporous silica nanoparticles: new formulations for bacterial infection treatment</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><issue>12</issue><fpage>2033</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics13122033</pub-id><pub-id pub-id-type="pmid">34959315</pub-id><pub-id pub-id-type="pmcid">PMC8703556</pub-id></element-citation><mixed-citation id="mc-CR167" publication-type="journal">&#193;lvarez E, Gonz&#225;lez B, Lozano D, Doadrio AL, Colilla M, Izquierdo-Barba I. Nanoantibiotics based in mesoporous silica nanoparticles: new formulations for bacterial infection treatment. Pharmaceutics. 2021;13(12):2033.<pub-id pub-id-type="pmid">34959315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13122033</pub-id><pub-id pub-id-type="pmcid">PMC8703556</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Du</surname><given-names>Z</given-names></name><name name-style="western"><surname>Bao</surname><given-names>G</given-names></name><name name-style="western"><surname>Fang</surname><given-names>G</given-names></name><name name-style="western"><surname>Cappadona</surname><given-names>M</given-names></name><name name-style="western"><surname>McClements</surname><given-names>L</given-names></name><name name-style="western"><surname>Tuch</surname><given-names>BE</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Smart drug-delivery system of upconversion nanoparticles coated with mesoporous silica for controlled release</article-title><source>Pharmaceutics</source><year>2022</year><volume>15</volume><issue>1</issue><fpage>89</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15010089</pub-id><pub-id pub-id-type="pmid">36678718</pub-id><pub-id pub-id-type="pmcid">PMC9864186</pub-id></element-citation><mixed-citation id="mc-CR168" publication-type="journal">Huang Y, Du Z, Bao G, Fang G, Cappadona M, McClements L, Tuch BE, Lu H, Xu X. Smart drug-delivery system of upconversion nanoparticles coated with mesoporous silica for controlled release. Pharmaceutics. 2022;15(1):89.<pub-id pub-id-type="pmid">36678718</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15010089</pub-id><pub-id pub-id-type="pmcid">PMC9864186</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Weng</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tang</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Selective manipulation of the mitochondria oxidative stress in different cells using intelligent mesoporous silica nanoparticles to activate on-demand immunotherapy for cancer treatment</article-title><source>Small</source><year>2024</year><volume>20</volume><issue>16</issue><fpage>2307310</fpage><pub-id pub-id-type="doi">10.1002/smll.202307310</pub-id><pub-id pub-id-type="pmid">38039438</pub-id></element-citation><mixed-citation id="mc-CR169" publication-type="journal">Chang X, Zhu Z, Weng L, Tang X, Liu T, Zhu M, Liu J, Tang W, Zhang Y, Chen X. Selective manipulation of the mitochondria oxidative stress in different cells using intelligent mesoporous silica nanoparticles to activate on-demand immunotherapy for cancer treatment. Small. 2024;20(16):2307310.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202307310</pub-id><pub-id pub-id-type="pmid">38039438</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title>Multifunctional mesoporous silica nanoparticles for biomedical applications</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><fpage>435</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01654-7</pub-id><pub-id pub-id-type="pmid">37996406</pub-id><pub-id pub-id-type="pmcid">PMC10667354</pub-id></element-citation><mixed-citation id="mc-CR170" publication-type="journal">Xu B, Li S, Shi R, Liu H. Multifunctional mesoporous silica nanoparticles for biomedical applications. Signal Transduct Target Ther. 2023;8:435.<pub-id pub-id-type="pmid">37996406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01654-7</pub-id><pub-id pub-id-type="pmcid">PMC10667354</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MK</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>TL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name></person-group><article-title>Hollow mesoporous silica nanoparticles with extra-large mesopores for enhanced cancer vaccine</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><fpage>34658</fpage><lpage>34666</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c09484</pub-id><pub-id pub-id-type="pmid">32662625</pub-id></element-citation><mixed-citation id="mc-CR171" publication-type="journal">Lee JY, Kim MK, Nguyen TL, Kim J. Hollow mesoporous silica nanoparticles with extra-large mesopores for enhanced cancer vaccine. ACS Appl Mater Interfaces. 2020;12:34658&#8211;66.<pub-id pub-id-type="pmid">32662625</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.0c09484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cha</surname><given-names>BG</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name></person-group><article-title>Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine efficacy</article-title><source>ACS Cent Sci</source><year>2018</year><volume>4</volume><fpage>484</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.8b00035</pub-id><pub-id pub-id-type="pmid">29721531</pub-id><pub-id pub-id-type="pmcid">PMC5920615</pub-id></element-citation><mixed-citation id="mc-CR172" publication-type="journal">Cha BG, Jeong JH, Kim J. Extra-large pore mesoporous silica nanoparticles enabling co-delivery of high amounts of protein antigen and toll-like receptor 9 agonist for enhanced cancer vaccine efficacy. ACS Cent Sci. 2018;4:484&#8211;92.<pub-id pub-id-type="pmid">29721531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acscentsci.8b00035</pub-id><pub-id pub-id-type="pmcid">PMC5920615</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>R</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>P</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kemell</surname><given-names>M</given-names></name><name name-style="western"><surname>Torrieri</surname><given-names>G</given-names></name><name name-style="western"><surname>Makila</surname><given-names>EM</given-names></name><name name-style="western"><surname>Salonen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Hirvonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Santos</surname><given-names>HA</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B</given-names></name></person-group><article-title>Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors</article-title><source>Adv Mater</source><year>2022</year><volume>34</volume><fpage>e2108012</fpage><pub-id pub-id-type="doi">10.1002/adma.202108012</pub-id><pub-id pub-id-type="pmid">34877724</pub-id></element-citation><mixed-citation id="mc-CR173" publication-type="journal">Li J, Huang D, Cheng R, Figueiredo P, Fontana F, Correia A, Wang S, Liu Z, Kemell M, Torrieri G, Makila EM, Salonen JJ, Hirvonen J, Gao Y, Li J, Luo Z, Santos HA, Xia B. Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors. Adv Mater. 2022;34: e2108012.<pub-id pub-id-type="pmid">34877724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202108012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkert</surname><given-names>SC</given-names></name><name name-style="western"><surname>He</surname><given-names>X</given-names></name><name name-style="western"><surname>Shurin</surname><given-names>GV</given-names></name><name name-style="western"><surname>Nefedova</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>VE</given-names></name><name name-style="western"><surname>Shurin</surname><given-names>MR</given-names></name><name name-style="western"><surname>Star</surname><given-names>A</given-names></name></person-group><article-title>Nitrogen-doped carbon nanotube cups for cancer therapy</article-title><source>ACS Appl Nano Mater</source><year>2022</year><volume>5</volume><fpage>13685</fpage><lpage>13696</lpage><pub-id pub-id-type="doi">10.1021/acsanm.1c03245</pub-id><pub-id pub-id-type="pmid">36711215</pub-id><pub-id pub-id-type="pmcid">PMC9879341</pub-id></element-citation><mixed-citation id="mc-CR174" publication-type="journal">Burkert SC, He X, Shurin GV, Nefedova Y, Kagan VE, Shurin MR, Star A. Nitrogen-doped carbon nanotube cups for cancer therapy. ACS Appl Nano Mater. 2022;5:13685&#8211;96.<pub-id pub-id-type="pmid">36711215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsanm.1c03245</pub-id><pub-id pub-id-type="pmcid">PMC9879341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quagliarini</surname><given-names>E</given-names></name><name name-style="western"><surname>Pozzi</surname><given-names>D</given-names></name><name name-style="western"><surname>Cardarelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Caracciolo</surname><given-names>G</given-names></name></person-group><article-title>The influence of protein corona on graphene oxide: implications for biomedical theranostics</article-title><source>J Nanobiotechnology</source><year>2023</year><volume>21</volume><fpage>267</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-02030-x</pub-id><pub-id pub-id-type="pmid">37568181</pub-id><pub-id pub-id-type="pmcid">PMC10416361</pub-id></element-citation><mixed-citation id="mc-CR175" publication-type="journal">Quagliarini E, Pozzi D, Cardarelli F, Caracciolo G. The influence of protein corona on graphene oxide: implications for biomedical theranostics. J Nanobiotechnology. 2023;21:267.<pub-id pub-id-type="pmid">37568181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02030-x</pub-id><pub-id pub-id-type="pmcid">PMC10416361</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Xing</surname><given-names>M</given-names></name><name name-style="western"><surname>He</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Chong</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Immunological gadolinium-doped mesoporous carbon nanoparticles for tumor-targeted MRI and photothermal-immune co-therapy</article-title><source>J Mater Chem B</source><year>2023</year><volume>11</volume><fpage>6147</fpage><lpage>6158</lpage><pub-id pub-id-type="doi">10.1039/D3TB00595J</pub-id><pub-id pub-id-type="pmid">37347177</pub-id></element-citation><mixed-citation id="mc-CR176" publication-type="journal">Song X, Zhang C, Xing M, He C, Wang D, Chong L, Zhang X, Chen M, Li J. Immunological gadolinium-doped mesoporous carbon nanoparticles for tumor-targeted MRI and photothermal-immune co-therapy. J Mater Chem B. 2023;11:6147&#8211;58.<pub-id pub-id-type="pmid">37347177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d3tb00595j</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>He</surname><given-names>N</given-names></name><name name-style="western"><surname>Fan</surname><given-names>P</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X</given-names></name></person-group><article-title>Potential efficacy of herbal medicine-derived carbon dots in the treatment of diseases: from mechanism to clinic</article-title><source>Int J Nanomedicine</source><year>2023</year><volume>18</volume><fpage>6503</fpage><lpage>6525</lpage><pub-id pub-id-type="doi">10.2147/IJN.S431061</pub-id><pub-id pub-id-type="pmid">37965279</pub-id><pub-id pub-id-type="pmcid">PMC10642355</pub-id></element-citation><mixed-citation id="mc-CR177" publication-type="journal">Zeng M, Wang Y, Liu M, Wei Y, Wen J, Zhang Y, Chen T, He N, Fan P, Dai X. Potential efficacy of herbal medicine-derived carbon dots in the treatment of diseases: from mechanism to clinic. Int J Nanomedicine. 2023;18:6503&#8211;25.<pub-id pub-id-type="pmid">37965279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S431061</pub-id><pub-id pub-id-type="pmcid">PMC10642355</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KS</given-names></name><name name-style="western"><surname>Na</surname><given-names>K</given-names></name></person-group><article-title>Nanoparticle platform comprising lipid-tailed pH-sensitive carbon dots with minimal drug loss</article-title><source>J Control Release</source><year>2023</year><volume>361</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2023.08.008</pub-id><pub-id pub-id-type="pmid">37558052</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Kim H, Kim KS, Na K. Nanoparticle platform comprising lipid-tailed pH-sensitive carbon dots with minimal drug loss. J Control Release. 2023;361:373&#8211;84.<pub-id pub-id-type="pmid">37558052</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.08.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G</given-names></name></person-group><article-title>Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant</article-title><source>Eur J Pharm Sci</source><year>2011</year><volume>44</volume><fpage>653</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2011.10.012</pub-id><pub-id pub-id-type="pmid">22064451</pub-id></element-citation><mixed-citation id="mc-CR179" publication-type="journal">Wang T, Zou M, Jiang H, Ji Z, Gao P, Cheng G. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. Eur J Pharm Sci. 2011;44:653&#8211;9.<pub-id pub-id-type="pmid">22064451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejps.2011.10.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elhassan</surname><given-names>E</given-names></name><name name-style="western"><surname>Devnarain</surname><given-names>N</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>M</given-names></name><name name-style="western"><surname>Govender</surname><given-names>T</given-names></name><name name-style="western"><surname>Omolo</surname><given-names>CA</given-names></name></person-group><article-title>Engineering hybrid nanosystems for efficient and targeted delivery against bacterial infections</article-title><source>J Control Release</source><year>2022</year><volume>351</volume><fpage>598</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.09.052</pub-id><pub-id pub-id-type="pmid">36183972</pub-id></element-citation><mixed-citation id="mc-CR180" publication-type="journal">Elhassan E, Devnarain N, Mohammed M, Govender T, Omolo CA. Engineering hybrid nanosystems for efficient and targeted delivery against bacterial infections. J Control Release. 2022;351:598&#8211;622.<pub-id pub-id-type="pmid">36183972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.09.052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Tianze</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mingzhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Wanyue</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name></person-group><article-title>Hybrid nanoparticle&#8211;mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines</article-title><source>Sci Adv</source><year>2024</year><volume>10</volume><issue>38</issue><fpage>eadn3002</fpage><pub-id pub-id-type="doi">10.1126/sciadv.adn3002</pub-id><pub-id pub-id-type="pmid">39292792</pub-id><pub-id pub-id-type="pmcid">PMC11409974</pub-id></element-citation><mixed-citation id="mc-CR181" publication-type="journal">Li J, Tianze W, Wang W, Gong Y, Mingzhu L, Zhang M, Wanyue L, Zhou Y, Yang Y. Hybrid nanoparticle&#8211;mediated simultaneous ROS scavenging and STING activation improve the antitumor immunity of in situ vaccines. Sci Adv. 2024;10(38):eadn3002. 10.1126/sciadv.adn3002.<pub-id pub-id-type="pmid">39292792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.adn3002</pub-id><pub-id pub-id-type="pmcid">PMC11409974</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M</given-names></name><name name-style="western"><surname>Peng</surname><given-names>D</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>Acidity and glutathione dual-responsive polydopamine-coated organic-inorganic hybrid hollow mesoporous silica nanoparticles for controlled drug delivery</article-title><source>ChemMedChem</source><year>2020</year><volume>15</volume><fpage>1940</fpage><lpage>1946</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202000263</pub-id><pub-id pub-id-type="pmid">32762008</pub-id></element-citation><mixed-citation id="mc-CR182" publication-type="journal">Chen Q, Chen Y, Zhang W, Huang Q, Hu M, Peng D, Peng C, Wang L, Chen W. Acidity and glutathione dual-responsive polydopamine-coated organic-inorganic hybrid hollow mesoporous silica nanoparticles for controlled drug delivery. ChemMedChem. 2020;15:1940&#8211;6.<pub-id pub-id-type="pmid">32762008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.202000263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma</article-title><source>J Control Release</source><year>2016</year><volume>228</volume><fpage>26</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.02.035</pub-id><pub-id pub-id-type="pmid">26921522</pub-id></element-citation><mixed-citation id="mc-CR183" publication-type="journal">Zhuang X, Wu T, Zhao Y, Hu X, Bao Y, Guo Y, Song Q, Li G, Tan S, Zhang Z. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma. J Control Release. 2016;228:26&#8211;37.<pub-id pub-id-type="pmid">26921522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2016.02.035</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dash</surname><given-names>P</given-names></name><name name-style="western"><surname>Piras</surname><given-names>AM</given-names></name><name name-style="western"><surname>Dash</surname><given-names>M</given-names></name></person-group><article-title>Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy</article-title><source>J Control Release</source><year>2020</year><volume>327</volume><fpage>546</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.09.012</pub-id><pub-id pub-id-type="pmid">32911013</pub-id></element-citation><mixed-citation id="mc-CR184" publication-type="journal">Dash P, Piras AM, Dash M. Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy. J Control Release. 2020;327:546&#8211;70.<pub-id pub-id-type="pmid">32911013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2020.09.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Targeting drugs to tumours using cell membrane-coated nanoparticles</article-title><source>Nat Rev Clin Oncol</source><year>2023</year><volume>20</volume><fpage>33</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00699-x</pub-id><pub-id pub-id-type="pmid">36307534</pub-id></element-citation><mixed-citation id="mc-CR185" publication-type="journal">Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20:33&#8211;48.<pub-id pub-id-type="pmid">36307534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41571-022-00699-x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>RH</given-names></name><name name-style="western"><surname>Hu</surname><given-names>CM</given-names></name><name name-style="western"><surname>Luk</surname><given-names>BT</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Copp</surname><given-names>JA</given-names></name><name name-style="western"><surname>Tai</surname><given-names>Y</given-names></name><name name-style="western"><surname>O'Connor</surname><given-names>DE</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery</article-title><source>Nano Lett</source><year>2014</year><volume>14</volume><fpage>2181</fpage><lpage>2188</lpage><pub-id pub-id-type="doi">10.1021/nl500618u</pub-id><pub-id pub-id-type="pmid">24673373</pub-id><pub-id pub-id-type="pmcid">PMC3985711</pub-id></element-citation><mixed-citation id="mc-CR186" publication-type="journal">Fang RH, Hu CM, Luk BT, Gao W, Copp JA, Tai Y, O&#8217;Connor DE, Zhang L. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14:2181&#8211;8.<pub-id pub-id-type="pmid">24673373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nl500618u</pub-id><pub-id pub-id-type="pmcid">PMC3985711</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cai</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>K</given-names></name></person-group><article-title>A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody</article-title><source>Bioact Mater</source><year>2023</year><volume>21</volume><fpage>299</fpage><lpage>312</lpage><pub-id pub-id-type="pmid">36157245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.08.028</pub-id><pub-id pub-id-type="pmcid">PMC9478499</pub-id></element-citation><mixed-citation id="mc-CR187" publication-type="journal">Li Z, Cai H, Li Z, Ren L, Ma X, Zhu H, Gong Q, Zhang H, Gu Z, Luo K. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody. Bioact Mater. 2023;21:299&#8211;312.<pub-id pub-id-type="pmid">36157245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.08.028</pub-id><pub-id pub-id-type="pmcid">PMC9478499</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188</label><citation-alternatives><element-citation id="ec-CR188" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name></person-group><article-title>Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1238649</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1238649</pub-id><pub-id pub-id-type="pmid">38022657</pub-id><pub-id pub-id-type="pmcid">PMC10652786</pub-id></element-citation><mixed-citation id="mc-CR188" publication-type="journal">Zhou F, Zhang D. Recent advance in the development of tuberculosis vaccines in clinical trials and virus-like particle-based vaccine candidates. Front Immunol. 2023;14:1238649.<pub-id pub-id-type="pmid">38022657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1238649</pub-id><pub-id pub-id-type="pmcid">PMC10652786</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR189"><label>189</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>YH</given-names></name><name name-style="western"><surname>Ortega-Rivera</surname><given-names>OA</given-names></name><name name-style="western"><surname>Volckaert</surname><given-names>BA</given-names></name><name name-style="western"><surname>Jung</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>NF</given-names></name></person-group><article-title>Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis</article-title><source>Proc Natl Acad Sci U S A</source><year>2023</year><volume>120</volume><fpage>e2221859120</fpage><pub-id pub-id-type="doi">10.1073/pnas.2221859120</pub-id><pub-id pub-id-type="pmid">37844250</pub-id><pub-id pub-id-type="pmcid">PMC10614828</pub-id></element-citation><mixed-citation id="mc-CR189" publication-type="journal">Chung YH, Ortega-Rivera OA, Volckaert BA, Jung E, Zhao Z, Steinmetz NF. Viral nanoparticle vaccines against S100A9 reduce lung tumor seeding and metastasis. Proc Natl Acad Sci U S A. 2023;120: e2221859120.<pub-id pub-id-type="pmid">37844250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2221859120</pub-id><pub-id pub-id-type="pmcid">PMC10614828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>N</given-names></name><name name-style="western"><surname>Somiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Horie</surname><given-names>M</given-names></name></person-group><article-title>Progress of endogenous and exogenous nanoparticles for cancer therapy and diagnostics</article-title><source>Genes</source><year>2023</year><volume>14</volume><issue>2</issue><fpage>259</fpage><pub-id pub-id-type="doi">10.3390/genes14020259</pub-id><pub-id pub-id-type="pmid">36833186</pub-id><pub-id pub-id-type="pmcid">PMC9957423</pub-id></element-citation><mixed-citation id="mc-CR190" publication-type="journal">Fujita H, Ohta S, Nakamura N, Somiya M, Horie M. Progress of endogenous and exogenous nanoparticles for cancer therapy and diagnostics. Genes. 2023;14(2):259. 10.3390/genes14020259.<pub-id pub-id-type="pmid">36833186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes14020259</pub-id><pub-id pub-id-type="pmcid">PMC9957423</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>J</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>S</given-names></name><name name-style="western"><surname>Cong</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name></person-group><article-title>Exosomes: key players in cancer and potential therapeutic strategy</article-title><source>Signal Transduct Target Ther</source><year>2020</year><volume>5</volume><fpage>145</fpage><pub-id pub-id-type="doi">10.1038/s41392-020-00261-0</pub-id><pub-id pub-id-type="pmid">32759948</pub-id><pub-id pub-id-type="pmcid">PMC7406508</pub-id></element-citation><mixed-citation id="mc-CR191" publication-type="journal">Dai J, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct Target Ther. 2020;5:145.<pub-id pub-id-type="pmid">32759948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-00261-0</pub-id><pub-id pub-id-type="pmcid">PMC7406508</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalluri</surname><given-names>R</given-names></name><name name-style="western"><surname>LeBleu</surname><given-names>VS</given-names></name></person-group><article-title>The biology, function and biomedical applications of exosomes</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>6478</fpage><pub-id pub-id-type="doi">10.1126/science.aau6977</pub-id><pub-id pub-id-type="pmcid">PMC7717626</pub-id><pub-id pub-id-type="pmid">32029601</pub-id></element-citation><mixed-citation id="mc-CR192" publication-type="journal">Kalluri R, LeBleu VS. The biology, function and biomedical applications of exosomes. Science. 2020;367:6478. 10.1126/science.aau6977.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aau6977</pub-id><pub-id pub-id-type="pmcid">PMC7717626</pub-id><pub-id pub-id-type="pmid">32029601</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Lv</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H</given-names></name></person-group><article-title>Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression</article-title><source>J Hematol Oncol</source><year>2019</year><volume>12</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0739-0</pub-id><pub-id pub-id-type="pmid">31142326</pub-id><pub-id pub-id-type="pmcid">PMC6542024</pub-id></element-citation><mixed-citation id="mc-CR193" publication-type="journal">Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol. 2019;12:53.<pub-id pub-id-type="pmid">31142326</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-019-0739-0</pub-id><pub-id pub-id-type="pmcid">PMC6542024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>M</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D</given-names></name></person-group><article-title>Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges</article-title><source>J Mater Chem B</source><year>2019</year><volume>7</volume><fpage>2421</fpage><lpage>2433</lpage><pub-id pub-id-type="doi">10.1039/C9TB00170K</pub-id><pub-id pub-id-type="pmid">32255119</pub-id></element-citation><mixed-citation id="mc-CR194" publication-type="journal">Zhang M, Zang X, Wang M, Li Z, Qiao M, Hu H, Chen D. Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. J Mater Chem B. 2019;7:2421&#8211;33.<pub-id pub-id-type="pmid">32255119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9tb00170k</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Geng</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jing</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Seow</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name></person-group><article-title>Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses</article-title><source>J Hematol Oncol</source><year>2022</year><volume>15</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s13045-022-01266-8</pub-id><pub-id pub-id-type="pmid">35488312</pub-id><pub-id pub-id-type="pmcid">PMC9052531</pub-id></element-citation><mixed-citation id="mc-CR195" publication-type="journal">Zuo B, Zhang Y, Zhao K, Wu L, Qi H, Yang R, Gao X, Geng M, Wu Y, Jing R, Zhou Q, Seow Y, Yin H. Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses. J Hematol Oncol. 2022;15:46.<pub-id pub-id-type="pmid">35488312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13045-022-01266-8</pub-id><pub-id pub-id-type="pmcid">PMC9052531</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>L</given-names></name><name name-style="western"><surname>Wei</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name></person-group><article-title>A critical role of outer membrane vesicles in antibiotic resistance in carbapenem-resistant Klebsiella pneumoniae</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2023</year><volume>22</volume><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s12941-023-00645-4</pub-id><pub-id pub-id-type="pmid">37919721</pub-id><pub-id pub-id-type="pmcid">PMC10623783</pub-id></element-citation><mixed-citation id="mc-CR196" publication-type="journal">Yao L, Wei B, Wang Y, Xu B, Yang M, Chen X, Chen F. A critical role of outer membrane vesicles in antibiotic resistance in carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2023;22:95.<pub-id pub-id-type="pmid">37919721</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12941-023-00645-4</pub-id><pub-id pub-id-type="pmcid">PMC10623783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>SH</given-names></name><name name-style="western"><surname>Melief</surname><given-names>CJM</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></name></person-group><article-title>Therapeutic cancer vaccines</article-title><source>Nat Rev Cancer</source><year>2021</year><volume>21</volume><fpage>360</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00346-0</pub-id><pub-id pub-id-type="pmid">33907315</pub-id></element-citation><mixed-citation id="mc-CR197" publication-type="journal">Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360&#8211;78.<pub-id pub-id-type="pmid">33907315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-021-00346-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Diao</surname><given-names>L</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Ding</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells</article-title><source>Adv Mater</source><year>2021</year><volume>33</volume><fpage>e2104849</fpage><pub-id pub-id-type="doi">10.1002/adma.202104849</pub-id><pub-id pub-id-type="pmid">34536044</pub-id></element-citation><mixed-citation id="mc-CR198" publication-type="journal">Ma L, Diao L, Peng Z, Jia Y, Xie H, Li B, Ma J, Zhang M, Cheng L, Ding D, Zhang X, Chen H, Mo F, Jiang H, Xu G, Meng F, Zhong Z, Liu M. Immunotherapy and prevention of cancer by nanovaccines loaded with whole-cell components of tumor tissues or cells. Adv Mater. 2021;33: e2104849.<pub-id pub-id-type="pmid">34536044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202104849</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berti</surname><given-names>C</given-names></name><name name-style="western"><surname>Boarino</surname><given-names>A</given-names></name><name name-style="western"><surname>Graciotti</surname><given-names>M</given-names></name><name name-style="western"><surname>Bader</surname><given-names>LPE</given-names></name><name name-style="western"><surname>Kandalaft</surname><given-names>LE</given-names></name><name name-style="western"><surname>Klok</surname><given-names>HA</given-names></name></person-group><article-title>Reduction-sensitive protein nanogels enhance uptake of model and tumor lysate antigens in vitro by mouse- and human-derived dendritic cells</article-title><source>ACS Appl Bio Mater</source><year>2021</year><volume>4</volume><fpage>8291</fpage><lpage>8300</lpage><pub-id pub-id-type="doi">10.1021/acsabm.1c00828</pub-id><pub-id pub-id-type="pmid">35005925</pub-id></element-citation><mixed-citation id="mc-CR199" publication-type="journal">Berti C, Boarino A, Graciotti M, Bader LPE, Kandalaft LE, Klok HA. Reduction-sensitive protein nanogels enhance uptake of model and tumor lysate antigens in vitro by mouse- and human-derived dendritic cells. ACS Appl Bio Mater. 2021;4:8291&#8211;300.<pub-id pub-id-type="pmid">35005925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsabm.1c00828</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berti</surname><given-names>C</given-names></name><name name-style="western"><surname>Graciotti</surname><given-names>M</given-names></name><name name-style="western"><surname>Boarino</surname><given-names>A</given-names></name><name name-style="western"><surname>Yakkala</surname><given-names>C</given-names></name><name name-style="western"><surname>Kandalaft</surname><given-names>LE</given-names></name><name name-style="western"><surname>Klok</surname><given-names>HA</given-names></name></person-group><article-title>Polymer nanoparticle-mediated delivery of oxidized tumor lysate-based cancer vaccines</article-title><source>Macromol Biosci</source><year>2022</year><volume>22</volume><fpage>e2100356</fpage><pub-id pub-id-type="doi">10.1002/mabi.202100356</pub-id><pub-id pub-id-type="pmid">34822219</pub-id></element-citation><mixed-citation id="mc-CR200" publication-type="journal">Berti C, Graciotti M, Boarino A, Yakkala C, Kandalaft LE, Klok HA. Polymer nanoparticle-mediated delivery of oxidized tumor lysate-based cancer vaccines. Macromol Biosci. 2022;22: e2100356.<pub-id pub-id-type="pmid">34822219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mabi.202100356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Zou</surname><given-names>ZZ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>QH</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H</given-names></name><name name-style="western"><surname>Yin</surname><given-names>QX</given-names></name><name name-style="western"><surname>Xing</surname><given-names>D</given-names></name></person-group><article-title>Targeting and specific activation of antigen-presenting cells by endogenous antigen-loaded nanoparticles elicits tumor-specific immunity advanced</article-title><source>Science</source><year>2020</year><volume>7</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1002/advs.201900069</pub-id><pub-id pub-id-type="pmcid">PMC6947714</pub-id><pub-id pub-id-type="pmid">31921548</pub-id></element-citation><mixed-citation id="mc-CR201" publication-type="journal">Chang HC, Zou ZZ, Wang QH, Li J, Jin H, Yin QX, Xing D. Targeting and specific activation of antigen-presenting cells by endogenous antigen-loaded nanoparticles elicits tumor-specific immunity advanced. Science. 2020;7:1. 10.1002/advs.201900069.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.201900069</pub-id><pub-id pub-id-type="pmcid">PMC6947714</pub-id><pub-id pub-id-type="pmid">31921548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee-Chang</surname><given-names>C</given-names></name><name name-style="western"><surname>Lesniak</surname><given-names>MS</given-names></name></person-group><article-title>Next-generation antigen-presenting cell immune therapeutics for gliomas</article-title><source>J Clinic Invest</source><year>2023</year><volume>133</volume><issue>3</issue><fpage>e163449</fpage><pub-id pub-id-type="doi">10.1172/JCI163449</pub-id><pub-id pub-id-type="pmcid">PMC9888388</pub-id><pub-id pub-id-type="pmid">36719372</pub-id></element-citation><mixed-citation id="mc-CR202" publication-type="journal">Lee-Chang C, Lesniak MS. Next-generation antigen-presenting cell immune therapeutics for gliomas. J Clinic Invest. 2023;133(3):e163449. 10.1172/JCI163449.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI163449</pub-id><pub-id pub-id-type="pmcid">PMC9888388</pub-id><pub-id pub-id-type="pmid">36719372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggermont</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Paulis</surname><given-names>LE</given-names></name><name name-style="western"><surname>Tel</surname><given-names>J</given-names></name><name name-style="western"><surname>Figdor</surname><given-names>CG</given-names></name></person-group><article-title>Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells</article-title><source>Trends Biotechnol</source><year>2014</year><volume>32</volume><fpage>456</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.tibtech.2014.06.007</pub-id><pub-id pub-id-type="pmid">24998519</pub-id><pub-id pub-id-type="pmcid">PMC4154451</pub-id></element-citation><mixed-citation id="mc-CR203" publication-type="journal">Eggermont LJ, Paulis LE, Tel J, Figdor CG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32:456&#8211;65.<pub-id pub-id-type="pmid">24998519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibtech.2014.06.007</pub-id><pub-id pub-id-type="pmcid">PMC4154451</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR204"><label>204</label><citation-alternatives><element-citation id="ec-CR204" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>DKY</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>AS</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>DJ</given-names></name></person-group><article-title>Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds</article-title><source>Nat Protoc</source><year>2020</year><volume>15</volume><fpage>773</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1038/s41596-019-0249-0</pub-id><pub-id pub-id-type="pmid">31932772</pub-id></element-citation><mixed-citation id="mc-CR204" publication-type="journal">Zhang DKY, Cheung AS, Mooney DJ. Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds. Nat Protoc. 2020;15:773&#8211;98.<pub-id pub-id-type="pmid">31932772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41596-019-0249-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR205"><label>205</label><citation-alternatives><element-citation id="ec-CR205" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>P</given-names></name><name name-style="western"><surname>Kimmelman</surname><given-names>AC</given-names></name><name name-style="western"><surname>DePinho</surname><given-names>RA</given-names></name></person-group><article-title>Metabolic codependencies in the tumor microenvironment</article-title><source>Cancer Discov</source><year>2021</year><volume>11</volume><fpage>1067</fpage><lpage>1081</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-1211</pub-id><pub-id pub-id-type="pmid">33504580</pub-id><pub-id pub-id-type="pmcid">PMC8102306</pub-id></element-citation><mixed-citation id="mc-CR205" publication-type="journal">Dey P, Kimmelman AC, DePinho RA. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 2021;11:1067&#8211;81.<pub-id pub-id-type="pmid">33504580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-20-1211</pub-id><pub-id pub-id-type="pmcid">PMC8102306</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR206"><label>206</label><citation-alternatives><element-citation id="ec-CR206" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elia</surname><given-names>I</given-names></name><name name-style="western"><surname>Haigis</surname><given-names>MC</given-names></name></person-group><article-title>Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism</article-title><source>Nat Metab</source><year>2021</year><volume>3</volume><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/s42255-020-00317-z</pub-id><pub-id pub-id-type="pmid">33398194</pub-id><pub-id pub-id-type="pmcid">PMC8097259</pub-id></element-citation><mixed-citation id="mc-CR206" publication-type="journal">Elia I, Haigis MC. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 2021;3:21&#8211;32.<pub-id pub-id-type="pmid">33398194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42255-020-00317-z</pub-id><pub-id pub-id-type="pmcid">PMC8097259</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR207"><label>207</label><citation-alternatives><element-citation id="ec-CR207" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumauthioz</surname><given-names>N</given-names></name><name name-style="western"><surname>Tschumi</surname><given-names>B</given-names></name><name name-style="western"><surname>Wenes</surname><given-names>M</given-names></name><name name-style="western"><surname>Marti</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Franco</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Lopez-Mejia</surname><given-names>IC</given-names></name><name name-style="western"><surname>Fajas</surname><given-names>L</given-names></name><name name-style="western"><surname>Ho</surname><given-names>PC</given-names></name><name name-style="western"><surname>Donda</surname><given-names>A</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Enforced PGC-1alpha expression promotes CD8 T cell fitness, memory formation and antitumor immunity</article-title><source>Cell Mol Immunol</source><year>2021</year><volume>18</volume><fpage>1761</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0365-3</pub-id><pub-id pub-id-type="pmid">32055005</pub-id><pub-id pub-id-type="pmcid">PMC8245409</pub-id></element-citation><mixed-citation id="mc-CR207" publication-type="journal">Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, Li W, Lopez-Mejia IC, Fajas L, Ho PC, Donda A, Romero P, Zhang L. Enforced PGC-1alpha expression promotes CD8 T cell fitness, memory formation and antitumor immunity. Cell Mol Immunol. 2021;18:1761&#8211;71.<pub-id pub-id-type="pmid">32055005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-020-0365-3</pub-id><pub-id pub-id-type="pmcid">PMC8245409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR208"><label>208</label><citation-alternatives><element-citation id="ec-CR208" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chekaoui</surname><given-names>A</given-names></name><name name-style="western"><surname>Ertl</surname><given-names>HCJ</given-names></name></person-group><article-title>PPARalpha agonist fenofibrate enhances cancer vaccine efficacy</article-title><source>Cancer Res</source><year>2021</year><volume>81</volume><fpage>4431</fpage><lpage>4440</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-0052</pub-id><pub-id pub-id-type="pmid">34244236</pub-id></element-citation><mixed-citation id="mc-CR208" publication-type="journal">Chekaoui A, Ertl HCJ. PPARalpha agonist fenofibrate enhances cancer vaccine efficacy. Cancer Res. 2021;81:4431&#8211;40.<pub-id pub-id-type="pmid">34244236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-21-0052</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR209"><label>209</label><citation-alternatives><element-citation id="ec-CR209" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>YT</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XH</given-names></name><name name-style="western"><surname>An</surname><given-names>JX</given-names></name><name name-style="western"><surname>Liang</surname><given-names>JL</given-names></name><name name-style="western"><surname>Li</surname><given-names>CX</given-names></name><name name-style="western"><surname>Jin</surname><given-names>XK</given-names></name><name name-style="western"><surname>Ji</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XZ</given-names></name></person-group><article-title>Dendritic cell-based in situ nanovaccine for reprogramming lipid metabolism to boost tumor immunotherapy</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>24947</fpage><lpage>24960</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c06784</pub-id><pub-id pub-id-type="pmid">38055727</pub-id></element-citation><mixed-citation id="mc-CR209" publication-type="journal">Qin YT, Liu XH, An JX, Liang JL, Li CX, Jin XK, Ji P, Zhang XZ. Dendritic cell-based in situ nanovaccine for reprogramming lipid metabolism to boost tumor immunotherapy. ACS Nano. 2023;17:24947&#8211;60.<pub-id pub-id-type="pmid">38055727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c06784</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR210"><label>210</label><citation-alternatives><element-citation id="ec-CR210" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name></person-group><article-title>Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy</article-title><source>Acta Pharm Sin B</source><year>2023</year><volume>13</volume><fpage>5074</fpage><lpage>5090</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2023.08.028</pub-id><pub-id pub-id-type="pmid">38045045</pub-id><pub-id pub-id-type="pmcid">PMC10692385</pub-id></element-citation><mixed-citation id="mc-CR210" publication-type="journal">Guo L, Ding J, Zhou W. Converting bacteria into autologous tumor vaccine via surface biomineralization of calcium carbonate for enhanced immunotherapy. Acta Pharm Sin B. 2023;13:5074&#8211;90.<pub-id pub-id-type="pmid">38045045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2023.08.028</pub-id><pub-id pub-id-type="pmcid">PMC10692385</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR211"><label>211</label><citation-alternatives><element-citation id="ec-CR211" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portillo</surname><given-names>AL</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>JK</given-names></name><name name-style="western"><surname>Rojas</surname><given-names>EA</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>TM</given-names></name><name name-style="western"><surname>Gillgrass</surname><given-names>A</given-names></name><name name-style="western"><surname>Ashkar</surname><given-names>AA</given-names></name></person-group><article-title>Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1286750</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1286750</pub-id><pub-id pub-id-type="pmid">38022679</pub-id><pub-id pub-id-type="pmcid">PMC10663242</pub-id></element-citation><mixed-citation id="mc-CR211" publication-type="journal">Portillo AL, Monteiro JK, Rojas EA, Ritchie TM, Gillgrass A, Ashkar AA. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment. Front Immunol. 2023;14:1286750.<pub-id pub-id-type="pmid">38022679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1286750</pub-id><pub-id pub-id-type="pmcid">PMC10663242</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR212"><label>212</label><citation-alternatives><element-citation id="ec-CR212" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>Overcoming T cell exhaustion in tumor microenvironment via immune checkpoint modulation with nano&#8208;delivery systems for enhanced immunotherapy</article-title><source>Small Methods</source><year>2023</year><volume>8</volume><issue>8</issue><fpage>e2301326</fpage><pub-id pub-id-type="doi">10.1002/smtd.202301326</pub-id><pub-id pub-id-type="pmid">38040834</pub-id></element-citation><mixed-citation id="mc-CR212" publication-type="journal">Huang X, Zhang W. Overcoming T cell exhaustion in tumor microenvironment via immune checkpoint modulation with nano&#8208;delivery systems for enhanced immunotherapy. Small Methods. 2023;8(8):e2301326. 10.1002/smtd.202301326.<pub-id pub-id-type="pmid">38040834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202301326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR213"><label>213</label><citation-alternatives><element-citation id="ec-CR213" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Niu</surname><given-names>M</given-names></name><name name-style="western"><surname>Mei</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name></person-group><article-title>Exploiting innate immunity for cancer immunotherapy</article-title><source>Mol Cancer</source><year>2023</year><volume>22</volume><fpage>187</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01885-w</pub-id><pub-id pub-id-type="pmid">38008741</pub-id><pub-id pub-id-type="pmcid">PMC10680233</pub-id></element-citation><mixed-citation id="mc-CR213" publication-type="journal">Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z, Wu K. Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023;22:187.<pub-id pub-id-type="pmid">38008741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01885-w</pub-id><pub-id pub-id-type="pmcid">PMC10680233</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR214"><label>214</label><citation-alternatives><element-citation id="ec-CR214" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldman</surname><given-names>AD</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>JM</given-names></name><name name-style="western"><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group><article-title>A guide to cancer immunotherapy: from T cell basic science to clinical practice</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><fpage>651</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id><pub-id pub-id-type="pmid">32433532</pub-id><pub-id pub-id-type="pmcid">PMC7238960</pub-id></element-citation><mixed-citation id="mc-CR214" publication-type="journal">Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651&#8211;68.<pub-id pub-id-type="pmid">32433532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0306-5</pub-id><pub-id pub-id-type="pmcid">PMC7238960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR215"><label>215</label><citation-alternatives><element-citation id="ec-CR215" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qin</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y</given-names></name><name name-style="western"><surname>You</surname><given-names>J</given-names></name></person-group><article-title>Enhanced immune memory through a constant photothermal-metabolism regulation for cancer prevention and treatment</article-title><source>Biomaterials</source><year>2021</year><volume>270</volume><fpage>120678</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.120678</pub-id><pub-id pub-id-type="pmid">33517205</pub-id></element-citation><mixed-citation id="mc-CR215" publication-type="journal">Luo L, Li X, Zhang J, Zhu C, Jiang M, Luo Z, Qin B, Wang Y, Chen B, Du Y, Lou Y, You J. Enhanced immune memory through a constant photothermal-metabolism regulation for cancer prevention and treatment. Biomaterials. 2021;270: 120678.<pub-id pub-id-type="pmid">33517205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.120678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR216"><label>216</label><citation-alternatives><element-citation id="ec-CR216" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Purde</surname><given-names>M-T</given-names></name><name name-style="western"><surname>Cupovic</surname><given-names>J</given-names></name><name name-style="western"><surname>Palmowski</surname><given-names>YA</given-names></name><name name-style="western"><surname>Makky</surname><given-names>A</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S</given-names></name><name name-style="western"><surname>Rochwarger</surname><given-names>A</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Stemeseder</surname><given-names>F</given-names></name><name name-style="western"><surname>Lercher</surname><given-names>A</given-names></name><name name-style="western"><surname>Abdou</surname><given-names>M-T</given-names></name><name name-style="western"><surname>Bomze</surname><given-names>D</given-names></name><name name-style="western"><surname>Besse</surname><given-names>L</given-names></name><name name-style="western"><surname>Berner</surname><given-names>F</given-names></name><name name-style="western"><surname>T&#252;ting</surname><given-names>T</given-names></name><name name-style="western"><surname>H&#246;lzel</surname><given-names>M</given-names></name><name name-style="western"><surname>Bergthaler</surname><given-names>A</given-names></name><name name-style="western"><surname>Kochanek</surname><given-names>S</given-names></name><name name-style="western"><surname>Ludewig</surname><given-names>B</given-names></name><name name-style="western"><surname>Lauterbach</surname><given-names>H</given-names></name><name name-style="western"><surname>Orlinger</surname><given-names>KK</given-names></name><name name-style="western"><surname>Bald</surname><given-names>T</given-names></name><name name-style="western"><surname>Schietinger</surname><given-names>A</given-names></name><name name-style="western"><surname>Sch&#252;rch</surname><given-names>C</given-names></name><name name-style="western"><surname>Ring</surname><given-names>SS</given-names></name><name name-style="western"><surname>Flatz</surname><given-names>L</given-names></name></person-group><article-title>A replicating LCMV-based vaccine for the treatment of solid tumors</article-title><source>Mol Therapy</source><year>2023</year><pub-id pub-id-type="doi">10.1016/j.ymthe.2023.11.026</pub-id><pub-id pub-id-type="pmcid">PMC10861942</pub-id><pub-id pub-id-type="pmid">38058126</pub-id></element-citation><mixed-citation id="mc-CR216" publication-type="journal">Purde M-T, Cupovic J, Palmowski YA, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou M-T, Bomze D, Besse L, Berner F, T&#252;ting T, H&#246;lzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger KK, Bald T, Schietinger A, Sch&#252;rch C, Ring SS, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. Mol Therapy. 2023. 10.1016/j.ymthe.2023.11.026.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2023.11.026</pub-id><pub-id pub-id-type="pmcid">PMC10861942</pub-id><pub-id pub-id-type="pmid">38058126</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR217"><label>217</label><citation-alternatives><element-citation id="ec-CR217" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Mai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>W</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA/mRNA tumor vaccine</article-title><source>Acta Biomater</source><year>2023</year><volume>169</volume><fpage>489</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2023.07.059</pub-id><pub-id pub-id-type="pmid">37536492</pub-id></element-citation><mixed-citation id="mc-CR217" publication-type="journal">Ma S, Li X, Mai Y, Guo J, Zuo W, Yang J. Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA/mRNA tumor vaccine. Acta Biomater. 2023;169:489&#8211;99.<pub-id pub-id-type="pmid">37536492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2023.07.059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR218"><label>218</label><citation-alternatives><element-citation id="ec-CR218" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yong</surname><given-names>T</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L</given-names></name></person-group><article-title>Engineered probiotic-based personalized cancer vaccine potentiates antitumor immunity through initiating trained immunity</article-title><source>Adv Sci</source><year>2024</year><volume>11</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1002/advs.202305081</pub-id><pub-id pub-id-type="pmcid">PMC10797439</pub-id><pub-id pub-id-type="pmid">38009498</pub-id></element-citation><mixed-citation id="mc-CR218" publication-type="journal">Chen Z, Yong T, Wei Z, Zhang X, Li X, Qin J, Li J, Hu J, Yang X, Gan L. Engineered probiotic-based personalized cancer vaccine potentiates antitumor immunity through initiating trained immunity. Adv Sci. 2024;11:3. 10.1002/advs.202305081.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202305081</pub-id><pub-id pub-id-type="pmcid">PMC10797439</pub-id><pub-id pub-id-type="pmid">38009498</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR219"><label>219</label><citation-alternatives><element-citation id="ec-CR219" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kadam</surname><given-names>P</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name></person-group><article-title>PD-1 immune checkpoint blockade promotes therapeutic cancer vaccine to eradicate lung cancer</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><issue>2</issue><fpage>317</fpage><pub-id pub-id-type="doi">10.3390/vaccines8020317</pub-id><pub-id pub-id-type="pmid">32570793</pub-id><pub-id pub-id-type="pmcid">PMC7350208</pub-id></element-citation><mixed-citation id="mc-CR219" publication-type="journal">Kadam P, Sharma S. PD-1 immune checkpoint blockade promotes therapeutic cancer vaccine to eradicate lung cancer. Vaccines. 2020;8(2):317. 10.3390/vaccines8020317.<pub-id pub-id-type="pmid">32570793</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8020317</pub-id><pub-id pub-id-type="pmcid">PMC7350208</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR220"><label>220</label><citation-alternatives><element-citation id="ec-CR220" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gacche</surname><given-names>RN</given-names></name></person-group><article-title>Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives</article-title><source>Biochim Biophys Acta Rev Cancer</source><year>2023</year><volume>1878</volume><fpage>189020</fpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2023.189020</pub-id><pub-id pub-id-type="pmid">37951481</pub-id></element-citation><mixed-citation id="mc-CR220" publication-type="journal">Gacche RN. Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives. Biochim Biophys Acta Rev Cancer. 2023;1878: 189020.<pub-id pub-id-type="pmid">37951481</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2023.189020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR221"><label>221</label><citation-alternatives><element-citation id="ec-CR221" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name><name name-style="western"><surname>Chehelgerdi</surname><given-names>M</given-names></name><name name-style="western"><surname>Allela</surname><given-names>OQB</given-names></name><name name-style="western"><surname>Pecho</surname><given-names>RDC</given-names></name><name name-style="western"><surname>Jayasankar</surname><given-names>N</given-names></name><name name-style="western"><surname>Rao</surname><given-names>DP</given-names></name><name name-style="western"><surname>Thamaraikani</surname><given-names>T</given-names></name><name name-style="western"><surname>Vasanthan</surname><given-names>M</given-names></name><name name-style="western"><surname>Viktor</surname><given-names>P</given-names></name><name name-style="western"><surname>Lakshmaiya</surname><given-names>N</given-names></name><name name-style="western"><surname>Saadh</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Amajd</surname><given-names>A</given-names></name><name name-style="western"><surname>Abo-Zaid</surname><given-names>MA</given-names></name><name name-style="western"><surname>Castillo-Acobo</surname><given-names>RY</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>AH</given-names></name><name name-style="western"><surname>Amin</surname><given-names>AH</given-names></name><name name-style="western"><surname>Akhavan-Sigari</surname><given-names>R</given-names></name></person-group><article-title>Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation</article-title><source>Mol Cancer</source><year>2023</year><volume>22</volume><fpage>169</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01865-0</pub-id><pub-id pub-id-type="pmid">37814270</pub-id><pub-id pub-id-type="pmcid">PMC10561438</pub-id></element-citation><mixed-citation id="mc-CR221" publication-type="journal">Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ, Amajd A, Abo-Zaid MA, Castillo-Acobo RY, Ismail AH, Amin AH, Akhavan-Sigari R. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22:169.<pub-id pub-id-type="pmid">37814270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01865-0</pub-id><pub-id pub-id-type="pmcid">PMC10561438</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR222"><label>222</label><citation-alternatives><element-citation id="ec-CR222" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>D</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T</given-names></name></person-group><article-title>Nanomedicine in cancer therapy</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><fpage>293</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01536-y</pub-id><pub-id pub-id-type="pmid">37544972</pub-id><pub-id pub-id-type="pmcid">PMC10404590</pub-id></element-citation><mixed-citation id="mc-CR222" publication-type="journal">Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8:293.<pub-id pub-id-type="pmid">37544972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01536-y</pub-id><pub-id pub-id-type="pmcid">PMC10404590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR223"><label>223</label><citation-alternatives><element-citation id="ec-CR223" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HH</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>LL</given-names></name><name name-style="western"><surname>Sun</surname><given-names>LP</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L</given-names></name></person-group><article-title>Angiogenic signaling pathways and anti-angiogenic therapy for cancer</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><fpage>198</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01460-1</pub-id><pub-id pub-id-type="pmid">37169756</pub-id><pub-id pub-id-type="pmcid">PMC10175505</pub-id></element-citation><mixed-citation id="mc-CR223" publication-type="journal">Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8:198.<pub-id pub-id-type="pmid">37169756</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01460-1</pub-id><pub-id pub-id-type="pmcid">PMC10175505</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR224"><label>224</label><citation-alternatives><element-citation id="ec-CR224" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lugano</surname><given-names>R</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>M</given-names></name><name name-style="western"><surname>Dimberg</surname><given-names>A</given-names></name></person-group><article-title>Tumor angiogenesis: causes, consequences, challenges and opportunities</article-title><source>Cell Mol Life Sci</source><year>2020</year><volume>77</volume><fpage>1745</fpage><lpage>1770</lpage><pub-id pub-id-type="doi">10.1007/s00018-019-03351-7</pub-id><pub-id pub-id-type="pmid">31690961</pub-id><pub-id pub-id-type="pmcid">PMC7190605</pub-id></element-citation><mixed-citation id="mc-CR224" publication-type="journal">Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745&#8211;70.<pub-id pub-id-type="pmid">31690961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-019-03351-7</pub-id><pub-id pub-id-type="pmcid">PMC7190605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR225"><label>225</label><citation-alternatives><element-citation id="ec-CR225" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>N</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name><name name-style="western"><surname>Shi</surname><given-names>M</given-names></name><name name-style="western"><surname>Xing</surname><given-names>M</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W</given-names></name></person-group><article-title>Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting endothelial smad2/3 signaling</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>7940</fpage><lpage>7958</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b08460</pub-id><pub-id pub-id-type="pmid">32413258</pub-id></element-citation><mixed-citation id="mc-CR225" publication-type="journal">Huang N, Liu Y, Fang Y, Zheng S, Wu J, Wang M, Zhong W, Shi M, Xing M, Liao W. Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting endothelial smad2/3 signaling. ACS Nano. 2020;14:7940&#8211;58.<pub-id pub-id-type="pmid">32413258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.9b08460</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR226"><label>226</label><citation-alternatives><element-citation id="ec-CR226" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ugel</surname><given-names>S</given-names></name><name name-style="western"><surname>Facciponte</surname><given-names>JG</given-names></name><name name-style="western"><surname>De Sanctis</surname><given-names>F</given-names></name><name name-style="western"><surname>Facciabene</surname><given-names>A</given-names></name></person-group><article-title>Targeting tumor vasculature: expanding the potential of DNA cancer vaccines</article-title><source>Cancer Immunol Immunother</source><year>2015</year><volume>64</volume><fpage>1339</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1007/s00262-015-1747-8</pub-id><pub-id pub-id-type="pmid">26267042</pub-id><pub-id pub-id-type="pmcid">PMC11028665</pub-id></element-citation><mixed-citation id="mc-CR226" publication-type="journal">Ugel S, Facciponte JG, De Sanctis F, Facciabene A. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. Cancer Immunol Immunother. 2015;64:1339&#8211;48.<pub-id pub-id-type="pmid">26267042</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-015-1747-8</pub-id><pub-id pub-id-type="pmcid">PMC11028665</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR227"><label>227</label><citation-alternatives><element-citation id="ec-CR227" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansaccal</surname><given-names>N</given-names></name><name name-style="western"><surname>Vieugue</surname><given-names>P</given-names></name><name name-style="western"><surname>Sarate</surname><given-names>R</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Minguijon</surname><given-names>E</given-names></name><name name-style="western"><surname>Miroshnikova</surname><given-names>YA</given-names></name><name name-style="western"><surname>Zeuschner</surname><given-names>D</given-names></name><name name-style="western"><surname>Collin</surname><given-names>A</given-names></name><name name-style="western"><surname>Allard</surname><given-names>J</given-names></name><name name-style="western"><surname>Engelman</surname><given-names>D</given-names></name><name name-style="western"><surname>Delaunois</surname><given-names>AL</given-names></name><name name-style="western"><surname>Liagre</surname><given-names>M</given-names></name><name name-style="western"><surname>de Groote</surname><given-names>L</given-names></name><name name-style="western"><surname>Timmerman</surname><given-names>E</given-names></name><name name-style="western"><surname>Van Haver</surname><given-names>D</given-names></name><name name-style="western"><surname>Impens</surname><given-names>F</given-names></name><name name-style="western"><surname>Salmon</surname><given-names>I</given-names></name><name name-style="western"><surname>Wickstrom</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sifrim</surname><given-names>A</given-names></name><name name-style="western"><surname>Blanpain</surname><given-names>C</given-names></name></person-group><article-title>The extracellular matrix dictates regional competence for tumour initiation</article-title><source>Nature</source><year>2023</year><volume>623</volume><fpage>828</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06740-y</pub-id><pub-id pub-id-type="pmid">37968399</pub-id><pub-id pub-id-type="pmcid">PMC7615367</pub-id></element-citation><mixed-citation id="mc-CR227" publication-type="journal">Bansaccal N, Vieugue P, Sarate R, Song Y, Minguijon E, Miroshnikova YA, Zeuschner D, Collin A, Allard J, Engelman D, Delaunois AL, Liagre M, de Groote L, Timmerman E, Van Haver D, Impens F, Salmon I, Wickstrom SA, Sifrim A, Blanpain C. The extracellular matrix dictates regional competence for tumour initiation. Nature. 2023;623:828&#8211;35.<pub-id pub-id-type="pmid">37968399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06740-y</pub-id><pub-id pub-id-type="pmcid">PMC7615367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR228"><label>228</label><citation-alternatives><element-citation id="ec-CR228" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Dou</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>M</given-names></name></person-group><article-title>Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments</article-title><source>Mol Cancer</source><year>2023</year><volume>22</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s12943-023-01744-8</pub-id><pub-id pub-id-type="pmid">36906534</pub-id><pub-id pub-id-type="pmcid">PMC10007858</pub-id></element-citation><mixed-citation id="mc-CR228" publication-type="journal">Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, Zhang Z, Yang S, Xiao M. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48.<pub-id pub-id-type="pmid">36906534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01744-8</pub-id><pub-id pub-id-type="pmcid">PMC10007858</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR229"><label>229</label><citation-alternatives><element-citation id="ec-CR229" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chan</surname><given-names>KI</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W</given-names></name></person-group><article-title>The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>1093990</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.1093990</pub-id><pub-id pub-id-type="pmid">36776395</pub-id><pub-id pub-id-type="pmcid">PMC9910179</pub-id></element-citation><mixed-citation id="mc-CR229" publication-type="journal">He L, Kang Q, Chan KI, Zhang Y, Zhong Z, Tan W. The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer. Front Immunol. 2022;13:1093990.<pub-id pub-id-type="pmid">36776395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.1093990</pub-id><pub-id pub-id-type="pmcid">PMC9910179</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR230"><label>230</label><citation-alternatives><element-citation id="ec-CR230" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name></person-group><article-title>Crosstalk and plasticity driving between cancer-associated fibroblasts and tumor microenvironment: significance of breast cancer metastasis</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><fpage>827</fpage><pub-id pub-id-type="doi">10.1186/s12967-023-04714-2</pub-id><pub-id pub-id-type="pmid">37978384</pub-id><pub-id pub-id-type="pmcid">PMC10657029</pub-id></element-citation><mixed-citation id="mc-CR230" publication-type="journal">Zhang W, Wang J, Liu C, Li Y, Sun C, Wu J, Wu Q. Crosstalk and plasticity driving between cancer-associated fibroblasts and tumor microenvironment: significance of breast cancer metastasis. J Transl Med. 2023;21:827.<pub-id pub-id-type="pmid">37978384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-04714-2</pub-id><pub-id pub-id-type="pmcid">PMC10657029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR231"><label>231</label><citation-alternatives><element-citation id="ec-CR231" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>A</given-names></name><name name-style="western"><surname>Tian</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name></person-group><article-title>Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger</article-title><source>Biomaterials</source><year>2020</year><volume>252</volume><fpage>120114</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2020.120114</pub-id><pub-id pub-id-type="pmid">32422491</pub-id></element-citation><mixed-citation id="mc-CR231" publication-type="journal">Hu Y, Lin L, Chen J, Maruyama A, Tian H, Chen X. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger. Biomaterials. 2020;252: 120114.<pub-id pub-id-type="pmid">32422491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2020.120114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR232"><label>232</label><citation-alternatives><element-citation id="ec-CR232" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Avila</surname><given-names>G</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>B</given-names></name><name name-style="western"><surname>Mendoza-Posada</surname><given-names>DA</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>C</given-names></name><name name-style="western"><surname>Garcia-Hernandez</surname><given-names>AA</given-names></name><name name-style="western"><surname>Falfan-Valencia</surname><given-names>R</given-names></name></person-group><article-title>Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer</article-title><source>Crit Rev Oncol Hematol</source><year>2019</year><volume>137</volume><fpage>57</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2019.02.010</pub-id><pub-id pub-id-type="pmid">31014516</pub-id></element-citation><mixed-citation id="mc-CR232" publication-type="journal">Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, Ramos C, Garcia-Hernandez AA, Falfan-Valencia R. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol. 2019;137:57&#8211;83.<pub-id pub-id-type="pmid">31014516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2019.02.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR233"><label>233</label><citation-alternatives><element-citation id="ec-CR233" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Q</given-names></name><name name-style="western"><surname>He</surname><given-names>W</given-names></name><name name-style="western"><surname>Yin</surname><given-names>L</given-names></name></person-group><article-title>Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>2830</fpage><lpage>2845</lpage><pub-id pub-id-type="doi">10.7150/thno.23209</pub-id><pub-id pub-id-type="pmid">29774078</pub-id><pub-id pub-id-type="pmcid">PMC5957012</pub-id></element-citation><mixed-citation id="mc-CR233" publication-type="journal">Lv Y, Zhao X, Zhu L, Li S, Xiao Q, He W, Yin L. Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis. Theranostics. 2018;8:2830&#8211;45.<pub-id pub-id-type="pmid">29774078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.23209</pub-id><pub-id pub-id-type="pmcid">PMC5957012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR234"><label>234</label><citation-alternatives><element-citation id="ec-CR234" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biffi</surname><given-names>G</given-names></name><name name-style="western"><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><article-title>Diversity and biology of cancer-associated fibroblasts</article-title><source>Physiol Rev</source><year>2021</year><volume>101</volume><issue>1</issue><fpage>147</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1152/physrev.00048.2019</pub-id><pub-id pub-id-type="pmid">32466724</pub-id><pub-id pub-id-type="pmcid">PMC7864232</pub-id></element-citation><mixed-citation id="mc-CR234" publication-type="journal">Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147&#8211;76. 10.1152/physrev.00048.2019.<pub-id pub-id-type="pmid">32466724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00048.2019</pub-id><pub-id pub-id-type="pmcid">PMC7864232</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR235"><label>235</label><citation-alternatives><element-citation id="ec-CR235" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nurmik</surname><given-names>M</given-names></name><name name-style="western"><surname>Ullmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>F</given-names></name><name name-style="western"><surname>Haan</surname><given-names>S</given-names></name><name name-style="western"><surname>Letellier</surname><given-names>E</given-names></name></person-group><article-title>In search of definitions: cancer-associated fibroblasts and their markers</article-title><source>Int J Cancer</source><year>2020</year><volume>146</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1002/ijc.32193</pub-id><pub-id pub-id-type="pmid">30734283</pub-id><pub-id pub-id-type="pmcid">PMC6972582</pub-id></element-citation><mixed-citation id="mc-CR235" publication-type="journal">Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146:895&#8211;905.<pub-id pub-id-type="pmid">30734283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.32193</pub-id><pub-id pub-id-type="pmcid">PMC6972582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR236"><label>236</label><citation-alternatives><element-citation id="ec-CR236" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahai</surname><given-names>E</given-names></name><name name-style="western"><surname>Astsaturov</surname><given-names>I</given-names></name><name name-style="western"><surname>Cukierman</surname><given-names>E</given-names></name><name name-style="western"><surname>DeNardo</surname><given-names>DG</given-names></name><name name-style="western"><surname>Egeblad</surname><given-names>M</given-names></name><name name-style="western"><surname>Evans</surname><given-names>RM</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>D</given-names></name><name name-style="western"><surname>Greten</surname><given-names>FR</given-names></name><name name-style="western"><surname>Hingorani</surname><given-names>SR</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>T</given-names></name><name name-style="western"><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>A framework for advancing our understanding of cancer-associated fibroblasts</article-title><source>Nat Rev Cancer</source><year>2020</year><volume>20</volume><issue>3</issue><fpage>174</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0238-1</pub-id><pub-id pub-id-type="pmid">31980749</pub-id><pub-id pub-id-type="pmcid">PMC7046529</pub-id></element-citation><mixed-citation id="mc-CR236" publication-type="journal">Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, Hynes RO. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174&#8211;86.<pub-id pub-id-type="pmid">31980749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0238-1</pub-id><pub-id pub-id-type="pmcid">PMC7046529</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR237"><label>237</label><citation-alternatives><element-citation id="ec-CR237" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chow</surname><given-names>DS</given-names></name><name name-style="western"><surname>Koay</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bankson</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>SE</given-names></name><name name-style="western"><surname>Overwijk</surname><given-names>W</given-names></name><name name-style="western"><surname>Maitra</surname><given-names>A</given-names></name><name name-style="western"><surname>Piwnica-Worms</surname><given-names>D</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>JB</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name></person-group><article-title>Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy</article-title><source>Biomaterials</source><year>2018</year><volume>159</volume><fpage>215</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.01.014</pub-id><pub-id pub-id-type="pmid">29331808</pub-id><pub-id pub-id-type="pmcid">PMC6203960</pub-id></element-citation><mixed-citation id="mc-CR237" publication-type="journal">Zhao J, Wang H, Hsiao CH, Chow DS, Koay EJ, Kang Y, Wen X, Huang Q, Ma Y, Bankson JA, Ullrich SE, Overwijk W, Maitra A, Piwnica-Worms D, Fleming JB, Li C. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018;159:215&#8211;28.<pub-id pub-id-type="pmid">29331808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2018.01.014</pub-id><pub-id pub-id-type="pmcid">PMC6203960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR238"><label>238</label><citation-alternatives><element-citation id="ec-CR238" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>B</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W</given-names></name></person-group><article-title>Cancer-associated fibroblasts suppress cancer development: the other side of the coin</article-title><source>Front Cell Dev Biol</source><year>2021</year><volume>9</volume><fpage>613534</fpage><pub-id pub-id-type="doi">10.3389/fcell.2021.613534</pub-id><pub-id pub-id-type="pmid">33614646</pub-id><pub-id pub-id-type="pmcid">PMC7890026</pub-id></element-citation><mixed-citation id="mc-CR238" publication-type="journal">Wang Z, Yang Q, Tan Y, Tang Y, Ye J, Yuan B, Yu W. Cancer-associated fibroblasts suppress cancer development: the other side of the coin. Front Cell Dev Biol. 2021;9: 613534.<pub-id pub-id-type="pmid">33614646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2021.613534</pub-id><pub-id pub-id-type="pmcid">PMC7890026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR239"><label>239</label><citation-alternatives><element-citation id="ec-CR239" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Han</surname><given-names>X</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J</given-names></name><name name-style="western"><surname>Ji</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G</given-names></name></person-group><article-title>Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>12357</fpage><lpage>12371</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b04857</pub-id><pub-id pub-id-type="pmid">31545587</pub-id></element-citation><mixed-citation id="mc-CR239" publication-type="journal">Lang J, Zhao X, Qi Y, Zhang Y, Han X, Ding Y, Guan J, Ji T, Zhao Y, Nie G. Reshaping prostate tumor microenvironment to suppress metastasis via cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem. ACS Nano. 2019;13:12357&#8211;71.<pub-id pub-id-type="pmid">31545587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.9b04857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR240"><label>240</label><citation-alternatives><element-citation id="ec-CR240" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y</given-names></name><name name-style="western"><surname>Jon</surname><given-names>S</given-names></name></person-group><article-title>Nanovaccine displaying immunodominant T cell epitopes of fibroblast activation protein is effective against desmoplastic tumors</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>10337</fpage><lpage>10352</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c00764</pub-id><pub-id pub-id-type="pmid">37184372</pub-id></element-citation><mixed-citation id="mc-CR240" publication-type="journal">Shin H, Kim Y, Jon S. Nanovaccine displaying immunodominant T cell epitopes of fibroblast activation protein is effective against desmoplastic tumors. ACS Nano. 2023;17:10337&#8211;52.<pub-id pub-id-type="pmid">37184372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c00764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR241"><label>241</label><citation-alternatives><element-citation id="ec-CR241" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atiya</surname><given-names>HI</given-names></name><name name-style="western"><surname>Gorecki</surname><given-names>G</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>GL</given-names></name><name name-style="western"><surname>Frisbie</surname><given-names>LG</given-names></name><name name-style="western"><surname>Baruwal</surname><given-names>R</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>L</given-names></name></person-group><article-title>Stromal-modulated epithelial-to-mesenchymal transition in cancer cells</article-title><source>Biomolecules</source><year>2023</year><volume>13</volume><issue>11</issue><fpage>1604</fpage><pub-id pub-id-type="doi">10.3390/biom13111604</pub-id><pub-id pub-id-type="pmid">38002286</pub-id><pub-id pub-id-type="pmcid">PMC10669774</pub-id></element-citation><mixed-citation id="mc-CR241" publication-type="journal">Atiya HI, Gorecki G, Garcia GL, Frisbie LG, Baruwal R, Coffman L. Stromal-modulated epithelial-to-mesenchymal transition in cancer cells. Biomolecules. 2023;13(11):1604.<pub-id pub-id-type="pmid">38002286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom13111604</pub-id><pub-id pub-id-type="pmcid">PMC10669774</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR242"><label>242</label><citation-alternatives><element-citation id="ec-CR242" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J</given-names></name><name name-style="western"><surname>Oltean</surname><given-names>S</given-names></name></person-group><article-title>Regulation of epithelial-mesenchymal transitions by alternative splicing: potential new area for cancer therapeutics</article-title><source>Genes</source><year>2023</year><volume>14</volume><issue>11</issue><fpage>2001</fpage><pub-id pub-id-type="doi">10.3390/genes14112001</pub-id><pub-id pub-id-type="pmid">38002944</pub-id><pub-id pub-id-type="pmcid">PMC10671305</pub-id></element-citation><mixed-citation id="mc-CR242" publication-type="journal">Li L, Zheng J, Oltean S. Regulation of epithelial-mesenchymal transitions by alternative splicing: potential new area for cancer therapeutics. Genes. 2023;14(11):2001.<pub-id pub-id-type="pmid">38002944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/genes14112001</pub-id><pub-id pub-id-type="pmcid">PMC10671305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR243"><label>243</label><citation-alternatives><element-citation id="ec-CR243" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuhwerk</surname><given-names>H</given-names></name><name name-style="western"><surname>Brabletz</surname><given-names>T</given-names></name></person-group><article-title>Mutual regulation of TGFbeta-induced oncogenic EMT, cell cycle progression and the DDR</article-title><source>Semin Cancer Biol</source><year>2023</year><volume>97</volume><fpage>86</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2023.11.009</pub-id><pub-id pub-id-type="pmid">38029866</pub-id></element-citation><mixed-citation id="mc-CR243" publication-type="journal">Schuhwerk H, Brabletz T. Mutual regulation of TGFbeta-induced oncogenic EMT, cell cycle progression and the DDR. Semin Cancer Biol. 2023;97:86&#8211;103.<pub-id pub-id-type="pmid">38029866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semcancer.2023.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR244"><label>244</label><citation-alternatives><element-citation id="ec-CR244" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakir</surname><given-names>B</given-names></name><name name-style="western"><surname>Chiarella</surname><given-names>AM</given-names></name><name name-style="western"><surname>Pitarresi</surname><given-names>JR</given-names></name><name name-style="western"><surname>Rustgi</surname><given-names>AK</given-names></name></person-group><article-title>EMT, MET, plasticity, and tumor metastasis</article-title><source>Trends Cell Biol</source><year>2020</year><volume>30</volume><fpage>764</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2020.07.003</pub-id><pub-id pub-id-type="pmid">32800658</pub-id><pub-id pub-id-type="pmcid">PMC7647095</pub-id></element-citation><mixed-citation id="mc-CR244" publication-type="journal">Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol. 2020;30:764&#8211;76.<pub-id pub-id-type="pmid">32800658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2020.07.003</pub-id><pub-id pub-id-type="pmcid">PMC7647095</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR245"><label>245</label><citation-alternatives><element-citation id="ec-CR245" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brabletz</surname><given-names>S</given-names></name><name name-style="western"><surname>Schuhwerk</surname><given-names>H</given-names></name><name name-style="western"><surname>Brabletz</surname><given-names>T</given-names></name><name name-style="western"><surname>Stemmler</surname><given-names>MP</given-names></name></person-group><article-title>Dynamic EMT: a multi-tool for tumor progression</article-title><source>EMBO J</source><year>2021</year><volume>40</volume><fpage>e108647</fpage><pub-id pub-id-type="doi">10.15252/embj.2021108647</pub-id><pub-id pub-id-type="pmid">34459003</pub-id><pub-id pub-id-type="pmcid">PMC8441439</pub-id></element-citation><mixed-citation id="mc-CR245" publication-type="journal">Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40: e108647.<pub-id pub-id-type="pmid">34459003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.2021108647</pub-id><pub-id pub-id-type="pmcid">PMC8441439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR246"><label>246</label><citation-alternatives><element-citation id="ec-CR246" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name><name name-style="western"><surname>Shan</surname><given-names>A</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C</given-names></name><name name-style="western"><surname>Liang</surname><given-names>B</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>E</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L</given-names></name></person-group><article-title>MicroRNAs target the Wnt/beta-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer (Review)</article-title><source>Oncol Rep</source><year>2020</year><volume>44</volume><fpage>1299</fpage><lpage>1313</lpage><pub-id pub-id-type="pmid">32700744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2020.7703</pub-id><pub-id pub-id-type="pmcid">PMC7448411</pub-id></element-citation><mixed-citation id="mc-CR246" publication-type="journal">Lei Y, Chen L, Zhang G, Shan A, Ye C, Liang B, Sun J, Liao X, Zhu C, Chen Y, Wang J, Zhang E, Deng L. MicroRNAs target the Wnt/beta-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer (Review). Oncol Rep. 2020;44:1299&#8211;313.<pub-id pub-id-type="pmid">32700744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/or.2020.7703</pub-id><pub-id pub-id-type="pmcid">PMC7448411</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR247"><label>247</label><citation-alternatives><element-citation id="ec-CR247" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>K</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>A</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>Z</given-names></name></person-group><article-title>Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk</article-title><source>Genes Diseases</source><year>2024</year><volume>11</volume><issue>1</issue><fpage>103</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2023.01.030</pub-id><pub-id pub-id-type="pmid">37588235</pub-id><pub-id pub-id-type="pmcid">PMC10425814</pub-id></element-citation><mixed-citation id="mc-CR247" publication-type="journal">Qin K, Yu M, Fan J, Wang H, Zhao P, Zhao G, Zeng W, Chen C, Wang Y, Wang A, Schwartz Z. Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk. Genes Diseases. 2024;11(1):103&#8211;34.<pub-id pub-id-type="pmid">37588235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.gendis.2023.01.030</pub-id><pub-id pub-id-type="pmcid">PMC10425814</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR248"><label>248</label><citation-alternatives><element-citation id="ec-CR248" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Beijnum</surname><given-names>JR</given-names></name><name name-style="western"><surname>Huijbers</surname><given-names>EJM</given-names></name><name name-style="western"><surname>van Loon</surname><given-names>K</given-names></name><name name-style="western"><surname>Blanas</surname><given-names>A</given-names></name><name name-style="western"><surname>Akbari</surname><given-names>P</given-names></name><name name-style="western"><surname>Roos</surname><given-names>A</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Denisov</surname><given-names>SS</given-names></name><name name-style="western"><surname>Hackeng</surname><given-names>TM</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>CR</given-names></name><name name-style="western"><surname>Nowak-Sliwinska</surname><given-names>P</given-names></name><name name-style="western"><surname>Griffioen</surname><given-names>AW</given-names></name></person-group><article-title>Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><fpage>2842</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30063-7</pub-id><pub-id pub-id-type="pmid">35606362</pub-id><pub-id pub-id-type="pmcid">PMC9126915</pub-id></element-citation><mixed-citation id="mc-CR248" publication-type="journal">van Beijnum JR, Huijbers EJM, van Loon K, Blanas A, Akbari P, Roos A, Wong TJ, Denisov SS, Hackeng TM, Jimenez CR, Nowak-Sliwinska P, Griffioen AW. Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. Nat Commun. 2022;13:2842.<pub-id pub-id-type="pmid">35606362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-30063-7</pub-id><pub-id pub-id-type="pmcid">PMC9126915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR249"><label>249</label><citation-alternatives><element-citation id="ec-CR249" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>RS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Dai</surname><given-names>SY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Lv</surname><given-names>XX</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>XT</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name></person-group><article-title>ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>7661</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-43548-w</pub-id><pub-id pub-id-type="pmid">37996458</pub-id><pub-id pub-id-type="pmcid">PMC10667515</pub-id></element-citation><mixed-citation id="mc-CR249" publication-type="journal">Shang S, Yang C, Chen F, Xiang RS, Zhang H, Dai SY, Liu J, Lv XX, Zhang C, Liu XT, Zhang Q. ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer. Nat Commun. 2023;14(1):7661.<pub-id pub-id-type="pmid">37996458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-43548-w</pub-id><pub-id pub-id-type="pmcid">PMC10667515</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR250"><label>250</label><citation-alternatives><element-citation id="ec-CR250" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Aicher</surname><given-names>A</given-names></name><name name-style="western"><surname>Bou Kheir</surname><given-names>T</given-names></name><name name-style="western"><surname>Sabanovic</surname><given-names>B</given-names></name><name name-style="western"><surname>Ananthanarayanan</surname><given-names>P</given-names></name><name name-style="western"><surname>Reina</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Gu</surname><given-names>JM</given-names></name><name name-style="western"><surname>He</surname><given-names>B</given-names></name><name name-style="western"><surname>Alcala</surname><given-names>S</given-names></name></person-group><article-title>Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity</article-title><source>J Exp Clin Cancer Res</source><year>2023</year><volume>42</volume><issue>1</issue><fpage>323</fpage><pub-id pub-id-type="doi">10.1186/s13046-023-02883-y</pub-id><pub-id pub-id-type="pmid">38012687</pub-id><pub-id pub-id-type="pmcid">PMC10683265</pub-id></element-citation><mixed-citation id="mc-CR250" publication-type="journal">Zheng Q, Tang J, Aicher A, Bou Kheir T, Sabanovic B, Ananthanarayanan P, Reina C, Chen M, Gu JM, He B, Alcala S. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. J Exp Clin Cancer Res. 2023;42(1):323.<pub-id pub-id-type="pmid">38012687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-023-02883-y</pub-id><pub-id pub-id-type="pmcid">PMC10683265</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR251"><label>251</label><citation-alternatives><element-citation id="ec-CR251" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurtova</surname><given-names>AV</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Pazhanisamy</surname><given-names>S</given-names></name><name name-style="western"><surname>Krasnow</surname><given-names>R</given-names></name><name name-style="western"><surname>Lerner</surname><given-names>SP</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Roh</surname><given-names>TT</given-names></name><name name-style="western"><surname>Lay</surname><given-names>E</given-names></name><name name-style="western"><surname>Ho</surname><given-names>PL</given-names></name><name name-style="western"><surname>Chan</surname><given-names>KS</given-names></name></person-group><article-title>Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance</article-title><source>Nature</source><year>2015</year><volume>517</volume><fpage>209</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1038/nature14034</pub-id><pub-id pub-id-type="pmid">25470039</pub-id><pub-id pub-id-type="pmcid">PMC4465385</pub-id></element-citation><mixed-citation id="mc-CR251" publication-type="journal">Kurtova AV, Xiao J, Mo Q, Pazhanisamy S, Krasnow R, Lerner SP, Chen F, Roh TT, Lay E, Ho PL, Chan KS. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517:209&#8211;13.<pub-id pub-id-type="pmid">25470039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14034</pub-id><pub-id pub-id-type="pmcid">PMC4465385</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR252"><label>252</label><citation-alternatives><element-citation id="ec-CR252" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chang</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Luming</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name></person-group><article-title>Redox&#8208;responsive dual drug delivery nanosystem suppresses cancer repopulation by abrogating doxorubicin&#8208;promoted cancer stemness, metastasis, and drug resistance</article-title><source>Adv Sci</source><year>2019</year><volume>6</volume><issue>7</issue><fpage>1801987</fpage><pub-id pub-id-type="doi">10.1002/advs.201801987</pub-id><pub-id pub-id-type="pmcid">PMC6446919</pub-id><pub-id pub-id-type="pmid">31139556</pub-id></element-citation><mixed-citation id="mc-CR252" publication-type="journal">Liu J, Chang B, Li Q, Luming X, Liu X, Wang G, Wang Z, Wang L. Redox&#8208;responsive dual drug delivery nanosystem suppresses cancer repopulation by abrogating doxorubicin&#8208;promoted cancer stemness, metastasis, and drug resistance. Adv Sci. 2019;6(7):1801987. 10.1002/advs.201801987.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.201801987</pub-id><pub-id pub-id-type="pmcid">PMC6446919</pub-id><pub-id pub-id-type="pmid">31139556</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR253"><label>253</label><citation-alternatives><element-citation id="ec-CR253" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>N</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Teitz-Tennenbaum</surname><given-names>S</given-names></name><name name-style="western"><surname>Egenti</surname><given-names>M</given-names></name><name name-style="western"><surname>Yet</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Ginestier</surname><given-names>C</given-names></name><name name-style="western"><surname>Wicha</surname><given-names>MS</given-names></name><name name-style="western"><surname>Moyer</surname><given-names>JS</given-names></name><name name-style="western"><surname>Prince</surname><given-names>ME</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>XL</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Chang</surname><given-names>AE</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name></person-group><article-title>Cancer stem cell vaccination confers significant antitumor immunity</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><fpage>1853</fpage><lpage>1864</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1400</pub-id><pub-id pub-id-type="pmid">22473314</pub-id><pub-id pub-id-type="pmcid">PMC3320735</pub-id></element-citation><mixed-citation id="mc-CR253" publication-type="journal">Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, Li M, Ginestier C, Wicha MS, Moyer JS, Prince ME, Xu Y, Zhang XL, Huang S, Chang AE, Li Q. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72:1853&#8211;64.<pub-id pub-id-type="pmid">22473314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-11-1400</pub-id><pub-id pub-id-type="pmcid">PMC3320735</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR254"><label>254</label><citation-alternatives><element-citation id="ec-CR254" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B</given-names></name><name name-style="western"><surname>Pan</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F</given-names></name><name name-style="western"><surname>Dou</surname><given-names>J</given-names></name></person-group><article-title>MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine</article-title><source>Int Immunopharmacol</source><year>2020</year><volume>85</volume><fpage>106631</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106631</pub-id><pub-id pub-id-type="pmid">32470879</pub-id></element-citation><mixed-citation id="mc-CR254" publication-type="journal">Guo M, Luo B, Pan M, Li M, Zhao F, Dou J. MUC1 plays an essential role in tumor immunity of colorectal cancer stem cell vaccine. Int Immunopharmacol. 2020;85: 106631.<pub-id pub-id-type="pmid">32470879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.intimp.2020.106631</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR255"><label>255</label><citation-alternatives><element-citation id="ec-CR255" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pratt</surname><given-names>SJP</given-names></name><name name-style="western"><surname>Lee</surname><given-names>RM</given-names></name><name name-style="western"><surname>Martin</surname><given-names>SS</given-names></name></person-group><article-title>The mechanical microenvironment in breast cancer</article-title><source>Cancers</source><year>2020</year><volume>12</volume><issue>6</issue><fpage>1452</fpage><pub-id pub-id-type="doi">10.3390/cancers12061452</pub-id><pub-id pub-id-type="pmid">32503141</pub-id><pub-id pub-id-type="pmcid">PMC7352870</pub-id></element-citation><mixed-citation id="mc-CR255" publication-type="journal">Pratt SJP, Lee RM, Martin SS. The mechanical microenvironment in breast cancer. Cancers. 2020;12(6):1452. 10.3390/cancers12061452.<pub-id pub-id-type="pmid">32503141</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers12061452</pub-id><pub-id pub-id-type="pmcid">PMC7352870</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR256"><label>256</label><citation-alternatives><element-citation id="ec-CR256" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>P</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L</given-names></name></person-group><article-title>Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment</article-title><source>Cancer Biol Med</source><year>2023</year><volume>20</volume><fpage>44</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2022.0491</pub-id><pub-id pub-id-type="pmid">36647779</pub-id><pub-id pub-id-type="pmcid">PMC9843446</pub-id></element-citation><mixed-citation id="mc-CR256" publication-type="journal">Zhu P, Lu H, Wang M, Chen K, Chen Z, Yang L. Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment. Cancer Biol Med. 2023;20:44&#8211;55.<pub-id pub-id-type="pmid">36647779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20892/j.issn.2095-3941.2022.0491</pub-id><pub-id pub-id-type="pmcid">PMC9843446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR257"><label>257</label><citation-alternatives><element-citation id="ec-CR257" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma</article-title><source>Theranostics</source><year>2018</year><volume>8</volume><fpage>3781</fpage><lpage>3796</lpage><pub-id pub-id-type="doi">10.7150/thno.24821</pub-id><pub-id pub-id-type="pmid">30083259</pub-id><pub-id pub-id-type="pmcid">PMC6071534</pub-id></element-citation><mixed-citation id="mc-CR257" publication-type="journal">Hou L, Liu Q, Shen L, Liu Y, Zhang X, Chen F, Huang L. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics. 2018;8:3781&#8211;96.<pub-id pub-id-type="pmid">30083259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.24821</pub-id><pub-id pub-id-type="pmcid">PMC6071534</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR258"><label>258</label><citation-alternatives><element-citation id="ec-CR258" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>D</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name></person-group><article-title>Circulating tumor cells: biology and clinical significance</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><fpage>404</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00817-8</pub-id><pub-id pub-id-type="pmid">34803167</pub-id><pub-id pub-id-type="pmcid">PMC8606574</pub-id></element-citation><mixed-citation id="mc-CR258" publication-type="journal">Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, Zhou J. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6:404.<pub-id pub-id-type="pmid">34803167</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00817-8</pub-id><pub-id pub-id-type="pmcid">PMC8606574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR259"><label>259</label><citation-alternatives><element-citation id="ec-CR259" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacob</surname><given-names>K</given-names></name><name name-style="western"><surname>Sollier</surname><given-names>C</given-names></name><name name-style="western"><surname>Jabado</surname><given-names>N</given-names></name></person-group><article-title>Circulating tumor cells: detection, molecular profiling and future prospects</article-title><source>Expert Rev Proteomics</source><year>2007</year><volume>4</volume><fpage>741</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1586/14789450.4.6.741</pub-id><pub-id pub-id-type="pmid">18067413</pub-id></element-citation><mixed-citation id="mc-CR259" publication-type="journal">Jacob K, Sollier C, Jabado N. Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics. 2007;4:741&#8211;56.<pub-id pub-id-type="pmid">18067413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14789450.4.6.741</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR260"><label>260</label><citation-alternatives><element-citation id="ec-CR260" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Punt</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Iannotti</surname><given-names>N</given-names></name><name name-style="western"><surname>Saidman</surname><given-names>BH</given-names></name><name name-style="western"><surname>Sabbath</surname><given-names>KD</given-names></name><name name-style="western"><surname>Gabrail</surname><given-names>NY</given-names></name><name name-style="western"><surname>Picus</surname><given-names>J</given-names></name><name name-style="western"><surname>Morse</surname><given-names>M</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>E</given-names></name><name name-style="western"><surname>Miller</surname><given-names>MC</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>GV</given-names></name><name name-style="western"><surname>Tissing</surname><given-names>H</given-names></name><name name-style="western"><surname>Terstappen</surname><given-names>LW</given-names></name><name name-style="western"><surname>Meropol</surname><given-names>NJ</given-names></name></person-group><article-title>Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3213</fpage><lpage>3221</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.8923</pub-id><pub-id pub-id-type="pmid">18591556</pub-id></element-citation><mixed-citation id="mc-CR260" publication-type="journal">Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213&#8211;21.<pub-id pub-id-type="pmid">18591556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2007.15.8923</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR261"><label>261</label><citation-alternatives><element-citation id="ec-CR261" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riethdorf</surname><given-names>S</given-names></name><name name-style="western"><surname>Fritsche</surname><given-names>H</given-names></name><name name-style="western"><surname>Muller</surname><given-names>V</given-names></name><name name-style="western"><surname>Rau</surname><given-names>T</given-names></name><name name-style="western"><surname>Schindlbeck</surname><given-names>C</given-names></name><name name-style="western"><surname>Rack</surname><given-names>B</given-names></name><name name-style="western"><surname>Janni</surname><given-names>W</given-names></name><name name-style="western"><surname>Coith</surname><given-names>C</given-names></name><name name-style="western"><surname>Beck</surname><given-names>K</given-names></name><name name-style="western"><surname>Janicke</surname><given-names>F</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>S</given-names></name><name name-style="western"><surname>Gornet</surname><given-names>T</given-names></name><name name-style="western"><surname>Cristofanilli</surname><given-names>M</given-names></name><name name-style="western"><surname>Pantel</surname><given-names>K</given-names></name></person-group><article-title>Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>920</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1695</pub-id><pub-id pub-id-type="pmid">17289886</pub-id></element-citation><mixed-citation id="mc-CR261" publication-type="journal">Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13:920&#8211;8.<pub-id pub-id-type="pmid">17289886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-06-1695</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR262"><label>262</label><citation-alternatives><element-citation id="ec-CR262" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinnear</surname><given-names>C</given-names></name><name name-style="western"><surname>Moore</surname><given-names>TL</given-names></name><name name-style="western"><surname>Rodriguez-Lorenzo</surname><given-names>L</given-names></name><name name-style="western"><surname>Rothen-Rutishauser</surname><given-names>B</given-names></name><name name-style="western"><surname>Petri-Fink</surname><given-names>A</given-names></name></person-group><article-title>Form follows function: nanoparticle shape and its implications for nanomedicine</article-title><source>Chem Rev</source><year>2017</year><volume>117</volume><fpage>11476</fpage><lpage>11521</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.7b00194</pub-id><pub-id pub-id-type="pmid">28862437</pub-id></element-citation><mixed-citation id="mc-CR262" publication-type="journal">Kinnear C, Moore TL, Rodriguez-Lorenzo L, Rothen-Rutishauser B, Petri-Fink A. Form follows function: nanoparticle shape and its implications for nanomedicine. Chem Rev. 2017;117:11476&#8211;521.<pub-id pub-id-type="pmid">28862437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.chemrev.7b00194</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR263"><label>263</label><citation-alternatives><element-citation id="ec-CR263" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>E</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>M</given-names></name></person-group><article-title>Principles of nanoparticle design for overcoming biological barriers to drug delivery</article-title><source>Nat Biotechnol</source><year>2015</year><volume>33</volume><fpage>941</fpage><lpage>951</lpage><pub-id pub-id-type="doi">10.1038/nbt.3330</pub-id><pub-id pub-id-type="pmid">26348965</pub-id><pub-id pub-id-type="pmcid">PMC4978509</pub-id></element-citation><mixed-citation id="mc-CR263" publication-type="journal">Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941&#8211;51.<pub-id pub-id-type="pmid">26348965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.3330</pub-id><pub-id pub-id-type="pmcid">PMC4978509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR264"><label>264</label><citation-alternatives><element-citation id="ec-CR264" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wei</surname><given-names>D</given-names></name><name name-style="western"><surname>Kang</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer</article-title><source>Biomaterials</source><year>2017</year><volume>113</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.10.033</pub-id><pub-id pub-id-type="pmid">27794222</pub-id></element-citation><mixed-citation id="mc-CR264" publication-type="journal">Yao J, Feng J, Gao X, Wei D, Kang T, Zhu Q, Jiang T, Wei X, Chen J. Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer. Biomaterials. 2017;113:1&#8211;17.<pub-id pub-id-type="pmid">27794222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.10.033</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR265"><label>265</label><citation-alternatives><element-citation id="ec-CR265" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CS</given-names></name><name name-style="western"><surname>Ponmudi</surname><given-names>V</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>AD</given-names></name><name name-style="western"><surname>King</surname><given-names>MR</given-names></name></person-group><article-title>E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells</article-title><source>J Control Release</source><year>2012</year><volume>160</volume><fpage>609</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2012.02.018</pub-id><pub-id pub-id-type="pmid">22421423</pub-id><pub-id pub-id-type="pmcid">PMC3749772</pub-id></element-citation><mixed-citation id="mc-CR265" publication-type="journal">Mitchell MJ, Chen CS, Ponmudi V, Hughes AD, King MR. E-selectin liposomal and nanotube-targeted delivery of doxorubicin to circulating tumor cells. J Control Release. 2012;160:609&#8211;17.<pub-id pub-id-type="pmid">22421423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2012.02.018</pub-id><pub-id pub-id-type="pmcid">PMC3749772</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR266"><label>266</label><citation-alternatives><element-citation id="ec-CR266" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaczanowska</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>RN</given-names></name></person-group><article-title>Mapping the switch that drives the pre-metastatic niche</article-title><source>Nat Cancer</source><year>2020</year><volume>1</volume><fpage>577</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-0076-9</pub-id><pub-id pub-id-type="pmid">35121974</pub-id></element-citation><mixed-citation id="mc-CR266" publication-type="journal">Kaczanowska S, Kaplan RN. Mapping the switch that drives the pre-metastatic niche. Nat Cancer. 2020;1:577&#8211;9.<pub-id pub-id-type="pmid">35121974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s43018-020-0076-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR267"><label>267</label><citation-alternatives><element-citation id="ec-CR267" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marar</surname><given-names>C</given-names></name><name name-style="western"><surname>Starich</surname><given-names>B</given-names></name><name name-style="western"><surname>Wirtz</surname><given-names>D</given-names></name></person-group><article-title>Extracellular vesicles in immunomodulation and tumor progression</article-title><source>Nat Immunol</source><year>2021</year><volume>22</volume><fpage>560</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00899-0</pub-id><pub-id pub-id-type="pmid">33753940</pub-id><pub-id pub-id-type="pmcid">PMC9389600</pub-id></element-citation><mixed-citation id="mc-CR267" publication-type="journal">Marar C, Starich B, Wirtz D. Extracellular vesicles in immunomodulation and tumor progression. Nat Immunol. 2021;22:560&#8211;70.<pub-id pub-id-type="pmid">33753940</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-021-00899-0</pub-id><pub-id pub-id-type="pmcid">PMC9389600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR268"><label>268</label><citation-alternatives><element-citation id="ec-CR268" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winkler</surname><given-names>J</given-names></name><name name-style="western"><surname>Abisoye-Ogunniyan</surname><given-names>A</given-names></name><name name-style="western"><surname>Metcalf</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Concepts of extracellular matrix remodelling in tumour progression and metastasis</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><fpage>5120</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18794-x</pub-id><pub-id pub-id-type="pmid">33037194</pub-id><pub-id pub-id-type="pmcid">PMC7547708</pub-id></element-citation><mixed-citation id="mc-CR268" publication-type="journal">Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.<pub-id pub-id-type="pmid">33037194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-18794-x</pub-id><pub-id pub-id-type="pmcid">PMC7547708</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR269"><label>269</label><citation-alternatives><element-citation id="ec-CR269" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yan</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Inflammation and tumor progression: signaling pathways and targeted intervention</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><fpage>263</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00658-5</pub-id><pub-id pub-id-type="pmid">34248142</pub-id><pub-id pub-id-type="pmcid">PMC8273155</pub-id></element-citation><mixed-citation id="mc-CR269" publication-type="journal">Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.<pub-id pub-id-type="pmid">34248142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00658-5</pub-id><pub-id pub-id-type="pmcid">PMC8273155</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR270"><label>270</label><citation-alternatives><element-citation id="ec-CR270" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>G</given-names></name><name name-style="western"><surname>Yi</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ying</surname><given-names>F</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name></person-group><article-title>Tumor-derived small extracellular vesicles facilitate omental metastasis of ovarian cancer by triggering activation of mesenchymal stem cells</article-title><source>Cell Commun Signal</source><year>2024</year><volume>22</volume><fpage>47</fpage><pub-id pub-id-type="doi">10.1186/s12964-023-01413-9</pub-id><pub-id pub-id-type="pmid">38233863</pub-id><pub-id pub-id-type="pmcid">PMC10795335</pub-id></element-citation><mixed-citation id="mc-CR270" publication-type="journal">Gong L, Li G, Yi X, Han Q, Wu Q, Ying F, Shen L, Cao Y, Liu X, Gao L, Li W, Wang Z, Cai J. Tumor-derived small extracellular vesicles facilitate omental metastasis of ovarian cancer by triggering activation of mesenchymal stem cells. Cell Commun Signal. 2024;22:47.<pub-id pub-id-type="pmid">38233863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-023-01413-9</pub-id><pub-id pub-id-type="pmcid">PMC10795335</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR271"><label>271</label><citation-alternatives><element-citation id="ec-CR271" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orbach</surname><given-names>SM</given-names></name><name name-style="western"><surname>DeVaull</surname><given-names>CY</given-names></name><name name-style="western"><surname>Bealer</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Ross</surname><given-names>BC</given-names></name><name name-style="western"><surname>Jeruss</surname><given-names>JS</given-names></name><name name-style="western"><surname>Shea</surname><given-names>LD</given-names></name></person-group><article-title>An engineered niche delineates metastatic potential of breast cancer</article-title><source>Bioeng Transl Med</source><year>2024</year><volume>9</volume><fpage>e10606</fpage><pub-id pub-id-type="doi">10.1002/btm2.10606</pub-id><pub-id pub-id-type="pmid">38193115</pub-id><pub-id pub-id-type="pmcid">PMC10771563</pub-id></element-citation><mixed-citation id="mc-CR271" publication-type="journal">Orbach SM, DeVaull CY, Bealer EJ, Ross BC, Jeruss JS, Shea LD. An engineered niche delineates metastatic potential of breast cancer. Bioeng Transl Med. 2024;9: e10606.<pub-id pub-id-type="pmid">38193115</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/btm2.10606</pub-id><pub-id pub-id-type="pmcid">PMC10771563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR272"><label>272</label><mixed-citation publication-type="other">K. Wu, Y. Li, Y. Ji, C. Liu, X. Wang, H. Guo, J. Zhang, Y. He, Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung. <italic toggle="yes">Cancer Immunol Res</italic>, OF1-OF19 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-23-0221</pub-id><pub-id pub-id-type="pmid">38215051</pub-id></mixed-citation></ref><ref id="CR273"><label>273</label><citation-alternatives><element-citation id="ec-CR273" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>B</given-names></name><name name-style="western"><surname>Jing</surname><given-names>R</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Rao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qi</surname><given-names>H</given-names></name><name name-style="western"><surname>Guo</surname><given-names>H</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H</given-names></name></person-group><article-title>Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models</article-title><source>J Hepatol</source><year>2017</year><volume>67</volume><fpage>739</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.05.019</pub-id><pub-id pub-id-type="pmid">28549917</pub-id></element-citation><mixed-citation id="mc-CR273" publication-type="journal">Lu Z, Zuo B, Jing R, Gao X, Rao Q, Liu Z, Qi H, Guo H, Yin H. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models. J Hepatol. 2017;67:739&#8211;48.<pub-id pub-id-type="pmid">28549917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2017.05.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR274"><label>274</label><citation-alternatives><element-citation id="ec-CR274" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>S</given-names></name><name name-style="western"><surname>Whitt</surname><given-names>AG</given-names></name><name name-style="western"><surname>Stamp</surname><given-names>BF</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Yaddanapudi</surname><given-names>K</given-names></name></person-group><article-title>Exosome-based cancer vaccine for prevention of lung cancer</article-title><source>Stem Cell Investig</source><year>2023</year><volume>10</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.21037/sci-2022-030</pub-id><pub-id pub-id-type="pmid">36742283</pub-id><pub-id pub-id-type="pmcid">PMC9892015</pub-id></element-citation><mixed-citation id="mc-CR274" publication-type="journal">Meng S, Whitt AG, Stamp BF, Eaton JW, Li C, Yaddanapudi K. Exosome-based cancer vaccine for prevention of lung cancer. Stem Cell Investig. 2023;10:2.<pub-id pub-id-type="pmid">36742283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/sci-2022-030</pub-id><pub-id pub-id-type="pmcid">PMC9892015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR275"><label>275</label><citation-alternatives><element-citation id="ec-CR275" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>M</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Q</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Immunogenic hydrogel toolkit disturbing residual tumor "seeds" and pre-metastatic "soil" for inhibition of postoperative tumor recurrence and metastasis</article-title><source>Acta Pharm Sin B</source><year>2022</year><volume>12</volume><fpage>3383</fpage><lpage>3397</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2022.02.017</pub-id><pub-id pub-id-type="pmid">35967277</pub-id><pub-id pub-id-type="pmcid">PMC9366231</pub-id></element-citation><mixed-citation id="mc-CR275" publication-type="journal">Zhou M, Zuo Q, Huang Y, Li L. Immunogenic hydrogel toolkit disturbing residual tumor &#8220;seeds&#8221; and pre-metastatic &#8220;soil&#8221; for inhibition of postoperative tumor recurrence and metastasis. Acta Pharm Sin B. 2022;12:3383&#8211;97.<pub-id pub-id-type="pmid">35967277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.02.017</pub-id><pub-id pub-id-type="pmcid">PMC9366231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR276"><label>276</label><citation-alternatives><element-citation id="ec-CR276" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rygiel</surname><given-names>KA</given-names></name><name name-style="western"><surname>Drozd</surname><given-names>M</given-names></name><name name-style="western"><surname>Bulas</surname><given-names>L</given-names></name></person-group><article-title>Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient's needs and goals</article-title><source>Arch Med Sci</source><year>2017</year><volume>13</volume><fpage>1483</fpage><lpage>1492</lpage><pub-id pub-id-type="doi">10.5114/aoms.2016.60509</pub-id><pub-id pub-id-type="pmid">29181081</pub-id><pub-id pub-id-type="pmcid">PMC5701682</pub-id></element-citation><mixed-citation id="mc-CR276" publication-type="journal">Rygiel KA, Drozd M, Bulas L. Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient&#8217;s needs and goals. Arch Med Sci. 2017;13:1483&#8211;92.<pub-id pub-id-type="pmid">29181081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5114/aoms.2016.60509</pub-id><pub-id pub-id-type="pmcid">PMC5701682</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR277"><label>277</label><citation-alternatives><element-citation id="ec-CR277" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D</given-names></name><name name-style="western"><surname>Qin</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D</given-names></name><name name-style="western"><surname>Vinters</surname><given-names>HV</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>E</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>G</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y</given-names></name><name name-style="western"><surname>Martinez-Maza</surname><given-names>O</given-names></name><name name-style="western"><surname>Widney</surname><given-names>D</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ISY</given-names></name><name name-style="western"><surname>Kamata</surname><given-names>M</given-names></name></person-group><article-title>Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice</article-title><source>Nat Biomed Eng</source><year>2019</year><volume>3</volume><fpage>706</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1038/s41551-019-0434-z</pub-id><pub-id pub-id-type="pmid">31384008</pub-id><pub-id pub-id-type="pmcid">PMC6736720</pub-id></element-citation><mixed-citation id="mc-CR277" publication-type="journal">Wen J, Wu D, Qin M, Liu C, Wang L, Xu D, Vinters HV, Liu Y, Kranz E, Guan X, Sun G, Sun X, Lee Y, Martinez-Maza O, Widney D, Lu Y, Chen ISY, Kamata M. Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. Nat Biomed Eng. 2019;3:706&#8211;16.<pub-id pub-id-type="pmid">31384008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41551-019-0434-z</pub-id><pub-id pub-id-type="pmcid">PMC6736720</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR278"><label>278</label><citation-alternatives><element-citation id="ec-CR278" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>L</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>He</surname><given-names>Q</given-names></name></person-group><article-title>Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes</article-title><source>J Control Release</source><year>2018</year><volume>292</volume><fpage>67</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.04.053</pub-id><pub-id pub-id-type="pmid">29723611</pub-id></element-citation><mixed-citation id="mc-CR278" publication-type="journal">Mei L, Rao J, Liu Y, Li M, Zhang Z, He Q. Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes. J Control Release. 2018;292:67&#8211;77.<pub-id pub-id-type="pmid">29723611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.04.053</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR279"><label>279</label><citation-alternatives><element-citation id="ec-CR279" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Luo</surname><given-names>YL</given-names></name><name name-style="western"><surname>Xu</surname><given-names>CF</given-names></name><name name-style="western"><surname>Du</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Du</surname><given-names>JZ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Enhanced primary tumor penetration facilitates nanoparticle draining into lymph nodes after systemic injection for tumor metastasis inhibition</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>8648</fpage><lpage>8658</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b03472</pub-id><pub-id pub-id-type="pmid">31328920</pub-id></element-citation><mixed-citation id="mc-CR279" publication-type="journal">Liu J, Li HJ, Luo YL, Xu CF, Du XJ, Du JZ, Wang J. Enhanced primary tumor penetration facilitates nanoparticle draining into lymph nodes after systemic injection for tumor metastasis inhibition. ACS Nano. 2019;13:8648&#8211;58.<pub-id pub-id-type="pmid">31328920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.9b03472</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR280"><label>280</label><citation-alternatives><element-citation id="ec-CR280" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N</given-names></name><name name-style="western"><surname>He</surname><given-names>H</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name></person-group><article-title>A booster for radiofrequency ablation: advanced adjuvant therapy via in situ nanovaccine synergized with anti-programmed death ligand 1 immunotherapy for systemically constraining hepatocellular carcinoma</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>19441</fpage><lpage>19458</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c08064</pub-id><pub-id pub-id-type="pmid">37733578</pub-id></element-citation><mixed-citation id="mc-CR280" publication-type="journal">Tian Z, Hu Q, Sun Z, Wang N, He H, Tang Z, Chen W. A booster for radiofrequency ablation: advanced adjuvant therapy via in situ nanovaccine synergized with anti-programmed death ligand 1 immunotherapy for systemically constraining hepatocellular carcinoma. ACS Nano. 2023;17:19441&#8211;58.<pub-id pub-id-type="pmid">37733578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c08064</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR281"><label>281</label><citation-alternatives><element-citation id="ec-CR281" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitt</surname><given-names>JM</given-names></name><name name-style="western"><surname>Andr&#233;</surname><given-names>F</given-names></name><name name-style="western"><surname>Amigorena</surname><given-names>S</given-names></name><name name-style="western"><surname>Soria</surname><given-names>JC</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L</given-names></name></person-group><article-title>Dendritic cell-derived exosomes for cancer therapy</article-title><source>J Clin Investig</source><year>2016</year><volume>126</volume><fpage>1224</fpage><lpage>1232</lpage><pub-id pub-id-type="doi">10.1172/JCI81137</pub-id><pub-id pub-id-type="pmid">27035813</pub-id><pub-id pub-id-type="pmcid">PMC4811123</pub-id></element-citation><mixed-citation id="mc-CR281" publication-type="journal">Pitt JM, Andr&#233; F, Amigorena S, Soria JC, Eggermont A, Kroemer G, Zitvogel L. Dendritic cell-derived exosomes for cancer therapy. J Clin Investig. 2016;126:1224&#8211;32.<pub-id pub-id-type="pmid">27035813</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI81137</pub-id><pub-id pub-id-type="pmcid">PMC4811123</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR282"><label>282</label><citation-alternatives><element-citation id="ec-CR282" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>QT</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sun</surname><given-names>SN</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T</given-names></name><name name-style="western"><surname>Han</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>JQ</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>YP</given-names></name><name name-style="western"><surname>Fan</surname><given-names>YY</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>XH</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>BB</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>SY</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>He</surname><given-names>YW</given-names></name></person-group><article-title>Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients</article-title><source>Cancer Immunol, Immunotherapy : CII</source><year>2020</year><volume>69</volume><fpage>1375</fpage><lpage>1387</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02496-w</pub-id><pub-id pub-id-type="pmid">32078016</pub-id><pub-id pub-id-type="pmcid">PMC11027674</pub-id></element-citation><mixed-citation id="mc-CR282" publication-type="journal">Wang QT, Nie Y, Sun SN, Lin T, Han RJ, Jiang J, Li Z, Li JQ, Xiao YP, Fan YY, Yuan XH, Zhang H, Zhao BB, Zeng M, Li SY, Liao HX, Zhang J, He YW. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol, Immunotherapy&#8239;: CII. 2020;69:1375&#8211;87.<pub-id pub-id-type="pmid">32078016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-020-02496-w</pub-id><pub-id pub-id-type="pmcid">PMC11027674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR283"><label>283</label><citation-alternatives><element-citation id="ec-CR283" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>JL</given-names></name><name name-style="western"><surname>Omofoye</surname><given-names>OA</given-names></name><name name-style="western"><surname>Rudnick</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Tighiouart</surname><given-names>M</given-names></name><name name-style="western"><surname>Phuphanich</surname><given-names>S</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Mazer</surname><given-names>M</given-names></name><name name-style="western"><surname>Ganaway</surname><given-names>T</given-names></name><name name-style="western"><surname>Chu</surname><given-names>RM</given-names></name><name name-style="western"><surname>Patil</surname><given-names>CG</given-names></name><name name-style="western"><surname>Black</surname><given-names>KL</given-names></name><name name-style="western"><surname>Shiao</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>JS</given-names></name></person-group><article-title>A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma</article-title><source>Clinical Cancer Res : Off J Am Assoc Cancer Res</source><year>2022</year><volume>28</volume><fpage>689</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-2867</pub-id><pub-id pub-id-type="pmid">34862245</pub-id></element-citation><mixed-citation id="mc-CR283" publication-type="journal">Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS. A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clinical Cancer Res&#8239;: Off J Am Assoc Cancer Res. 2022;28:689&#8211;96.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-21-2867</pub-id><pub-id pub-id-type="pmid">34862245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR284"><label>284</label><citation-alternatives><element-citation id="ec-CR284" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;nchez Ram&#237;rez</surname><given-names>J</given-names></name><name name-style="western"><surname>Morera D&#237;az</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bequet-Romero</surname><given-names>M</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Bernal</surname><given-names>F</given-names></name><name name-style="western"><surname>Mart&#237;n Bauta</surname><given-names>Y</given-names></name><name name-style="western"><surname>Selman-Housein Bernal</surname><given-names>KH</given-names></name><name name-style="western"><surname>de la Torre Santos</surname><given-names>AV</given-names></name><name name-style="western"><surname>P&#233;rez de la Iglesia</surname><given-names>M</given-names></name><name name-style="western"><surname>Trimi&#241;o Lorenzo</surname><given-names>L</given-names></name><name name-style="western"><surname>Ayala Avila</surname><given-names>M</given-names></name></person-group><article-title>Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program</article-title><source>BMC Immunol</source><year>2020</year><volume>21</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/s12865-020-0338-4</pub-id><pub-id pub-id-type="pmid">32171254</pub-id><pub-id pub-id-type="pmcid">PMC7071683</pub-id></element-citation><mixed-citation id="mc-CR284" publication-type="journal">S&#225;nchez Ram&#237;rez J, Morera D&#237;az Y, Bequet-Romero M, Hern&#225;ndez-Bernal F, Mart&#237;n Bauta Y, Selman-Housein Bernal KH, de la Torre Santos AV, P&#233;rez de la Iglesia M, Trimi&#241;o Lorenzo L, Ayala Avila M. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. BMC Immunol. 2020;21:12.<pub-id pub-id-type="pmid">32171254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12865-020-0338-4</pub-id><pub-id pub-id-type="pmcid">PMC7071683</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR285"><label>285</label><citation-alternatives><element-citation id="ec-CR285" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMaria</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Lee-Wisdom</surname><given-names>K</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>RN</given-names></name><name name-style="western"><surname>Madan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Karzai</surname><given-names>F</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>A</given-names></name><name name-style="western"><surname>Palena</surname><given-names>C</given-names></name><name name-style="western"><surname>Jochems</surname><given-names>C</given-names></name><name name-style="western"><surname>Floudas</surname><given-names>C</given-names></name><name name-style="western"><surname>Strauss</surname><given-names>J</given-names></name><name name-style="western"><surname>Mart&#233;</surname><given-names>JL</given-names></name><name name-style="western"><surname>Redman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Dombi</surname><given-names>E</given-names></name><name name-style="western"><surname>Widemann</surname><given-names>B</given-names></name><name name-style="western"><surname>Korchin</surname><given-names>B</given-names></name><name name-style="western"><surname>Adams</surname><given-names>T</given-names></name><name name-style="western"><surname>Pico-Navarro</surname><given-names>C</given-names></name><name name-style="western"><surname>Heery</surname><given-names>C</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J</given-names></name><name name-style="western"><surname>Bilusic</surname><given-names>M</given-names></name></person-group><article-title>Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer</article-title><source>J Immunotherapy Cancer</source><year>2021</year><volume>9</volume><fpage>e003238</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-003238</pub-id><pub-id pub-id-type="pmcid">PMC8420671</pub-id><pub-id pub-id-type="pmid">34479925</pub-id></element-citation><mixed-citation id="mc-CR285" publication-type="journal">DeMaria PJ, Lee-Wisdom K, Donahue RN, Madan RA, Karzai F, Schwab A, Palena C, Jochems C, Floudas C, Strauss J, Mart&#233; JL, Redman JM, Dombi E, Widemann B, Korchin B, Adams T, Pico-Navarro C, Heery C, Schlom J, Bilusic M. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. J Immunotherapy Cancer. 2021;9:e003238.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-003238</pub-id><pub-id pub-id-type="pmcid">PMC8420671</pub-id><pub-id pub-id-type="pmid">34479925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR286"><label>286</label><citation-alternatives><element-citation id="ec-CR286" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMaria</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Lee-Wisdom</surname><given-names>K</given-names></name><name name-style="western"><surname>Donahue</surname><given-names>RN</given-names></name><name name-style="western"><surname>Madan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Karzai</surname><given-names>F</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>A</given-names></name><name name-style="western"><surname>Palena</surname><given-names>C</given-names></name><name name-style="western"><surname>Jochems</surname><given-names>C</given-names></name><name name-style="western"><surname>Floudas</surname><given-names>C</given-names></name><name name-style="western"><surname>Strauss</surname><given-names>J</given-names></name><name name-style="western"><surname>Marte</surname><given-names>JL</given-names></name><name name-style="western"><surname>Redman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Dombi</surname><given-names>E</given-names></name><name name-style="western"><surname>Widemann</surname><given-names>B</given-names></name><name name-style="western"><surname>Korchin</surname><given-names>B</given-names></name><name name-style="western"><surname>Adams</surname><given-names>T</given-names></name><name name-style="western"><surname>Pico-Navarro</surname><given-names>C</given-names></name><name name-style="western"><surname>Heery</surname><given-names>C</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J</given-names></name><name name-style="western"><surname>Bilusic</surname><given-names>M</given-names></name></person-group><article-title>Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer</article-title><source>J Immunotherapy Cancer</source><year>2021</year><volume>9</volume><fpage>e003238</fpage><lpage>e003238</lpage><pub-id pub-id-type="doi">10.1136/jitc-2021-003238</pub-id><pub-id pub-id-type="pmcid">PMC8420671</pub-id><pub-id pub-id-type="pmid">34479925</pub-id></element-citation><mixed-citation id="mc-CR286" publication-type="journal">DeMaria PJ, Lee-Wisdom K, Donahue RN, Madan RA, Karzai F, Schwab A, Palena C, Jochems C, Floudas C, Strauss J, Marte JL, Redman JM, Dombi E, Widemann B, Korchin B, Adams T, Pico-Navarro C, Heery C, Schlom J, Bilusic M. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. J Immunotherapy Cancer. 2021;9:e003238&#8211;e003238.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-003238</pub-id><pub-id pub-id-type="pmcid">PMC8420671</pub-id><pub-id pub-id-type="pmid">34479925</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR287"><label>287</label><citation-alternatives><element-citation id="ec-CR287" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>LA</given-names></name><name name-style="western"><surname>Sethna</surname><given-names>Z</given-names></name><name name-style="western"><surname>Soares</surname><given-names>KC</given-names></name><name name-style="western"><surname>Olcese</surname><given-names>C</given-names></name><name name-style="western"><surname>Pang</surname><given-names>N</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>E</given-names></name><name name-style="western"><surname>Lihm</surname><given-names>J</given-names></name><name name-style="western"><surname>Ceglia</surname><given-names>N</given-names></name><name name-style="western"><surname>Guasp</surname><given-names>P</given-names></name><name name-style="western"><surname>Chu</surname><given-names>A</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>AK</given-names></name><name name-style="western"><surname>Waters</surname><given-names>T</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>J</given-names></name><name name-style="western"><surname>Amisaki</surname><given-names>M</given-names></name><name name-style="western"><surname>Zebboudj</surname><given-names>A</given-names></name><name name-style="western"><surname>Odgerel</surname><given-names>Z</given-names></name><name name-style="western"><surname>Payne</surname><given-names>G</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>VP</given-names></name></person-group><article-title>Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer</article-title><source>Nature</source><year>2023</year><volume>618</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></element-citation><mixed-citation id="mc-CR287" publication-type="journal">Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Yu R, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144&#8211;50.<pub-id pub-id-type="pmid">37165196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06063-y</pub-id><pub-id pub-id-type="pmcid">PMC10171177</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR288"><label>288</label><citation-alternatives><element-citation id="ec-CR288" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>JS</given-names></name><name name-style="western"><surname>Carlino</surname><given-names>MS</given-names></name><name name-style="western"><surname>Khattak</surname><given-names>A</given-names></name><name name-style="western"><surname>Meniawy</surname><given-names>T</given-names></name><name name-style="western"><surname>Ansstas</surname><given-names>G</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KB</given-names></name><name name-style="western"><surname>McKean</surname><given-names>M</given-names></name><name name-style="western"><surname>Long</surname><given-names>GV</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Faries</surname><given-names>M</given-names></name></person-group><article-title>Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study</article-title><source>Lancet</source><year>2024</year><volume>403</volume><issue>10427</issue><fpage>632</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)02268-7</pub-id><pub-id pub-id-type="pmid">38246194</pub-id></element-citation><mixed-citation id="mc-CR288" publication-type="journal">Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632&#8211;44.<pub-id pub-id-type="pmid">38246194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)02268-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR289"><label>289</label><citation-alternatives><element-citation id="ec-CR289" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srikrishna</surname><given-names>D</given-names></name><name name-style="western"><surname>Sachsenmeier</surname><given-names>K</given-names></name></person-group><article-title>We need to bring R0 &lt; 1 to treat cancer too</article-title><source>Genome medicine</source><year>2021</year><volume>13</volume><fpage>120</fpage><pub-id pub-id-type="doi">10.1186/s13073-021-00940-9</pub-id><pub-id pub-id-type="pmid">34311780</pub-id><pub-id pub-id-type="pmcid">PMC8312206</pub-id></element-citation><mixed-citation id="mc-CR289" publication-type="journal">Srikrishna D, Sachsenmeier K. We need to bring R0 &lt; 1 to treat cancer too. Genome medicine. 2021;13:120.<pub-id pub-id-type="pmid">34311780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-021-00940-9</pub-id><pub-id pub-id-type="pmcid">PMC8312206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR290"><label>290</label><citation-alternatives><element-citation id="ec-CR290" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Pang</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ren</surname><given-names>E</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lv</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name></person-group><article-title>A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy</article-title><source>Nat Nanotechnol</source><year>2022</year><volume>17</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1038/s41565-022-01098-0</pub-id><pub-id pub-id-type="pmid">35410368</pub-id></element-citation><mixed-citation id="mc-CR290" publication-type="journal">Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, Ren E, Zhang L, Liu X, Lv P, Wang X, Luo W, Xia N, Chen X, Liu G. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol. 2022;17:531&#8211;40.<pub-id pub-id-type="pmid">35410368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-022-01098-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR291"><label>291</label><citation-alternatives><element-citation id="ec-CR291" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>LG</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Reichow</surname><given-names>JL</given-names></name><name name-style="western"><surname>Childs</surname><given-names>JS</given-names></name><name name-style="western"><surname>Coveler</surname><given-names>AL</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>DM</given-names></name><name name-style="western"><surname>Waisman</surname><given-names>J</given-names></name><name name-style="western"><surname>Allison</surname><given-names>KH</given-names></name><name name-style="western"><surname>Dang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Disis</surname><given-names>ML</given-names></name></person-group><article-title>Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial</article-title><source>JAMA Oncol</source><year>2017</year><volume>3</volume><fpage>969</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.6007</pub-id><pub-id pub-id-type="pmid">28114604</pub-id><pub-id pub-id-type="pmcid">PMC5824239</pub-id></element-citation><mixed-citation id="mc-CR291" publication-type="journal">Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, Waisman J, Allison KH, Dang Y, Disis ML. Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial. JAMA Oncol. 2017;3:969&#8211;73.<pub-id pub-id-type="pmid">28114604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2016.6007</pub-id><pub-id pub-id-type="pmcid">PMC5824239</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR292"><label>292</label><citation-alternatives><element-citation id="ec-CR292" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alyamani</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>F</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M</given-names></name><name name-style="western"><surname>Przybycin</surname><given-names>C</given-names></name><name name-style="western"><surname>Posadas</surname><given-names>EM</given-names></name><name name-style="western"><surname>Madan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gulley</surname><given-names>JL</given-names></name><name name-style="western"><surname>Rini</surname><given-names>B</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>JA</given-names></name><name name-style="western"><surname>Klein</surname><given-names>EA</given-names></name><name name-style="western"><surname>Sharifi</surname><given-names>N</given-names></name></person-group><article-title>Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure</article-title><source>Annals Oncol : Off J European Soc Med Oncol</source><year>2020</year><volume>31</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2019.12.002</pub-id><pub-id pub-id-type="pmcid">PMC7460727</pub-id><pub-id pub-id-type="pmid">32057540</pub-id></element-citation><mixed-citation id="mc-CR292" publication-type="journal">Alyamani M, Li J, Patel M, Taylor S, Nakamura F, Berk M, Przybycin C, Posadas EM, Madan RA, Gulley JL, Rini B, Garcia JA, Klein EA, Sharifi N. Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. Annals Oncol&#8239;: Off J European Soc Med Oncol. 2020;31:369&#8211;76.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2019.12.002</pub-id><pub-id pub-id-type="pmcid">PMC7460727</pub-id><pub-id pub-id-type="pmid">32057540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR293"><label>293</label><citation-alternatives><element-citation id="ec-CR293" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>KT</given-names></name><name name-style="western"><surname>Karzai</surname><given-names>F</given-names></name><name name-style="western"><surname>Bilusic</surname><given-names>M</given-names></name><name name-style="western"><surname>Cordes</surname><given-names>LM</given-names></name><name name-style="western"><surname>Chau</surname><given-names>CH</given-names></name><name name-style="western"><surname>Peer</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Wroblewski</surname><given-names>S</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>ADR</given-names></name><name name-style="western"><surname>Schellens</surname><given-names>JHM</given-names></name><name name-style="western"><surname>Gulley</surname><given-names>JL</given-names></name><name name-style="western"><surname>Dahut</surname><given-names>WL</given-names></name><name name-style="western"><surname>Figg</surname><given-names>WD</given-names></name><name name-style="western"><surname>Madan</surname><given-names>RA</given-names></name></person-group><article-title>A single-arm phase II study combining NLG207, a nanoparticle camptothecin, with enzalutamide in advanced metastatic castration-resistant prostate cancer post-enzalutamide</article-title><source>Oncologist</source><year>2022</year><volume>27</volume><fpage>718</fpage><lpage>e694</lpage><pub-id pub-id-type="doi">10.1093/oncolo/oyac100</pub-id><pub-id pub-id-type="pmid">35640474</pub-id><pub-id pub-id-type="pmcid">PMC9438911</pub-id></element-citation><mixed-citation id="mc-CR293" publication-type="journal">Schmidt KT, Karzai F, Bilusic M, Cordes LM, Chau CH, Peer CJ, Wroblewski S, Huitema ADR, Schellens JHM, Gulley JL, Dahut WL, Figg WD, Madan RA. A single-arm phase II study combining NLG207, a nanoparticle camptothecin, with enzalutamide in advanced metastatic castration-resistant prostate cancer post-enzalutamide. Oncologist. 2022;27:718-e694.<pub-id pub-id-type="pmid">35640474</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oncolo/oyac100</pub-id><pub-id pub-id-type="pmcid">PMC9438911</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR294"><label>294</label><citation-alternatives><element-citation id="ec-CR294" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>N</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name></person-group><article-title>Normalizing the immune macroenvironment via debulking surgery to strengthen tumor nanovaccine efficacy and eliminate metastasis</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>437</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1021/acsnano.2c08880</pub-id><pub-id pub-id-type="pmid">36534945</pub-id></element-citation><mixed-citation id="mc-CR294" publication-type="journal">Ma N, Chen Z, Liu G, Yue Y, Li Y, Cheng K, Ma X, Feng Q, Liang J, Zhang T, Gao X, Wang X, Guo X, Zhu F, Nie G, Zhao X. Normalizing the immune macroenvironment via debulking surgery to strengthen tumor nanovaccine efficacy and eliminate metastasis. ACS Nano. 2023;17:437&#8211;52.<pub-id pub-id-type="pmid">36534945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c08880</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR295"><label>295</label><citation-alternatives><element-citation id="ec-CR295" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J</given-names></name><name name-style="western"><surname>Hanqing Qian</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>HS</given-names></name><name name-style="western"><surname>Cen</surname><given-names>L</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M</given-names></name><name name-style="western"><surname>Qiuping</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Lixia</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name></person-group><article-title>Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high&#8208;risk gastric/gastroesophageal junction cancer</article-title><source>Adv Sci</source><year>2022</year><volume>10</volume><issue>1</issue><fpage>e2203298</fpage><pub-id pub-id-type="doi">10.1002/advs.202203298</pub-id><pub-id pub-id-type="pmcid">PMC9811442</pub-id><pub-id pub-id-type="pmid">36351249</pub-id></element-citation><mixed-citation id="mc-CR295" publication-type="journal">Liu Q, Chu Y, Shao J, Hanqing Qian J, Yang HS, Cen L, Tian M, Qiuping X, Chen F, Yang Y, Wang W, Wang K, Lixia Y, Wei J, Liu B. Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high&#8208;risk gastric/gastroesophageal junction cancer. Adv Sci. 2022;10(1):e2203298. 10.1002/advs.202203298.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202203298</pub-id><pub-id pub-id-type="pmcid">PMC9811442</pub-id><pub-id pub-id-type="pmid">36351249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR296"><label>296</label><citation-alternatives><element-citation id="ec-CR296" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Nanovaccines with cell-derived components for cancer immunotherapy</article-title><source>Adv Drug Deliv Rev</source><year>2022</year><volume>182</volume><fpage>114107</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.114107</pub-id><pub-id pub-id-type="pmid">34995678</pub-id></element-citation><mixed-citation id="mc-CR296" publication-type="journal">Meng Z, Zhang Y, Zhou X, Ji J, Liu Z. Nanovaccines with cell-derived components for cancer immunotherapy. Adv Drug Deliv Rev. 2022;182: 114107.<pub-id pub-id-type="pmid">34995678</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.114107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR297"><label>297</label><citation-alternatives><element-citation id="ec-CR297" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dai</surname><given-names>R</given-names></name><name name-style="western"><surname>Roche</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Min</surname><given-names>Y</given-names></name></person-group><article-title>Chemotherapy-induced neoantigen nanovaccines enhance checkpoint blockade cancer immunotherapy</article-title><source>ACS Nano</source><year>2023</year><volume>17</volume><fpage>18818</fpage><lpage>18831</lpage><pub-id pub-id-type="doi">10.1021/acsnano.3c03274</pub-id><pub-id pub-id-type="pmid">37750443</pub-id></element-citation><mixed-citation id="mc-CR297" publication-type="journal">Chen G, Li X, Li R, Wu K, Lei Z, Dai R, Roche K, Wang AZ, Min Y. Chemotherapy-induced neoantigen nanovaccines enhance checkpoint blockade cancer immunotherapy. ACS Nano. 2023;17:18818&#8211;31.<pub-id pub-id-type="pmid">37750443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c03274</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR298"><label>298</label><citation-alternatives><element-citation id="ec-CR298" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Fusciello</surname><given-names>M</given-names></name><name name-style="western"><surname>Groeneveldt</surname><given-names>C</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiaro</surname><given-names>J</given-names></name><name name-style="western"><surname>Feola</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Makila</surname><given-names>EM</given-names></name><name name-style="western"><surname>Salonen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Hirvonen</surname><given-names>JT</given-names></name><name name-style="western"><surname>Cerullo</surname><given-names>V</given-names></name><name name-style="western"><surname>Santos</surname><given-names>HA</given-names></name></person-group><article-title>Biohybrid vaccines for improved treatment of aggressive melanoma with checkpoint inhibitor</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>6477</fpage><lpage>6490</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b09613</pub-id><pub-id pub-id-type="pmid">31100004</pub-id><pub-id pub-id-type="pmcid">PMC6595659</pub-id></element-citation><mixed-citation id="mc-CR298" publication-type="journal">Fontana F, Fusciello M, Groeneveldt C, Capasso C, Chiaro J, Feola S, Liu Z, Makila EM, Salonen JJ, Hirvonen JT, Cerullo V, Santos HA. Biohybrid vaccines for improved treatment of aggressive melanoma with checkpoint inhibitor. ACS Nano. 2019;13:6477&#8211;90.<pub-id pub-id-type="pmid">31100004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.8b09613</pub-id><pub-id pub-id-type="pmcid">PMC6595659</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR299"><label>299</label><citation-alternatives><element-citation id="ec-CR299" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name></person-group><article-title>Hybrid membrane nanovaccines combined with immune checkpoint blockade to enhance cancer immunotherapy</article-title><source>Int J Nanomedicine</source><year>2022</year><volume>17</volume><fpage>73</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2147/IJN.S346044</pub-id><pub-id pub-id-type="pmid">35027827</pub-id><pub-id pub-id-type="pmcid">PMC8752078</pub-id></element-citation><mixed-citation id="mc-CR299" publication-type="journal">Zhao P, Xu Y, Ji W, Li L, Qiu L, Zhou S, Qian Z, Zhang H. Hybrid membrane nanovaccines combined with immune checkpoint blockade to enhance cancer immunotherapy. Int J Nanomedicine. 2022;17:73&#8211;89.<pub-id pub-id-type="pmid">35027827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S346044</pub-id><pub-id pub-id-type="pmcid">PMC8752078</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR300"><label>300</label><citation-alternatives><element-citation id="ec-CR300" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterfield</surname><given-names>LH</given-names></name><name name-style="western"><surname>Najjar</surname><given-names>YG</given-names></name></person-group><article-title>Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations</article-title><source>Nat Rev Immunol</source><year>2024</year><volume>24</volume><fpage>399</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/s41577-023-00973-8</pub-id><pub-id pub-id-type="pmid">38057451</pub-id><pub-id pub-id-type="pmcid">PMC11460566</pub-id></element-citation><mixed-citation id="mc-CR300" publication-type="journal">Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol. 2024;24:399&#8211;416.<pub-id pub-id-type="pmid">38057451</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-023-00973-8</pub-id><pub-id pub-id-type="pmcid">PMC11460566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR301"><label>301</label><citation-alternatives><element-citation id="ec-CR301" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picon</surname><given-names>MA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Da Fonseca Ferreira</surname><given-names>A</given-names></name><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name><name name-style="western"><surname>Marzouka</surname><given-names>GR</given-names></name></person-group><article-title>Extracellular vesicles as delivery systems in disease therapy</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>24</issue><fpage>17134</fpage><pub-id pub-id-type="doi">10.3390/ijms242417134</pub-id><pub-id pub-id-type="pmid">38138963</pub-id><pub-id pub-id-type="pmcid">PMC10742668</pub-id></element-citation><mixed-citation id="mc-CR301" publication-type="journal">Picon MA, Wang L, Da Fonseca Ferreira A, Dong C, Marzouka GR. Extracellular vesicles as delivery systems in disease therapy. Int J Mol Sci. 2023;24(24):17134.<pub-id pub-id-type="pmid">38138963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms242417134</pub-id><pub-id pub-id-type="pmcid">PMC10742668</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR302"><label>302</label><citation-alternatives><element-citation id="ec-CR302" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>X</given-names></name></person-group><article-title>Outer membrane vesicles from acinetobacter baumannii: biogenesis, functions, and vaccine application</article-title><source>Vaccines</source><year>2023</year><volume>12</volume><issue>1</issue><fpage>49</fpage><pub-id pub-id-type="doi">10.3390/vaccines12010049</pub-id><pub-id pub-id-type="pmid">38250862</pub-id><pub-id pub-id-type="pmcid">PMC10818702</pub-id></element-citation><mixed-citation id="mc-CR302" publication-type="journal">Weng Z, Yang N, Shi S, Xu Z, Chen Z, Liang C, Zhang X, Du X. Outer membrane vesicles from acinetobacter baumannii: biogenesis, functions, and vaccine application. Vaccines. 2023;12(1):49.<pub-id pub-id-type="pmid">38250862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines12010049</pub-id><pub-id pub-id-type="pmcid">PMC10818702</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR303"><label>303</label><citation-alternatives><element-citation id="ec-CR303" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bao</surname><given-names>W</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W</given-names></name></person-group><article-title>Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><fpage>4505</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40207-y</pub-id><pub-id pub-id-type="pmid">37495590</pub-id><pub-id pub-id-type="pmcid">PMC10372023</pub-id></element-citation><mixed-citation id="mc-CR303" publication-type="journal">Meng J, Lv Y, Bao W, Meng Z, Wang S, Wu Y, Li S, Jiao Z, Tian Z, Ma G, Wei W. Generation of whole tumor cell vaccine for on-demand manipulation of immune responses against cancer under near-infrared laser irradiation. Nat Commun. 2023;14:4505.<pub-id pub-id-type="pmid">37495590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-40207-y</pub-id><pub-id pub-id-type="pmcid">PMC10372023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR304"><label>304</label><citation-alternatives><element-citation id="ec-CR304" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Engineering nanoscale artificial antigen-presenting cells by metabolic dendritic cell labeling to potentiate cancer immunotherapy</article-title><source>Nano Lett</source><year>2021</year><volume>21</volume><fpage>2094</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c04783</pub-id><pub-id pub-id-type="pmid">33622034</pub-id></element-citation><mixed-citation id="mc-CR304" publication-type="journal">Xiao P, Wang J, Zhao Z, Liu X, Sun X, Wang D, Li Y. Engineering nanoscale artificial antigen-presenting cells by metabolic dendritic cell labeling to potentiate cancer immunotherapy. Nano Lett. 2021;21:2094&#8211;103.<pub-id pub-id-type="pmid">33622034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.0c04783</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR305"><label>305</label><citation-alternatives><element-citation id="ec-CR305" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Facciponte</surname><given-names>JG</given-names></name><name name-style="western"><surname>Ugel</surname><given-names>S</given-names></name><name name-style="western"><surname>De Sanctis</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Nair</surname><given-names>G</given-names></name><name name-style="western"><surname>Sehgal</surname><given-names>S</given-names></name><name name-style="western"><surname>Raj</surname><given-names>A</given-names></name><name name-style="western"><surname>Matthaiou</surname><given-names>E</given-names></name><name name-style="western"><surname>Coukos</surname><given-names>G</given-names></name><name name-style="western"><surname>Facciabene</surname><given-names>A</given-names></name></person-group><article-title>Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><fpage>1497</fpage><lpage>1511</lpage><pub-id pub-id-type="doi">10.1172/JCI67382</pub-id><pub-id pub-id-type="pmid">24642465</pub-id><pub-id pub-id-type="pmcid">PMC3973096</pub-id></element-citation><mixed-citation id="mc-CR305" publication-type="journal">Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, Facciabene A. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest. 2014;124:1497&#8211;511.<pub-id pub-id-type="pmid">24642465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI67382</pub-id><pub-id pub-id-type="pmcid">PMC3973096</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR306"><label>306</label><citation-alternatives><element-citation id="ec-CR306" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>M</given-names></name><name name-style="western"><surname>Huo</surname><given-names>D</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>BZ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>JD</given-names></name></person-group><article-title>Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system</article-title><source>J Nanobiotechnol</source><year>2024</year><volume>22</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s12951-023-02273-8</pub-id><pub-id pub-id-type="pmcid">PMC10763241</pub-id><pub-id pub-id-type="pmid">38166929</pub-id></element-citation><mixed-citation id="mc-CR306" publication-type="journal">Jin M, Huo D, Sun J, Hu J, Liu S, Zhan M, Zhang BZ, Huang JD. Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system. J Nanobiotechnol. 2024;22:15.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-02273-8</pub-id><pub-id pub-id-type="pmcid">PMC10763241</pub-id><pub-id pub-id-type="pmid">38166929</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR307"><label>307</label><citation-alternatives><element-citation id="ec-CR307" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Jagodinsky</surname><given-names>JC</given-names></name><name name-style="western"><surname>Vera</surname><given-names>JM</given-names></name><name name-style="western"><surname>Clark</surname><given-names>PA</given-names></name><name name-style="western"><surname>Zuleger</surname><given-names>CL</given-names></name><name name-style="western"><surname>Erbe</surname><given-names>AK</given-names></name><name name-style="western"><surname>Ong</surname><given-names>IM</given-names></name><name name-style="western"><surname>Le</surname><given-names>T</given-names></name><name name-style="western"><surname>Tetreault</surname><given-names>K</given-names></name><name name-style="western"><surname>Berg</surname><given-names>T</given-names></name><name name-style="western"><surname>Rakhmilevich</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Newton</surname><given-names>MA</given-names></name><name name-style="western"><surname>Albertini</surname><given-names>MR</given-names></name><name name-style="western"><surname>Sondel</surname><given-names>PM</given-names></name><name name-style="western"><surname>Morris</surname><given-names>ZS</given-names></name></person-group><article-title>NK cells propagate T cell immunity following in situ tumor vaccination</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><fpage>113556</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.113556</pub-id><pub-id pub-id-type="pmid">38096050</pub-id><pub-id pub-id-type="pmcid">PMC10843551</pub-id></element-citation><mixed-citation id="mc-CR307" publication-type="journal">Jin WJ, Jagodinsky JC, Vera JM, Clark PA, Zuleger CL, Erbe AK, Ong IM, Le T, Tetreault K, Berg T, Rakhmilevich AL, Kim K, Newton MA, Albertini MR, Sondel PM, Morris ZS. NK cells propagate T cell immunity following in situ tumor vaccination. Cell Rep. 2023;42: 113556.<pub-id pub-id-type="pmid">38096050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2023.113556</pub-id><pub-id pub-id-type="pmcid">PMC10843551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR308"><label>308</label><citation-alternatives><element-citation id="ec-CR308" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>R</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>P</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>F</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kemell</surname><given-names>M</given-names></name><name name-style="western"><surname>Torrieri</surname><given-names>G</given-names></name><name name-style="western"><surname>M&#228;kil&#228;</surname><given-names>EM</given-names></name><name name-style="western"><surname>Salonen</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Hirvonen</surname><given-names>J</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Santos</surname><given-names>HA</given-names></name><name name-style="western"><surname>Xia</surname><given-names>B</given-names></name></person-group><article-title>Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors</article-title><source>Adv Mater</source><year>2022</year><volume>34</volume><fpage>e2108012</fpage><pub-id pub-id-type="doi">10.1002/adma.202108012</pub-id><pub-id pub-id-type="pmid">34877724</pub-id></element-citation><mixed-citation id="mc-CR308" publication-type="journal">Li J, Huang D, Cheng R, Figueiredo P, Fontana F, Correia A, Wang S, Liu Z, Kemell M, Torrieri G, M&#228;kil&#228; EM, Salonen JJ, Hirvonen J, Gao Y, Li J, Luo Z, Santos HA, Xia B. Multifunctional biomimetic nanovaccines based on photothermal and weak-immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors. Adv Mater. 2022;34: e2108012.<pub-id pub-id-type="pmid">34877724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202108012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR309"><label>309</label><citation-alternatives><element-citation id="ec-CR309" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hung</surname><given-names>SI</given-names></name><name name-style="western"><surname>Chu</surname><given-names>MT</given-names></name><name name-style="western"><surname>Hou</surname><given-names>MM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>YS</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CK</given-names></name><name name-style="western"><surname>Chu</surname><given-names>SY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>FY</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>HC</given-names></name><name name-style="western"><surname>Pao</surname><given-names>SC</given-names></name><name name-style="western"><surname>Teng</surname><given-names>YC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CB</given-names></name><name name-style="western"><surname>Chao</surname><given-names>A</given-names></name><name name-style="western"><surname>Chung</surname><given-names>WH</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JW</given-names></name><name name-style="western"><surname>Lai</surname><given-names>CH</given-names></name></person-group><article-title>Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>169</volume><fpage>115928</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115928</pub-id><pub-id pub-id-type="pmid">38011788</pub-id></element-citation><mixed-citation id="mc-CR309" publication-type="journal">Hung SI, Chu MT, Hou MM, Lee YS, Yang CK, Chu SY, Liu FY, Hsu HC, Pao SC, Teng YC, Chen CB, Chao A, Chung WH, Chang JW, Lai CH. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer. Biomed Pharmacother. 2023;169: 115928.<pub-id pub-id-type="pmid">38011788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.115928</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR310"><label>310</label><citation-alternatives><element-citation id="ec-CR310" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>JA</given-names></name><name name-style="western"><surname>Matta</surname><given-names>B</given-names></name><name name-style="western"><surname>Battaglia</surname><given-names>J</given-names></name><name name-style="western"><surname>Somerville</surname><given-names>C</given-names></name><name name-style="western"><surname>Harris</surname><given-names>BD</given-names></name><name name-style="western"><surname>LaPan</surname><given-names>M</given-names></name><name name-style="western"><surname>Atwal</surname><given-names>GS</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>BJ</given-names></name></person-group><article-title>Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis</article-title><source>J Immunotherapy Cancer</source><year>2023</year><volume>11</volume><issue>12</issue><fpage>e007935</fpage><pub-id pub-id-type="doi">10.1136/jitc-2023-007935</pub-id><pub-id pub-id-type="pmcid">PMC10749072</pub-id><pub-id pub-id-type="pmid">38135347</pub-id></element-citation><mixed-citation id="mc-CR310" publication-type="journal">Carter JA, Matta B, Battaglia J, Somerville C, Harris BD, LaPan M, Atwal GS, Barnes BJ. Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis. J Immunotherapy Cancer. 2023;11(12): e007935.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2023-007935</pub-id><pub-id pub-id-type="pmcid">PMC10749072</pub-id><pub-id pub-id-type="pmid">38135347</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR311"><label>311</label><citation-alternatives><element-citation id="ec-CR311" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R</given-names></name><name name-style="western"><surname>Petrik</surname><given-names>S</given-names></name><name name-style="western"><surname>Laiko</surname><given-names>M</given-names></name><name name-style="western"><surname>Leatherman</surname><given-names>JM</given-names></name><name name-style="western"><surname>Asquith</surname><given-names>JM</given-names></name><name name-style="western"><surname>Daphtary</surname><given-names>MM</given-names></name><name name-style="western"><surname>Garrett-Mayer</surname><given-names>E</given-names></name><name name-style="western"><surname>Davidson</surname><given-names>NE</given-names></name><name name-style="western"><surname>Hirt</surname><given-names>K</given-names></name><name name-style="western"><surname>Berg</surname><given-names>M</given-names></name><name name-style="western"><surname>Uram</surname><given-names>JN</given-names></name><name name-style="western"><surname>Dauses</surname><given-names>T</given-names></name><name name-style="western"><surname>Fetting</surname><given-names>J</given-names></name><name name-style="western"><surname>Duus</surname><given-names>EM</given-names></name><name name-style="western"><surname>Atay-Rosenthal</surname><given-names>S</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>AC</given-names></name><name name-style="western"><surname>Stearns</surname><given-names>V</given-names></name><name name-style="western"><surname>Emens</surname><given-names>LA</given-names></name></person-group><article-title>A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer</article-title><source>Cancer Immunol Res</source><year>2014</year><volume>2</volume><fpage>949</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0058</pub-id><pub-id pub-id-type="pmid">25116755</pub-id><pub-id pub-id-type="pmcid">PMC4211036</pub-id></element-citation><mixed-citation id="mc-CR311" publication-type="journal">Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, Atay-Rosenthal S, Ye X, Wolff AC, Stearns V, Emens LA. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014;2:949&#8211;61.<pub-id pub-id-type="pmid">25116755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2326-6066.CIR-14-0058</pub-id><pub-id pub-id-type="pmcid">PMC4211036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR312"><label>312</label><citation-alternatives><element-citation id="ec-CR312" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincent</surname><given-names>BG</given-names></name><name name-style="western"><surname>File</surname><given-names>DM</given-names></name><name name-style="western"><surname>McKinnon</surname><given-names>KP</given-names></name><name name-style="western"><surname>Moore</surname><given-names>DT</given-names></name><name name-style="western"><surname>Frelinger</surname><given-names>JA</given-names></name><name name-style="western"><surname>Collins</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>JG</given-names></name><name name-style="western"><surname>Bixby</surname><given-names>L</given-names></name><name name-style="western"><surname>Reisdorf</surname><given-names>S</given-names></name><name name-style="western"><surname>Laurie</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>YA</given-names></name><name name-style="western"><surname>Anders</surname><given-names>CK</given-names></name><name name-style="western"><surname>Collichio</surname><given-names>FA</given-names></name><name name-style="western"><surname>Muss</surname><given-names>HB</given-names></name><name name-style="western"><surname>Carey</surname><given-names>LA</given-names></name><name name-style="western"><surname>van Deventer</surname><given-names>HW</given-names></name><name name-style="western"><surname>Dees</surname><given-names>EC</given-names></name><name name-style="western"><surname>Serody</surname><given-names>JS</given-names></name></person-group><article-title>Efficacy of a dual-epitope dendritic cell vaccine as part of combined immunotherapy for HER2-expressing breast tumors</article-title><source>J Immunol Baltimore Md</source><year>2023</year><volume>1950</volume><issue>211</issue><fpage>219</fpage><lpage>228</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2300077</pub-id><pub-id pub-id-type="pmcid">PMC10315441</pub-id><pub-id pub-id-type="pmid">37204246</pub-id></element-citation><mixed-citation id="mc-CR312" publication-type="journal">Vincent BG, File DM, McKinnon KP, Moore DT, Frelinger JA, Collins EJ, Ibrahim JG, Bixby L, Reisdorf S, Laurie SJ, Park YA, Anders CK, Collichio FA, Muss HB, Carey LA, van Deventer HW, Dees EC, Serody JS. Efficacy of a dual-epitope dendritic cell vaccine as part of combined immunotherapy for HER2-expressing breast tumors. J Immunol Baltimore Md. 2023;1950(211):219&#8211;28.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.2300077</pub-id><pub-id pub-id-type="pmcid">PMC10315441</pub-id><pub-id pub-id-type="pmid">37204246</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR313"><label>313</label><citation-alternatives><element-citation id="ec-CR313" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Edil</surname><given-names>BH</given-names></name><name name-style="western"><surname>Soares</surname><given-names>KC</given-names></name><name name-style="western"><surname>El-Shami</surname><given-names>K</given-names></name><name name-style="western"><surname>Uram</surname><given-names>JN</given-names></name><name name-style="western"><surname>Judkins</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Onners</surname><given-names>B</given-names></name><name name-style="western"><surname>Laheru</surname><given-names>D</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>EM</given-names></name><name name-style="western"><surname>Schulick</surname><given-names>RD</given-names></name></person-group><article-title>A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer</article-title><source>Ann Surg Oncol</source><year>2014</year><volume>21</volume><fpage>3931</fpage><lpage>3937</lpage><pub-id pub-id-type="doi">10.1245/s10434-014-3844-x</pub-id><pub-id pub-id-type="pmid">24943235</pub-id><pub-id pub-id-type="pmcid">PMC4192092</pub-id></element-citation><mixed-citation id="mc-CR313" publication-type="journal">Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Ann Surg Oncol. 2014;21:3931&#8211;7.<pub-id pub-id-type="pmid">24943235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-014-3844-x</pub-id><pub-id pub-id-type="pmcid">PMC4192092</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR314"><label>314</label><citation-alternatives><element-citation id="ec-CR314" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>DT</given-names></name><name name-style="western"><surname>Picozzi</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Ko</surname><given-names>AH</given-names></name><name name-style="western"><surname>Wainberg</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Kindler</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang-Gillam</surname><given-names>A</given-names></name><name name-style="western"><surname>Oberstein</surname><given-names>P</given-names></name><name name-style="western"><surname>Morse</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zeh</surname><given-names>HJ</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Weekes</surname><given-names>C</given-names></name><name name-style="western"><surname>Reid</surname><given-names>T</given-names></name><name name-style="western"><surname>Borazanci</surname><given-names>E</given-names></name><name name-style="western"><surname>Crocenzi</surname><given-names>T</given-names></name><name name-style="western"><surname>LoConte</surname><given-names>NK</given-names></name><name name-style="western"><surname>Musher</surname><given-names>B</given-names></name><name name-style="western"><surname>Laheru</surname><given-names>D</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>A</given-names></name><name name-style="western"><surname>Whiting</surname><given-names>C</given-names></name><name name-style="western"><surname>Nair</surname><given-names>N</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>EM</given-names></name></person-group><article-title>Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study)</article-title><source>Clinical Cancer Res: Off J Am Assoc Cancer Res</source><year>2019</year><volume>25</volume><fpage>5493</fpage><lpage>5502</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2992</pub-id><pub-id pub-id-type="pmcid">PMC7376746</pub-id><pub-id pub-id-type="pmid">31126960</pub-id></element-citation><mixed-citation id="mc-CR314" publication-type="journal">Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ 3rd, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Jaffee EM. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clinical Cancer Res: Off J Am Assoc Cancer Res. 2019;25:5493&#8211;502.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-18-2992</pub-id><pub-id pub-id-type="pmcid">PMC7376746</pub-id><pub-id pub-id-type="pmid">31126960</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR315"><label>315</label><citation-alternatives><element-citation id="ec-CR315" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>E</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>K</given-names></name><name name-style="western"><surname>Hobeika</surname><given-names>AC</given-names></name><name name-style="western"><surname>Clay</surname><given-names>TM</given-names></name><name name-style="western"><surname>Broadwater</surname><given-names>G</given-names></name><name name-style="western"><surname>Ren</surname><given-names>XR</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><name name-style="western"><surname>Castro</surname><given-names>H</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>F</given-names></name><name name-style="western"><surname>Spector</surname><given-names>N</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Osada</surname><given-names>T</given-names></name><name name-style="western"><surname>Lyerly</surname><given-names>HK</given-names></name><name name-style="western"><surname>Morse</surname><given-names>MA</given-names></name></person-group><article-title>Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]</article-title><source>J Transl Med</source><year>2012</year><volume>10</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1186/1479-5876-10-28</pub-id><pub-id pub-id-type="pmid">22325452</pub-id><pub-id pub-id-type="pmcid">PMC3306270</pub-id></element-citation><mixed-citation id="mc-CR315" publication-type="journal">Hamilton E, Blackwell K, Hobeika AC, Clay TM, Broadwater G, Ren XR, Chen W, Castro H, Lehmann F, Spector N, Wei J, Osada T, Lyerly HK, Morse MA. Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]. J Transl Med. 2012;10:28.<pub-id pub-id-type="pmid">22325452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1479-5876-10-28</pub-id><pub-id pub-id-type="pmcid">PMC3306270</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR316"><label>316</label><citation-alternatives><element-citation id="ec-CR316" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adot&#233;vi</surname><given-names>O</given-names></name><name name-style="western"><surname>Vernerey</surname><given-names>D</given-names></name><name name-style="western"><surname>Jacoulet</surname><given-names>P</given-names></name><name name-style="western"><surname>Meurisse</surname><given-names>A</given-names></name><name name-style="western"><surname>Laheurte</surname><given-names>C</given-names></name><name name-style="western"><surname>Almotlak</surname><given-names>H</given-names></name><name name-style="western"><surname>Jacquin</surname><given-names>M</given-names></name><name name-style="western"><surname>Kaulek</surname><given-names>V</given-names></name><name name-style="western"><surname>Boullerot</surname><given-names>L</given-names></name><name name-style="western"><surname>Malfroy</surname><given-names>M</given-names></name><name name-style="western"><surname>Orillard</surname><given-names>E</given-names></name><name name-style="western"><surname>Eberst</surname><given-names>G</given-names></name><name name-style="western"><surname>Lagrange</surname><given-names>A</given-names></name><name name-style="western"><surname>Favier</surname><given-names>L</given-names></name><name name-style="western"><surname>Gainet-Brun</surname><given-names>M</given-names></name><name name-style="western"><surname>Doucet</surname><given-names>L</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>L</given-names></name><name name-style="western"><surname>Ghrieb</surname><given-names>Z</given-names></name><name name-style="western"><surname>Clairet</surname><given-names>AL</given-names></name><name name-style="western"><surname>Westeel</surname><given-names>V</given-names></name></person-group><article-title>Safety, immunogenicity, and 1-year efficacy of universal cancer peptide-based vaccine in patients with refractory advanced non-small-cell lung cancer: a phase Ib/Phase IIa de-escalation study</article-title><source>J Clin Oncol : Off J Am Soc Clin Oncol</source><year>2023</year><volume>41</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.00096</pub-id><pub-id pub-id-type="pmid">36070539</pub-id></element-citation><mixed-citation id="mc-CR316" publication-type="journal">Adot&#233;vi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Westeel V. Safety, immunogenicity, and 1-year efficacy of universal cancer peptide-based vaccine in patients with refractory advanced non-small-cell lung cancer: a phase Ib/Phase IIa de-escalation study. J Clin Oncol&#8239;: Off J Am Soc Clin Oncol. 2023;41:373&#8211;84.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.00096</pub-id><pub-id pub-id-type="pmid">36070539</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR317"><label>317</label><citation-alternatives><element-citation id="ec-CR317" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pol</surname><given-names>JG</given-names></name><name name-style="western"><surname>Acuna</surname><given-names>SA</given-names></name><name name-style="western"><surname>Yadollahi</surname><given-names>B</given-names></name><name name-style="western"><surname>Tang</surname><given-names>N</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Atherton</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hanwell</surname><given-names>D</given-names></name><name name-style="western"><surname>El-Warrak</surname><given-names>A</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>A</given-names></name><name name-style="western"><surname>Moloo</surname><given-names>B</given-names></name><name name-style="western"><surname>Turner</surname><given-names>PV</given-names></name></person-group><article-title>Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials</article-title><source>Oncoimmunology</source><year>2019</year><volume>8</volume><issue>1</issue><fpage>e1512329</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2018.1512329</pub-id><pub-id pub-id-type="pmid">30546947</pub-id><pub-id pub-id-type="pmcid">PMC6287790</pub-id></element-citation><mixed-citation id="mc-CR317" publication-type="journal">Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, Hanwell D, El-Warrak A, Goldstein A, Moloo B, Turner PV. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8(1): e1512329.<pub-id pub-id-type="pmid">30546947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2018.1512329</pub-id><pub-id pub-id-type="pmcid">PMC6287790</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>